

REC'D 2 9 JUL 2003

WIPO

10/518283

P1 1042811

HIERONIUND STAVIBS OF MUDERICE

TO ALL TO WHOM: THESE: PRESENTS SHATE, COME:

UNITED STATES DEPARTMENT OF COMMERCE **United States Patent and Trademark Office**

July 24, 2003

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 10/174,014

FILING DATE: June 17, 2002

RELATED PCT APPLICATION NUMBER: PCT/US03/18923

By Authority of the COMMISSIONER OF PATENTS AND TRADEMARKS

> E. BORNETT **Certifying Officer**

> > PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN COMPLIANCE WITH RULE 17.1(a) OR (b)



DOCKET NO.: PTS-0012

06-19-0221-4014-061703

Date of Deposit:

11" Label No.: EL918916361US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: C. Frank Bennett, Susan M. Freier and Kenneth W. Dobie

For:

Antisense Modulation of SMRT Expression

BOX SEQUENCE
Assistant Commissioner for Patents
Washington DC 20231

PATENT APPLICATION TRANSMITTAL LETTER

Transmitted herewith for filing, please find the following:

- · The specification of the above-referenced patent application;
- · An executed Declaration or Oath and Power of Attorney;
- J. An Assignment of the invention to Isis Pharmaceuticals Inc. with recordation cover sheet (PTO Form PTO-1595) and \$40.00 cover fee;
- Statement to Support Filing and Submission of DNA/Amino Acid Sequences in Accordance with 37 CFR § § 1.821 through 1.825;
- Sequence listing in computer readable form in accordance with 37 C.F.R. § 1.821(e);
- · An Information Disclosure Statement with references.

The filing fee has been calculated as shown below:

has been carculated as shown below.				
	[1] 在1900年 (1900年)			
For:	No. Filed	No. Extra	Rate	Fee
BASE FEE				\$740.00
Total Claims	20 - 20 =	0	x \$9=	\$0
Indep. Claims	2 - 3 =	0	x\$40=	\$0
TOTAL				\$ 740.00

The Commissioner is hereby authorized to charge the following fees to Deposit Account No. 500252:

- the amount of \$780.00 for the above listed fees;
- payment of the following fees associated with this communication or credit any overpayment;
- any additional filing fees required under 37 CFR 1.16 including fees for presentation of extra claims; and
- any additional patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20 (d).

Triplicate copies of this transmittal are enclosed.

Date: June 17, 2002

Donna T. Ward

Registration No. 48,271
Isis Pharmaceuticals, Inc.

Please address all correspondence to: Jane Massey Licata or Kathleen A. Tyrrell Licata & Tyrrell, P.C. 66 East Main Street Marlton NJ 08053 (856) 810-1515

,

DOCKET NO .: PTS-0012

"Express Mail" Label No.: EL918916361US Date of Deposit: (0112002)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): C. Frank Bennett, Susan M. Freier and Kenneth W. Dobie

Serial No.: not yet assigned Filing Date: herewith

Title: Antisense Modulation of SMRT Expression

BOX SEQUENCE Assistant Commissioner for Patents Washington, D.C., 20231

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821 THROUGH 1.825

I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same.

Date: June 17, 2007

Respectfully submitted,

Donna T. Ward Registration No. 48,271

Isis Pharmaceuticals, Inc.

Please address all correspondence to:

Licata & Tyrrell, P.C. 66 East Main Street Marlton NJ 08053 (856) 810-1515 PTS-0012

5

20

25

30

35

-1-

PATENT

ANTISENSE MODULATION OF SMRT EXPRESSION

FIELD OF THE INVENTION

The present invention provides compositions and methods for modulating the expression of SMRT. In particular, this invention relates to compounds, particularly oligonucleotides, specifically hybridizable with nucleic acids encoding SMRT. Such compounds have been shown to modulate the expression of SMRT.

BACKGROUND OF THE INVENTION

Steroids, retinoids, thyroid hormones, and vitamin D play critical roles in the regulation of reproduction, development, metabolism, and homeostasis. The intracellular receptors for these hormones and lipophilic compounds comprise a large family of transcription factors that regulate ligand-dependent expression of target genes. This family can be divided into two classes: the steroid receptors are normally inactive and associated with heat shock proteins in the absence of hormone, and the nuclear hormone receptors, which bind DNA and repress transcription in the absence of ligand and activate transcription upon ligand treatment. By activating or repressing target genes, the steroid/nuclear hormone receptors elicit a broad range of cellular responses, such as differentiation, proliferation, and cell death (Chen and Li, Crit. Rev. Eukaryot. Gene Expr., 1998, 8, 169-190).

The highly ordered chromatin structure of chromosomal DNA within the nuclei of eukaryotic cells presents a physical obstacle for gene transcription, by limiting access of

PTS-0012 -2- PATENT

transcription factors and RNA polymerase II core machinery to DNA templates. Posttranslational modifications such as phosphorylation, acetylation, ADP-ribosylation, and ubiquitination can reversibly modify histone proteins within chromatin, and these histone modifications affect structural 5 alterations in local chromatin architecture during transcription. The dynamic state of histone acetylation is tightly regulated and maintained by histone acetyltransferase (HAT) and histone deacetylase (HDAC) enzyme activities. Histone modification plays a pivotal role in controlling 10 access of transcriptional activators, repressors, and the basal transcription machinery to regulatory sequences in the underlying DNA template to positively or negatively affect the rate of gene transcription. Hyperacetylation of core histones in gene promoters results in decondensation of 15 chromatin, increases accessibility of transcription factors, and is correlated with gene activation. Conversely, hypoacetylation is thought to reestablish the condensed chromatin structure, favoring transcriptional repression and gene silencing (Chen and Li, Crit. Rev. Eukaryot. Gene Expr., 20 1998, 8, 169-190; Xu et al., Curr. Opin. Genet. Dev., 1999, 9. 140-147).

Repression of basal transcription by nuclear hormone receptors such as thyroid receptor (TR) and retinoic acid receptor (RAR) plays a critical role in oncogenesis and cellular differentiation. Several cofactors of nuclear receptors have been identified as important components of transcriptional regulation, and these coactivators and corepressors have been found to harbor intrinsic HAT and HDAC activities, respectively. The nuclear receptor corepressors, N-CoR and SMRT, interact with several unliganded nuclear receptors and recruit multisubunit protein complexes containing HDACs and several other proteins. Furthermore, recent studies of RAR and TR nuclear hormone receptors have revealed that, upon ligand binding, a HDAC-containing complex is displaced from the nuclear receptor in exchange for binding of a HAT-containing complex to promoters of target

25

30

35

PTS-0012 -3- PATENT

genes. Thus, ligand-dependent recruitment of chromatin-remodeling activities, in the form of histone acetylation and deacetylation enzyme complexes, is believed to serve as a general mechanism underlying the switch of nuclear receptors from a transcriptionally repressed to a transcriptionally active state (Xu et al., Curr. Opin. Genet. Dev., 1999, 9, 140-147).

Nuclear hormone corepressor proteins have been demonstrated to associate with mSin3 and HDAC-containing complexes, presumably to induce chromatin condensation and in doing so, these corepressors modulate transcriptional activation or silencing of a wide variety of gene targets involved in development, differentiation, and cellular proliferation (Lee et al., J. Biol. Chem., 2000, 275, 12470-12474; Li et al., Embo J., 2000, 19, 4342-4350; Wu et al., J. Biol. Chem., 2001, 276, 24177-24185).

SMRT (also known as silencing mediator for retinoid and thyroid hormone action, Nuclear receptor co-repressor 2, NCoR2, TRAC-1, CTG26, TNRC14, and SMRTe) was originally identified and cloned from a human B-cell cDNA library as a 20 RAR-interacting protein in a two-hybrid screen (Chen and Evans, Nature, 1995, 377, 454-457). RAR and TR directly interact with SMRT, and these protein-protein interactions bring the receptors to target promoters in the nucleus, resulting in gene repression. Ligand binding to the receptors 25 causes dissociation of SMRT from them, resulting in liganddependent activation of target genes (Chen and Evans, Nature, 1995, 377, 454-457). In an accompanying paper, nuclear receptor corepressor (N-CoR) was identified and found to be related to SMRT; thus, the name TRAC was proposed for a newly 30 identified family of thyroid-hormone- and retinoic-acidreceptor-associated corepressor proteins (Horlein et al., Nature, 1995, 377, 397-404).

The original isolate of SMRT showed significant homology to N-CoR, but was substantially shorter in length. A longer isoform was later isolated and named SMRT, as it was predicted to be the major form in vivo, and the shorter,

PTS-0012 -4- PATENT

original isolate was renamed s-SMRT (Ordentlich et al., Proc. Natl. Acad. Sci. U. S. A., 1999, 96, 2639-2644). Concurrently, a second group independently identified the human and mouse SMRT-extended (SMRTe) isoforms, which included 1000 amino acids at the N-terminus bearing striking 5 similarity to N-CoR, and found that SMRTe expression was cell-cycle regulated and transcripts were present in many mouse embryonic tissues (Park et al., Proc. Natl. Acad. Sci. U. S. A., 1999, 96, 3519-3524). Furthermore, a polyclonal antibody has been generated against SMRT and used to study 10 its cell cycle dependent localization. SMRT is ubiquitously expressed in the nuclei of all interphase cells, and is found to be dispersed in the cytoplasm and excluded from the metaphase chromosomes in mitotic cells (Chen et al., Proc. Natl. Acad. Sci. U. S. A., 1996, 93, 7567-7571). The relative .15 levels of SMRT expression also vary with tissue type and upon hormone treatment (Misiti et al., Endocrinology, 1998, 139, 2493-2500).

Posttranslational modification of SMRT may alter its subcellular localization and its ability to interact with nuclear hormone receptors. SMRT is a substrate for phosphorylation by multiple components of the mitogenactivated protein kinase (MAPK) cascade that operates downstream of the epidermal growth factor (EGF) receptor, and this phosphorylation appears to inhibit the ability of SMRT to bind to nuclear receptors, and correlates with a relocalization from the nucleus to the cytoplasm (Hong and Privalsky, Mol. Cell. Biol., 2000, 20, 6612-6625).

Nuclear receptors inhibit synthesis of matrix metalloproteinase-1 (MMP-1), an enzyme that degrades interstitial collagens and contributes to the pathology in numerous disorders, including the joint erosion observed in rheumatoid arthritis. Primary synovial fibroblasts express SMRT, and overexpression of SMRT was found to inhibit MMP-1 promoter activity, suggesting that SMRT maintains a repressive state of the MMP-1 gene and strictly controls

30

35

PATENT -5-PTS-0012

regulation of interstitial collagenase (Schroen et al., Biochem. Biophys. Res. Commun., 1997, 237, 52-58).

10

15

25

30

35

In addition to its role in inflammation, SMRT plays a role in several cancers. The MCF-7 breast cancer cell line 5 expresses the aryl hydrocarbon receptor (AhR) and AhR nuclear translocator (Arnt), and SMRT physically as well as functionally interacts with these proteins, suggesting that nuclear receptor corepressors can modulate aryl hydrocarbon responsiveness in breast cancer cells (Nguyen et al., Arch. Biochem. Biophys., 1999, 367, 250-257).

Mutations in members of the nuclear receptor superfamily frequently result in neoplastic and endocrine disorders. The genetic disease characterized by resistance to thyroid hormone (RTH) exemplifies such a disorder. RTH is attributed to mutations in the $\text{TR}\beta$ allele of the thyroid hormone receptor. These mutations act in a dominant negative manner, interfering with receptor function and displaying an aberrant association with SMRT, in which ligand treatment no longer results in dissociation of SMRT from the receptor (Matsushita et al., J. Endocrinol., 2000, 167, 493-503).

SMRT is also involved in human acute promyelocytic leukemia (APL), in which the majority of patients harbor a specific gene translocation involving the RARa allele. At least five different fusion partners of RAR α have been identified, but the two best-studied fusion proteins, PML- $RAR\alpha$ and PLZF- $RAR\alpha$ retain a wild-type affinity for retinoic acid (RA), and are able to bind to promoters of retinoic acid responsive genes. The PML-RARlpha and PLZF-RARlpha fusions have increased affinity for the corepressor SMRT, and the dissociation of SMRT from RAR normally induced by RA no longer occurs, leading to aberrant expression of target genes. Thus, PML-RAR α and PLZF-RAR α are leukemogenic at physiological concentrations of RA (Lin and Evans, Mol. Cell., 2000, 5, 821-830).

The pharmacological modulation of the activity and/or expression components of SMRT corepressor-containing

The state of the s

PTS-0012 -6- PATENT

complexes is believed to be an appropriate point of therapeutic intervention in pathological conditions such as inflammatory or autoimmune diseases, rheumatoid arthritis, resistance to thyroid hormone and other metabolic diseases, and cancers such as acute promyelocytic leukemia.

5

10

15

20

25

30

35

Disclosed and claimed in WO 00/53734 are nucleic acids encoding SMRT, allelic variants of SMRT, nucleic acids with 90% homology to SMRT or which can hybridize to SMRT, as well as BAC, PAC, and cosmid clones comprising genomic or cDNA sequences encoding SMRT, DNA constructs and expression cassettes bearing suitable regulatory sequences for expression of SMRT as a biologically active protein, antisense targeted to the SMRT gene, and antibodies against the SMRT protein. Further claimed are host cells containing said nucleic acid molecules and methods for producing polypeptides encoded by SMRT, or fragments thereof, as well as the use of the DNA or polypeptide sequences of SMRT as tools to identify potential drugs for the treatment of angiogenic diseases, rheumatoid arthritis, psoriasis, eye diseases such as diabetic retinopathy and neovascular glaucoma, kidney diseases such as glomerulonephritis and diabetic nephropathy (Thierauch et al., 2000).

Currently, there are no known therapeutic agents which effectively inhibit the synthesis of SMRT and investigative strategies aimed at studying SMRT function have involved the use of antibodies for cellular localization studies (Chen et al., Proc. Natl. Acad. Sci. U. S. A., 1996, 93, 7567-7571).

Consequently, there exists a long felt need to identify methods of modulating transcriptional repression complexes and specifically for agents capable of effectively modulating SMRT function.

Antisense technology is emerging as an effective means for reducing the expression of specific gene products and may therefore prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications for the modulation of SMRT expression.

and the second of the second o

PTS-0012 -7- PATENT

The present invention provides compositions and methods for modulating SMRT expression, including modulation of the extended isoform of SMRT, known as SMRTe.

SUMMARY OF THE INVENTION

5 ,

10

15

20

25

30

· 35

The present invention is directed to compounds, particularly antisense oligonucleotides, which are targeted to a nucleic acid encoding SMRT, and which modulate the expression of SMRT. Pharmaceutical and other compositions comprising the compounds of the invention are also provided. Further provided are methods of modulating the expression of SMRT in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further provided are methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of SMRT by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention employs oligomeric compounds, particularly antisense oligonucleotides, for use in modulating the function of nucleic acid molecules encoding SMRT, ultimately modulating the amount of SMRT produced. This is accomplished by providing antisense compounds which specifically hybridize with one or more nucleic acids encoding SMRT. As used herein, the terms "target nucleic acid" and "nucleic acid encoding SMRT" encompass DNA encoding SMRT, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as "antisense". The functions of

PTS-0012 -8- PATENT

DNA to be interfered with include replication and The functions of RNA to be interfered with transcription. include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translocation of the RNA to sites within the cell which are distant from the site of RNA synthesis, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is 10 modulation of the expression of SMRT. In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and 15 mRNA is a preferred target.

It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the 20 identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. 25 present invention, the target is a nucleic acid molecule encoding SMRT. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, 30 will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in 35 transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred

PTS-0012 -9- PATENT

to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start 10 codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used in vivo to 15 initiate translation of an mRNA molecule transcribed from a gene encoding SMRT, regardless of the sequence(s) of such codons.

It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.

20

25

30

35

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region

PTS-0012 -10- PATENT

(5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an 10 . N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent The 5' cap region may also be a preferred target to the cap. 15 region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intronexon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. mRNA transcripts produced via the process of splicing of two (or more) mRNAs from different gene sources are known as "fusion transcripts". It has also been found that introns can be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

20

25

30

35

It is also known in the art that alternative RNA transcripts can be produced from the same genomic region of DNA. These alternative transcripts are generally known as "variants". More specifically, "pre-mRNA variants" are

PTS-0012 -11- PATENT

transcripts produced from the same genomic DNA that differ from other transcripts produced from the same genomic DNA in either their start or stop position and contain both intronic and extronic regions.

5

10

15

20

25

30

35

Upon excision of one or more exon or intron regions or portions thereof during splicing, pre-mRNA variants produce smaller "mRNA variants". Consequently, mRNA variants are processed pre-mRNA variants and each unique pre-mRNA variant must always produce a unique mRNA variant as a result of splicing. These mRNA variants are also known as "alternative splice variants". If no splicing of the pre-mRNA variant occurs then the pre-mRNA variant is identical to the mRNA variant.

It is also known in the art that variants can be produced through the use of alternative signals to start or stop transcription and that pre-mRNAs and mRNAs can possess more that one start codon or stop codon. Variants that originate from a pre-mRNA or mRNA that use alternative start codons are known as "alternative start variants" of that pre-mRNA or mRNA. Those transcripts that use an alternative stop codon are known as "alternative stop variants" of that pre-mRNA or mRNA. One specific type of alternative stop variant is the "polyA variant" in which the multiple transcripts produced result from the alternative selection of one of the "polyA stop signals" by the transcription machinery, thereby producing transcripts that terminate at unique polyA sites.

Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. "Complementary," as used

PTS-0012 -12- PATENT

herein, refers to the capacity for precise pairing between For example, if a nucleotide at a certain two nucleotides. position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. 10 "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the 15 sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable.

An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule . .20 interferes with the normal function of the target DNA or RNA to cause a loss of activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under 25 physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed. It is preferred that the antisense compounds of the present invention comprise at least 80% sequence complementarity to a 30 target region within the target nucleic acid, moreover that they comprise 90% sequence complementarity and even more comprise 95% sequence complementarity to the target region within the target nucleic acid sequence to which they are targeted. For example, an antisense compound in which 18 of 35 20 nucleobases of the antisense compound are complementary, and would therefore specifically hybridize, to a target

PATENT -13-PTS-0012

region would represent 90 percent complementarity. Percent complementarity of an antisense compound with a region of a target nucleic acid can be determined routinely using basic local alignment search tools (BLAST programs) (Altschul et al., J. Mol. Biol., 1990, 215, 403-410; Zhang and Madden, Genome Res., 1997, 7, 649-656).

5

10

15

25

30

35

Antisense and other compounds of the invention, which hybridize to the target and inhibit expression of the target, are identified through experimentation, and representative sequences of these compounds are hereinbelow identified as preferred embodiments of the invention. The sites to which these preferred antisense compounds are specifically hybridizable are hereinbelow referred to as "preferred target regions" and are therefore preferred sites for targeting. used herein the term "preferred target region" is defined as at least an 8-nucleobase portion of a target region to which an active antisense compound is targeted. While not wishing to be bound by theory, it is presently believed that these target regions represent regions of the target nucleic acid which are accessible for hybridization. 20

While the specific sequences of particular preferred target regions are set forth below, one of skill in the art will recognize that these serve to illustrate and describe particular embodiments within the scope of the present invention. Additional preferred target regions may be identified by one having ordinary skill.

Target regions 8-80 nucleobases in length comprising a stretch of at least eight (8) consecutive nucleobases selected from within the illustrative preferred target regions are considered to be suitable preferred target regions as well.

Exemplary good preferred target regions include DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 5'-terminus of one of the illustrative preferred target regions (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately upstream of the 5'-terminus of the target region PTS-0012 -14- PATENT

and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). Similarly good preferred target regions are represented by DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 3'-terminus of one of the illustrative preferred target regions (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately downstream of the 3'-terminus of the target region and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). One having skill in the art, once armed with the empirically-derived preferred 10 target regions illustrated herein will be able, without undue experimentation, to identify further preferred target In addition, one having ordinary skill in the art will also be able to identify additional compounds, including oligonucleotide probes and primers, that specifically 15 hybridize to these preferred target regions using techniques available to the ordinary practitioner in the art.

Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

20

25

30

35

For use in kits and diagnostics, the antisense compounds of the present invention, either alone or in combination with other antisense compounds or therapeutics, can be used as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion or the entire complement of genes expressed within cells and tissues.

Expression patterns within cells or tissues treated with one or more antisense compounds are compared to control cells or tissues not treated with antisense compounds and the patterns produced are analyzed for differential levels of gene expression as they pertain, for example, to disease

PTS-0012 -15- PATENT

association, signaling pathway, cellular localization, expression level, size, structure or function of the genes examined. These analyses can be performed on stimulated or unstimulated cells and in the presence or absence of other compounds which affect expression patterns.

5

Examples of methods of gene expression analysis known in the art include DNA arrays or microarrays (Brazma and Vilo, FEBS Lett., 2000, 480, 17-24; Celis, et al., FEBS Lett., 2000, 480, 2-16), SAGE (serial analysis of gene

- expression) (Madden, et al., Drug Discov. Today, 2000, 5, 415-425), READS (restriction enzyme amplification of digested cDNAs) (Prashar and Weissman, Methods Enzymol., 1999, 303, 258-72), TOGA (total gene expression analysis) (Sutcliffe, et al., Proc. Natl. Acad. Sci. U. S. A., 2000, 97, 1976-81),
- protein arrays and proteomics (Celis, et al., FEBS Lett., 2000, 480, 2-16; Jungblut, et al., Electrophoresis, 1999, 20, 2100-10), expressed sequence tag (EST) sequencing (Celis, et al., FEBS Lett., 2000, 480, 2-16; Larsson, et al., J. Biotechnol., 2000, 80, 143-57), subtractive RNA
- fingerprinting (SuRF) (Fuchs, et al., Anal. Biochem., 2000, 286, 91-98; Larson, et al., Cytometry, 2000, 41, 203-208), subtractive cloning, differential display (DD) (Jurecic and Belmont, Curr. Opin. Microbiol., 2000, 3, 316-21), comparative genomic hybridization (Carulli, et al., J. Cell
- 25 Biochem. Suppl., 1998, 31, 286-96), FISH (fluorescent in situ hybridization) techniques (Going and Gusterson, Eur. J. Cancer, 1999, 35, 1895-904) and mass spectrometry methods (reviewed in To, Comb. Chem. High Throughput Screen, 2000, 3, 235-41).
- The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotide drugs, including ribozymes, have been safely and effectively administered to humans and
 - nave been sarely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic

PTS-0012 -16- PATENT

modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.

5

10

15

20

25

30

35

"oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 80 nucleobases (i.e. from about 8 to about 80 nucleosides). Particularly preferred antisense compounds are antisense oligonucleotides from about 8 to about 50 nucleobases, even more preferably those comprising from about 12 to about 30 nucleobases. Antisense compounds include ribozymes, external guide sequence (EGS) oligonucleotides (oligozymes), and other short catalytic RNAs or catalytic oligonucleotides which hybridize to the target nucleic acid and modulate its expression.

Antisense compounds 8-80 nucleobases in length comprising a stretch of at least eight (8) consecutive nucleobases selected from within the illustrative antisense compounds are considered to be suitable antisense compounds as well.

Exemplary preferred antisense compounds include DNA or RNA sequences that comprise at least the 8 consecutive

PTS-0012 -17- PATENT

nucleobases from the 5'-terminus of one of the illustrative preferred antisense compounds (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately upstream of the 5'-terminus of the antisense compound which is specifically hybridizable to the target nucleic acid and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). Similarly preferred antisense compounds are represented by DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 3'-terminus of one of the illustrative preferred antisense compounds (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately downstream of the 3'-terminus of the antisense compound which is specifically hybridizable to the target nucleic acid and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). One having skill in the art, once armed with the empirically-derived preferred antisense compounds illustrated herein will be able, without undue experimentation, to identify further preferred antisense compounds.

10

15

20

25

30

35

Antisense and other compounds of the invention, which hybridize to the target and inhibit expression of the target, are identified through experimentation, and representative sequences of these compounds are herein identified as preferred embodiments of the invention. While specific sequences of the antisense compounds are set forth herein, one of skill in the art will recognize that these serve to illustrate and describe particular embodiments within the scope of the present invention. Additional preferred antisense compounds may be identified by one having ordinary skill.

As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the

PTS-0012 -18- PATENT

For those nucleosides that include a nucleoside. pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear In turn, the respective ends of this polymeric compound. linear polymeric structure can be further joined to form a circular structure, however, open linear structures are In addition, linear structures may also generally preferred. have internal nucleobase complementarity and may therefore fold in a manner as to produce a double stranded structure. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

5

10

15

20

25

30

35

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphoramidates, thionoalkylphosphorates, thionoalkylphosphotriesters, selenophosphates and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or

PTS-0012 -19- PATENT

more internucleotide linkages is a 3' to 3', 5' to 5' or 2' to 2' linkage. Preferred oligonucleotides having inverted polarity comprise a single 3' to 3' linkage at the 3'-most internucleotide linkage i.e. a single inverted nucleoside residue which may be abasic (the nucleobase is missing or has a hydroxyl group in place thereof). Various salts, mixed salts and free acid forms are also included.

Representative United States patents that teach the preparation of the above phosphorus-containing linkages

include, but are not limited to, U.S.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697 and 5,625,050, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are 20 formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. include those having morpholino linkages (formed in part from 25 the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and 30 methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH, component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564;

35

PTS-0012 -20- PATENT

5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

5

30

35

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. 10 base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the 15 sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine The nucleobases are retained and are bound backbone. directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States 20 patents that teach the preparation of PNA compounds include, but are not limited to, U.S.: 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., Science, 1991, 254, 1497-1500. 25

Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular -CH₂-NH-O-CH₂-, -CH₂-N(CH₃)-O-CH₂- [known as a methylene (methylimino) or MMI backbone], -CH₂-O-N(CH₃)-CH₂-, -CH₂-N(CH₃)-N(CH₃)-CH₂- and -O-N(CH₃)-CH₂-CH₂- [wherein the native phosphodiester backbone is represented as -O-P-O-CH₂-] of the above referenced U.S. patent 5,489,677, and the amide backbones of the above referenced U.S. patent 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. patent 5,034,506.

PTS-0012 -21- PATENT

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C_1 to C_{10} alkyl or C_2 to C_{10} alkenyl and alkynyl. Particularly preferred are $O[(CH_2)_nO]_nCH_3$, $O(CH_2)_nOCH_3$, $O(CH_2)_nNH_2$, $O(CH_2)_nCH_3$, $O(CH_2)_nONH_2$, and O(CH₂) ON[(CH₂) CH₃], where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the 10 following at the 2' position: C_1 to C_{10} lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH, OCN, Cl, Br, CN, CF, OCF, SOCH, SO2CH, ONO2, NO2, N3, NH2, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, 15 substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred 20 modification includes 2'-methoxyethoxy (2'-O-CH2CH2OCH3, also known as 2'-0-(2-methoxyethyl) or 2'-MOE) (Martin et al., Helv. Chim. Acta, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'dimethylaminooxyethoxy, i.e., a O(CH,),ON(CH,), group, also 25 known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-0dimethyl-amino-ethoxy-ethyl or 2'-DMAEOE), i.e., 2'-O-CH,-O-CH2-N(CH3)2, also described in examples hereinbelow.

Other preferred modifications include 2'-methoxy (2'-O-CH₃), 2'-aminopropoxy (2'-OCH₂CH₂CH₂NH₂), 2'-allyl (2'-CH₂-CH=CH₂), 2'-O-allyl (2'-O-CH₂-CH=CH₂) and 2'-fluoro (2'-F). The 2'-modification may be in the arabino (up) position or ribo (down) position. A preferred 2'-arabino modification is 2'-F. Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-

PTS-0012 -22- PATENT

5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl mojeties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

10

15 ·

20

25

30

35

A further preferred modification includes Locked Nucleic Acids (LNAs) in which the 2'-hydroxyl group is linked to the 3' or 4' carbon atom of the sugar ring thereby forming a bicyclic sugar moiety. The linkage is preferably a methelyne (-CH₂-)_n group bridging the 2' oxygen atom and the 4' carbon atom wherein n is 1 or 2. LNAs and preparation thereof are described in WO 98/39352 and WO 99/14226.

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5hydroxymethyl cytosine, xanthine, hypoxanthine, 2aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl (-C≡C-CH3) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8hydroxyl and other 8-substituted adenines and guanines, 5halo particularly 5-bromo, 5-trifluoromethyl and other 5substituted uracils and cytosines, 7-methylguanine and 7PTS-0012 -23- PATENT

methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3deazaguanine and 3-deazaadenine. Further modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine(1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido[5,4b][1,4]benzoxazin-2(3H)-one), carbazole cytidine (2Hpyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-10 pyrido[3',2':4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed 15 in United States Patent No. 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613, and those disclosed by 20 Sanghvi, Y.S., Chapter 15, Antisense Research and Applications, pages 289-302, Crooke, S.T. and Lebleu, B., ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-25 substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and 30 Lebleu, B., eds., Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-0-methoxyethyl sugar modifications.

Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include,

35

PTS-0012 -24- PATENT

but are not limited to, the above noted U.S. 3,687,808, as well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588; 6,005,096; and 5,681,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference, and United States patent 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

10

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. The compounds of the invention can include 15 conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of 20 oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugate groups include cholesterols, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance 25 the pharmacodynamic properties, in the context of this invention, include groups that improve oligomer uptake, enhance oligomer resistance to degradation, and/or strengthen sequence-specific hybridization with RNA. Groups that enhance the pharmacokinetic properties, in the context of 30 this invention, include groups that improve oligomer uptake, distribution, metabolism or excretion. Representative conjugate groups are disclosed in International Patent Application PCT/US92/09196, filed October 23, 1992 the entire disclosure of which is incorporated herein by reference. 35 Conjugate moieties include but are not limited to lipid moiețies such as a cholesterol moiety (Letsinger et al.,

PTS-0012 -25- PATENT

Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Let., 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10, 1111-1118; Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a 10 phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a 15 polyamine or a polyethylene glycol chain (Manoharan et al., Nucleo'sides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, · 3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), or an octadecylamine or 20 hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923-937). Oligonucleotides of the invention may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S) - (+) pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic 25 acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indomethicin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic. Oligonucleotide-drug conjugates and their preparation are described in United 30 States Patent Application 09/334,130 (filed June 15, 1999) which is incorporated herein by reference in its entirety. Representative United States patents that teach the

preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802;

35

PTS-0012 -26- PATENT

5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 10 5,688,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one 15 of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds which are chimeric compounds. antisense compounds or "chimeras," in the context of this 20 invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide These oligonucleotides typically contain at least 25 one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, increased stability and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide 30 may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNAse H is a cellular endonuclease which cleaves the RNA strand of an RNA: DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the 35 efficiency of oligonucleotide inhibition of gene expression. The cleavage of RNA:RNA hybrids can, in like fashion, be accomplished through the actions of endoribonucleases, such

PTS-0012 -27- PATENT

as interferon-induced RNAseL which cleaves both cellular and viral RNA. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothicate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

5

10

15

20

25

30

35

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.: 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor-targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption-assisting formulations

-28-PATENT PTS-0012

include, but are not limited to, U.S.: 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable 15 salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

10

20

25

30

35

The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., published December 9, 1993 or in WO 94/26764 and U.S. 5,770,713 to Imbach et al.

The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the Examples of suitable amines are like.

PTS-0012 -29- PATENT

N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., "Pharmaceutical Salts," J. of Pharma Sci., 1977, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the The free acid forms free acid in the conventional manner. 10 differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically 15 acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts 20 are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or 25 phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, 30 benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in 35 nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic

PTS-0012 -30- PATENT

acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate,

5

10

15

20

25

30

35

....

N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of SMRT is treated by administering antisense compounds in accordance with this invention. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable

PTS-0012 -31- PATENT

pharmaceutically acceptable diluent or carrier. Use of the antisense compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.

5

10

15

20

25

30

35

The antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding SMRT, enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding SMRT can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of SMRT in a sample may also be prepared.

The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aeròsols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2'-0methoxyethyl modification are believed to be particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be

PTS-0012 -32- PATENT

necessary or desirable. Coated condoms, gloves and the like may also be useful. Preferred topical formulations include those in which the oligonucleotides of the invention are in admixture with a topical delivery agent such as lipids,

- 5 liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Preferred lipids and liposomes include neutral (e.g. dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearolyphosphatidyl choline) negative (e.g.
- dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g. dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA). Oligonucleotides of the invention may be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes. Alternatively,
- oligonucleotides may be complexed to lipids, in particular to cationic lipids. Preferred fatty acids and esters include but are not limited arachidonic acid, oleic acid, eicosanoic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid,
- dicaprate, tricaprate, monoolein, dilaurin, glyceryl
 1-monocaprate, 1-dodecylazacycloheptan-2-one, an
 acylcarnitine, an acylcholine, or a C₁₋₁₀ alkyl ester (e.g.
 isopropylmyristate IPM), monoglyceride, diglyceride or
 pharmaceutically acceptable salt thereof. Topical
- formulations are described in detail in United States patent application 09/315,298 filed on May 20, 1999 which is incorporated herein by reference in its entirety.

Compositions and formulations for oral administration include powders or granules, microparticulates,

30 nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

Preferred oral formulations are those in which oligonucleotides of the invention are administered in conjunction with one or more penetration enhancers

surfactants and chelators. Preferred surfactants include

PTS-0012 -33- PATENT

fatty acids and/or esters or salts thereof, bile acids and/or salts thereof. Preferred bile acids/salts include chenodeoxycholic acid (CDCA) and ursodeoxychenodeoxycholic acid (UDCA), cholic acid, dehydrocholic acid, deoxycholic acid, glucholic acid, glycholic acid, glycodeoxycholic acid, 5 taurocholic acid, taurodeoxycholic acid, sodium tauro-24,25dihydro-fusidate and sodium glycodihydrofusidate. Preferred fatty acids include arachidonic acid, undecanoic acid, oleic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, 10 dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a monoglyceride, a diglyceride or a pharmaceutically acceptable salt thereof (e.g. sodium). Also preferred are combinations of penetration enhancers, for example, fatty acids/salts in combination with bile acids/salts. A particularly preferred combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. Oligonucleotides of the 20 invention may be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. Oligonucleotide complexing agents include poly-amino acids; polyimines; polyacrylates; polyalkylacrylates, polyoxethanes, polyalkylcyanoacrylates; 25 cationized gelatins, albumins, starches, acrylates, polyethyleneglycols (PEG) and starches; polyalkylcyanoacrylates; DEAE-derivatized polyimines, pollulans, celluloses and starches. Particularly preferred complexing agents include chitosan, N-trimethylchitosan, 30 poly-L-lysine, polyhistidine, polyornithine, polyspermines, protamine, polyvinylpyridine, polythiodiethylaminomethylethylene P(TDAE), polyaminostyrene (e.g. p-amino), poly(methylcyanoacrylate), poly(ethylcyanoacrylate), poly(butylcyanoacrylate), poly(isobutylcyanoacrylate), 35 poly(isohexylcynaoacrylate), DEAE-methacrylate, DEAEhexylacrylate, DEAE-acrylamide, DEAE-albumin and DEAE-

)

PTS-0012 -34- PATENT

dextran, polymethylacrylate, polyhexylacrylate, poly(D,L-lactic acid), poly(DL-lactic-co-glycolic acid (PLGA), alginate, and polyethyleneglycol (PEG). Oral formulations for oligonucleotides and their preparation are described in detail in United States applications 08/886,829 (filed July 1, 1997), 09/108,673 (filed July 1, 1998), 09/256,515 (filed February 23, 1999), 09/082,624 (filed May 21, 1998) and 09/315,298 (filed May 20, 1999), each of which is incorporated herein by reference in their entirety.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

10

15

20

25

30

35

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated

PTS-0012 -35- PATENT

as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

Emulsions

10

15

The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in 20 another in the form of droplets usually exceeding 0.1 μm in diameter (Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, 25 Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, 1985, p. 301). 30 Emulsions are often biphasic systems comprising two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be of either the water-in-oil (w/o) or the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as 35 minute droplets into a bulk oily phase, the resulting composition is called a water-in-oil (w/o) emulsion.

PTS-0012 -36- PATENT

Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase, the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases, and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed.

Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do

15 not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous phase

provides an o/w/o emulsion.

35

20 Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a 25 semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. 30 may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger,

-37-PATENT PTS-0012

in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, : 15 p. 285).

10

20

25

30

Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, 35 in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in Pharmaceutical Dosage Forms, Lieberman,

PTS-0012 -38- PATENT

Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

5

10

30

35

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

Since emulsions often contain a number of ingredients

such as carbohydrates, proteins, sterols and phosphatides
that may readily support the growth of microbes, these
formulations often incorporate preservatives. Commonly used
preservatives included in emulsion formulations include
methyl paraben, propyl paraben, quaternary ammonium salts,

benzalkonium chloride, esters of p-hydroxybenzoic acid, and
boric acid. Antioxidants are also commonly added to emulsion
formulations to prevent deterioration of the formulation.
Antioxidants used may be free radical scavengers such as
tocopherols, alkyl gallates, butylated hydroxyanisole,

butylated hydroxytoluene, or reducing agents such as ascorbic
acid and sodium metabisulfite, and antioxidant synergists
such as citric acid, tartaric acid, and lecithin.

The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of ease of formulation, as well as efficacy from an absorption and bioavailability standpoint (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker,

PATENT PTS-0012 -39-

Inc., New York, N.Y., volume 1, p. 245; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

10

In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first dispersing an oil in an 15 aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of 20 two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: Controlled Release of Drugs: Polymers and Aggregate Systems, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination 25 of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of 30 the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, 1985, p. 271).

The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive 35 knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, in Pharmaceutical Dosage Forms,

PTS-0012 -40- PATENT

Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

Surfactants used in the preparation of microemulsions 10 include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), 15 decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the 20 surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying 25 microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene The oil phase may include, but is not limited to, 30 materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and triglycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone 35 oil.

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption

PTS-0012 -41- PATENT

of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (Constantinides et al., Pharmaceutical Research, 1994, 11, 1385-1390; Ritschel, Meth. Find. Exp. Clin. Pharmacol., 1993, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical 10 potency, and decreased toxicity (Constantinides et al., Pharmaceutical Research, 1994, 11, 1385; Ho et al., J. Pharm. Sci., 1996, 85, 138-143). Often microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous 15 when formulating thermolabile drugs, peptides or oligonucleotides. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected 20. that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides and nucleic acids within the gastrointestinal tract, vagina, buccal cavity and other areas 25 of administration.

Microemulsions of the present invention may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the oligonucleotides and nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention may be classified as belonging to one of five broad categories - surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., Critical Reviews in Therapeutic

30

35

PTS-0012 -42-PATENT

Drug Carrier Systems, 1991, p. 92). Each of these classes has been discussed above.

Liposomes

10

15

20

25

30

35

5 · There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery. As used in the present invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Noncationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages in vivo.

In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

PTS-0012 -43- PATENT

Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes and as the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

5

10

15

20

. 25

30

35

Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., Biochem. Biophys. Res. Commun., 1987, 147, 980-985).

Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive

PTS-0012 -44- PATENT

liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., Journal of Controlled Release, 1992, 19, 269-274).

5

10

15

20

25

30

35

One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (e.g. as a solution or as an emulsion) were ineffective (Weiner et al., Journal of Drug Targeting, 1992, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis et al., Antiviral Research, 1992, 18, 259-265).

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising NovasomeTM I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and NovasomeTM II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to

deliver cyclosporin-A into the dermis of mouse skin.

PTS-0012 -45- PATENT

indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu et al. S.T.P.Pharma. Sci., 1994, 4, 6, 466).

Liposomes also include "sterically stabilized"
liposomes, a term which, as used herein, refers to liposomes
comprising one or more specialized lipids that, when
incorporated into liposomes, result in enhanced circulation
lifetimes relative to liposomes lacking such specialized

- lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G_m , or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol
- 15 (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized
- liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., FEBS Letters, 1987, 223, 42; Wu et al., Cancer Research, 1993, 53, 3765).

Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (Ann. N.Y. Acad.

- Sci., 1987, 507, 64) reported the ability of monosialoganglioside G_M, galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (Proc. Natl. Acad. Sci. U.S.A., 1988, 85, 6949). U.S.
- Patent No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G_m or a galactocerebroside sulfate ester. U.S. Patent No. 5,543,152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-
- dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim et al.).

PTS-0012 -46- PATENT

Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto et al. (Bull. Chem. Soc. Jpn., 1980, 53, 2778) described liposomes comprising a nonionic detergent, $2C_{12}15G$, that contains a PEG moiety. Illum et al. (FEBS Lett., 1984, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are 10 described by Sears (U.S. Patent Nos. 4,426,330 and 4,534,899). Klibanov et al. (FEBS Lett., 1990, 268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG 15 stearate have significant increases in blood circulation half-lives. Blume et al. (Biochimica et Biophysica Acta, . 1990, 1029, 91) extended such observations to other PEGderivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and Liposomes having covalently bound PEG moieties on their 20 external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle et al. (U.S. Patent Nos. 5,013,556 and 5,356,633) and Martin et al. (U.S. 25 Patent No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Patent No. 5,225,212 (both to Martin et al.) and in WO 94/20073 (Zalipsky et al.) Liposomes comprising PEG-modified ceramide 30 lipids are described in WO 96/10391 (Choi et al.). U.S. Patent Nos. 5,540,935 (Miyazaki et al.) and 5,556,948 (Tagawa et al.) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry et al. discloses methods for encapsulating high molecular weight

35

PTS-0012 -47- PATENT

nucleic acids in liposomes. U.S. Patent No. 5,264,221 to Tagawa et al. discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an antisense RNA. U.S. Patent No. 5,665,710 to Rahman et al. describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love et al. discloses liposomes comprising antisense oligonucleotides targeted to the raf gene.

10

15

. 20

25

30

Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g. they are selfoptimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in Pharmaceutical Dosage Forms, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products

PTS-0012 -48- PATENT

and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include 30 'acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, **1988**, p. 285).

Penetration Enhancers

10

15

20

25

35

PTS-0012 -49- PATENT

In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

5

10

15

35

Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

20 Surfactants: In connection with the present invention, surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides through the 25 mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., Critical Reviews 30 in Therapeutic Drug Carrier Systems, 1991, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., J. Pharm. Pharmacol., 1988, 40, 252).

Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-

PTS-0012 -50- PATENT

monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C₁₋₁₀ alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p.92; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; El Hariri et al., J. Pharm. Pharmacol., 1992, 44, 651-654).

10

Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fatsoluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Hardman 15 et al. Eds., McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as 20 well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucholic acid (sodium glucholate), 25 glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium 30 tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92; Swinyard, Chapter 39 In: Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA, 1990, pages 782-783; Muranishi, 35 Critical Reviews in Therapeutic Drug Carrier Systems, 1990,

PTS-0012 -51- PATENT

7, 1-33; Yamamoto et al., J. Pharm. Exp. Ther., 1992, 263, 25; Yamashita et al., J. Pharm. Sci., 1990, 79, 579-583).

Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as 5 compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also 10 serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, J. Chromatogr., 1993, 618, 315-339). Chelating agents of the invention include but are not limited to disodium .15 ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of beta-diketones (enamines) (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 20 1991, page 92; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; Buur et al., J. Control Rel., 1990, 14, 43-51).

Non-chelating non-surfactants: As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary mucosa (Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33). This class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin

PTS-0012 -52- PATENT

and phenylbutazone (Yamashita et al., J. Pharm. Pharmacol., 1987, 39, 621-626).

Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S. Patent No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), are also known to enhance the cellular uptake of oligonucleotides.

Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

Carriers

5

10

15

Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, "carrier compound" or "carrier" can refer to a 20 nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity per se) but is recognized as a nucleic acid by in vivo processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic 25 acid or promoting its removal from circulation. coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory 30 reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'isothiocyano-stilbene-2,2'-35 disulfonic acid (Miyao *et al., Antisense Res. Dev.,* **1995**, *5,*

PTS-0012 -53- PATENT

115-121; Takakura et al., Antisense & Nucl. Acid Drug Dev., 1996, 6, 177-183).

Excipients

30

35

In contrast to a carrier compound, a "pharmaceutical 5 carrier" or "excipient" is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an The excipient may be liquid or solid and is 10 selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., . when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or 15 hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., 20 magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium 25 lauryl sulphate, etc.).

Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or

PTS-0012 -54- PATENT

solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Other Components

10

The compositions of the present invention may additionally contain other adjunct components conventionally 15 found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, 20 antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, 25 when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, 30 preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

35 Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for

PTS-0012 -55- PATENT

example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include but are not limited to daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin,

- esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine, arabinoside, bis-chloroethylnitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine,
- mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin, 4hydroxyperoxycyclophosphoramide, 5-fluorouracil (5-FU), 5
 - fluorodeoxyuridine (5-FUdR), methotrexate (MTX), colchicine, taxol, vincristine, vinblastine, etoposide (VP-16), trimetrexate, irinotecan, topotecan, gemcitabine, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, The Merck Manual of Diagnosis and Therapy, 15th Ed. 1987, pp.
 - 25 1206-1228, Berkow et al., eds., Rahway, N.J. When used with the compounds of the invention, such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by MTX and oligonucleotide), or in combination
 - with one or more other such chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not
 - limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, The Merck Manual of Diagnosis and Therapy, 15th

PTS-0012 -56- PATENT

Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 2499-2506 and 46-49, respectively). Other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

10

15

20

25

30

35

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on ECsas found to be effective in in vitro and in vivo animal models. In general, dosage is from 0.01 ug to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years.

PTS-0012

-57-

PATENT

While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

PTS-0012 -58- PATENT

EXAMPLES

Example 1

5

10

15

20

25

30

35

Nucleoside Phosphoramidites for Oligonucleotide Synthesis Deoxy and 2'-alkoxy amidites

2'-Deoxy and 2'-methoxy beta-cyanoethyldiisopropyl phosphoramidites were purchased from commercial sources (e.g. Chemgenes, Needham MA or Glen Research, Inc. Sterling VA).

Other 2'-O-alkoxy substituted nucleoside amidites are prepared as described in U.S. Patent 5,506,351, herein incorporated by reference. For oligonucleotides synthesized using 2'-alkoxy amidites, optimized synthesis cycles were developed that incorporate multiple steps coupling longer wait times relative to standard synthesis cycles.

The following abbreviations are used in the text: thin layer chromatography (TLC), melting point (MP), high pressure liquid chromatography (HPLC), Nuclear Magnetic Resonance (NMR), argon (Ar), methanol (MeOH), dichloromethane (CH₂Cl₂), triethylamine (TEA), dimethyl formamide (DMF), ethyl acetate (EtOAc), dimethyl sulfoxide (DMSO), tetrahydrofuran (THF).

Oligonucleotides containing 5-methyl-2'-deoxycytidine (5-Me-dC) nucleotides were synthesized according to published methods (Sanghvi, et. al., *Nucleic Acids Research*, 1993, 21, 3197-3203) using commercially available phosphoramidites (Glen Research, Sterling VA or ChemGenes, Needham MA) or prepared as follows:

Preparation of 5'-O-Dimethoxytrityl-thymidine intermediate for 5-methyl dC amidite

To a 50 L glass reactor equipped with air stirrer and Ar gas line was added thymidine (1.00 kg, 4.13 mol) in anhydrous pyridine (6 L) at ambient temperature. Dimethoxytrityl (DMT) chloride (1.47 kg, 4.34 mol, 1.05 eq) was added as a solid in four portions over 1 h. After 30 min, TLC indicated approx. 95% product, 2% thymidine, 5% DMT reagent and by-products and 2 % 3',5'-bis DMT product (R, in EtOAc 0.45, 0.05, 0.98, 0.95

PTS-0012 -59- PATENT

respectively). Saturated sodium bicarbonate (4 L) and CH,Cl, were added with stirring (pH of the aqueous layer 7.5). additional 18 L of water was added, the mixture was stirred, the phases were separated, and the organic layer was transferred to a second 50 L vessel. The aqueous layer was extracted with additional CH,Cl, $(2 \times 2 L)$. The combined organic layer was washed with water (10 L) and then concentrated in a rotary evaporator to approx. 3.6 kg total weight. This was redissolved in CH,Cl, (3.5 L), added to the reactor followed by water (6 L) and hexanes (13 L). 10 mixture was vigorously stirred and seeded to give a fine white suspended solid starting at the interface. After stirring for 1 h, the suspension was removed by suction through a 1/2" diameter teflon tube into a 20 L suction flask, poured onto a 25 cm Coors Buchner funnel, washed with 15 water (2 x 3 L) and a mixture of hexanes- CH₂Cl₂ (4:1, 2x3 L) and allowed to air dry overnight in pans (1" deep). This was further dried in a vacuum oven (75°C, 0.1 mm Hg, 48 h) to a constant weight of 2072 g (93%) of a white solid, (mp 122-124°C). TLC indicated a trace contamination of the bis DMT 20 product. NMR spectroscopy also indicated that 1-2 mole percent pyridine and about 5 mole percent of hexanes was still present.

25 Preparation of 5'-O-Dimethoxytrity1-2'-deoxy-5-methylcytidine intermediate for 5-methyl-dC amidite

To a 50 L Schott glass-lined steel reactor equipped with an electric stirrer, reagent addition pump (connected to an addition funnel), heating/cooling system, internal

30 thermometer and an Ar gas line was added 5'-0-dimethoxytrityl-thymidine (3.00 kg, 5.51 mol), anhydrous acetonitrile (25 L) and TEA (12.3 L, 88.4 mol, 16 eq). The mixture was chilled with stirring to -10°C internal temperature (external -20°C). Trimethylsilylchloride (2.1 L, 16.5 mol, 3.0 eq) was added over 30 minutes while maintaining the internal temperature below -5°C, followed by a wash of anhydrous acetonitrile (1 L). Note: the reaction is mildly

PTS-0012 -60- PATENT

exothermic and copious hydrochloric acid fumes form over the The reaction was allowed to warm to course of the addition. 0°C and the reaction progress was confirmed by TLC (EtOAchexanes 4:1; R, 0.43 to 0.84 of starting material and silyl product, respectively). Upon completion, triazole (3.05 kg, 44 mol, 8.0 eq) was added the reaction was cooled to -20°C internal temperature (external -30°C). Phosphorous oxychloride (1035 mL, 11.1 mol, 2.01 eq) was added over 60 min so as to maintain the temperature between -20°C and -10°C 10 during the strongly exothermic process, followed by a wash of anhydrous acetonitrile (1 L). The reaction was warmed to 0 °C and stirred for 1 h. TLC indicated a complete conversion to the triazole product (R, 0.83 to 0.34 with the product spot glowing in long wavelength UV light). The reaction mixture 15 was a peach-colored thick suspension, which turned darker red upon warming without apparent decomposition. The reaction was cooled to -15°C internal temperature and water (5 L) was slowly added at a rate to maintain the temperature below +10°C in order to quench the reaction and to form a 20 (Caution: this reaction is initially homogenous solution. very strongly exothermic). Approximately one-half of the reaction volume (22 L) was transferred by air pump to another vessel, diluted with EtOAc (12 L) and extracted with water (2 The combined water layers were back-extracted with EtOAc (6 L). The water layer was discarded and the organic 25 layers were concentrated in a 20 L rotary evaporator to an The foam was coevaporated with anhydrous acetonitrile (4 L) to remove EtOAc. (note: dioxane may be used instead of anhydrous acetonitrile if dried to a hard 30 foam). The second half of the reaction was treated in the same way. Each residue was dissolved in dioxane (3 L) and concentrated ammonium hydroxide (750 mL) was added. homogenous solution formed in a few minutes and the reaction was allowed to stand overnight (although the reaction is 35 complete within 1 h).

TLC indicated a complete reaction (product $R_{\rm f}$ 0.35 in EtOAc-MeOH 4:1). The reaction solution was concentrated on a

PTS-0012 -61- PATENT

rotary evaporator to a dense foam. Each foam was slowly redissolved in warm EtOAc (4 L; 50°C), combined in a 50 L glass reactor vessel, and extracted with water $(2 \times 4L)$ to remove the triazole by-product. The water was back-extracted with EtOAc (2 L). The organic layers were combined and concentrated to about 8 kg total weight, cooled to 0°C and seeded with crystalline product. After 24 hours, the first crop was collected on a 25 cm Coors Buchner funnel and washed repeatedly with EtOAc (3 x 3L) until a white powder was left and then washed with ethyl ether $(2 \times 3L)$. 10 The solid was put in pans (1" deep) and allowed to air dry overnight. filtrate was concentrated to an oil, then redissolved in EtOAc (2 L), cooled and seeded as before. The second crop was collected and washed as before (with proportional solvents) and the filtrate was first extracted with water (2 15 x 1L) and then concentrated to an oil. The residue was dissolved in EtOAc (1 L) and yielded a third crop which was . treated as above except that more washing was required to remove a yellow oily layer.

20 After air-drying, the three crops were dried in a vacuum oven (50°C, 0.1 mm Hg, 24 h) to a constant weight (1750, 600 and 200 g, respectively) and combined to afford 2550 g (85%) of a white crystalline product (MP 215-217°C) when TLC and NMR spectroscopy indicated purity. The mother liquor still 25 contained mostly product (as determined by TLC) and a small amount of triazole (as determined by NMR spectroscopy), bis DMT product and unidentified minor impurities. If desired, the mother liquor can be purified by silica gel chromatography using a gradient of MeOH (0-25%) in EtOAc to 30 further increase the yield.

Preparation of 5'-O-Dimethoxytrity1-2'-deoxy-N4-benzoy1-5-methylcytidine penultimate intermediate for 5-methyl dC amidite

35 Crystalline 5'-O-dimethoxytrityl-5-methyl-2'deoxycytidine (2000 g, 3.68 mol) was dissolved in anhydrous
DMF (6.0 kg) at ambient temperature in a 50 L glass reactor

PTS-0012 -62- PATENT

vessel equipped with an air stirrer and argon line. anhydride (Chem Impex not Aldrich, 874 g, 3.86 mol, 1.05 eq) was added and the reaction was stirred at ambient temperature for 8 h., TLC (CH₂Cl₂-EtOAc; CH₂Cl₂-EtOAc 4:1; R_e 0.25) indicated approx. 92% complete reaction. An additional amount of benzoic anhydride (44 g, 0.19 mol) was added. After a total of 18 h, TLC indicated approx. 96% reaction completion. The solution was diluted with EtOAc (20 L), TEA (1020 mL, 7.36 mol, ca 2.0 eq) was added with stirring, and the mixture was extracted with water (15 L, then 2 x 10 L). 10 The aqueous layer was removed (no back-extraction was needed) and the organic layer was concentrated in 2 x 20 L rotary evaporator flasks until a foam began to form. The residues were coevaporated with acetonitrile (1.5 L each) and dried 15 (0.1 mm Hg, 25°C, 24 h) to 2520 g of a dense foam. pressure liquid chromatography (HPLC) revealed a contamination of 6.3% of N4, 3'-O-dibenzoyl product, but very little other impurities.

THe product was purified by Biotage column 20 chromatography (5 kg Biotage) prepared with 65:35:1 hexanes-EtOAc-TEA (4L). The crude product (800 g), dissolved in CH2Cl2 (2 L), was applied to the column. The column was washed with the 65:35:1 solvent mixture (20 kg), then 20:80:1 solvent mixture (10 kg), then 99:1 EtOAc:TEA (17kg). The fractions containing the product were collected, and any fractions 25 containing the product and impurities were retained to be resubjected to column chromatography. The column was reequilibrated with the original 65:35:1 solvent mixture (17 A second batch of crude product (840 g) was applied to the column as before. The column was washed with the 30 following solvent gradients: 65:35:1 (9 kg), 55:45:1 (20 kg), 20:80:1 (10 kg), and 99:1 EtOAc:TEA(15 kg). The column was reequilibrated as above, and a third batch of the crude product (850 g) plus impure fractions recycled from the two 35 previous columns (28 g) was purified following the procedure for the second batch. The fractions containing pure product combined and concentrated on a 20L rotary evaporator, coPTS-0012 -63- PATENT

evaporated with acetontirile (3 L) and dried (0.1 mm Hg, 48 h, 25°C) to a constant weight of 2023 g (85%) of white foam and 20 g of slightly contaminated product from the third run. HPLC indicated a purity of 99.8% with the balance as the diBenzoyl product.

[5'-O-(4,4'-Dimethoxytriphenylmethy1)-2'-deoxy-N'-benzoy1-5-methylcytidin-3'-O-y1]-2-cyanoethy1-N,N-diisopropylphosphoramidite (5-methy1 dC amidite)

5'-0-(4,4'-Dimethoxytriphenylmethyl)-2'-deoxy-N'-benzoyl-10 5-methylcytidine (998 g, 1.5 mol) was dissolved in anhydrous DMF (2 L). The solution was co-evaporated with toluene (300 ml) at 50°C under reduced pressure, then cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (680 g, 2.26 mol) and tetrazole (52.5 g, 0.75 mol) were 15 The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (15 ml) was added and the mixture was left at room temperature for 5 hours. TEA (300 ml) was added, the mixture was diluted with DMF (2.5 L) and 20 water (600 ml), and extracted with hexane (3 \times 3 L). mixture was diluted with water (1.2 L) and extracted with a mixture of toluene (7.5 L) and hexane (6 L). The two layers were separated, the upper layer was washed with DMF-water (7:3 v/v, 3 x 2 L) and water (3 x 2 L), and the phases were separated. The organic layer was dried (Na2SO4), filtered and 25 rotary evaporated. The residue was co-evaporated with acetonitrile (2 x 2 L) under reduced pressure and dried to a constant weight (25 °C, 0.1mm Hg, 40 h) to afford 1250 g an off-white foam solid (96%).

2'-Fluoro amidites


5

30

35

2'-Fluorodeoxyadenosine amidites

2'-fluoro oligonucleotides were synthesized as described previously [Kawasaki, et. al., J. Med. Chem., 1993, 36, 831-841] and United States patent 5,670,633, herein incorporated by reference. The preparation of 2'-fluoropyrimidines containing a 5-methyl substitution are described in US Patent



PTS-0012 -64- PATENT

5,861,493. Briefly, the protected nucleoside N6-benzoy1-2'-deoxy-2'-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material and whereby the 2'-alpha-fluoro atom is introduced by a S_N2-displacement of a 2'-beta-triflate group. Thus N6-benzoy1-9-beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP) intermediate. Deprotection of the THP and N6-benzoyl groups was accomplished using standard methodologies to obtain the 5'-dimethoxytrityl-(DMT) and 5'-DMT-3'-phosphoramidite intermediates.

2'-Fluorodeoxyguanosine

The synthesis of 2'-deoxy-2'-fluoroguanosine was 15 accomplished using tetraisopropyldisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and conversion to the intermediate isobutyrylarabinofuranosylguanosine. Alternatively, isobutyrylarabinofuranosylguanosine was prepared as described by Ross 20 et al., (Nucleosides & Nucleosides, 16, 1645, 1997). Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give isobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment of the crude product 25 with fluoride, then deprotection of the THP groups. methodologies were used to obtain the 5'-DMT- and 5'-DMT-3'phosphoramidites.

2'-Fluorouridine

Synthesis of 2'-deoxy-2'-fluorouridine was accomplished by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil was treated with 70% hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

2'-Fluorodeoxycytidine

2'-deoxy-2'-fluorocytidine was synthesized via amination

10

PTS-0012 -65- PATENT

of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

5

10

30

35

2'-0-(2-Methoxyethyl) modified amidites

2'-O-Methoxyethyl-substituted nucleoside amidites (otherwise known as MOE amidites) are prepared as follows, or alternatively, as per the methods of Martin, P., (Helvetica Chimica Acta, 1995, 78, 486-504).

Preparation of 2'-0-(2-methoxyethy1)-5-methyluridine intermediate

2,2'-Anhydro-5-methyl-uridine (2000 g, 8.32 mol), 15 tris(2-methoxyethyl)borate (2504 g, 10.60 mol), sodium bicarbonate (60 g, 0.70 mol) and anhydrous 2-methoxyethanol (5 L) were combined in a 12 L three necked flask and heated to 130 °C (internal temp) at atmospheric pressure, under an argon atmosphere with stirring for 21 h. TLC indicated a complete reaction. The solvent was removed under reduced 20 pressure until a sticky gum formed (50-85°C bath temp and 100-11 mm Hg) and the residue was redissolved in water (3 L) and heated to boiling for 30 min in order the hydrolyze the borate esters. The water was removed under reduced pressure until a foam began to form and then the process was repeated. 25 HPLC indicated about 77% product, 15% dimer (5' of product attached to 2' of starting material) and unknown derivatives, and the balance was a single unresolved early eluting peak.

The gum was redissolved in brine (3 L), and the flask was rinsed with additional brine (3 L). The combined aqueous solutions were extracted with chloroform (20 L) in a heavier-than continuous extractor for 70 h. The chloroform layer was concentrated by rotary evaporation in a 20 L flask to a sticky foam (2400 g). This was coevaporated with MeOH (400 mL) and EtOAc (8 L) at 75°C and 0.65 atm until the foam dissolved at which point the vacuum was lowered to about 0.5 atm. After 2.5 L of distillate was collected a precipitate

PTS-0012 -66- PATENT

began to form and the flask was removed from the rotary evaporator and stirred until the suspension reached ambient temperature. EtOAc (2 L) was added and the slurry was filtered on a 25 cm table top Buchner funnel and the product was washed with EtOAc (3 x 2 L). The bright white solid was air dried in pans for 24 h then further dried in a vacuum oven (50°C, 0.1 mm Hg, 24 h) to afford 1649 g of a white crystalline solid (mp 115.5-116.5°C).

further extracted for 72 h with recycled chloroform. The chloroform was concentrated to 120 g of oil and this was combined with the mother liquor from the above filtration (225 g), dissolved in brine (250 mL) and extracted once with chloroform (250 mL). The brine solution was continuously extracted and the product was crystallized as described above to afford an additional 178 g of crystalline product containing about 2% of thymine. The combined yield was 1827 g (69.4%). HPLC indicated about 99.5% purity with the balance being the dimer.

20

Preparation of 5'-O-DMT-2'-O-(2-methoxyethyl)-5-methyluridine penultimate intermediate

In a 50 L glass-lined steel reactor, 2'-0-(2methoxyethyl)-5-methyl-uridine (MOE-T, 1500 g, 4.738 mol), lutidine (1015 g, 9.476 mol) were dissolved in anhydrous 25 acetonitrile (15 L). The solution was stirred rapidly and chilled to -10°C (internal temperature). Dimethoxytriphenylmethyl chloride (1765.7 g, 5.21 mol) was added as a solid in one portion. The reaction was allowed to 30 warm to -2°C over 1 h. (Note: The reaction was monitored closely by TLC (EtOAc) to determine when to stop the reaction so as to not generate the undesired bis-DMT substituted side The reaction was allowed to warm from -2 to $3^{\circ}C$ over 25 min. then quenched by adding MeOH (300 mL) followed after 10 min by toluene (16 L) and water (16 L). The 35 solution was transferred to a clear 50 L vessel with a bottom outlet, vigorously stirred for 1 minute, and the layers

PTS-0012 -67- PATENT

separated. The aqueous layer was removed and the organic layer was washed successively with 10% aqueous citric acid (8 L) and water (12 L). The product was then extracted into the aqueous phase by washing the toluene solution with aqueous sodium hydroxide (0.5N, 16 L and 8 L). The combined aqueous layer was overlayed with toluene (12 L) and solid citric acid (8 moles, 1270 g) was added with vigorous stirring to lower the pH of the aqueous layer to 5.5 and extract the product into the toluene. The organic layer was washed with water (10 L) and TLC of the organic layer indicated a trace of DMT-O-Me, bis DMT and dimer DMT.

10

The toluene solution was applied to a silica gel column (6 L sintered glass funnel containing approx. 2 kg of silica gel slurried with toluene (2 L) and TEA(25 mL)) and the 15 fractions were eluted with toluene (12 L) and EtOAc (3 \times 4 L) using vacuum applied to a filter flask placed below the The first EtOAc fraction containing both the desired product and impurities were resubjected to column chromatography as above. The clean fractions were combined, 20 rotary evaporated to a foam, coevaporated with acetonitrile (6 L) and dried in a vacuum oven (0.1 mm Hg, 40 h, 40°C) to afford 2850 g of a white crisp foam. NMR spectroscopy indicated a 0.25 mole % remainder of acetonitrile (calculates to be approx. 47 g) to give a true dry weight of 2803 g 25 (96%). HPLC indicated that the product was 99.41% pure, with the remainder being 0.06 DMT-O-Me, 0.10 unknown, 0.44 bis DMT, and no detectable dimer DMT or 3'-O-DMT.

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-5-methyluridine (1237 g, 2.0 mol) was dissolved in anhydrous DMF (2.5 L). The solution was co-evaporated with toluene (200 ml) at 50°C under reduced pressure, then cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (900 g, 3.0 mol) and

PTS-0012 -68- PATENT

tetrazole (70 g, 1.0 mol) were added. The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (20 ml) was added and the solution was left at room temperature for 5 hours. TEA (300 ml) was added, the mixture was diluted with DMF (3.5 L) and water (600 ml) and extracted with hexane (3 x 3L). The mixture was diluted with water (1.6 L) and extracted with the mixture of toluene (12 L) and hexanes (9 L). The upper layer was washed with DMF-water (7:3 v/v, 3x3 L) and water (3x3 L). The organic layer was dried (Na₂SO₄), filtered and evaporated. The residue was co-evaporated with acetonitrile (2 x 2 L) under reduced pressure and dried in a vacuum oven (25°C, 0.1mm Hg, 40 h) to afford 1526 g of an off-white foamy solid (95%).

15 Preparation of 5'-O-Dimethoxytrity1-2'-O-(2-methoxyethy1)-5-methylcytidine intermediate

10

To a 50 L Schott glass-lined steel reactor equipped with an electric stirrer, reagent addition pump (connected to an addition funnel), heating/cooling system, internal thermometer and argon gas line was added 5'-0-20 dimethoxytrity1-2'-0-(2-methoxyethy1)-5-methyl-uridine (2.616 kg, 4.23 mol, purified by base extraction only and no scrub column), anhydrous acetonitrile (20 L), and TEA (9.5 L, 67.7 mol, 16 eq). The mixture was chilled with stirring to -10°C internal temperature (external -20°C). 25 Trimethylsilylchloride (1.60 L, 12.7 mol, 3.0 eq) was added over 30 min. while maintaining the internal temperature below -5°C, followed by a wash of anhydrous acetonitrile (1 L). (Note: the reaction is mildly exothermic and copious hydrochloric acid fumes form over the course of the 30 addition). The reaction was allowed to warm to 0°C and the reaction progress was confirmed by TLC (EtOAc, R, 0.68 and 0.87 for starting material and silyl product, respectively). Upon completion, triazole (2.34 kg, 33.8 mol, 8.0 eq) was added the reaction was cooled to -20°C internal temperature

35 added the reaction was cooled to -20°C internal temperature (external -30°C). Phosphorous oxychloride (793 mL, 8.51 mol, 2.01 eq) was added slowly over 60 min so as to maintain the

PTS-0012 -69- PATENT

temperature between -20°C and -10°C (note: strongly exothermic), followed by a wash of anhydrous acetonitrile (1 L). The reaction was warmed to 0°C and stirred for 1 h, at which point it was an off-white thick suspension. indicated a complete conversion to the triazole product (EtOAc, R, 0.87 to 0.75 with the product spot glowing in long wavelength UV light). The reaction was cooled to -15°C water (5 L) was slowly added at a rate to maintain the temperature below +10°C in order to quench the reaction and 10 to form a homogenous solution. (Caution: this reaction is initially very strongly exothermic). Approximately one-half of the reaction volume (22 L) was transferred by air pump to another vessel, diluted with EtOAc (12 L) and extracted with water $(2 \times 8 L)$. The second half of the reaction was treated 15 'in the same way. The combined aqueous layers were backextracted with EtOAc (8 L) The organic layers were combined and concentrated in a 20 L rotary evaporator to an oily foam. The foam was coevaporated with anhydrous acetonitrile (4 L) to remove EtOAc. (note: dioxane may be used instead of anhydrous acetonitrile if dried to a hard foam). . 20 was dissolved in dioxane (2 L) and concentrated ammonium hydroxide (750 mL) was added. A homogenous solution formed in a few minutes and the reaction was allowed to stand overnight

25 TLC indicated a complete reaction (CH2Cl2-acetone-MeOH, 20:5:3, R, 0.51). The reaction solution was concentrated on a rotary evaporator to a dense foam and slowly redissolved in warm CH,Cl, (4 L, 40°C) and transferred to a 20 L glass extraction vessel equipped with a air-powered stirrer. 30 organic layer was extracted with water (2 \times 6 L) to remove the triazole by-product. (Note: In the first extraction an emulsion formed which took about 2 h to resolve). layer was back-extracted with CH2Cl, (2 x 2 L), which in turn was washed with water (3 L). The combined organic layer was 35 concentrated in 2 x 20 L flasks to a gum and then recrystallized from EtOAc seeded with crystalline product. After sitting overnight, the first crop was collected on a 25

PTS-0012 -70- PATENT

cm Coors Buchner funnel and washed repeatedly with EtOAc until a white free-flowing powder was left (about 3 x 3 L). The filtrate was concentrated to an oil recrystallized from EtOAc, and collected as above. The solid was air-dried in pans for 48 h, then further dried in a vacuum oven (50°C, 0.1mm Hg, 17 h) to afford 2248 g of a bright white, dense solid (86%). An HPLC analysis indicated both crops to be 99.4% pure and NMR spectroscopy indicated only a faint trace of EtOAc remained.

10

Preparation of 5'-O-dimethoxytrity1-2'-O-(2-methoxyethy1)-N4-benzoy1-5-methy1-cytidine penultimate intermediate:

Crystalline 5'-0-dimethoxytrityl-2'-0-(2-methoxyethyl)-5-methyl-cytidine (1000 g, 1.62 mol) was suspended in 15 anhydrous DMF (3.kg) at ambient temperature and stirred under an Ar atmosphere. Benzoic anhydride (439.3 g, 1.94 mol) was added in one portion. The solution clarified after 5 hours and was stirred for 16 h. HPLC indicated 0.45% starting material remained (as well as 0.32% N4, 3'-O-bis Benzoyl). An additional amount of benzoic anhydride (6.0 g, 0.0265 mol) 20 was added and after 17 h, HPLC indicated no starting material TEA (450 mL, 3.24 mol) and toluene (6 L) were added with stirring for 1 minute. The solution was washed with water (4 x 4 L), and brine (2 x 4 L). The organic layer was partially evaporated on a 20 L rotary evaporator to 25 remove 4 L of toluene and traces of water. HPLC indicated that the bis benzoyl side product was present as a 6% impurity. The residue was diluted with toluene (7 L) and anhydrous DMSO (200 mL, 2.82 mol) and sodium hydride (60% in oil, 70 g, 1.75 mol) was added in one portion with stirring 30 at ambient temperature over 1 h. The reaction was quenched by slowly adding then washing with aqueous citric acid (10%, 100 mL over 10 min, then 2 x 4 L), followed by aqueous sodium bicarbonate (2%, 2 L), water (2 x 4 L) and brine (4 L). organic layer was concentrated on a 20 L rotary evaporator to 35 about 2 L total volume. The residue was purified by silica gel column chromatography (6 L Buchner funnel containing 1.5

PTS-0012 -71- PATENT

kg of silica gel wetted with a solution of EtOAc-hexanes-TEA(70:29:1)). The product was eluted with the same solvent (30 L) followed by straight EtOAc (6 L). The fractions containing the product were combined, concentrated on a rotary evaporator to a foam and then dried in a vacuum oven (50°C, 0.2 mm Hg, 8 h) to afford 1155 g of a crisp, white foam (98%). HPLC indicated a purity of >99.7%.

Preparation of [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'
O-(2-methoxyethyl)-N'-benzoyl-5-methylcytidin-3'-O-yl]-2
cyanoethyl-N,N-diisopropylphosphoramidite (MOE 5-Me-C

amidite)

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2methoxyethyl)-N⁴-benzoyl-5-methylcytidine (1082 g, 1.5 mol) 15 was dissolved in anhydrous DMF (2 L) and co-evaporated with toluene (300 ml) at 50 °C under reduced pressure. The mixture was cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (680 g, 2.26 mol) and tetrazole (52.5 g, 0.75 mol) were added. The mixture was 20 shaken until all tetrazole was dissolved, N-methylimidazole (30 ml) was added, and the mixture was left at room temperature for 5 hours. TEA (300 ml) was added, the mixture was diluted with DMF (1 L) and water (400 ml) and extracted with hexane $(3 \times 3 L)$. The mixture was diluted with water 25 (1.2 L) and extracted with a mixture of toluene (9 L) and hexanes (6 L). The two layers were separated and the upper layer was washed with DMF-water (60:40 v/v, 3 x 3 L) and water (3 x 2 L). The organic layer was dried (Na_2SO_4) , filtered and evaporated. The residue was co-evaporated with 30 acetonitrile (2 x 2 L) under reduced pressure and dried in a vacuum oven (25 °C, 0.1mm Hg, 40 h) to afford 1336 g of an off-white foam (97%).

Preparation of $[5'-O-(4,4'-Dimethoxytriphenylmethy1)-2'-O-(2-methoxyethy1)-N^6-benzoyladenosin-3'-O-y1]-2-cyanoethy1-N,N-diisopropylphosphoramidite (MOE A amdite)$

 $5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N^6-benzoyladenosine (purchased from Reliable$

35

PTS-0012 -72- PATENT

Biopharmaceutical, St. Lois, MO), 1098 g, 1.5 mol) was dissolved in anhydrous DMF (3 L) and co-evaporated with toluene (300 ml) at 50 °C. The mixture was cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (680 g, 2.26 mol) and tetrazole (78.8 g, 1.24 mol) were added. The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (30 ml) was added, and mixture was left at room temperature for 5 hours. TEA (300 ml) was added, the mixture was diluted with DMF (1 L) and water (400 10 ml) and extracted with hexanes $(3 \times 3 L)$. The mixture was diluted with water (1.4 L) and extracted with the mixture of toluene (9 L) and hexanes (6 L). The two layers were separated and the upper layer was washed with DMF-water (60:40, v/v, 3 x 3 L) and water (3 x 2 L). The organic layer 15 was dried (Na2SO4), filtered and evaporated to a sticky foam. The residue was co-evaporated with acetonitrile (2.5 L) under reduced pressure and dried in a vacuum oven (25 °C, 0.1mm Hg, 40 h) to afford 1350 g of an off-white foam solid (96%).

Prepartion of [5'-0-(4,4'-Dimethoxytriphenylmethyl)-2'-0-(2-methoxyethyl)-N'-isobutyrylguanosin-3'-0-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE G amidite)

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2methoxyethyl)-N'-isobutyrlguanosine (purchased from Reliable Biopharmaceutical, St. Louis, MO, 1426 g, 2.0 mol) was 25 dissolved in anhydrous DMF (2 L). The solution was coevaporated with toluene (200 ml) at 50 °C, cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (900 g, 3.0 mol) and tetrazole (68 g, 0.97 mol) were added. 30 The mixture was shaken until all tetrazole was dissolved, Nmethylimidazole (30 ml) was added, and the mixture was left at room temperature for 5 hours. TEA (300 ml) was added, the mixture was diluted with DMF (2 L) and water (600 ml) and extracted with hexanes $(3 \times 3 L)$. The mixture was diluted with water (2 L) and extracted with a mixture of toluene (10 L) and hexanes (5 L). The two layers were separated and the upper layer was washed with DMF-water (60:40, v/v, 3x3 L).

PTS-0012 -73- PATENT

EtOAc (4 L) was added and the solution was washed with water (3 x 4 L). The organic layer was dried (Na_2SO_4), filtered and evaporated to approx. 4 kg. Hexane (4 L) was added, the mixture was shaken for 10 min, and the supernatant liquid was decanted. The residue was co-evaporated with acetonitrile (2 x 2 L) under reduced pressure and dried in a vacuum oven (25 °C, 0.1mm Hg, 40 h) to afford 1660 g of an off-white foamy solid (91%).

2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminooxyethyl) nucleoside amidites

.10

15

20

2'-(Dimethylaminooxyethoxy) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites (also known in the art as 2'-O-(dimethylaminooxyethyl) nucleoside amidites) are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine.

5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine

O²-2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, 25 Italy, 100.0g, 0.416 mmol), dimethylaminopyridine (0.66g, 0.013eq, 0.0054mmol) were dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. tert-Butyldiphenylchlorosilane (125.8g, 119.0mL, 1.1eq, 0.458mmol) was added in one portion. 30 reaction was stirred for 16 h at ambient temperature. 0.22, EtOAc) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. partitioned between CH,Cl, (1 L) and saturated sodium bicarbonate (2 x 1 L) and brine (1 L). The organic layer was 35 dried over sodium sulfate, filtered, and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of EtOAc and ethyl ether (600mL) and cooling the

PTS-0012 -74- PATENT

solution to -10° C afforded a white crystalline solid which was collected by filtration, washed with ethyl ether (3 x2 00 mL) and dried (40°C, 1mm Hg, 24 h) to afford 149g of white solid (74.8%). TLC and NMR spectroscopy were consistent with pure product.

5

35

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine

In the fume hood, ethylene glycol (350 mL, excess) was 10 added cautiously with manual stirring to a 2 L stainless steel pressure reactor containing borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). (Caution: evolves hydrogen gas). 5'-O-tert-Butyldiphenylsilyl-O2-2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and 15 heated in an oil bath until an internal temperature of 160 °C was reached and then maintained for 16 h (pressure < 100 The reaction vessel was cooled to ambient temperature TLC (EtOAc, R_f 0.67 for desired product and R_f 0.82 for ara-T side product) indicated about 70% conversion 20 to the product. The solution was concentrated under reduced pressure (10 to 1mm Hg) in a warm water bath (40-100°C) with the more extreme conditions used to remove the ethylene (Alternatively, once the THF has evaporated the 25 solution can be diluted with water and the product extracted into EtOAc). The residue was purified by column chromatography (2kg silica gel, EtOAc-hexanes gradient 1:1 to The appropriate fractions were combined, evaporated and dried to afford 84 g of a white crisp foam (50%), 30 contaminated starting material (17.4g, 12% recovery) and pure reusable starting material (20g, 13% recovery). TLC and NMR spectroscopy were consistent with 99% pure product.

2'-O-([2-phthalimidoxy)ethy1]-5'-t-butyldiphenylsily1-5-methyluridine

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine (20g, 36.98mmol) was mixed with

PTS-0012 -75- PATENT

triphenylphosphine (11.63g, 44.36mmol) and Nhydroxyphthalimide (7.24g, 44.36mmol) and dried over P_2O_5 . under high vacuum for two days at 40°C. The reaction mixture was flushed with argon and dissolved in dry THF (369.8mL, Aldrich, sure seal bottle). Diethyl-azodicarboxylate (6.98mL, 44.36mmol) was added dropwise to the reaction mixture with the rate of addition maintained such that the resulting deep red coloration is just discharged before adding the next drop. The reaction mixture was stirred for 4 hrs., after which time TLC (EtOAc:hexane, 60:40) indicated 10 that the reaction was complete. The solvent was evaporated in vacuuo and the residue purified by flash column chromatography (eluted with 60:40 EtOAc:hexane), to yield 2'-O-([2-phthalimidoxy)ethy1]-5'-t-butyldiphenylsilyl-5methyluridine as white foam (21.819 g, 86%) upon rotary 15 evaporation.

5'-0-tert-butyldiphenylsily1-2'-0-[(2-formadoximinooxy)ethyl]-5-methyluridine

2'-0-([2-phthalimidoxy)ethy1]-5'-t-butyldiphenylsilyl-5-20 methyluridine (3.1g, 4.5mmol) was dissolved in dry CH₂Cl₂ (4.5mL) and methylhydrazine (300mL, 4.64mmol) was added dropwise at -10°C to 0°C . After 1 h the mixture was filtered, the filtrate washed with ice cold CH,Cl2, and the combined organic phase was washed with water and brine and dried 25 (anhydrous Na_2SO_4). The solution was filtered and evaporated to afford 2'-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5mL). Formaldehyde (20% aqueous solution, w/w, 1.1 eq.) was added and the resulting mixture was stirred for 1 h. The solvent was removed under vacuum 30 and the residue was purified by column chromatography to yield 5'-0-tert-butyldiphenylsily1-2'-0-[(2-formadoximinooxy) ethyl]-5-methyluridine as white foam (1.95 g, 78%) upon rotary evaporation. 35 .

5'-0-tert-Butyldiphenylsilyl-2'-0-[N,N dimethylaminooxyethyl]-5-methyluridine

PTS-0012

25

30

-76-

PATENT

5'-0-tert-butyldiphenylsilyl-2'-0-[(2formadoximinooxy)ethyl]-5-methyluridine (1.77g, 3.12mmol) was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6mL) and cooled to 10°C under inert Sodium cyanoborohydride (0.39g, 6.13mmol) was atmosphere. added and the reaction mixture was stirred. After 10 minutes the reaction was warmed to room temperature and stirred for 2 h. while the progress of the reaction was monitored by TLC (5% MeOH in CH₂Cl₂). Aqueous NaHCO, solution (5%, 10mL) was added and the product was extracted with EtOAc (2 \times 20 mL). 10 The organic phase was dried over anhydrous Na2SO4, filtered, and evaporated to dryness. This entire procedure was repeated with the resulting residue, with the exception that formaldehyde (20% w/w, 30 mL, 3.37 mol) was added upon 15 dissolution of the residue in the PPTS/MeOH solution. After the extraction and evaporation, the residue was purified by flash column chromatography and (eluted with 5% MeOH in CH,Cl,) to afford 5'-0-tert-butyldiphenylsilyl-2'-0-[N,Ndimethylaminooxyethyl]-5-methyluridine as a white foam 20 (14.6g, 80%) upon rotary evaporation.

2'-0-(dimethylaminooxyethyl)-5-methyluridine

Triethylamine trihydrofluoride (3.91mL, 24.0mmol) was dissolved in dry THF and TEA (1.67mL, 12mmol, dry, stored over KOH) and added to 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine (1.40g, 2.4mmol). The reaction was stirred at room temperature for 24 hrs and monitored by TLC (5% MeOH in CH₂Cl₂). The solvent was removed under vacuum and the residue purified by flash column chromatography (eluted with 10% MeOH in CH₂Cl₂) to afford 2'-O-(dimethylaminooxyethyl)-5-methyluridine (766mg, 92.5%) upon rotary evaporation of the solvent.

5'-O-DMT-2'-O-(dimethylaminooxyethyl)-5-methyluridine

2'-0-(dimethylaminooxyethyl)-5-methyluridine (750 mg, 2.17 mmol) was dried over P_2O_5 under high vacuum overnight at 40°C, co-evaporated with anhydrous pyridine (20 mL), and

PTS-0012 -77- PATENT

dissolved in pyridine (11 mL) under argon atmosphere. 4-dimethylaminopyridine (26.5 mg, 2.60 mmol) and 4,4'-dimethoxytrityl chloride (880 mg, 2.60 mmol) were added to the pyridine solution and the reaction mixture was stirred at room temperature until all of the starting material had reacted. Pyridine was removed under vacuum and the residue was purified by column chromatography (eluted with 10% MeOH in CH₂Cl₂ containing a few drops of pyridine) to yield 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13g, 80%) upon rotary evaporation.

5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite)

10

- 15 5'-0-DMT-2'-0-(dimethylaminooxyethyl)-5-methyluridine (1.08 g, 1.67 mmol) was co-evaporated with toluene (20 mL), N,N-diisopropylamine tetrazonide (0.29 g, 1.67 mmol) was added and the mixture was dried over P2O5 under high vacuum overnight at 40°C. This was dissolved in anhydrous 20 acetonitrile (8.4 mL) and 2-cyanoethyl-N,N, N^1 , N^1 tetraisopropylphosphoramidite (2.12 mL, 6.08 mmol) was added. The reaction mixture was stirred at ambient temperature for 4 h under inert atmosphere. The progress of the reaction was monitored by TLC (hexane: EtOAc 1:1). The solvent was 25 evaporated, then the residue was dissolved in EtOAc (70mL) and washed with 5% aqueous NaHCO, (40mL). The EtOAc layer was dried over anhydrous Na,SO, filtered, and concentrated. residue obtained was purified by column chromatography (EtOAc as eluent) to afford 5'-O-DMT-2'-O-(2-N,N-30 dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N, N-diisopropylphosphoramidite] as a foam (1.04g, 74.9%) upon
 - 2'-(Aminooxyethoxy) nucleoside amidites

rotary evaporation.

2'-(Aminooxyethoxy) nucleoside amidites (also known in the art as 2'-O-(aminooxyethyl) nucleoside amidites) are prepared as described in the following paragraphs. Adenosine, PTS-0012 -78- PATENT

cytidine and thymidine nucleoside amidites are prepared similarly.

5

30

35

N2-isobutyry1-6-0-diphenylcarbamoy1-2'-0-(2-ethylacety1)-5'-0-(4,4'-dimethoxytrity1)guanosine-3'-[(2-cyanoethy1)-N,N-diisopropylphosphoramidite]

The 2'-O-aminooxyethyl guanosine analog may be obtained by selective 2'-O-alkylation of diaminopurine riboside. Multigram quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2'-0-(2-10 ethylacetyl) diaminopurine riboside along with a minor amount of the 3'-O-isomer. 2'-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2'-0-(2ethylacetyl) guanosine by treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinosso, C. J., WO 94/02501 15 940203.) Standard protection procedures should afford 2'-0-(2-ethylacetyl)-5'-0-(4,4'-dimethoxytrityl)guanosine and 2-N-isobutyryl-6-0-diphenylcarbamoyl-2'-0-(2-ethylacetyl)-5'-0-(4,4'-dimethoxytrityl) guanosine which may be reduced to provide 2-N-isobutyryl-6-0-diphenylcarbamoyl-2'-0-(2-20 hydroxyethyl)-5'-0-(4,4'-dimethoxytrityl)guanosine. As before the hydroxyl group may be displaced by N-hydroxyphthalimide via a Mitsunobu reaction, and the protected nucleoside may be phosphitylated as usual to yield 2-N-isobutyryl-6-0diphenylcarbamoy1-2'-O-([2-phthalmidoxy]ethyl)-5'-O-(4,4'-25 dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,Ndiisopropylphosphoramidite].

2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside amidites

2'-dimethylaminoethoxyethoxy nucleoside amidites (also known in the art as 2'-O-dimethylaminoethoxyethyl, i.e., 2'-O-CH₂-O-CH₂-N(CH₂)₂, or 2'-DMAEOE nucleoside amidites) are prepared as follows. Other nucleoside amidites are prepared similarly.

2'-0-[2(2-N, N-dimethylaminoethoxy)ethyl]-5-methyl uridine

PTS-0012 -79- PATENT

2[2-(Dimethylamino)ethoxy]ethanol (Aldrich, 6.66 g, 50 mmol) was slowly added to a solution of borane in tetrahydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL (Caution: Hydrogen gas evolves as the solid dissolves). 0^2 -, 2'-anhydro-5-methyluridine (1.2 g, 5 mmol), and sodium bicarbonate (2.5 mg) were added and the bomb was sealed, placed in an oil bath and heated to 155°C for 26 h. then cooled to room temperature. The crude solution was concentrated, the residue was diluted with water (200 mL) and extracted with hexanes (200 mL). The product was extracted from the aqueous layer with EtOAc (3 \times 200 mL) and the combined organic layers were washed once with water, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (eluted with 5:100:2 MeOH/CH,Cl,/TEA) as the eluent. appropriate fractions were combined and evaporated to afford the product as a white solid.

·5

10

15

20

25

30

35

and the second

5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy) ethyl)]-5-methyl uridine

To 0.5 g (1.3 mmol) of 2'-O-[2(2-N,N-dimethylamino-ethoxy)ethyl)]-5-methyl uridine in anhydrous pyridine (8 mL), was added TEA (0.36 mL) and dimethoxytrityl chloride (DMT-Cl, 0.87 g, 2 eq.) and the reaction was stirred for 1 h. The reaction mixture was poured into water (200 mL) and extracted with CH₂Cl₂ (2 x 200 mL). The combined CH₂Cl₂ layers were washed with saturated NaHCO₃ solution, followed by saturated NaCl solution, dried over anhydrous sodium sulfate, filtered and evaporated. The residue was purified by silica gel column chromatography (eluted with 5:100:1 MeOH/CH₂Cl₂/TEA) to afford the product.

5'-O-Dimethoxytrity1-2'-O-[2(2-N,N-dimethylaminoethoxy)-ethyl)]-5-methyl uridine-3'-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite

Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxy-N,N-diisopropyl phosphoramidite (1.1 mL, 2 eq.) were added to PTS-0012 -80- PATENT

a solution of 5'-O-dimethoxytrity1-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl)]-5-methyluridine (2.17 g, 3 mmol) dissolved in CH₂Cl₂ (20 mL) under an atmosphere of argon. The reaction mixture was stirred overnight and the solvent evaporated. The resulting residue was purified by silica gel column chromatography with EtOAc as the eluent to afford the title compound.

Example 2

· 15

30

10 Oligonucleotide synthesis

Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 394) using standard phosphoramidite chemistry with oxidation by iodine.

Phosphorothicates (P=S) are synthesized similar to phosphodiester oligonucleotides with the following exceptions: thiation was effected by utilizing a 10% w/v solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the oxidation of the phosphite linkages.

The thiation reaction step time was increased to 180 sec and preceded by the normal capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55°C (12-16 hr), the oligonucleotides were recovered by precipitating with >3 volumes of ethanol from a 1 M NH₄oAc solution. Phosphinate oligonucleotides are prepared as described in U.S. Patent 5,508,270, herein incorporated by reference.

Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by reference.

3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or 5,625,050, herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as

described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878,
herein incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared as

PTS-0012 -81- PATENT

described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein incorporated by reference.

Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

Example 3

5

15 Oligonucleoside Synthesis

Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Patents 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.

Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated by reference.

35 **Example 4**

30

PNA Synthesis

Peptide nucleic acids (PNAs) are prepared in accordance

PTS-0012 -82- PATENT

with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, Bioorganic & Medicinal Chemistry, 1996, 4, 5-23. They may also be prepared in accordance with U.S. Patents 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

Example 5

Synthesis of Chimeric Oligonucleotides

Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap" segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers".

[2'-O-Me]--[2'-deoxy]--[2'-O-Me] Chimeric Phosphorothioate Oligonucleotides

Chimeric oligonucleotides having 2'-0-alkyl phosphorothicate and 2'-deoxy phosphorothicate oligo-25 nucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 394, as above. Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytrity1-3'-0-phosphoramidite for the DNA portion and 5'-dimethoxytrity1-2'-0-30 methyl-3'-0-phosphoramidite for 5' and 3' wings. standard synthesis cycle is modified by incorporating coupling steps with increased reaction times for the 5'dimethoxytrityl-2'-0-methyl-3'-0-phosphoramidite. The fully protected oligonucleotide is cleaved from the support and 35 deprotected in concentrated ammonia (NH,OH) for 12-16 hr at 55°C. The deprotected oligo is then recovered by an appropriate method (precipitation, column chromatography,

PTS-0012 -83- PATENT

volume reduced *in vacuo* and analyzed spetrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

[2'-0-(2-Methoxyethy1)]--[2'-deoxy]--[2'-0-(Methoxyethy1)] Chimeric Phosphorothioate Oligonucleotides

[2'-0-(2-methoxyethyl)]--[2'-deoxy]--[-2'-0-(methoxyethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2'-0-methyl chimeric oligonucleotide, with the substitution of 2'-0-(methoxyethyl) amidites for the 2'-0-methyl amidites.

[2'-0-(2-Methoxyethyl)Phosphodiester]--[2'-deoxy Phosphorothioate]--[2'-0-(2-Methoxyethyl) Phosphodiester] Chimeric Oligonucleotides

[2'-O-(2-methoxyethyl phosphodiester]--[2'-deoxy phosphorothicate]--[2'-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2'-O-methyl chimeric oligonucleotide with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidation with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3,H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) to generate the phosphorothicate internucleotide linkages for the center gap.

Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric

30 oligonucleotides/oligonucleosides are synthesized according to United States patent 5,623,065, herein incorporated by reference.

Example 6

10

15

20

25

35 Oligonucleotide Isolation

After cleavage from the controlled pore glass solid support and deblocking in concentrated ammonium hydroxide at

PTS-0012 -84- PATENT

55°C for 12-16 hours, the oligonucleotides or oligonucleosides are recovered by precipitation out of 1 M NH₄OAc with >3 volumes of ethanol. Synthesized oligonucleotides were analyzed by electrospray mass spectroscopy (molecular weight determination) and by capillary gel electrophoresis and judged to be at least 70% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in the synthesis was determined by the ratio of correct molecular weight relative to the -16 amu product (+/-32 +/-48). For some studies oligonucleotides were purified by HPLC, as described by Chiang et al., J. Biol. Chem. 1991, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

15

20

25

30

35

20.00

10

5

Example 7

Oligonucleotide Synthesis - 96 Well Plate Format

Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a 96-well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyl-diiso-propyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per standard or patented methods. They are utilized as base protected beta-cyanoethyldiisopropyl phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated NH₄OH at elevated temperature (55-60°C) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and

PTS-0012 -85- PATENT

test plate samples are then diluted utilizing robotic pipettors.

Example 8

5 Oligonucleotide Analysis - 96-Well Plate Format

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96-well format (Beckman P/ACETM MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACETM 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

20 Example 9

10

15

Cell culture and oligonucleotide treatment

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at

25 measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily

30 determined by methods routine in the art, for example Northern blot analysis, ribonuclease protection assays, or RT-PCR.

T-24 cells:

The human transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in

PTS-0012 -86- PATENT

complete McCoy's 5A basal media (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal calf serum (Invitrogen Corporation, Carlsbad, CA), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, CA). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 cells:

10

- The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal calf serum (Invitrogen Corporation, Carlsbad, CA),
- penicillin 100 units per mL, and streptomycin 100 micrograms
 per mL (Invitrogen Corporation, Carlsbad, CA). Cells were
 routinely passaged by trypsinization and dilution when they
 reached 90% confluence.

25 NHDF cells:

30

Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville, MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville, MD) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

HEK cells:

Human embryonic keratinocytes (HEK) were obtained from
the Clonetics Corporation (Walkersville, MD). HEKs were
routinely maintained in Keratinocyte Growth Medium (Clonetics
Corporation, Walkersville, MD) formulated as recommended by

PTS-0012 -87- PATENT

the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

Treatment with antisense compounds:

5

10

When cells reached 70% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 100 μL OPTI-MEMTM-1 reduced-serum medium (Invitrogen Corporation, Carlsbad, CA) and then treated with 130 μL of OPTI-MEMTM-1 containing 3.75 μg/mL LIPOFECTINTM (Invitrogen Corporation, Carlsbad, CA) and the desired concentration of oligonucleotide. After 4-7 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal 15 oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations. For human cells the positive control oligonucleotide is selected from either ISIS 13920 20 (TCCGTCATCGCTCCTCAGGG, SEQ ID NO: 1) which is targeted to human H-ras, or ISIS 18078, (GTGCGCGCGAGCCCGAAATC, SEQ ID NO: which is targeted to human Jun-N-terminal kinase-2 (JNK2). Both controls are 2'-O-methoxyethyl gapmers (2'-Omethoxyethyls shown in bold) with a phosphorothicate 25 backbone. For mouse or raticells the positive control oligonucleotide is ISIS 15770, ATGCATTCTGCCCCCAAGGA, SEQ ID NO: 3, a 2'-0-methoxyethyl gapmer (2'-0-methoxyethyls shown in bold) with a phosphorothicate backbone which is targeted to both mouse and rat c-raf. The concentration of positive control oligonucleotide that results in 80% inhibition of c-Ha-ras (for ISIS 13920) or c-raf (for ISIS 15770) mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell If 80% inhibition is not achieved, the lowest 35 concentration of positive control oligonucleotide that results in 60% inhibition of H-ras or c-raf mRNA is then utilized as the oligonucleotide screening concentration in

PTS-0012 -88- PATENT

subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection experiments.

5 Example 10

10

15

20

25

Analysis of oligonucleotide inhibition of SMRT expression

Antisense modulation of SMRT expression can be assayed in a variety of ways known in the art. For example, SMRT mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. The preferred method of RNA analysis of the present invention is the use of total cellular RNA as described in other examples herein. Methods of RNA isolation are taught in, for example, Ausubel, F.M. et al., Current Protocols in Molecular Biology, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F.M. et al., Current Protocols in Molecular Biology, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM TM 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to

Protein levels of SMRT can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or

fluorescence-activated cell sorting (FACS). Antibodies directed to SMRT can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional antibody generation methods. Methods for

manufacturer's instructions.

preparation of polyclonal antisera are taught in, for example, Ausubel, F.M. et al., (Current Protocols in Molecular Biology, Volume 2, pp. 11.12.1-11.12.9, John Wiley

PTS-0012 -89- PATENT

& Sons, Inc., 1997). Preparation of monoclonal antibodies is taught in, for example, Ausubel, F.M. et al., (Current Protocols in Molecular Biology, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997).

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al., (Current Protocols in Molecular Biology, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998). Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F.M. et al., (Current Protocols in Molecular Biology, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997). Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F.M. et al., (Current Protocols in Molecular Biology, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991).

Example 11

Poly(A) + mRNA isolation

20 Poly(A) + mRNA was isolated according to Miura et al., (Clin. Chem., 1996, 42, 1758-1764). Other methods for poly(A) + mRNA isolation are taught in, for example, Ausubel, F.M. et al., (Current Protocols in Molecular Biology, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993). Briefly, for cells grown on 96-well plates, growth medium was removed 25 from the cells and each well was washed with 200 µL cold PBS. 60 μ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55 μL of 30 lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200 μL of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to 35 remove excess wash buffer and then air-dried for 5 minutes.

PTS-0012 -90- PATENT

60 μ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C, was added to each well, the plate was incubated on a 90°C hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.

Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

Example 12

5

15

20

25

30

10 Total RNA Isolation

Total RNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia, CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μL cold PBS. 150 μ L Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 150 µL of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96^{TM} well plate attached to a QIAVACTM manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 1 minute. 500 µL of Buffer RW1 was added to each well of the RNEASY 96™ plate and incubated for 15 minutes and the vacuum was again applied for 1 minute. additional 500 µL of Buffer RW1 was added to each well of the RNEASY 96^{TM} plate and the vacuum was applied for 2 minutes. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 90 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 3 minutes. The plate was then removed from the QIAVAC TM manifold and blotted dry on paper The plate was then re-attached to the OIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 170 μL

PTS-0012 -91- PATENT

water into each well, incubating 1 minute, and then applying the vacuum for 3 minutes.

The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially, after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are carried out.

10

. 5

Example 13

Real-time Quantitative PCR Analysis of SMRT mRNA Levels

Ouantitation of SMRT mRNA levels was determined by realtime quantitative PCR using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closedtube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR in which amplification products are quantitated after the 20 PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye 25 (e.g., FAM or JOE, obtained from either PE-Applied Biosystems, Foster City, CA, Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA) is attached to the 5' end of the probe and a quencher dye (e.g., TAMRA, obtained from either PE-Applied Biosystems, 30 Foster City, CA, Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the 35 probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase.

-92-PTS-0012 PATENT

During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dve from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be "multiplexed" with a GAPDH amplification reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is 20 amplified in the presence of primer-probe sets specific for GAPDH only, target gene only ("single-plexing"), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed 25 If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed multiplexable. Other 30 methods of PCR are also known in the art.

PCR reagents were obtained from Invitrogen Corporation, (Carlsbad, CA). RT-PCR reactions were carried out by adding 20 µL PCR cocktail (2.5x PCR buffer (-MgCl2), 6.6 mM MgCl2, 375 µM each of dATP, dCTP, dCTP and dGTP, 375 nM each of forward primer and reverse primer, 125 nM of probe, 4 Units

RNAse inhibitor, 1.25 Units PLATINUM® Taq, 5 Units MuLV

5

10

15

35

PTS-0012 -93- PATENT

reverse transcriptase, and 2.5x ROX dye) to 96-well plates containing 30 µL total RNA solution. The RT reaction was carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the PLATINUM® Taq, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension).

Gene target quantities obtained by real time RT-PCR are normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using RiboGreenTM (Molecular Probes, Inc. Eugene, OR). GAPDH expression is quantified by real time RT-PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA is quantified using RiboGreenTM RNA quantification reagent from Molecular Probes. Methods of RNA quantification by RiboGreenTM are taught in Jones, L.J., et al, (Analytical Biochemistry, 1998, 265, 368-374).

10

15

20

In this assay, 170 µL of RiboGreenTM working reagent (RiboGreenTM reagent diluted 1:350 in 10mM Tris-HCl, 1 mM EDTA, pH 7.5) is pipetted into a 96-well plate containing 30 µL purified, cellular RNA. The plate is read in a CytoFluor 4000 (PE Applied Biosystems) with excitation at 480nm and emission at 520nm.

Probes and primers to human SMRT were designed to

25 hybridize to a human SMRT sequence, using published sequence information (GenBank accession number AF125672.1, incorporated herein as SEQ ID NO:4). For human SMRT the PCR primers were:

forward primer: CACACATCGTTGCCGCAG (SEQ ID NO: 5)

30 reverse primer: AAGGTATCAAAAATATACCCTGTAAACCA (SEQ ID NO: 6) and the PCR probe was: FAM-TGGGAAGGAAAGGCAGATGTAAATGATGTG-TAMRA

(SEQ ID NO: 7) where FAM is the fluorescent dye and TAMRA is the quencher dye. For human GAPDH the PCR primers were:

forward primer: GAAGGTGAAGGTCGGAGTC(SEQ ID NO:8)
reverse primer: GAAGATGGTGATGGGATTTC (SEQ ID NO:9) and the

PTS-0012 -94- PATENT

PCR probe was: 5' JOE-CAAGCTTCCCGTTCTCAGCC-TAMRA 3' (SEQ ID NO: 10) where JOE is the fluorescent reporter dye and TAMRA is the quencher dye.

5

35

Example 14

Northern blot analysis of SMRT mRNA levels

Eighteen hours after antisense treatment, cell monolayers were washed twice with cold PBS and lysed in 1 mL RNAZOLTM (TEL-TEST "B" Inc., Friendswood, TX). 10 Total RNA was prepared following manufacturer's recommended protocols. Twenty micrograms of total RNA was fractionated by electrophoresis through 1.2% agarose gels containing 1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon, 15 RNA was transferred from the gel to HYBOND™-N+ nylon membranes (Amersham Pharmacia Biotech, Piscataway, NJ) by overnight capillary transfer using a Northern/Southern Transfer buffer system (TEL-TEST "B" Inc., Friendswood, TX). RNA transfer was confirmed by UV visualization. Membranes were fixed by UV cross-linking using a STRATALINKERTM UV 20 Crosslinker 2400 (Stratagene, Inc, La Jolla, CA) and then probed using QUICKHYB™ hybridization solution (Stratagene, La Jolla, CA) using manufacturer's recommendations for stringent conditions.

To detect human SMRT, a human SMRT specific probe was prepared by PCR using the forward primer CACACATCGTTGCCGCAG (SEQ ID NO: 5) and the reverse primer

AAGGTATCAAAAATATACCCTGTAAACCA (SEQ ID NO: 6). To normalize for variations in loading and transfer efficiency membranes

were stripped and probed for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGERTM and IMAGEQUANTTM Software V3.3 (Molecular Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels in untreated controls.

PTS-0012 -95- PATENT

Example 15

Antisense inhibition of human SMRT expression by chimeric phosphorothicate oligonucleotides having 2'-MOE wings and a decay gap

In accordance with the present invention, a series of 5 oligonucleotides were designed to target different regions of the human SMRT RNA, using published sequences (GenBank accession number AF125672.1, incorporated herein as SEQ ID NO: 4; GenBank accession number NM_006312.1, incorporated herein as SEQ ID NO: 11; the complement of residues 39001-10 260000 of GenBank accession number NT_009459.3, representing a partial genomic sequence of SMRT, incorporated herein as SEQ ID NO: 12; and GenBank accession number S83390.1, incorporated herein as SEQ ID NO: 13). The oligonucleotides are shown in Table 1. "Target site" indicates the first (5'-15 most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 1 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 20 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE) nucleotides. internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their 25 effect on human SMRT mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments in which A549 cells were treated with the anitsense oligonucleotides of the present invention. The positive control for each datapoint is identified in the 30 table by sequence ID number. If present, "N.D." indicates "no data".

Table 1

Inhibition of human SMRT mRNA levels by chimeric phosphorothicate oligonucleotides having 2'-MOE wings and a deoxy gap

PATENT

ISIS #	REGION	TARGET	TARGET	C C C C C C C C C C C C C C C C C C C			·
	I ALLO I OI	SEQ ID	SITE	SEQUENCE	% INHIB	SEQ ID	CONTROL
1		NO			TMUTD	МО	SEQ ID
121624	5'UTR	4	61	agtcctcgtcatcagctcac	13	14	NO 2
152703	Coding	11	2705	ctcttggcagtggtggccct	63	15	2
152708	Coding	11	6987	atgttcctgcaccgcctggc	82	16	2
195343	5'UTR	4	10	ctccagcgaggctgtgtcct	77	17	2
195344	5'UTR	4	30	tcactggcaccagaaactgc	32	18	2
195345	Start	4	150	tggagcccgacatggtggtg	27	19	2
	Codon						-
195346		4	635	ccgtggcggcaccagctcca	63	20	2
195347		4	1203	gctggcccaccctctgcatg	70	21	2
195348		4	1856	gctgttggcagttttgcggc	21	22	2
195349	1	4	2311	ttgacagtggcttcagcctc	24	23	2
195350		4	3194	aggettetetgeeteettgt	49	24	2
195351		4	3752	tgtgctgggaatgcctttgg	75	25	2
195352		4	5930	ctccttgggcagcaagacgg	73	26	2
195353	+	4	7307	gccgccacctggcgaggtga	52	27	2
195354		4	7670	tgttctgagtcactcgctgt	57	28	2
105355	Codon						
195355		4	8323	catcatttacatctgccttt	39	29	2
195356 195357		11	1048	ggcccaccctgctctgcatg	69	30	2
195357		11	2159	gcatgtaaggcttcagcctc	0	31	2
		11	2172	ctcattcccagaggcatgta	76	32	2
195359 195360		11	2210	ttgacagtggctgggccact	38	33	2
195361		11	3092	gctgcgaaggcctccttgtc	48	34	2
T3220T	Exon: Intron	12	926	atgaacctaccagaaactgc	33	35	2
1	Junction]				}	
195362		12	5600	accagacaaggctctgggct	-30		
195363	Intron:	12	41188	tcactggcacctgcgggaaa	38	36 37	2
	Exon		41100	ccaccygcacctycyggaaa	30	3/	2
	Junction					 	
195364		12	41410	accccttaccgtgtgcgtc	31	38	2
]	Intron		· ·			30	٤
	Junction					ł	ļ
195365		12	72430	cccagtgtcctgaattccta	51	39	2
195366	Intron:	12	82830	cagccttcttctgcagggtg	34	40	2
1	Exon				l	1	
	Junction						
195367	Intron:	12	110566	cgctggcccaccctgctggg	48	41	2
	Exon			1	1		
105260	Junction						
195368 195369	Intron	12	121997	gaccgagttcagccccaggc	30	42	2
130363	Intron: Exon	12	166452	gcatgtaaggctggaaggaa	68	43	2
	Junction			1	Ì	ļ	
195370	Exon:	12	3.C.E.0.3				
155570	Intron	12	100203	acattcgtacctgggccact	66	44	2
	Junction		j	ı	1	l	
195371	Intron:	12	184100	ggcttctctgctgagggcag	-60		
	Exon		-04103	ggccccccgcggagggcag	69	45	2
	Junction	ļ	J		i		ŀ
195372	Intron:	12	184133	gctgcgaaggctgggaagaa	68	46	
	Exon			guadaaccaaaaaa	00	**0	-
	Junction		l	J	•]		ł
		·	••				

PTS-0012

. 10

15

20

-97-

PATENT

195373	Intron	12	195790	cacttgttacttactgccct	63	47	2
195374	Exon:	12	217191	tcatatttacccatgagtgc	63	48	2
	Intron		1			İ	
	Junction						
195375	Exon:	12	217330	ggcctgcagacctggcgagg	62	49	2
	Intron					1	
	Junction					·	
195376	Coding	13	2392	gccgccacccatgagtgcct	72	50	2

As shown in Table 1, SEQ ID NOS 15, 16, 17, 20, 21, 24, 25, 26, 27, 28, 30, 32, 34, 39, 41, 43, 44, 45, 46, 47, 48, 49 and 50 demonstrated at least 40% inhibition of human SMRT expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as "preferred target regions" and are therefore preferred sites for targeting by compounds of the present invention. These preferred target regions are shown in Table 2. The sequences represent the reverse complement of the preferred antisense compounds shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number of the corresponding target nucleic acid. Also shown in Table 2 is the species in which each of the preferred target regions was found.

Table 2
Sequence and position of preferred target regions identified in SMRT.

SITEID	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	REV COMP OF SEQ ID	ACTIVE IN	SEQ ID NO
68267	11	2705	agggccaccactgccaagag	15	H. sapiens	51
68272	11	6987	gccaggcggtgcaggaacat	16	H. sapiens	52
113455	4	10	aggacacagcctcgctggag	17	H. sapiens	53
113458	4	635	tggagctggtgccgccacgg	20	H. sapiens	54
113459	4	1203	catgcagagggtgggccagc	21	H. sapiens	55
113462	4	3194	acaaggaggcagagaagcct	24	H. sapiens	56
113463	4	3752	ccaaaggcattcccagcaca	25	H. sapiens	57
113464	4	5930	ccgtcttgctgcccaaggag	26	H. sapiens	58
113465	4	7307	tcacctcgccaggtggcggc	27	H. sapiens	59
113466	4	7670	acagcgagtgactcagaaca	28	H. sapiens	60
113468	1.1	1048	catgcagagcagggtgggcc	30	H. sapiens	61

PTS-0012	-98-	PATENT

113470	11	2172	tacatgcctctgggaatgag	32	H. sapiens	62
113472	11_	3092	gacaaggaggccttcgcagc	34	H. sapiens	63
113477	12	72430	taggaattcaggacactggg	39	H. sapiens	64
113479	12	110566	cccagcagggtgggccagcg	41	H. sapiens	65
113481	12	166452	ttccttccagccttacatgc	43	H. sapiens	66
113482	12		agtggcccaggtacgaatgt	44	H. sapiens	67
113483	12	184109	ctgccctcagcagagaagcc	45	H. sapiens	68
113484	12	184133	ttcttcccagccttcgcagc	46	H. sapiens	69
113485	12		agggcagtaagtaacaagtg	47	H. sapiens	70
113486	12		gcactcatgggtaaatatga	48	H. sapiens	71
113487	12		cctcgccaggtctgcaggcc	49	H. sapiens	72
113488	.13	2392	aggcactcatgggtggcggc	50	H. sapiens	73

As these "preferred target regions" have been found by experimentation to be open to, and accessible for,

5 hybridization with the antisense compounds of the present invention, one of skill in the art will recognize or be able to ascertain, using no more than routine experimentation, further embodiments of the invention that encompass other compounds that specifically hybridize to these sites and consequently inhibit the expression of SMRT.

Example 16 Western blot analysis of SMRT protein levels

Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to SMRT is used, with a radiolabeled or fluorescently labeled secondary antibody directed against the primary antibody species.

Bands are visualized using a PHOSPHORIMAGERTM (Molecular Dynamics, Sunnyvale CA).

PTS-0012 -99- PATENT

What is claimed is:

- 1. A compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding SMRT, wherein said compound specifically hybridizes with said nucleic acid molecule encoding SMRT and inhibits the expression of SMRT.
- 2. The compound of claim 1 which is an antisense oligonucleotide.
- 3. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
- 4. The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothicate linkage.
- 5. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
- 6. The compound of claim 5 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
- 7. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
- 8. The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine.
- 9. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
- 10. A compound 8 to 80 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of a preferred target region on a nucleic acid molecule encoding SMRT.
- 11. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
- 12. The composition of claim 11 further comprising a colloidal dispersion system.
- 13. The composition of claim 11 wherein the compound is an antisense oligonucleotide.
- 14. A method of inhibiting the expression of SMRT in cells or tissues comprising contacting said cells or tissues

PTS-0012 -100- PATENT

with the compound of claim 1 so that expression of SMRT is inhibited.

- 15. A method of treating an animal having a disease or condition associated with SMRT comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of SMRT is inhibited.
- 16. The method of claim 15 wherein the disease or condition is an inflammatory disorder.
- 17. The method of claim 16 wherein the inflammatory disorder is rheumatoid arthritis.
- 18. The method of claim 15 wherein the disease or condition is a hyperproliferative disorder.
- 19. The method of claim 18 wherein the hyperproliferative disorder is cancer.
- 20. The method of claim 19 wherein the cancer is selected from the group consisting of leukemia and breast cancer.

PTS-0012

-101-

PATENT

ABSTRACT

5

Antisense compounds, compositions and methods are provided for modulating the expression of SMRT. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding SMRT. Methods of using these compounds for modulation of SMRT expression and for treatment of diseases associated with expression of SMRT are provided.

DOCKET NO.: PTS-0012

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and

I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: Antisense Modulation of SMRT Expression the specification of which:

(XX) is attached hereto.

()	was	filed on	as	Application	Serial	No.	and
		was	amended	on	_ (if application	able).		

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to the patentability of this application in accordance with 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a-d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of any application on which priority is claimed:

Country	Number	Date Filed	Priority	Claimed
			Yes	No
			Yes	No
			Yes	No

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status (pending, patented)
<u></u>		·

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Provisional Application No.	Filing Date

DOCKET NO.: PTS-0012

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Herb Boswell, Registration No. 27,311; Laurel Spear Bernstein, Registration No. 37,280; Neil S. Bartfeld, Registration No. 39,901; and April C. Logan, Registration No. 33,950, of Isis Pharmaceuticals, Inc.; and Jane Massey Licata, Registration No. 32,257, and Kathleen A. Tyrrell, Registration No. 38,350 of the firm of Licata and Tyrrell P.C., 66 East Main Street, Marlton NJ 08053.

Address all telephone calls and correspondence to:

Jane Massey Licata or Kathleen A. Tyrrell Licata and Tyrrell P.C. 66 East Main Street Marlton NJ 08053 (856) 810-1515

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1	Full Name: C. Frank Bennett	Inventor's Signature:	Date:
	Residence: 1347 Cassins Street Carlsbad California 92009	Citizenship: USA	
	Post Office Address:same as above		
2	Full Name: Susan M. Freier	Inventor's Signature:	Date: 5/23/02
	Residence: 2946 Renault Street San Diego California 92122	Citizenship: USA	
	Post Office Address:same as above		
3	Full Name: Kenneth W. Dobie	Inventor's Signature:	Date: 5/23/02
	Residence: 703 Stratford Ct., #4 Del Mar California 92014	Citizenship: UK	
	Post Office Address: same as above		

PATENT

SEQUENCE LISTING

<110> C. Frank Bennett Susan M. Freier Kenneth W. Dobie

<120> ANTISENSE MODULATION OF SMRT EXPRESSION

<130> PTS-0012

<160> 73

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 1

tccgtcatcg ctcctcaggg

20

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 2

<u> Barriera (j. 1848)</u>


PATENT

gtgcgcgcga gcccgaaatc	20
•	
<210> 3	
<211> 20	,
<212> DNA	
<213> Artificial Sequence	
<220>	
•	
<223> Antisense Oligonucleotide	
<400> 3	
atgcattctg cccccaagga	20
· · · · · · · · · · · · · · · · · · ·	
<210> 4	
<211> 8686	
<212> DNA	•
<213> H. sapiens	
<220>	
<220>	
<221> CDS	
<222> (157)(7680)	
<400> 4	
gagtetttga ggacacagee tegetggagg cagtttetgg tgccagtgae ggggtggeee	60
gtgagctgat gacgaggact ggcttttaat ccttggtggt gattaagaga aagcttattg	120
gggcctggga gcagctcccc gccgaccccc accacc atg tcg ggc tcc aca cag	174
Met Ser Gly Ser Thr Gln	
1 5	
cct gtg gca cag acg tgg agg gcc act gag ccc cgc tac ccg ccc cac	222
Pro Val Ala Gln Thr Trp Arg Ala Thr Glu Pro Arg Tyr Pro Pro His	
10 15 20	
ago ott too tac coa gtg cag atc gcc cgg acg cac acg gac gtc ggg	270
Ser Leu Ser Tyr Pro Val Gln Ile Ala Arg Thr His Thr Asp Val Gly	•
25 30 35	

PTS-0012

ctc	ctg	gag	tac	cag	cac	cac	tcc	cgc	gac	tat	gcc	tcc	cac	ctg	tcg	318
Leu	Leu	Glu	Tyr	Gln	His	His	Ser	Arg	Asp	Tyr	Ala	Ser	His	Leu	Ser	
	40					45					50					
ccc	ggc	tcc	atc	atc	cag	ccc	cag	cgg	cgg	agg	ccc	tcc	ctg	ctg	tct	366
Pro	Gly	Ser	Ile	Ile	Gln	Pro	Gln	Arg	Arg	Arg	Pro	Ser	Leu	Leu	Ser	
55					60					65					70	
gag	ttc	cag	ccc	ggg	aat	gaa	cgg	tcc	cag	gag	ctc	cac	ctg	cgg	cca	414
Glu	Phe	Gln	Pro	Gly	Asn	Glu	Arg	Ser	Gln	Glu	Leu	His	Leu	Arg	Pro	
			•	75					80					85		
gag	tcc	cac	tca	tac	ctg	ccc	gag	ctg	ggg	aag	tca	gag	atg	gag	ttc	462
Glu	Ser	His	Ser	Tyr	Leu	Pro	Glu	Leu	Gly	Lys	Ser	Glu	Met	Glu	Phe	
			90					95					100			
att	gaa	agc	aag	cgc	cct	cgg	cta	gag	ctg	ctg	cct	gac	ccc	ctg	ctg	510
Ile	Glu	Ser	Lys	Arg	Pro	Arg	Leu	Glu	Leu	Leu	Pro	Asp	Pro	Leu	Leu	
		105					110					115				
cga	ccg	tca	ccc	ctg	ctg	gcc	acg	ggc	cag	cct	gcg	gga	tct	gaa	gac	558
Arg	Pro	Ser	Pro	Leu	Leu	Ala	Thr	Gly	Gln	Pro	Ala	Gly	Ser	Glu	Asp	
	120					125					130					
ctc	acc	aag	gac	cgt	agc	ctg	acg	ggc	aag	ctg	gaa	ccg	gtg	tct	ccc	606
Leu	Thr	Ĺys	Asp	Arg	Ser	Leu	Thr	Gly	Lys	Leu	Glu	Pro	Val	Ser	Pro	
135					140			-		145					150	
ccc	agc	ccc	ccg	cac	act	gac	cct	gag	ctg	gag	ctg	gtg	ccg	cca	cgg	654
Pro	Ser	Pro	Pro	His	Thr	Asp	Pro	Glu	Leu	Glu	Leu	Val	Pro	Pro	Arg	
				155					160					165		
ctg	tcc	aag	gag	gag	ctg	atc	cag	aac	atg	gac	cgc	gtg	gac	cga	gag	702
Leu	Ser	Lys	Glu	Glu	Leu	Ile	Gln	Asn	Met	Asp	Arg	Val	Asp	Arg	Glu	
			170					175					180			
atc	acc	atg	gta	gag	cag	cag	atc	tct	aag	ctg	aag	aag	aag	cag	caa	750
Ile	Thr	Met	Val	Glu	Gln	Gln	Ile	Ser	Lys	Leu	ГЛЗ	Lys	Lys	Gln	Gln	
		185					190					195				
cag	ctg	gag	gag	gag	gct	gcc	aag	ccg	ccc	gag	cct	gag	aag	ccc	gtg	798
Gln	Leu	Glu	Glu	Glu	Ala	Ala	Lys	Pro	Pro	Glu	Pro	Glu	Lys	Pro	Val	
	200					205					210					
tca	ccg	ccg	ccc	atc	gag	tcg	aag	cac	cgc	agc	ctg	gtg	cag	atc	atc	846
Ser	Pro	Pro	Pro	Ile	Glu	Ser	Lys	His	Arg	Ser	Leu	Val	Gln	Ile	Ile	
215					220					225					230	
tac	gac	gag	aac	cgg	aag	aag	gct	gaa	gct	gca	cat	cgg	att	ctg	gaa	894
Tyr	Asp	Glu	Asn	Arg	Lys	Lys	Ala	Glu	Ala	Ala	His	Arg	Ile	Leu	Glu	
				235					240					245		

ggc	ctg	ggg	ccc	cag	gtg	gag	ctg	ccg	ctg	tac	aac	cag	ccc	tcc	gac	942
			Pro												_	
			250					255				•	260		-	
acc	cgg	cag	tat	cat	gag	aac	atc	aaa	ata	aac	cag	gcg	atg	cgg	aag	990
Thr	Arg	Gln	Tyr	His	Glu	Asn	Ile	Lys	Ile	Asn	Gln	Ala	Met	Arg	Lys	
		265					270					275				
aag	cta	atc	ttg	tac	ttc	aag	agg	agg	aat	cac	gct	cgg	aaa	caa	tgg	1038
Lys	Leu	Ile	Leu	Tyr	Phe	Lys	Arg	Arg	Asn	His	Ala	Arg	Lys	Gln	Trp	
	280					285					290					
gag	cag	aag	ttc	tgc	cag	cgc	tat	gac	cag	ctc	atg	gag	gcc	tgg	gag	1086
Glu	Gln	Lys	Phe	Cys	Gln	Arg	Tyr	Asp	Gln	Leu	Met	Glu	Ala	Trp	Glu	
295					300					305					310	
			gag												-	1134
Lys	Lys	Val	Glu	Arg	Ile	Glu	Asn	Asn	Pro	Arg	Arg	Arg	Ala	Lys	Glu	
				315					320					325		
			cgc													1182
Ser	Lys	Val	Arg	Glu	Tyr	Tyr	Glu		Gln	Phe	Pro	Glu	Ile	Arg	Lys	
			330					335			``		340			
			ctg -													1230
GIN	Arg		Leu	GIn	Glu	Arg		Gln	Arg	Val	Gly		Arg	Gly	Ser	
		345	_ •				350					355				
			atg													1278
GIĀ	360	ser	Met	ser	Pro		Arg	Ser	Glu	His		Val	Ser	Glu	Ile	
ata	_	a aa	ata			365					370					
			ctc													1326
375	изр	GLY	Leu	261	380	GIII	GIU	ASII	Leu		гàг	GIN	Met	Arg		
	acc	ata	atc	cca		ato	cta	tac	424	385	~~~	~~			390	1274
			Ile													1374
				395			204	-y -	400	ALG	vsħ	GLII	GIII	405	116	
aag	ttc	atc	aac		aac	aaa	ctt	atσ		gac	CCC	ato	aad		tac	1422
			Asn													1422
			410			-		415					420	V C.	-3-	
aaa	gac	cgc	cag	gtc	atg	aac	atg	taa	agt	gag	caq	σaσ	_	gag	acc	1470
			Gln													
		425					430	-				435	_			
ttc	cgg	gag	aag	ttc	atg	cag	cat	ccc	aag	aac	ttt	ggc	ctg	atc	gca	1518
			Lys													
	440					445					450	-				



PTS-0012 -5- PATENT

		ctg			_			-		_	_					1566
	Phe	Leu	Glu	Arg		Thr	Val	Ala	Glu		Val	Leu	Tyr	Tyr		
455					460					465					470	_
	_	aag			_									_		1614
Leu	Thr	Lys	Lys		Glu	Asn	Tyr	Lys		Leu	Val	Arg	Arg	Ser	Tyr	
				475					480				•	485		
cgg	cgc	cgc	ggc	aag	agc	cag	cag	caa	caa	cag	cag	cag	cag	cag	cag	1662
Arg	Arg	Arg	Gly	Lys	Ser	Gln										
			490					495					500			
cag	cag	cag	cag	cag	cag	cag	ccc	atg	ccc	cgc	agc	agc	cag	gag	gag	1710
Gln	Gln	Gln	Gln	Gln	Gln	Gln	Pro	Met	Pro	Arg	Ser	Ser	Gln	Glu	Glu	
		505				•	510					515				
		gag		-				-		_	_				_	1758
Lys	Asp	Glu	Lys	Glu	Lys	Glu	Lys	Glu	Ala	Glu	Lys	Glu	Glu	Glu	Lys	
	520					525					530					
ccg	gag	gtg	gag	aac	gac	aag	gaa	gac	ctc	ctc	aag	gag	aag	aca	gac	1806
Pro	Glu	Val	Glu	Asn	Asp	Lys	Glu	Asp	Leu	Leu	Lys	Glu	Lys	Thr	Asp	
535					540					545					550	
gac	acc	tca	ggg	gag	gac	aac	gac	gag	aag	gag	gct	gtg	gcc	tcc	aaa	1854
Asp	Thr	Ser	Gly	Glu	Asp	Asn	Asp	Glu	Lys	Glu	Ala	Val	Ala	Ser	Lys	
				555					560			•		565		
ggc	cgc	aaa	act	gcc	aac	agc	cag	gga	aga	cgc	aaa	ggc	cgc	atc	acc	1902
Gly	Arg	Lys	Thr	Ala	Asn	Ser	Gln	Gly	Arg	Arg	ГЛЗ	Gly	Arg	Ile	Thr	
			570					575					580			
cgc	tca	atg	gct	aat	gag	gcc	aac	agc	gag	gag	gcc	atc	acc	ccc	cag	1950
Arg	Ser	Met	Ala	Asn	Glu	Ala	Asn	Ser	Glu	Glu	Ala	Ile	Thr	Pro	Gln	
		585					590					595				
cag	agc	gcc	gag	cţg	gcc	tcc	atg	gag	ctg	aat	gag	agt	tct	cgc	tgg	1998
Gln	Ser	Ala	Glu	Leu	Ala	Ser	Met	Glu	Leu	Asn	Glu	Ser	Ser	Arg	Trp	
	600					605					610					
aca	gaa	gaa	gaa	atg	gaa	aca	gcc	aag	aaa	ggt	ctc	ctg	gaa	cac	ggc	2046
Thr	Glu	Glu	Glu	Met	Glu	Thr	Ala	Lys	Lys	Gly	Leu	Leu	Glu	His	Gly	
615					620					625					630	
cgc	aac	tgg	tcg	gcc	atc	gcc	cgg	atg	gtg	ggc	tcc	aag	act	gtg	tcg	2094
Arg	Asn	Trp	Ser	Ala	Ile	Ala	Arg	Met	Val	Gly	Ser	Lys	Thr	Val	Ser	
				635					640					645		
cag	tgt	aag	aac	ttc	tac	ttc	aac	tac	aag	aag	agg	cag	aac	ctc	gat	2142
Gln	Cys	Lys	Asn	Phe	Tyr	Phe	Asn	Tyr	Lys	Lys	Arg	Gln	Asn	Leu	Asp	
			650					655					660			

-6- PATENT

gag	atc	ttg	cag	cag	cac	aag	ctg	aag	atg	gag	aag	gag	agg	aac	gcg	2190
Glu	Ile	Leu	Gln	Gln	His	Lys	Leu	Lys	Met	Glu	Lys	Glu	Arg	Asn	Ala	
		665					670					675				
cgg	agg	aag	aag	aag	aaa	gcg	ccg	gcg	gcg	gcc	agc	gag	gag	gct	gca	2238
Arg	Arg	Lys	Lys	Lys	Lys	Ala	Pro	Ala	Ala	Ala	Ser	Glu	Glu	Ala	Ala	
	680					685					690					
ttc	ccg	CCC	gtg	gtg	gag	gat	gag	gag	atg	gag	gcg	tcg	ggc	gtg	acg	2286
Phe	Pro	Pro	Val	Val	Glu	Asp	Gl u	Glu	Met	Glu	Ala	Ser	Gly	Val	Thr	
695					700					705					710	
gga	aat	gag	gag	gag	atg	gtg	gag	gag	gct	gaa	gcc	act	gtc	aac	aac	2334
Gly	Asn	Glu	Glu	Glu	Met	Val	Glu	Glu	Ala	Glu	Ala	Thr	Val	Asn	Asn	
				715					720					725		
			acc											_	-	2382
Ser	Ser	Asp	Thr	Glu	Ser	Ile	Pro	Ser	Pro	His	Thr	Glu	Ala	Ala	Lys	
			730					735					740			
			cag													2430
Yzb	Thr		Gln	Asn	Gly	Pro	Lys	Pro	Pro	Ala	Thr	Leu	Gly	Ala	Asp	
		745					750					755				
			cca												-	2478
GTA		Pro	Pro	Gly	Pro		Thr	Pro	Pro	Pro		Asp	Ile	Pro	Ala	
	760					765					770					
			tcc													2526
	Thr	GIU	Ser	Thr		Ala	Ser	GIU.	Ala		Leu	Ala	Pro	Thr		
775					780					785		_			790	
			CCC													2574
PIO	PLO	Ala	Pro	795	Pne	PIO	ser	ser		Pro	Pro	vaı	Val		гàз	
nan	aaa	224	~a~		~~~	200	~~~	~~~	800					805		2622
			gag Glu													2622
	024	2,5	810	GIG	Giu	1111	AIG	815	AIG	FIO	PLO	Val	820	GIU	GIY	
gag	gag	caq	aag	כככ	ccc	aca	act		aaa	cta	uc a	ata		202	aaa	2670
			Lys													2070
		825					830	0.1.4	-	204	*****	835	,,,op	~***	Cly	
aaq	gcc	gag	gag	ccc	atc	aaσ	_	gag	tac	aca	gag		מככ	nan	aaa	2718
			Glu													2.20
_	840					845			-2 -		850					
ggg	ccg	gcc	aag	ggc	aag		gcg	gaq	gcc	act		acc	acσ	acc	gag	2766
			Lys													
855				-	860	~				865					870	
															-	

agg	aca	ctc	aag	gca	gag	aad	aarr	nan	aac	~~~	200	aaa	200			2014
			Lys													2814
	mu	Deu	- -	875	GIU	цуъ	пуз	GIU		GIŸ	ser	GTĀ	Arg		Thr	
363	~~~								880					885		
			agc													2862
THE	ATA	гÀЗ	Ser	ser	GТĀ	Ala	Pro		Asp	Ser	Asp	Ser	Ser	Ala	Thr	
			890			٠		895					900			
			gac													2910
Суѕ	Ser		Asp	Glu	Val	Asp	Glu	Ala	Glu	Gly	Gly	Asp	Lys	Asn	Arg	
		905					910					915				
			cca													2958
Leu	Leu	Ser	Pro	Arg	Pro	Ser	Leu	Leu	Thr	Pro	Thr	Gly	Asp	Pro	Arg	
	920					925					930					
gcc	aat	gcc	tca	CCC	cag	aag	cca	ctg	gac	ctg	aag	cag	ctg	aag	cag	3006
Ala	Asn	Ala	Ser	Pro	Gln	гуs	Pro	Leu	Asp	Leu	Lys	Gln	Leu	Lys	Gln	
935					940					945					950	
cga	gcg	gct	gcc	atc	ccc	ccc	atc	cag	gtc	acc	aaa	gtc	cat	gag	ccc	3054
Arg	Ala	Ala	Ala	Ile	Pro	Pro	Ile	Gln	Val	Thr	Lys	Val	His	Glu	Pro	
				955					960					965		
ccc	cgg	gag	gac	gca	gct	ccc	acc	aag	cca	gct	ccc	cca	gcc	cca	ccg	3102
Pro	Arg	Glu	Asp	Ala	Ala	Pro	Thr	Lys	Pro	Ala	Pro	Pro	Ala	Pro	Pro	
			970					975					980			
cca	ccg	caa	aac	ctg	cag	ccg	gag	agc	gac	gcc	cct	cag	cag	cct	ggc	3150
Pro	Pro	Gln	Asn	Leu	Gln	Pro	Glu	Ser	Asp	Ala	Pro	Gln	Gln	Pro	Gly	
		985					990					995				
agc	agc	ccc	cgg	ggc	aag	agc	agg	agc	ccg	gca	ccc	ccc	gcc	gac	aag	3198
Ser	Ser	Pro	Arg	Gly	Lys	Ser	Arg	Ser	Pro	Ala	Pro	Pro	Ala	Asp	Lys	
	1000)				1005	•				1010)		•		
gag	gca	gag	aag	cct	gtg	ttc	ttc	cca	gcc	ttc	gca	gcc	gag	gcc	cag	3246
Glu	Ala	Glu	Lys	Pro	Val	Phe	Phe	Pro	Ala	Phe	Ala	Ala	Glu	Ala	Gln	
1015	•				1020)				1025	5				1030	
aag	ctg	cct	ggg	gac	ccc	cct	tgc	tgg	act	tcc	ggc	ctg	ccc	ttc	ccc	3294.
			Gly													
				1035					1040					1045		
gtg	ccc	ccc	cgt	gag	gtg	atc	aag	gcc	tcc	ccg	cat	gcc	cca	gac	ccc	3342
			Arg													
			1050					1055				•	1060			
tca	gcc	ttc	tcc	tac	gct	cca	cct			cca	cta	CCC			ctc	3390
			Ser													2270
		1065		_			1070					1075		~-3		
							,, •						•			

						-										
cat	gac	act	gcc	cgg	ccc	gto	ctg	ccg	cgc	сса	ccc	acc	ato	tcc	aac	3438
His	Asp	Thr	Ala	Arg	, Pro	Val	Leu	Pro	Arg	Pro	Pro	Thr	Ile	Ser	Asn	
	108	0				108	5				109	0				
ccg	cct	ccc	ctc	ato	tcc	tct	gcc	aag	cac	ccc	ago	gtc	ctc	gag	agg	3486
Pro	Pro	Pro	Leu	Ile	Ser	Ser	Ala	Lys	His	Pro	Ser	Val	Leu	Glu	Arg	
109	5				110	0	•			110	5				1110	
caa	ata	ggt	gcc	atc	tcc	caa	gga	atg	tcg	gtc	cag	ctc	cac	gto	ccg	3534
Gln	Ile	Gly	Ala	Ile	Ser	Gln	Gly	Met	Ser	Val	Gln	Leu	His	Val	Pro	
				111	5				112	0				112	5	
tac	tca	gag	cat	gcc	aag	gcc	ccg	gtg	ggc	cct	gtc	acc	atg	ggg	ctg	3582
Tyr	Ser	Glu	His	Ala	Lys	Ala	Pro	Va1	Gly	Pro	Val	Thr	Met	Gly	Leu	
			113	0				113	5				114	0		
ccc	ctg	ccc	atg	gac	ccc	aaa	aag	ctg	gca	CCC	ttc	agc	gga	gtg	aag	3630
Pro	Leu	Pro	Met	Asp	Pro	Lys	Lys	Leu	Ala	Pro	Phe	Ser	Gly	Val	Lys	
		114	5				115	O				115	5			
cag	gag	cag	ctg	tcc	cca	cgg	ggc	cag	gct	ggg	cca	ccg	gag	agc	ctg	3678
Gln	Glu	Gln	Leu	Ser	Pro	Arg	Gly	Gln	Ala	Gly	Pro	Pro	Glu	Ser	Leu	
	116	0				116	5				117	0				
ggg	gtg	CCC	aca	gcc	cag	gag	gcg	tçc	gtg	ctg	aga	ggg	aca	gct	ctg	3726
Gly	Val	Pro	Thr	Ala	Gln	Glu	Ala	Ser	Val	Leu	Arg	Gly	Thr	Ala	Leu	
1179	5				1180)				118	5				1190	
ggc	tca	gtt	ccg	ggc	gga	agc	atc	acc	aaa	ggc	att	ccc	agc	aca	cgg	3774
Gly	Ser	Val	Pro	Gly	Gly	Ser	Ile	Thr	Lys	Gly	Ile	Pro	Ser	Thr	Arg	
				119					120					120		
		tcg														3822
Val	Pro	Ser	Asp	Ser	Ala	Ile	Thr	Tyr	Arg	Gly	Ser	Ile	Thr	His	Gly	
			1210					1215					1220			
		gct														3870
Thr	Pro	Ala	Asp	Val	Leu	Tyr	Lys	Gly	Thr	Ile	Thr	Arg	Ile	Ile	Gly	
		1225					1230					1235				
		agc														3918
Glu	Asp	Ser	Pro	Ser	Arg	Leu	qaA	Arg	Gly	Arg	Glu	Asp	Ser	Leu	Pro	
	1240					1245					1250					
		cac														3966
		His	Val	Ile	Tyr	Glu	Gly	Lys	Lys	Gly	His	Val	Leu	Ser	Tyr	
1255					1260					1265			1		1270	
gag	ggt	ggc	atg	tct	gtg	acc	cag	tgc	tcc	aag	gag	gac	ggc	aga	agc	4014
Glu	Gly	Gly	Met	Ser	Val	Thr	Gln	Cys	Seŗ.	Lys	Glu	Asp	Gly	Arg	Ser	
				1275	;				1280	•				1285		

ago	: tca	gga	ccc	CCC	· cat	. usu	. 200								gac	
															gac Asp	4062
			129			. 014		129		LIC	л пуз	, ALC			qzA	
atg	atq	gag		_	ata	ggc	aga		_	· too	, tas		130	_	gaa	4440
															gaa Glu	4110
		130				OL,	131		. 116	. ser	. ser	131		тте	GIU	
ggt	ctc			cat	acc	atc		_	. usu	cas			_			4450
	Leu															4158
	132		-	_		132			0_0		133		FIO	UTS	HIS	
ctc	aaa	gag	cag	cac	cac	atc	cac	aaa	tcc	ato			aaa	atc	cct	4206
	Lys															4206
133					134		_			134		0	913	410	1350	
cgg	tcc	tac	gtg	gag	gca	cag	gag	gac	tac	ctg	cgt	caa	gag	acc		4254
	Ser															1231
				135					136					136		
ctc	cta	aag	cgg	gag	ggc	acg	cct	ccg	ccc	cca	ccg	ccc	tca	cgg	gac	4302
	Leu															
			1370					137					138			
ctg	acc	gag	gcc	tac	aag	acg	cag	gcc	ctg	ggc	ccc	ctg	aag	ctg	aag	4350
Leu	Thr	Glu	Ala	Tyr	Lys	Thr	Gln	Ala	Leu	Gly	Pro	Leu	Lys	Leu	Lys	
		1385	5				1390	0				139	5			
	gcc															4398
Pro	Ala		Glu	Gly	Leu	Val	Ala	Thr	Val	Lyś	Glu	Ala	Gly	Arg	Ser	
•	1400					1405					1410	-				
	cat															4446
	His	Glu	Ile	Pro	Arg	Glu	Glu	Leu	Arg	His	Thr	Pro	Glu	Leu	Pro	
1415					1420					142	_				1430	
	gcc															4494
Leu	Ата	Pro				Lys	Glu	Gly	Ser	Ile	Thr	Gln	Gly	Thr	Pro	
a ta				1435					1440					1445		
	aag															4542
Leu	Lys		ASP 1450		СТĀ	Ala	Ser			Gly	Ser	Lys			Asp	
ata	caa :							1455					1460			
Val	cgc	coc :	Lon '	alC	ggc	agc	ccc -	ggc	cgg -	acg	ttc	cca	CCC	gtg	cac	4590
var	Arg :	1465	Leu .	TYG	GIĀ				Arg	Thr				Val	His	
gca			ata ·	a+~	~~ ~		1470 					1475				
ccg	Len 1	Asp !	geg (Val)	ver Ver	900 ·	yac (ycc	cgg ~==	gca	ctg	gaa	cgt -	gcc	tgc	tac	4638
	Leu <i>l</i> 1480		- 41				нта.	Arg .	ATS			Arg	Ala	Cys	Tyr	
						1485					1490					

١

gag	gag	agc	ctg	aag	agc	cgg	cca	ggg	acc	gcc	ago	agc	tcg	ggg	ggc	4686
Glu	Glu	Ser	Leu	Lys	Ser	Arg	Pro	Gly	Thr	Ala	Ser	Ser	Ser	Gly	Gly	
149	5				150	0				150	5				1510	
tcc	att	gcg	cgc	ggc	gcc	ccg	gtc	att	gtg	cct	gag	ctg	ggt	aag	ccg	4734
Ser	Ile	Ala	Arg	Gly	Ala	Pro	Val	Ile	Val	Pro	Glu	Leu	Gly	Lys	Pro	
				151	.5				152	0				152	5	
cgg	cag	agc	ccc	ctg	acc	tat	gag	gac	cac	ggg	gca	ccc	ttt	gcc	ggc	4782
Arg	Gln	Ser	Pro	Leu	Thr	Tyr	Glu	Asp	His	Gly	Ala	Pro	Phe	Ala	Gly	
			153	0				153	5				154	0		
cac	ctc	cca	cga	ggt	tcg	CCC	gtg	acc	atg	cgg	gag	CCC	acg	ccg	cgc	4830
His	Leu	Pro	Arg	Gly	Ser	Pro	Val	Thr	Met	Arg	Glu	Pro	Thr	Pro	Arg	
		154	5				155	0				155	5			
ctg	cag	gag	ggc	agc	ctt	tcg	tcc	agc	aag	gca	tcc	cag	gac	cga	aag	4878
Leu	Gln	Glu	Gly	Ser	Leu	Ser	Ser	Ser	Lys	Ala	Ser	Gln	Asp	Arg	Lys	
	156	0				1569	5				157	0				
ctg	acg	tcg	acg	cct	cgt	gag	atc	gcc	aag	tcc	ccg	cac	agc	acc	gtg	4926
Leu	Thr	Ser	Thr	Pro	Arg	Glu	Ile	Ala	Lys	Ser	Pro	His	Ser	Thr	Val	
1579	5				1580	0				1585	5				1590	
ĊCC	gag	cac	cac	cca	cac	ĊCC	atc	tcg	CCC	tat	gag	cac	ctg	ctt	cgg	4974
Pro	Glu	His	His	Pro	His	Pro	Ile	Ser	Pro	Tyr	Glu	His	Leu	Leu	Arg	
				159	5				1600)				160	5	
ggc	gtg	agt	ggc	gtg	gac	ctg	tat	cgc	agc	cac	atc	ccc	ctg	gcc	ttc	5022
Gly	Val	Ser	Gly	Val	Asp	Leu	Tyr	Arg	Ser	His	Ile	Pro	Leu	Ala	Phe	
			1610)				1615	5				1620)		
					ccc											5070
qaA	Pro	Thr	Ser	Ile	Pro	Arg	Gly	Ile	Pro	Leu	Asp	Ala	Ala	Ala	Ala	
		1629					1630					1635				
					cac											5118
Туr	Tyr	Leu	Pro	Arg	His	Leu	Ala	Pro	Aşn	Pro	Thr	Tyr	Pro	His	Leu	
	1640					1645					1650					•
					atc											5166
		Pro	Tyr	Leu	Ile	Arg	Gly	Tyr	Pro	Asp	Thr	Ala	Ala	Leu	Glu	
1655					1660					1665					1670	
					atc											5214
Asn	Arg	Gln	Thr	Ile	Ile	Asn	Asp	Тут	Ile	Thr	Ser	Gln	Gln	Met	His	
				1675					1680					1685		
cac																5262
His .	Asn	Thr	Ala	Thr	Ala	Met	Ala	Gln	Arg	Ala .	Asp	Met	Leu	Arg	Gly	
			1690					1695					1700			

PTS-0012

-11-

												•					
(ctc	tcg	ccc	cgc	gag	tcc	tcg	ctg	gca	ctc	aac	tac	gct	gcg	ggt	CCC	5310
1	Leu	Ser	Pro	Arg	Glu	Ser	Ser	Leu	Ala	Leu	Asn	Tyr	Ala	Ala	Gly	Pro	
			170	5				1710)				171	5			
•	cga	ggc	atc	atc	gac	ctg	tcc	caa	gtg	cca	cac	ctg	cct	gtg	ctc	gtg	5358
2	Arg	Gly	Ile	Ile	Asp	Leu	Ser	Gln	Val	Pro	His	Leu	Pro	Val	Leu	Val	
		1720	0				172	5				173	0				
•	ccc	ccg	aca	cca	ggc	acc	cca	gcc	acc	gcc	atg	gac	cgc	ctt	gcc	tac	5406
1	Pro	Pro	Thr	Pro	Gly	Thr	Pro	Ala	Thr	Ala	Met	Asp	Arg	Leu	Ala	Tyr	
2	1735	5				1740)				174	5				1750	
C	ctc	ccc	acc	gcg	ccc	cag	ccc	ttc	agc	agc	cgc	cac	agc	agc	tcc	cca	5454
1	Leu	Pro	Thr	Ala	Pro	Gln	Pro	Phe	Ser	Ser	Arg	His	Ser	Ser	Ser	Pro	
					175	5				176	0				176	5	
•	ctc	tcc	cca	gga	ggt	cca	aca	cac	ttg	aca	aaa	cca	acc	acc	acg	tcc	5502
Ι	ieu	Ser	Pro	Gly	G1y	Pro	Thr	His	Leu	Thr	Lys	Pro	Thr	Thr	Thr	Ser	
				1770	ס				177	5				178	0		,
t	cg	tcc	gag	cgg	gag	cga	gac	cgg	gat	cga	gag	cgg	gac	cgg	gat	cgg	5550
5	Ser	Ser	Glu	Arg	Glu	Arg	Asp	Arg	Asp	Arg	Glu	Arg	Asp	Arg	Asp	Arg	
			178	5				1790)				1799	ō			
ç	gag	cgg	gaa	aag	tcc	atc	ctc	acg	tcc	acc	acg	acg	gtg	gag	cac	gca	5598
(31u	Arg	Glu	Lys	Ser	Ile	Leu	Thr	Ser	Thr	Thr	Thr	Val	Glu	His	Ala	
		1800)				1805	5				181)				
c	cc	atc	tgg	aga	cct	ggt	aca	gag	cag	agc	agc	ggc	agc	agc	ggc	agc	5646
Ę	?ro	Ile	Trp	Arg	Pro	Gly	Thr	Glu	Gln	Ser	Ser	Gly	Ser	Ser	Gly	Ser	
1	1815	5				1820)				1825	õ				1830	
ē	agc	ggc	ggg	ggt	ggg	ggc	agc	agc	agc	cgc	ccc	gcc	tcc	cac	tcc	cat	5694
٤	Ser	Gly	Gly	Gly	Gly	Gly	Ser	Ser	Ser	Arg	Pro	Ala	Ser	His	Ser	His	
					1835	5				1840)				1845	5	
ç	gcc	cac	cag	cac	tcg	ccc	atc	tcc	cct	cgg	acc	cag	gat	gcc	ctc	cag	5742
P	Ala	His	Gln	His	Ser	Pro	Ile	Ser	Pro	Arg	Thr	Gln	Asp	Ala	Leu	Gln	
				1850)				1855	5				1860)		
c	ag	aga	ccc	agt	gtg	ctt	cac	aac	aca	ggc	atg	aag	ggt	atc	atc	acc	5790
G	ln	Arg	Pro	Ser	Val	Leu	His	Asn	Thr	Gly	Met	Lys	Gly	Ile	Ile	Thr	
			1865	5				1870)				1875	5			
9	ıct	gtg	gag	ccc	agc	aag	ccc	acg	gtc	ctg	agg	tcc	acc	tcc	acc	tcc	5838
A	la	Val	Glu	Pro	Ser	Lys	Pro	Thr	Val	Leu	Arg	Ser	Thr	Ser	Thr	Ser	
		1880)				1885	•				1890)				
t	ca	ccc	gtt	cgc	cca	gct	gcc	aca	ttc	cca	cct	gcc	acc	cac	tgc	cca	5886
				Arg													
	895					1900					1905					1910	

ctg ggc gg	c acc ctc o	at oog ot	c tac co	t 200 of	c atg gag		
Leu Gly Gly	v Thr Leu	an Cly Va	I men no	c acc ct	c atg gag	ccc gtc	5934
	1915	-op orl va			eu Met Glu	Pro Val	
tta cta cca		100 000 00	19			1925	
ttg ctg ccc	o Lvs Glu z	la Pro Am	g gtc gc	c cgg cc	a gag cgg	ccc cga	5982
Leu Leu Pro	1930	ra FIO AL		a Arg Pr	o Glu Arg	Pro Arg	
aca dac aco	-		1935		1940		
gca gac acc	gge cat g	lee tte et	c gcc aa	g ccc cc	a gcc cgc t	cc ggg	6030
Ala Asp Thr				s Pro Pr	o Ala Arg S	Ser Gly	
	_	19:			1955		
ctg gag ccc	gee tee t	CC CCC age	c aag ggo	c tcg ga	g ccc cgg c	cc cta	6078
Leu Glu Pro	Ata Ser S		r Lys Gly	Ser Gl	u Pro Arg P	ro Leu	
1960		1965		19			
gtg cct cct	gtc tct g	gc cac gc	c acc ato	gcc cg	c acc cct g	cg aag	6126
Val Pro Pro			Thr Ile	Ala Ar	g Thr Pro A	la Lys	
1975	_	980		1985		1990	
aac ctc gca	cct cac c	ac gcc ago	ccg gac	cca cci	g gcg cca c	ct gcc	6174
Asn Leu Ala	Pro His H	is Ala Ser	Pro Asp	Pro Pro	Ala Pro P	ro Ala	
	1995	•	200			005	
tcg gcc tcg	gac ccg ca	ac cgg gaa	aag act	caa agt	aaa ccc t	tt tcc	6222
Ser Ala Ser	Asp Pro H	is Arg Glu	Lys Thr	Gln Ser	Lys Pro P	he Ser	
	2010		2015		2020		
atc cag gaa	ctg gaa ct	c cgt tct	ctg ggt	tac cac	ggc agc a	gc tac	6270
Ile Gln Glu	Leu Glu Le	eu Arg Ser	Leu Gly	Tyr His	Gly Ser Se	er Tyr	
2025	5	203			2035	-	
· agc ccc gaa	ggg gtg ga	g ccc gtc	agc cct	gtg agc	tca ccc ag	at cta	6318
Ser Pro Glu	Gly Val Gl	u Pro Val	Ser Pro	Val Ser	Ser Pro Se	er Leu	
2040		2045		205			
acc cac gac	aag ggg ct	c ccc aag	cac ctg	gaa gag	ctc gac as	age	6366
Thr His Asp	Lys Gly Le	u Pro Lys	His Leu	Glu Glu	Leu Asp Lv	s Ser	0500
2055		60		2065	I -3	2070	
cac ctg gag	ggg gag ct	g cgg ccc	aag cag	cca qqc	ccc ata aa		6414
His Leu Glu	Gly Glu Le	u Arg Pro	Lys Gln	Pro Glv	Pro Val IN	e Len	0414
	2075		2080			85	
ggc ggg gag	gcc gcc ca	c ctc cca					6462
Gly Gly Glu	Ala Ala Hi	s Leu Pro	His Lev	Ara Pro	Ten Pro C1	y ayc	6462
	2090		2095	9 110	2100	u ser	
cag ccc tcg	tcc agc cc	g ctg ctc		acc co-		• mark:	
Gln Pro Ser	Ser Ser Pro	Leu Leu	Gin Thr	Ala nas	ggg gtc aa	a ggt	6510
2105		2110		wra blo		s GIÀ	
		2,10			2115		

PTS-0012 -13-

	cag										-		_			6558
His	Gln	Arg	Val	Val	Thr	Leu	Ala	Gln	His	Ile	Ser	Glu	Val	Ile	Thr	
	2120			·		2125					213					
cag	gac	tac	acc	cgg	cac	cac	cca	cag	cag	ctc	agc	gca	CCC	ctg	CCC	6606
Gln	Asp	Tyr	Thr	Arg	His	His	Pro	Gln	Gln	Leu	Ser	Ala	Pro	Leu	Pro	
213	5				214)				2145	5		-		2150	
gcc	CCC	ctc	tac	tcc	ttc	cct	ggg	gcc	agc	tgc	ccc	gtc	ctg	gac	ctc	6654
Ala	Pro	Leu	Tyr	Ser	Phe	Pro	Gly	Ala	Ser	Cys	Pro	Val	Leu	Asp	Leu	
				215	5				2160)				216	5	
cgc	cgc	cca	CCC	agt	gac	ctc	tac	ctc	ccg	ccc	ccg	gac	cat	ggt	gcc	6702
Arg	Arg	Pro	Pro	Ser	Asp	Leu	Tyr	Leu	Pro	Pro	Pro	Asp	His	Gly	Ala	
			2170)				2179	5				2180	כ		
ccg	gcc	cgt	ggc	tcc	ccc	cac	agc	gaa	ggg	ggc	aag	agg	tct	cca	gag	6750
Pro	Ala	Arg	Gly	Ser	Pro	His	Ser	Glu	Gly	Gly	Lys	Arg	Ser	Pro	Glu	
		218	5				2190)				2199	5			
cca	aac	aag	acg	tcg	gtc	ttg	ggt	ggt	ggt	gag	gac	ggt	att	gaa	cct	6798
Pro	Asn	Lys	Thr	Ser	Val	Leu	Gly	Gly	Gly	Glu	Asp	Gly	Ile	Glu	Pro	
	2200)				2205	5				2210)				
gtg	tcc	cca	ccg	gag	ggc	atg	acg	gag	cca	ggg	cac	tcc	cgg	agt	gct	6846
Val	Ser	Pro	Pro	\mathbf{Glu}	Gly	Met	Thr	Glu	Pro	Gly	His	Ser	Arg	Ser	Ala	
2215	5				2220)				2225	5				2230	
gtg	tac	ccg	ctg	ctg	tac	cgg	gat	ggg	gaa	cag	acg	gag	ccc	agc	agg	6894
Val	Tyr	Pro	Leu	Leu	Tyr	Arg	Asp	Gly	Glu	Gln	Thr	Glu	Pro	Ser	Arg	
				2235	5				2240)				2245	5	
atg	ggc	tcc	aag	tct	cca	ggc	aac	acc	agc	cag	ccg	cca	gcc	ttc	ttc	6942
Met	Gly	Ser	Lys	Ser	Pro	Gly	Asn	Thr	Ser	Gln	Pro	Pro	Ala	Phe	Phe	
			2250)				2255	5				2260)		
agc	aag	ctg	acc	gag	agc	aac	tcc	gcc	atg	gtc	aag	tcc	aag	aag	caa	6990
Ser	Lys	Leu	Thr	Glu	Ser	Asn	Ser	Ala	Met	Val	Lys	Ser	Lys	Lys	Gln	
		2265	5				2270)				2275	5			
gag	atc	aac	aag	aag	ctg	aac	acc	cac	aac	cgg	aat	gag	cct	gaa	tac	7038
Glu	Ile	Asn	Гўз	Lys	Leu	Asn	Thr	His	Asn	Arg	Asn	Glu	Pro	Glu	Tyr	
	2280)				2285	i				2290)				
aat	atc	agc	cag	cct	ggg	acg	gag	atc	ttc	aat	atg	ccc	gcc	atc	acc	7086
Asn	Ile	Ser	Gln	Pro	Gly	Thr	Glu	Ile	Phe	Asn	Met	Pro	Ala	Ile	Thr	
2295	5				2300)				2305	5				2310	
gga	aca	ggc	ctt	atg	acc	tat	aga	agc	cag	gcg	gtg	cag	gaa	cat	gcc	7134
Gly	Thr	Gly	Leu	Met	Thr	Tyr	Arg	Ser	Gln	Ala	Val	Gln	Glu	His	Ala	
				2315	5				2320)				2325	;	

PTS-0012 -14- PATENT

agc	acc	aac	atg	ggg	ctg	gag	gcc	ata	att	aga	aag	gca	ctc	atg	ggt	7182
Ser	Thr	Asn	Met	Gly	Leu	Glu	Ala	Ile	Ile	Arg	Lys	Ala	Leu	Met	Gly	•
	•		2330)			•	2335	5				2340)		
aaa	tat	gac	cag	tgg	gaa	gag	tcc	ccg	ccg	ctc	agc	gcc	aat	gct	ttt	7230
Lys	Tyr	Asp	Gln	Trp	Glu	Glu	Ser	Pro	Pro	Leu	Ser	Ala	Asn	Ala	Phe	
		2345	5				2350)				2355	5			
aac	cct	ctg	aat	gcc	agt	gcc	agc	ctg	ccc	gct	gct	atg	ccc	ata	acc	7278
Asņ	Pro	Leu	Asn	Ala	Ser	Ala	Ser	Leu	Pro	Ala	Ala	Met	Pro	Ile	Thr	
	2360)				2365	5				2370)				
gct	gct	gac	gga	cgg	agt	gac	cac	aca	ctc	acc	tcg	cca	ggt	ggc	ggc	7326
Ala	Ala	Asp	Gly	Arg	Ser	Asp	His	Thr	Leu	Thr	Ser	Pro	Gly	Gly	Gly	
237	5				2380)				2385	5				2390	
ggg	aag	gcc	aag	gtc	tct	ggc	aga	CCC	agc	agc	cga	aaa	gcc	aag	tcc	7374
Gly	Lys	Ala	Lys	Val	Ser	Gly	Arg	Pro	Ser	Ser	Arg	Lys	Ala	Lys	Ser	
				2395	5				2400	כ				2409	5	
ccg	gcc	ccg	ggc	ctg	gca	tct	ggg	gac	cgg	cca	ccc	tct	gtc	tcc	tca	7422
Pro	Ala	Pro	Gly	Leu	Ala	Ser	Gly	Asp	Arg	Pro	Pro	Ser	Val	Ser	Ser	
			2410)				2415	5				2420)		
gtg	cac	tcg	gag	gga	gac	tgc	aac	cgc	cgg	acg	ccg	ctc	acc	aac	cgc	7470
Val	His	Ser	Glu	Gly	Asp	Cys	Asn	Arg	Arg	Thr	Pro	Leu	Thr	Asn	Arg	
•		242	5				2430)				2435	5			
gtg	tgg	gag	gac	agg	ccc	tcg	tcc	gca	ggt	tcc	acg	cca	ttc	ccc	tac	7518
٧al	Trp	Glu	Asp	Arg	Pro	Ser	Ser	Ala	Gly	Ser	Thr	Pro	Phe	Pro	Tyr	
	2440)				244	5				245	0				
aac	ccc	ctg	atc	atg	cgg	ctg	cag	gcg	ggt	gtc	atg	gct	tcc	cca	ccc	7 566
Asn	Pro	Leu	Ile	Met	Arg	Leu	Gln	Ala	Gly	Val	Met	Ala	Ser	Pro	Pro	
245	5				246	0				246	5				2470	
cca	ccg	ggc	ctc	ccc	gcg	ggc	agc	ggg	ccc	ctc	gct	ggc	ccc	cac	cac	7614
Pro	Pro	Gly	Leu	Pro	Ala	Gly	Ser	Gly	Pro	Leu	Ala	Gly	Pro	His	His	
			•	2479	5				248	ο,				248	5	
gcc	tgg	gac	gag	gag	ccc	aag	cca	ctg	ctc	tgc	tcg	cag	tac	gag	aca	7662
Ala	Trp	Asp	Glu	Glu	Pro	Lys	Pro	Leu	Leu	Cys	Ser	Gln	Tyr	Glu	Thr	
			2490)				2499	5				2500)		
ctc	tcc	gac	agc	gag	tga	ctca	agaad	cag g	ggcg	gggg	gg gg	geggg	gcggt	t gto	caggtcc	c 7720
Leu	Ser	Asp	Ser	Glu												
		250	5													
agc	gagco	cac a	aggaa	acggo	cc c1	tgca	ggag	ggg	ggcg	gctg	ccga	actco	ccc o	caac	caagga	7780
agg	agcco	ect q	gagto	cgc	ct g	gcci	tccat	t cca	atct	gtcc	gtc	caga	gcc (gca	taattg	7840
cct	gtcta	aaa q	gccti	taact	ca a	gact	ccg	ccc	ggg	ctgg	ccc	tgtg	cag a	acct	tactca	7900

PTS-0012 -15- PATENT

ggggatgttt acctggtgct cgggaaggga ggggaagggg ccggggaggg ggcacggcag 7960 gcgtgtggca gccacacaca ggcggccagg gcggccaggg acccaaagca ggatgaccac 8020 gcacctccac gccactgcct cccccgaatg catttggaac caaagtctaa actgagetcg 8080 cagcccccgc gccctccctc cgcctcccat cccgcttagc gctctggaca gatggacgca 8140 ggccctgtcc agcccccagt gcgctcgttc cggtccccac agactgcccc agccaacqaq 8200 attgctggaa accaagtcag gccaggtggg cggacaaaag ggccaggtgc ggcctggggg 8260 gaacggatgc tccgaggact ggactgtttt tttcacacat cgttgccgca·gcggtgggaa 8320 ggaaaggcag atgtaaatga tgtgttggtt tacagggtat atttttgata ccttcaatga 8380 attaattcag atgttttacg caaggaagga cttacccagt attactgctg ctgtgctttt 8440 gatetetget tacegtteaa gaggegtgtg caggeegaca gteggtgace ceateacteg 8500 caggaccaag ggggcgggga ctgctcgtca cgccccgctg tgtcctccct ccctcccttc 8560 cttgggcaga atgaattcga tgcgtattct gtggccgcca tttgcgcagg gtggtggtat 8620 8680 aaaaaa 8686

<210> 5

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 5

cacacatcgt tgccgcag

<210> 6

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 6

aaggtatcaa aaatataccc tgtaaacca

18

<210>	7
<211>	30

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 7

tgggaaggaa aggcagatgt aaatgatgtg

30

<210> 8

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 8

gaaggtgaag gtcggagtc

19

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 9

gaagatggtg atgggatttc

```
<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> PCR Probe
<400> 10
caagetteec gtteteagee
                                                                       20
<210> 11
<211> 8561
<212> DNA
<213> Homo sapiens
<220>
<221> CDS
<222> (2)...(7555)
<400> 11
c atg tcg ggc tcc aca cag ctt gtg gca cag acg tgg agg gcc act gag 49
  Met Ser Gly Ser Thr Gln Leu Val Ala Gln Thr Trp Arg Ala Thr Glu
ccc cgc tac ccg ccc cac agc ctt tcc tac cca gtg cag atc gcc cgg
                                                                    97
Pro Arg Tyr Pro Pro His Ser Leu Ser Tyr Pro Val Gln Ile Ala Arg
             20
acg cac acg gac gtc ggg ctc ctg gag tac cag cac cac tcc cgc gac
                                                                   145
Thr His Thr Asp Val Gly Leu Leu Glu Tyr Gln His His Ser Arg Asp
         35
                              40
tat gcc tcc cac ctg tcg ccg ggc tcc atc atc cag ccc cag cgg cgg
                                                                   193
Tyr Ala Ser His Leu Ser Pro Gly Ser Ile Ile Gln Pro Gln Arg Arg
     50
                         55
                                              60
agg ccc tcc ctg ctg tct gag ttc cag ccc ggg aat gaa cgg tcc cag
                                                                   241
```

-18-

Arg	Pro	Ser	Leu	Leu	Ser	Glu	Phe	Gln	Pro	Gly	Asn	Glu	Arg	Ser	Gln	
65					70					75					80	
gag	ctc	cac	ctg	cgg	cca	gag	tcc	cac	tca	tac	ctg	CCC	gag	ctg	ggg	289
Glu	Leu	His	Leu	Arg	Pro	Glu	Ser	His	Ser	Tyr	Leu	Pro	Glu	Leu	Gly	
				85					90					95		
•					ttc										_	337
Lys	Ser	Glu	Met	Glu	Phe	Ile	Glu	Ser	Lys	Arg	Pro	Arg	Leu	Glu	Leu	
			100					105					110			
					ctg								-		_	385
Leu	Pro		Pro	Leu	Leu	Arg	Pro	Ser	Pro	Leu	Leu	Ala	Thr	Gly	Gln	
		115					120					125				
					gac											433
Pro		Gly	Ser	Glu	Asp		Thr	Lys	Asp	Arg	Ser	Leu	Thr	Gly	Lys	
	130			•		135					140					
					CCC											481
	GIU	Pro	Val	Ser	Pro	Pro	Ser	Pro	Pro		Thr	Asp	Pro	Glu		
145					150					155					160	
					cgg											529
GIU	ьец	vaı	Pro		Arg	Leu	Ser	Lys		Glu	Leu	Ile	Gln		Met	
		~~~		165					170					175		
					gag											577
Asp	ALG	Val	180	Arg	Glu	тте	Thr		vaı	GIU	GIn	GIn		Ser	Lys	
cta	224	220		<b>6</b> 26	ann		at a	185					190			605
					caa Gln											625
пец	цуз	195	nys	GIII	GIII	GTII	200	GIU	GIU	Glu	Ala		гÃа	Pro	Pro	
nan	cct		224	ccc	gtg	tea		999		250		205				672
					Val											673
0_4	210	O.L.	د ډيد	110	Val	215	FIU	FIO	FIO	TTE	220	ser	ъуѕ	пля	Arg	
agc		ata	cag	atc	atc		cac	nen	220	000		226	~a+	~~~	eat.	721
					Ile											121
225					230	-1-	p	<u> </u>	71311	235	ыуз	цуз	AIG	GIU	240	
	cat	caa	att	cta	gaa	aac	cta	aaa	CCC		ata	ກຂກ	cta	cca	•	769
					Glu											703
		_		245		4		<u>,</u>	250	0	<b>V</b> 4.	014	200	255	ncu.	
tac	aac	cag	ccc		gac	acc	caa	caa		cat	gag	aac	atc		ata	817
					Asp											J.,
_			260		~			265	~	w			270	_, _		
aac	cag	gcg	atg	cgg	aag	aag	cta		tta	tac	tta	aaq		agg	aat	865
	-	_	_	- <del>-</del>	_	-						5	~33	-22		

Asn	Gln	Ala 275	Met	Arg	Lys	Lys	Leu 280	Ile	Leu	Tyr	Phe	Lys 285	Arg	Arg	Asn	
cac	gct	cgg	aaa	caa	tgg	aag	cag	aag	ttc	tgc	cag	cac	tat	gac	cag	913
											Gln			_	_	
	290				-	295		_		-	300		•	•		
ctc	atg	gag	gcc	ttg	gaa	aaa	aag	gtg	gag	cgc	atc	gaa	aac	aac	ccg	961
Leu	Met	Glu	Ala	Leu	Glu	Lys	Lys	Val	Glu	Arg	Ile	Glu	Asn	Asn	Pro	
305					310					315					320	
cgc	cgg	cgg	gcc	aag	gag	agc	aag	gtg	cgc	gag	tac	tac	gaa	aag	cag	1009
Arg	Arg	Arg	Ala	Lys	Glu	Ser	Lys	Val	Arg	Glu	Tyr	Tyr	Glu	Lys	Gln	
				325					330					335		
ttc	cct	gag	atc	cgc	aag	cag	cgc	gag	ctg	cag	gag	cgc	atg	cag	agc	1057
Phe	Pro	Glu	Ile	Arg	Lys	Gln	Arg	Glu	Leu	Gln	Glu	Arg	Met	Gln	Ser	
			340					345					350			
agg	gtg	ggc	cag	cgg	ggc	agt	ggg	ctg	tcc	atg	tcg	gcc	gcc	cgc	agc	1105
Arg	Val	Gly	Gln	Arg	Gly	Ser	Gly	Leu	Ser	Met	Ser	Ala	Ala	Arg	Ser	
		355					360					365				
gag	cac	gag	gtg	tca	gag	atc	atc	gat	ggc	ctc	tca	gag	cag	gag	aac	1153
Glu	His	Glu	Val	Ser	Glu	Ile	Ile	Asp	Gly	Leu	Ser	Glu	Gln	Glu	Asn	
	370					375					380					
ctg	gag	aag	cag	atg	cgc	cag	ctg	gcc	gtg	atc	ccg	çcc	atg	ctg	tac	1201
Leu	Glu	Lys	Gln	Met	Arg	Gln	Leu	Ala	Val	Ile	Pro	Pro	Met	Leu	Tyr	•
385					390					395					400	
gac	gct	gac	cag	cag	cgc	atc	aag	ttc	atc	aac	atg	aac	ggg	ctt	atg	1249
Asp	Ala	Asp	Gln	Gln	Arg	Ile	Lys	Phe	Ile	Asn	Met	Asn	Gly	Leu	Met	
				405					410					415		
gcc	gac	ccc	atg	aag	gtg	tac	aaa	gac	cgc	cag	gtc	atg	aac	atg	tgg	1297
Ala	qzA	Pro	Met	Lys	Val	Tyr	Lys	Asp	Arg	Gln	Val	Met	Asn	Met	Trp	
			420					425					430			
											ttc					1345
Ser	Glu	Gln	Glu	Lys	Glu	Thr	Phe	Arg	Glu	Lys	Phe	Met	Gln	His	Pro	
		435					440					445				
											agg					1393
Lys	Asn	Phe	Gly	Leu	Ile	Ala	Ser	Phe	Leu	Glu	Arg	Lys	Thr	Val	Ala	
	450					455					460					
											aat					1441
Glu	Cys	Val	Leu	Tyr	Tyr	Tyr	Leu	Thr	Lys	Lys	Asn	Glu	Asn	Tyr	Lys	
465					470					475					480	
agc	ctg	gtg	aga	cgg	agc	tat	cgg	cgc	cgc	ggc	aag	agc	cag	cag	caa	1489

PTS-0012

								,								
Ser	Leu	Va]	. Arg	Arg	Ser	Туг	Arg	Arg	Arg	Gly	r Lys	Ser	Glr	Gln	Gln	
•				485					490					495		
															atg	1537
GIn	Gin	Gln			Gln	Gln	Gln			Gln	Gln	Gln	Gln	Pro	Met	
			500					505					510			
															gag	1585
FIO	MIG	515		GIN	GIU	GIU			GIu	Lys	Glu			Lys	Glu	
aca	aaa			a a a		224	520					525				,
															gac -	1633
	530	ى رى	GIU	Giu	Gra	535	PLO	GIU	val	GIU			Lys	GIU	Asp	
ctc		aaq	gag	aaq	aca		gac	200	tas	888	540			~	gag	1.001
															gag Glu	1681
545		-			550					555		nsp	ASII	Asp	560	
aag	gag	gct	gtg	gcc	tcc	aaa	ggc	cqc	aaa			aac	agc	cag		1729
			Val													1,25
				565					570					575	2	
aga	cgc	aaa	ggc	cgc	atc	acc	cgc	tca	atg	gct	aat	gag	gcc	aac	agc	1777
			Gly													
			580					585					590			
gag	gag	gcc	atc	acc	ccc	cag	cag	agc	gcc	gag	ctg	gcc	tcc	atg	gag	1825
Glu	Glu	Ala	Ile	Thr	Pro	Gln	Gln	Ser	Ala	Glu	Leu	Ala	Ser	Met	Glu	
		595					600					605				
			agt													1873
Leu		Glu	Ser	Ser	Arg	Trp	Thr	Glu	Glu	Glu	Met	Glu	Thr	Ala	Lys	
	610					615					620					
			ctg -													1921
	GIĀ	Leu	Leu	Glu		Gly	Arg	Asn	Trp		Ala	Ile	Ala	Arg	Met	
625	<b>a</b> aa	+			630	,				635					640	
			aag													1969
VUL	GLY	Ser	Lys	645	vai	ser	GIN	суѕ		Asn	Phe	Tyr	Phe		Tyr	
аад	ааα	agg	cag		ctc	an t	~~~	- <del>-</del> -	650					655		
			Gln												_	2017
		5	660		200	nsp	Gru	665	beu	GIII	GIII	HIS	ьуs 670	ьеи	ràs	
atg	gag	aag	gag	agq	aac	aca	caa		aar	aar	224	222		~~~	<b>aa</b> a	2065
			Glu													2065
		675		-			680	3			-, -	685	- 34 64		·JTG	
gcg	gcc	agc	gag	gag	gct			cca	CCC	ata	ata		oat.	gag	gag	2113
								_			3			J-5	33	

Ala	Ala 690	Ser	Glu	Glu	Ala	Ala 695	Phe	Pro	Pro	Val	Val	Glu	Asp	Glu	Glu	
atq		gcg	tca	aac	ata		aaa	aat	πασ	nan		ato	ata	nen	αaα	2161
		Ala		_	_	•				_		_				2101
705				3	710					715	024				720	
	gaa	gcc	tta	cat		tct	aaa	aat	gag		ccc	aga	aaa	gaa		2209
		Ala													_	2205
				725					730			5	2	735	0,10	
agt	ggc	cca	gcc	act	gtc	aac	aac	age		gac	acc	gag	agc		ccc	2257
		Pro	_	_												
			740					745		-			750			
tct	cct	cac	act	gag	gcc	gcc	aag	gac	aca	ggg	cag	aat	ggg	ccc	aag	2305
		His														
		<b>7</b> 55					760					765				
ccc	cca	gcc	acc	ctg	ggc	gcc	gac	ggg	cca	ccc	cca	ggc	cca	ccc	acc	2353
Pro	Pro	Ala	Thr	Leu	Gly	Ala	Asp	Gly	Pro	Pro	Pro	Gly	Pro	Pro	Thr	
	770					775					780					
сса	cca	cgg	agg	aca	tcc	cgg	gcc	ccc	att	gag	ccc	acc	ccg	gcc	tct	2401
Pro	Pro	Arg	Arg	Thr	Ser	Arg	Ala	Pro	Ile	${f Glu}$	Pro	Thr	Pro	Ala	Ser	
785					790					795					800	
gaa	gcc	acc	gga	gcc	çcţ	acg	ccc	cca	cca	gca	ccc	cca	tcg	ccc	tct	2449
Glu	Ala	Thr	Gly	Ala	Pro	Thr	Pro	Pro	Pro	Ala	Pro	Pro	Ser	Pro	Ser	
				805					810					815		
gca	cct	cct	cct	gtg	gtc	ccc	aag	gag	gag	aag	gag	gag	gag	acc	gca	2497
Ala	Pro	Pro	Pro	Val	Val	Pro	ГÀЗ	Glu	Glu	Lys	Glu	Glu	Glu	Thr	Ala	
			820					825					830			
		ccc														2545
Ala	Ala	Pro	Pro	Val	Glu	Glu	Gly	Glu	Glu	Gln	Lys	Pro	Pro	Ala	Ala	
		835					840					845				
		ctg														2593
Glu		Leu	Ala	Val	Asp		Gly	Lys	Ala	Glu	Glu	Pro	Val	Lys	Ser	
	850					855					860					
		acg														2641
	Cys	Thr	Glu	Glu			Glu	Gly	Pro	Ala	Lys	Gly	Lys	Asp	Ala	
865					870					875					880	
		gct														2689
GLu	Ala	Ala	Glu		Thr	Ala	Glu	Gly		Leu	Lys	Ala	Glu		Lys	
				885					890					895		
gag	ggc	àāā	agc	ggc	agg	gcc	acc	act	gcc	aag	agc	tcg	ggc	gcc	ccc	2737

PTS-0012 -22-

Gli	Gly	Gly	Ser	Gly	Arg	Ala	Thr	Thr	Ala	Lys	Ser	Ser	Gly	Ala	Pro	
			900					905					910			
cag	gac	agc	gac	tcc	agt	gċt	acc	tgc	agt	gca	gac	gag	gtg	gat	gag	2785
Glr	Asp	Ser	Asp	Ser	Ser	Ala	Thr	Cys	Ser	Ala	Asp	Glu	Val	Asp	Glu	
		915					920					925				
gco	gag	ggc	ggc	gac	aag	aac	cgġ	ctg	ctg	tcc	cca	agg	ccc	agc	ctc	2833
A1a	Glu	Gly	Gly	Asp	Lys	Asn	Arg	Leu	Leu	Ser	Pro	Arg	Pro	Ser	Leu	
	930					935					940					
cto	acc	ccg	act	ggc	gac	ccc	cgg	gcc	aat	gcc	tca	ccc	cag	aag	cca	2881
Lev	t Thr	Pro	Thr	G1y	Asp	Pro	Arg	Ala	Asn	Ala	Ser	Pro	Gln	Lys	Pro	
945	•				950					955					960	
ctg	gac	ctg	aag	cag	ctg	aag	cag	cga	gcg	gct	gcc	atc	ccc	ccc	atc	2929
Let	Asp	Leu	Lys	Gln	Leu	Lys	Gln	Arg	Ala	Ala	Ala	Ile	Pro	Pro	Ile	
				965					970					975		
cag	gtc	acc	aaa	gtc	cat	gag	ccc	ccc	cgg	gag	gac	gca	gct	ccc	acc	2977
Glr	val	Thr	Lys	Val	His	Glu	Pro	Pro	Arg	Glu	Asp	Ala	Ala	Pro	Thr	
			980					985					990			
aag	r cca	gct	ccc	cca	gcc	cca	ccg	cca	ccg	caa	aac	ctg	cag	ccg	gag	3025
Lys	Pro	Ala	Pro	Pro	Ala	Pro	Pro	Pro	Pro	Gln	Asn	Leu	Gln	Pro	Glu	
		999	5				1000	)				1005	5			
ago	gac	gcc	cct	cag	cag	cct	ggc	agc	agc	ccc	cgg	ggc	aag	agc	agg_	3073
Sei	Asp	Ala	Pro	Gln	Gln	Pro	Gly	Ser	Ser	Pro	Arg	Gly	Lys	Ser	Arg	
	101	0				1015	5				1020	)				
ago	ccg	gca	ccc	ccc	gcc	gac	aag	gag	gcc	ttc	gca	gcc	gag	gcc	cag	. 3121
Ser	Pro	Ala	Pro	Pro	Ala	Asp	Lys	Glu	Ala	Phe	Ala	Ala	Glu	Ala	Gln	
102	5				1030	)				1035	5				1040	
·aag	ctg	cct	aaa	gac	CCC	cct	tgc	tgg	act	tcc	ggc	ctg	ccc	ttc	ccc	3169
Lys	Leu	Pro	Gly	Asp	Pro	Pro	Cys	$\mathtt{Trp}$	Thr	Ser	Gly	Leu	Pro	Phe	Pro	
				1045	5				1050	)				1055	5	
gto	ccc	ccc	cgt	gag	gtg	atc	aag	gcc	tcc	ccg	cat	gcc	ccģ	gac	ccc	3217
Va]	Pro	Pro	Arg	Glu	Val	Ile	Lys	Ala	Ser	Pro	His	Ala	Pro	Asp	Pro	
			1060	)			•	1065	5				1070	)		
tca	gcc	ttc	tcc	tac	gct	cca	cct	ggt	cac	cca	ctg	CCC	ctg	ggc	ctc	3265
Ser	Ala	Phe	Ser	Tyr	Ala	Pro	Pro	Gly	His	Pro	Leu	Pro	Leu	Gly	Leu	
·		1075	5				1080	)				1085	5			
cat	gac	act	gcc	cgg	ccc	gtc	ctg	ccg	cgc	cca	ccc	acc	atc	tcc	aac	3313
His	Asp	Thr	Ala	Arg	Pro	Val	Leu	Pro	Arg	Pro	Pro	Thr	Ile	Ser	Asn	
	1090	)				1095	5				1100	)				
CC9	cct	ccc	ctc	atc	tcc	tct	gcc	aag	cac	ccc	agc	gtc	ctc	gag	agg ·	3361

PTS-0012 -23- PATENT

Pro Pro Pro Leu Ile Ser Ser Ala Lys His Pro Ser Val Leu Glu Arg	
1105 1110 1115 1120	
caa ata ggt gcc atc tcc caa gga atg tcg gtc cag ctc cac gtc ccg	3409
Gln Ile Gly Ala Ile Ser Gln Gly Met Ser Val Gln Leu His Val Pro	
1125 1130 1135	
tac tca gag cat gcc aag gcc ccg gtg ggc cct gtc acc atg ggg ctg	3457
Tyr Ser Glu His Ala Lys Ala Pro Val Gly Pro Val Thr Met Gly Leu	
1140 1145 1150	
ccc ctg ccc atg gac ccc aaa aag ctg gca ccc ttc agc gga gtg aag	3505
Pro Leu Pro Met Asp Pro Lys Lys Leu Ala Pro Phe Ser Gly Val Lys	
1155 1160 1165	
cag gag cag ctg tcc cca cgg ggc cag gct ggg cca ccg gag agc ctg	3553
Gln Glu Gln Leu Ser Pro Arg Gly Gln Ala Gly Pro Pro Glu Ser Leu	
1170 1175 1180	
ggg gtg ccc aca gcc cag gag gcg tcc gtg ctg aga ggg aca gct ctg	3601
Gly Val Pro Thr Ala Gln Glu Ala Ser Val Leu Arg Gly Thr Ala Leu	
1185 1190 1195 1200	
ggc tca gtt ccg ggc gga agc atc acc aaa ggc att ccc agc aca cgg	3649
Gly Ser Val Pro Gly Gly Ser Ile Thr Lys Gly Ile Pro Ser Thr Arg	
1205 1210 1215	
gtg ccc tcg gac agc gcc atc aca tac cgc ggc tcc atc acc cac ggc	3697
Val Pro Ser Asp Ser Ala Ile Thr Tyr Arg Gly Ser Ile Thr His Gly	
1220 1225 1230	
acg cca gct gac gtc ctg tac aag ggc acc atc acc agg atc atc ggc	3745
Thr Pro Ala Asp Val Leu Tyr Lys Gly Thr Ile Thr Arg Ile Ile Gly	
1235 1240 1245	
gag gac agc ccg agt cgc ttg gac cgc ggc cgg gag gac agc ctg ccc	3793
Glu Asp Ser Pro Ser Arg Leu Asp Arg Gly Arg Glu Asp Ser Leu Pro	
1250 1255 1260	
aag ggc cac gtc atc tac gaa ggc aag aag ggc cac gtc ttg tcc tat	3841
Lys Gly His Val Ile Tyr Glu Gly Lys Lys Gly His Val Leu Ser Tyr	
1265 1270 1275 1280	
gag ggt ggc atg tct gtg acc cag tgc tcc aag gag gac ggc aga agc	3889
Glu Gly Gly Met Ser Val Thr Gln Cys Ser Lys Glu Asp Gly Arg Ser	3003
1285 1290 1295	
age tea gga eee eee cat gag aeg gee gee eee aag ege ace tat gae	3937
Ser Ser Gly Pro Pro His Glu Thr Ala Ala Pro Lys Arg Thr Tyr Asp	JJJ,
1300 1305 1310	
atg atg gag ggc cgc gtg ggc aga gcc atc tcc tca gcc agc atc gaa	2005
55 5-5 550 Cyc grey gyc aga god acc too toa god ago atc gaa	3985

PTS-0012 -24- PATENT

Met	Met	Glu	Gly	Arg	Val	Gly	Arg	Ala	Ile	Ser	Ser	Ala	Ser	Ile	Glu	
		1315	5				1320	0				132	5			
gġt	ctc	atg	ggc	cgt	gcc	atc	ccg	ccg	gag	cga	cac	agc	ccc	cac	cac	4033
Gly	Leu	Met	Gly	Arg	Ala	Ile	Pro	Pro	Glu	Arg	His	Ser	Pro	His	His	
	1330	)				133	5				1340	0				
ctc	aaa	gag	cag	cac	cac	atc	cgc	ggg	tcc	atc	aca	caa	ggg	atc	cct	4081
Leu	Lys	Glu	Gln	His	His	Ile	Arg	Gly	Ser	Ile	Thr	Gln	Gly	Ile	Pro	
1345	5				1350	כ				1355	5				1360	
cgg	tcc	tac	gtg	gag	gca	cag	gag	gac	tac	ctg	cgt	cgg	gag	gcc	aag	4129
Arg	Ser	Tyr	Val	Glu	Ala	Gln	Glu	Asp	Tyr	Leu	Arg	Arg	Glu	Ala	Lys	
				1365	5				1370	כ				1375	5	
ctc	cta	aag	cgg	gag	ggc	acg	cct	ccg	ccc	cca	ccg	CCC	tca	cgg	gac	4177
Leu	Leu	Lys	Arg	Glu	Gly	Thr	Pro	Pro	Pro	Pro	Pro	Pro	Ser	Arg	Asp	
			1380	)				1389	5				1390	0		
ctg	acc	gag	gcc	tac	aag	acg	cag	gcc	ctg	ggc	ccc	ctg	aag	ctg	aag	4225
Leu	Thr	Glu	Ala	Tyr	Lys	Thr	Gln	Ala	Leu	Gly	Pro	Leu	Lys	Leu	Lys	
		139	5				1400	0				140	5			
ccg	gcc	cat	gag	ggc	ctg	gtg	gcc	acg	gtg	aag	gag	gcg	ggc	cgc	tcc	4273
Pro	Ala	His	Glu	Gly	Leu	Val	Ala	Thr	Val	Lys	Glu	Ala	Gly	Arg	Ser	
	1410	)				1419	5				1420	)				
atc	cat	gag	atc	ccg	cgc	gag	gag	ctg	cgg	cac	acg	ccc	gag	ctg	CCC	4321
Ile	His	Glu	Ile	Pro	Arg	Glu	G1u	Leu	Arg	His	Thr	Pro	Glu	Leu	Pro	
1425	5				1430	)				1435	5				1440	
ctg	gcc	ccg	cgg	ccg	ctc	aag	gag	ggc	tcc	atc	acg	cag	ggc	acc	ccg	4369
Leu	Ala	Pro	Arg	Pro	Leu	Lys	<b>Gl</b> u	Gly	Ser	Ile	Thr	Gln	Gly	.Thr	Pro	
				1445	5				1450	)				1455	5	
ctc	aag	tac	gac	acc	ggc	gcg	tcc	acc	act	ggc	tcc	aaa	aag	cac	gac	4417
Leu	Lys	Tyr	Asp	Thr	Gly	Ala	Ser	Thr	Thr	Gly	Ser	Lys	Lys	His	Asp	
			1460					1465					1470			
										acg						4465
Val	Arg	Ser	Leu	Ile	Gly	Ser	Pro	Gly	Arg	Thr	Phe	Pro	Pro	Val	His	
		1475	5				1480	)				1485	5			
										ctg						4513
Pro	Leu	Asp	Val	Met	Ala	Asp	Ala	Arg	Ala	Leu	Glu	Arg	Ala	Cys	Tyr	
	1490	)				1495	5				1500	)				
gag	gag	agc	ctg	aag	agc	cgg	cca	ggg	acc	gcc	agc	agc	tcg	ggg	ggc	4561
Glu	Glu	Ser	Leu	Lys	Ser	Arg	Pro	Gly	Thr	Ala	Ser	Ser	Ser	Gly	Gly	
1505	;				1510	)				1515	<b>;</b>				1520	
tcc	att	gcg	cgc	ggc	gcc	ccg	gtc	att	gtg	·cct	gag	ctg	ggt	aag	ccg	4609

Ser	Ile	Ala	Arg	Gly	Ala	Pro	Val	Ile	Val	Pro	Glu	Leu	Gly	Lys	Pro	
				152	5				153	0				153	5	
cgg	cag	agc	CCC	ctg	acc	tat	gag	gac	cac	ggg	gca	CCC	ttt	gcc	ggc	4657
Arg	Gln	Ser	Pro	Leu	Thr	Tyr	Glu	Asp	His	Gly	Ala	Pro	Phe	Ala	Gly	
			1540	0				154	5				155	0		
cac	ctc	cca	cga	ggt	tcg	ccc	gtg	acc	atg	cgg	gag	ccc	acg	ccg	cgc	4705
His	Leu	Pro	Arg	Gly	Ser	Pro	Va1	Thr	Met	Arg	Glu	Pro	Thr	Pro	Arg	
		155	5				156	0				156	5			
ctg	cag	gag	ggc	agc	ctt	tcg	tcc	agc	aag	gca	tcc	cag	gac	cga	aag	4753
Leu	Gln	Glu	Gly	Ser	Leu	Ser	Ser	Ser	Lys	Ala	Ser	Gln	Asp	Arg	Lys	
	157	0				157	5				158	0				
ctg	acg	tcg	acg	cct	cgt	gag	atc	gcc	aag	tcc	ccg	cac	agc	acc	gtg	4801
Leu	Thr	Ser	Thr	Pro	Arg	Glu	Ile	Ala	Lys	Ser	Pro	His	Ser	Thr	Val	
158	5				159	0				1599	5				1600	
. ccc	gag	cac	cac	cca	cac	ccc	atc	tcg	CCC	tat	gag	cac	ctg	ctt	cgg	4849
Pro	Glu	His	His	Pro	His	Pro	'Ile	Ser	Pro	Tyr	Glu	His	Leu	Leu	Arg	
				1605	5				161	o				161	5	
ggc	gtg	agt	ggc	gtg	gac	ctg	tat	cgc	agc	cac	atc	ccc	ctg	gcc	ttc	4897
Gly	Val	Ser	Gly	Val	Asp	Leu	Tyr	Arg	Ser	His	Ile	Pro	Leu	Ala	Phe	
			1620	)				1629	5				1630	)		
gac	ccc	acc	tcc	ata	ccc	cgc	ggc	atc	cct	ctg	gac	gca	gcc	gct	gcc	4945
Asp	Pro	Thr	Ser	Ile	Pro	Arg	Gly	Ile	Pro	Leu	Asp	Ala	Ala	Ala	Ala	
		1635	5				1640	)				1645	5			
tac	tac	ctg	ccc	cga	cac	ctg	gcc	CCC	aac	ccc	acc	tac	ccg	cac	ctg	4993
Tyr	Tyr	Leu	Pro	Arg	His	Leu	Ala	Pro	Asn	Pro	Thr	Tyr	Pro	His	Leu	•
	1650	)				1655	i .				1660	)				•
tac	cca	ccc	tac	ctc	atc	cgc	ggc	tac	ccc	gac	acg	gcg	gcg	ctg	gag	5041
Tyr	Pro	Pro	Tyr	Leu	Ile	Arg	Gly	Tyr	Pro	Asp	Thr	Ala	Ala	Leu	Glu	
1669	5				1670	)				1675	<b>i</b>				1680	
aac	cgg	cag	acc	atc	atc	aat	gac	tac	atc	acc	tcg	cag	cag	atg	cac	5089
Asn	Arg	Gln	Thr	Ile	Ile	Asn	Asp	Tyr	Ile	Thr	Ser	Gln	Gln	Met	His	
				1685	ı				1690	)				1695	j	
cac	aac	acg	gcc	acc	gcc	atg	gcc	cag	cga	gct	gat	atg	ctg	agg	ggc	5137
His	Asn	Thr	Ala	Thr	Ala	Met	Ala	Gln	Arg	Ala	Asp	Met	Leu	Arg	Gly	
			1700					1705	;				1710	)		•
ctc	tcg	ccc	cgc	gagʻ	tcc	tcg	ctg	gca	ctc	aac	tac	gct	gcg	ggt	CCC	5185
Leu	Ser	Pro	Arg	Glu	Ser	Ser	Leu	Ala	Leu	Asn	Tyr	Ala	Ala	Gly	Pro	
		1715					1720	)				1725				
cga	ggc	atc	atc	gac	ctg	tcc	caa	gtg	cca	cac	ctg	cçt	gtg	ctc	gtg	5233

PTS-0012 -26- PATENT

Arg	Gly	Ile	Ile	Asp	Leu	Ser	Gln	Val	Pro	His	Leu	Pro	Val	Leu	Val	
_	1730			-		1735					1740					
CCC	ccg	aca	cca	ggc	acc	cca	gcc	acc	gcc	atg	gac	cgc	ctt	gcc	tac	5281
Pro	Pro	Thr	Pro	Gly	Thr	Pro	Ala	Thr	Ala	Met	Asp	Arg	Leu	Ala	Tyr	
1745	5			_	1750	)				1755	5				1760	
ctc	ccc	acc	gcg	ccc	cag	ccc	ttc	agc	agc	cgc	cac	agc	agc	tcc	cca	5329
Leu	Pro	Thr	Ala	Pro	Gln	Pro	Phe	Ser	Ser	Arg	His	Ser	Ser	Ser	Pro	
				1765	5				1770	)				1775	5	
ctc	tcc	cca	gga	ggt	cca	aca	cac	ttg	aca	aaa	cca	acc	acc	acg	tcc	5377
Leu	Ser	Pro	Gly	Gly	Pro	Thr	His	Leu	Thr	Lys	Pro	Thr	Thr	Thr	Ser	
			1780	0				1785	5				1790	)		
tcg	tcc	gag	cgg	gag	cga	gac	cgg	gat	cga	gag	cgg	gac	cgg	gat	cgg	5425
Ser	Ser	Glu	Arg	Glu	Arg	Asp	Arg	Asp	Arg	Glu	Arg	qaA	Arg	Asp	Arg	
		1799	5				1800	)				1805	5			
gag	cgg	gaa	aag	tcc	atc	ctc	acg	tcc	acc	acg	acg	gtg	gag	cac	gca	5473
Glu ,	Arg	Glu	Lys	Ser	Ile	Leu	Thr	Ser	Thr	Thr	Thr	Val	Glu	His	Ala	
	1810	)				1815	5				1820	)				
CCC	atc	tgg	aga	cct	ggt	aca	gag	cag	agc	agc	ggc	agc	agc	ggc	agc	5521
		Trp	Arg	Pro	Gly	Thr	Glu	Gln	Ser	Ser	Gly	Ser	Ser	Gly	Ser	
182	5				1830	)				1839	5				1840	
		ggg			_		_	_	_				_			5569
Ser	GГĀ	Gly	Gly	_	_	Ser	Ser	Ser	_		Ala	Ser	His			
				184					1850					185		
	cac	cag	cac	tcg	CCC	atc			caa		can	mat	acc	CEC	$rac{1}{2}$	
Ата	*** -															5617
	His	Gln	His	Ser				Pro	Arg				Ala	Leu		3017
020		Gln	His 186	Ser 0	Pro	Ile	Ser	Pro 1865	Arg	Thr	Gln	Asp	Ala 187	Leu )	Gln	
	aga	Gln	His 1860 agt	Ser O gtg	Pro	Ile , cac	Ser aac	Pro 1865 aca	Arg 5 ggc	Thr atg	Gln	<b>Asp</b>	Ala 1870 atc	Leu ) atc	Gln	5665
	aga	Gln ccc Pro	His 1860 agt Ser	Ser O gtg	Pro	Ile cac His	Ser aac Asn	Pro 1865 aca Thr	Arg 5 ggc	Thr atg	Gln	Asp ggt Gly	Ala 1870 atc Ile	Leu ) atc	Gln	
Gln	aga Arg	Gln ccc Pro 187	His 1860 agt Ser	Ser 0 gtg Val	Pro ctt Leu	Ile cac His	ser aac Asn 1880	Pro 1865 aca Thr	Arg ggc Gly	Thr atg Met	Gln aag Lys	Asp ggt Gly 188	Ala 1870 atc Ile	Leu ) atc Ile	Gln acc Thr	5665
Gln gct	aga Arg gtg	Gln ccc Pro 1879 gag	His 1860 agt Ser 5	Ser 0 gtg Val	Pro ctt Leu	Ile cac His	ser aac Asn 1880 acg	Pro 1865 aca Thr )	Arg ggc Gly	Thr atg Met	Gln aag Lys	ggt Gly 1889	Ala 1870 atc Ile tcc	Leu ) atc Ile acc	Gln acc Thr	
Gln gct	aga Arg gtg	Gln ccc Pro 187! gag Glu	His 1860 agt Ser 5	Ser 0 gtg Val	Pro ctt Leu	Ile cac His	ser aac Asn 1880 acg	Pro 1865 aca Thr )	Arg ggc Gly	Thr atg Met	Gln aag Lys	ggt Gly 1889 acc	Ala 1870 atc Ile tcc	Leu ) atc Ile acc	Gln acc Thr	5665
Gln gct Ala	aga Arg gtg Val	CCC Pro 187! gag Glu	His 1860 agt Ser CCC	Ser 0 gtg Val agc Ser	Pro ctt Leu aag Lys	Cac His Ccc Pro	Ser  aac Asn 1880 acg Thr	Pro 1865 aca Thr ) gtc Val	Arg ggc Gly ctg Leu	Thr atg Met agg Arg	Gln aag Lys tcc Ser 1900	ggt Gly 1889 acc Thr	Ala 1870 atc Ile tcc	Leu  atc Ile  acc Thr	Gln acc Thr tcc Ser	5665
Gln gct Ala tca	aga Arg gtg Val 1890	Gln ccc Pro 187! gag Glu	His 1860 agt Ser ccc Pro	Ser 0 gtg Val agc Ser	ctt Leu aag Lys	cac His ccc Pro 1899	aac Asn 1880 acg Thr	Pro 1865 aca Thr ) gtc Val	Arg ggc Gly ctg Leu cca	Thr atg Met agg Arg	Gln aag Lys tcc Ser 1900 gcc	ggt Gly 1889 acc Thr	Ala 1870 atc Ile tcc Ser	Leu  atc Ile  acc Thr	Gln acc Thr tcc Ser	5665 5713
Gln gct Ala tca	aga Arg gtg Val 1890 ccc Pro	Gln  CCC Pro 1879 gag Glu O gtt	His 1860 agt Ser ccc Pro	Ser 0 gtg Val agc Ser	ctt Leu aag Lys	Cac His Ccc Pro 1899 gcc	aac Asn 1880 acg Thr	Pro 1865 aca Thr ) gtc Val	Arg ggc Gly ctg Leu cca	Thr atg Met agg Arg	Gln aag Lys tcc Ser 1900 gcc Ala	ggt Gly 1889 acc Thr	Ala 1870 atc Ile tcc Ser	Leu  atc Ile  acc Thr	Gln acc Thr tcc Ser	5665 5713
gct Ala tca Ser	aga Arg gtg Val 1890 ccc Pro	Gln  CCC Pro 1879 gag Glu O gtt	His 1860 agt Ser CCC Pro CgC	Ser  gtg  Val  agc  Ser  cca  Pro	ctt Leu aag Lys gct Ala 1910	Cac His Ccc Pro 1899 gcc Ala	aac Asn 1880 acg Thr aca	Pro 1865 aca Thr ) gtc Val ttc Phe	Arg ggc Gly ctg Leu cca Pro	Thr atg Met agg Arg cct Pro 1915	Gln aag Lys tcc Ser 1900 gcc Ala	ggt Gly 1889 acc Thr acc	Ala 1870 atc Ile tcc Ser cac	Leu  atc Ile  acc Thr  tgc Cys	Gln acc Thr tcc Ser cca Pro 1920	5665 5713
gct Ala tca Ser 1909	aga Arg gtg Val 1896 ccc Pro 5	CCC Pro 1879 gag Glu O gtt Val	His 1860 agt Ser CCC Pro CGC Arg	Ser  gtg Val  agc Ser  cca Pro	ctt Leu aag Lys gct Ala 1910 gat	Cac His Ccc Pro 1899 gcc Ala	aac Asn 1880 acg Thr aca Thr	Pro 1865 aca Thr  gtc Val  ttc Phe	Arg ggc Gly ctg Leu cca Pro	Thr atg Met agg Arg cct Pro 1915	Gln aag Lys tcc Ser 1900 gcc Ala 5	ggt Gly 1889 acc Thr acc Thr	Ala 1870 atc Ile tcc Ser cac His	atc Ile acc Thr tgc Cys	Gln acc Thr tcc Ser cca Pro 1920 gtc	5665 5713 5761
gct Ala tca Ser 1909	aga Arg gtg Val 1896 ccc Pro 5	Gln  ccc Pro 1879 gag Glu O gtt Val	His 1860 agt Ser CCC Pro CGC Arg	Ser  gtg Val  agc Ser  cca Pro	ctt Leu aag Lys gct Ala 1910 gat	Cac His Ccc Pro 1899 gcc Ala	aac Asn 1880 acg Thr aca Thr	Pro 1865 aca Thr  gtc Val  ttc Phe	Arg ggc Gly ctg Leu cca Pro	Thr atg Met agg Arg cct Pro 1919 acc Thr	Gln aag Lys tcc Ser 1900 gcc Ala 5	ggt Gly 1889 acc Thr acc Thr	Ala 1870 atc Ile tcc Ser cac His	atc Ile acc Thr tgc Cys	Gln acc Thr tcc Ser cca Pro 1920 gtc Val	5665 5713 5761

PTS-0012 -27- PATENT

_				_												
Leu	Leu	Pro			Ala	Pro	Arg	Val	Ala	Arg	Pro	Glu	Arg	Pro	Arg	
			1940					194	-				195	-		
							ctc									5905
Ala	Asp	Thr	Gly	His	Ala	Phe	Leu	Ala	Lys	Pro	Pro	Ala	Arg	Ser	Gly	
		1959	5				1960	)				196	5			
ctg	gag	ccc	gcc	tcc	tcc	ccc	agc	aag	ggc	tcg	gag	ccc	cgg	ccc	cta	5953
Leu	Glu	Pro	Ala	Ser	Ser	Pro	Ser	Lys	Gly	Ser	Glu	Pro	Arg	Pro	Leu	
	197	0				197	5				1980	)				
gtg	cct	cct	gtc	tct	ggc	cac	gcc	acc	atc	gcc	cgc	acc	cct	gcg	aag	6001
Val	Pro	Pro	Val	Ser	Gly	His	Ala	Thr	Ile	Ala	Arg	Thr	Pro	Ala	Lys	
1989	5				1990	)				1999	5				2000	
aac	ctc	gca	cct	cac	cac	gcc	agc	ccg	gac	ccg	ccg	gcg	cca	cct	gcc	6049
Asn	Leu	Ala	Pro	His	His	Ala	Ser	Pro	Asp	Pro	Pro	Ala	Pro	Pro	Ala	
•				2009	5				2010	)				201	5	•
tcg	gcc	tcg	gac	ccg	cac	cgg	gaa	aag	act	caa	agt	aaa	ccc	ttt	tcc	6097
Ser	Ala	Ser	Asp	Pro	His	Arg	Glu	Lys	Thr	Gln	Ser	Lys	Pro	Phe	Ser	
			2020	)				2025	5				2030	)		
atc	cag	gaa	ctg	gaa	ctc	cgt	tct	ctg	ggt	tac	cac	ggc	agc	agc	tac	6145
Ile	Gln	Glu	Leu	Glu	Leu	Arg	Ser	Leu	Gly	Tyr	His	Gly	Ser	Ser	Tyr	
		2035	5				2040	)				2049	5			
agc	CCC	gaa	ggg	gtg	gag	ccc	gtc	agc	cct	gtg	agc	tca	ccc	agt	ctg	6193
Ser	Pro	Glu	Gly	Vạ1	Glu	Pro	Val	Ser	Pro	Val	Ser	Ser	Pro	Ser	Leu	
	2050	)				2055	5				2060	)				
acc	cac	gac	aag	ggg	ctc	ccc	aag	cac	ctg	gaa	gag	ctc	gac	aag	agc	6241
Thr	His	Asp	Lys	Gly	Leu	Pro	Lys	His	Leu	Glu	Glu	Leu	Asp	Lys	Ser	
2065	<b>5</b>				2070	)				2079	5				2080	
cac	ctg	gag	ggg	gag	ctg	cgg	ccc	aag	cag	cca	ggc	ccc	gtg	aag	ctt	6289
His	Leu	Glu	Gly	Glu	Leu	Arg	Pro	Lys	Gln	Pro	Gly	Pro	Val	Lys	Leu	
				2085	5				2090	)				2095	5	
ggc	ggg	gag	gcc	gcc	cac	ctc	cca	cac	ctg	cgg	ccg	ctg	cct	gag	agc	6337
Gly	Gly	Glu	Ala	Ala	His	Leu	Pro	His	Leu	Arg	Pro	Leu	Pro	Glu	Ser	
			2100	)				2105	;				2110	)		
cag	ccc	tcg	tcc	agc	ccg	ctg	ctc	cag	acc	gcc	cca	ggg	gtc	aaa	ggt	6385
Gln	Pro	Ser	Ser	Ser	Pro	Leu	Leu	Gln	Thr	Ala	Pro	Gly	Val	Lys	Gly	
		2115	;				2120	)				2125	j			
cac	cag	cgg	gtg	gtc	acc	ctg	gcc	cag	cac	atc	agt	gag	gtc	atc	aca	6433
							Ala									
	2130					2135					2140					
caģ	gac	tac	acc	cgg	cac	cac	cca	cag	cag	ctc	agc	gca	ccc	ctg	ccc	6481
						•			_		-			_		

PTS-0012

2150   2155   2160   2529   2520   2620   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520   2520		Thr Arg Hi	s His Pro	Gln Glr	Leu Ser	Ala Pro	Leu Pro	
Ala Pro Leu Tyr Ser Phe Pro Gly Ala Ser Cys Pro Val Leu Asp Leu   2165   2170   2175   2175   2165   2170   2175   2175   2280   2280   22185   2190   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   2295   229	2145	21	50		2155		2160	
2165   2170   2175   6577   6577   6577   6577   6778   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779   6779	gcc ccc ctc	tac tcc tt	c cct ggg	gcc ago	tge cec	gtc ctg	g gac ctc	6529
CgC cgc cca ccc agt gac ctc tac ctc ccg ccc ccg gac cat ggt gcc	Ala Pro Leu '	Tyr Ser Ph	e Pro Gly	Ala Ser	Cys Pro	Val Le	ı Asp Leu	
Arg Arg Pro   Pro   Ser Asp   Leu Tyr   Leu Pro   Pro   Asp   His   Gly   Ala   2180   2185   2190   2190   2185   2190   2190   2185   2190   2190   2195   2200   2205   2205   2205   2200   2205   2205   2200   2205   2205   2200   2205   2205   2200   2205   2205   2200   2205   2205   2200   2205   2205   2200   2205   2205   2200   2205   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2215   2220   2220   2220   2200   2215   2220   2220   2220   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2200   2205   2205   2200   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205   2205		2165		217	0		2175	
2185 2190  Ccg gcc cgt ggc tcc ccc cac agc gaa ggg ggc aag agg tct cca gag 6625  Pro Ala Arg Gly Ser Pro His Ser Glu Gly Gly Lys Arg Ser Pro Glu 2195  Cca aac aag acg tcg gtc ttg ggt ggt ggt gag gac ggt att gaa cct 6673  Pro Asn Lys Thr Ser Val Leu Gly Gly Gly Glu Asp Gly Ile Glu Pro 2210  2210  2215  2220  gtg tcc cca ccg gag ggc atg acg ggg cac tcc cgg agt gct 871  Val Ser Pro Pro Glu Gly Met Thr Glu Pro Gly His Ser Arg Ser Ala 872  gtg tac cca ccg gag ggc atg ggg gac acg acg gag cca ccg agg acc acg acg	cgc cgc cca	ccc agt ga	c ctc tac	ctc ccg	ccc ccg	gac cat	ggt gcc	6577
Ccc   gcc   cgt   ggc   tcc   ccc   cac   agc   gaa   ggg   ggc   agg   ggc   agg   gtc   cca   gag   cgc   cgc   ggc   cgc    Arg Arg Pro	Pro Ser As	p Leu Tyr	Leu Pro	Pro Pro	Asp His	Gly Ala		
Pro Ala Arg Gly Ser Pro His Ser Glu Gly Gly Lys Arg Ser Pro Glu   2195   2200   2205   2205   2205   2206   2205   2205   2205   2205   2206   2205   2205   2205   2205   2205   2205   2210   2215   2220   2220   2215   2220   2215   2220   2215   2220   2215   2220   2215   2220   2215   2220   2215   2220   2215   2220   2215   2220   2235   2240   2225   2230   2235   2235   2240   2225   2230   2235   2235   2240   2255   2230   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255								
2195 2200 2205  Cca aac aag acg tcg gtc ttg ggt ggt ggt ggt ggg gac ggt att gaa cct 6673  Pro Asn Lys Thr Ser Val Leu Gly Gly Glu Asp Gly Ile Glu Pro 2210 2215 2220  gtg tcc cca ccg gag ggc atg acg gag cca ggg cac tcc cgg agt gct 6721  Val Ser Pro Pro Glu Gly Met Thr Glu Pro Gly His Ser Arg Ser Ala 2225 2230 2230 2235 2240  gtg tac ccg ctg ctg tac cgg gat ggg gaa cag acg acg acg acg acg acg acg								6625
CCC acc acc acc acc acc acc acc acc acc	Pro Ala Arg (	Gly Ser Pr	o His Ser	Glu Gly	Gly Lys	Arg Ser	Pro Glu	
Pro				-				
2210 2215 2220  gtg tcc cca ccg gag ggc atg acg gag cca ggg cac tcc cgg agt gct 6721  Val Ser Pro Pro Glu Gly Met Thr Glu Pro Gly His Ser Arg Ser Ala  2225 2230 2235 2240  gtg tac ccg ctg ctg tac cgg gat ggg gaa cag acg gag ccc agc agg 6769  Val Tyr Pro Leu Leu Tyr Arg Asp Gly Glu Gln Thr Glu Pro Ser Arg  2245 2250 2255 2255  atg ggc tcc aag tct cca ggc aac acc agc cag ccg cca gcc ttc tc c 2265  atg ggc tcc aag tct cca ggc aac acc agc cag ccg cca gcc ttc tc c 2260 2265 2270  agc aag ctg acc gag agc aac tcc gcc atg gtc aag tcc aag aag ca 6865  Ser Lys Leu Thr Glu Ser As Ser Ala Met Val Lys Ser Lys Lys Gln 2270  gag atc aac aag aag aac ac cac cac aac cgg aat gag cct gaa tac 6913  Glu Ile Asn Lys Lys Leu Asn Thr His Asn Arg Asn Glu Pro Glu Tyr 2290 2295 2300  aat atc agc cag cct ggg acg gag atc ttc aat atg ccc gcc atc acc 6961  Asn Ile Ser Gln Pro Gly Thr Glu Ile Phe Asn Met Pro Ala Ile Thr 2305 2310 2315 2320  gga aca ggc ctt atg acc tat aga agc cag cag ggg gtg cag gaa cat gcc 7009  Gly Thr Gly Leu Met Thr Tyr Arg Ser Gln Ala Val Gln Glu His Ala  2325 2330 2335								6673
gtg tcc cca ccg gag ggc atg acg cca ggg cac tcc cgg agt gct   6721  Val Ser Pro Pro Glu Gly Met Thr Glu Pro Gly His Ser Arg Ser Ala   2225   2230   2235   2240    gtg tac ccg ctg ctg tac cgg gat ggg gaa cag acg gag ccc agc agg   6769  Val Tyr Pro Leu Leu Tyr Arg Asp Gly Glu Gln Thr Glu Pro Ser Arg   2245   2250   2255    atg ggc tcc aag tct cca ggc aac acc agc cag ccg cca gcc ttc ttc   6817  Met Gly Ser Lys Ser Pro Gly Asn Thr Ser Gln Pro Pro Ala Phe Phe   2260   2265   2270    agc aag ctg acc gag agc aac tcc gcc atg gtc aag tcc aag aag caa   6865  Ser Lys Leu Thr Glu Ser Asn Ser Ala Met Val Lys Ser Lys Lys Gln   2275   2280   2285    gag atc aac aag aag ctg acc acc acc acc acc gg aat gag cct gaa tac   6913  Glu Ile Asn Lys Lys Leu Asn Thr His Asn Arg Asn Glu Pro Glu Tyr   2290   2295   2300    aat atc agc cag cct ggg acg gag atc ttc aat atg ccc gcc atc acc   6961  Asn Ile Ser Gln Pro Gly Thr Glu Ile Phe Asn Met Pro Ala Ile Thr   2305   2310   2315   2320    gga aca ggc ctt atg acc tat aga agc cag acg gtg cag gaa cat gcc   7009  Gly Thr Gly Leu Met Thr Tyr Arg Ser Gln Ala Val Gln Glu His Ala   2325   2330   2335    agc acc acc acc acc acc acc acc acc acc		Thr Ser Va	1 Leu Gly	Gly Gly	Glu Asp	Gly Ile	Glu Pro	
Yal Ser Pro Pro Glu Gly Met Thr Glu Pro Gly His Ser Arg Ser Ala   2225   2230   2235   2240   2245   2240   2235   2240   2245   2240   2245   2240   2245   2245   2245   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255   2255								
2235 2240  gtg tac ccg ctg ctg tac cgg gat ggg gaa cag acg gag ccc agc agg 6769  Val Tyr Pro Leu Leu Tyr Arg Asp Gly Glu Gln Thr Glu Pro Ser Arg  2245 2250 2255  atg ggc tcc aag tct cca ggc aac acc agc cag ccg cca gcc ttc ttc  Agg aag ctg Ser Lys Ser Pro Gly Asn Thr Ser Gln Pro Pro Ala Phe Phe  2260 2265 2270  agc aag ctg acc gag agc aac tcc gcc atg gtc aag tcc aag aag caa  Ser Lys Leu Thr Glu Ser Asn Ser Ala Met Val Lys Ser Lys Lys Gln  2275  gag atc aac aag aag ctg aac acc cac aac cgg aat gag cct gaa tac  Glu Ile Asn Lys Lys Leu Asn Thr His Asn Arg Asn Glu Pro Glu Tyr  2290 2295 2300  aat atc agc cag cct ggg acg gag atc ttc aat atg ccc gcc atc acc  Asn Ile Ser Gln Pro Gly Thr Glu Ile Phe Asn Met Pro Ala Ile Thr  2305 2310 2315 2320  Gga aca ggc ctt atg acc tat aga agc cag gcg gtg cag gaa cat gcc  Gly Thr Gly Leu Met Thr Tyr Arg Ser Gln Ala Val Gln Glu His Ala  2325 2330 2335								6721
gtg tac ccg ctg ctg tac cgg gat ggg gaa cag acg gag ccc agc agg 6769  Val Tyr Pro Leu Leu Tyr Arg Asp Gly Glu Glu Thr Glu Pro Ser Arg 2245  atg ggc tcc aag tct cca ggc aac acc agc cag ccg cca gcc ttc ttc  Act Gly Ser Lys Ser Pro Gly Asn Thr Ser Gln Pro Pro Ala Phe Phe 2260  2265  agc aag ctg acc gag agc aac tcc gcc atg gtc aag tcc aag aag caa 6865  Ser Lys Leu Thr Glu Ser Asn Ser Ala Met Val Lys Ser Lys Lys Gln 2275  gag atc aac aag aag ctg aac acc cac aac cgg aat gag cct gaa tac Glu Ile Asn Lys Lys Leu Asn Thr His Asn Arg Asn Glu Pro Glu Tyr 2290  aat atc agc cag cct ggg acg gag atc ttc aat atg ccc gcc atc acc Asn Ile Ser Gln Pro Gly Thr Glu Ile Phe Asn Met Pro Ala Ile Thr 2305  gga aca ggc ctt atg acc tat aga agc cag gcg gtg cag gaa cat gcc Gly Thr Gly Leu Met Thr Tyr Arg Ser Gln Ala Val Gln Glu His Ala 2325  2330  acc acc acc act ggg ctg gag acg cat att att aga aag gca ctc att ggt 7009  agc acc acc act att ggg ctg gag acg cat att aga aag gca ctc att ggt 7057	•			Glu Pro		Ser Arg	Ser Ala	
Val Tyr Pro Leu Leu Tyr Arg Asp Gly Glu Gln Thr Glu Pro Ser Arg  2245  2250  2255  atg ggc tcc aag tct cca ggc aac acc agc cag ccg cca gcc ttc ttc  6817  Met Gly Ser Lys Ser Pro Gly Asn Thr Ser Gln Pro Pro Ala Phe Phe  2260  2265  2270  agc aag ctg acc gag agc aac tcc gcc atg gtc aag tcc aag aag caa  6865  Ser Lys Leu Thr Glu Ser Asn Ser Ala Met Val Lys Ser Lys Lys Gln  2275  2280  2285  gag atc aac aag aag ctg aac acc cac aac cgg aat gag cct gaa tac  6913  Glu Ile Asn Lys Lys Leu Asn Thr His Asn Arg Asn Glu Pro Glu Tyr  2290  2295  2310  2315  2320  Gly Thr Gly Leu Met Thr Tyr Arg Ser Gln Ala Val Gln Glu His Ala  2325  2330  7057							· -	
2250 2255 2270  atg ggc tcc aag tct cca ggc aac acc agc cag ccg cca gcc ttc ttc tc 6817  Met Gly Ser Lys Ser Pro Gly Asn Thr Ser Gln Pro Pro Ala Phe Phe 2260 2265 2270  agc aag ctg acc gag agc aac tcc gcc atg gtc aag tcc aag aag caa 6865  Ser Lys Leu Thr Glu Ser Asn Ser Ala Met Val Lys Ser Lys Lys Gln 2275  gag atc aac aag aag ctg aac acc cac aac cgg aat gag cct gaa tac 6913  Glu Ile Asn Lys Lys Leu Asn Thr His Asn Arg Asn Glu Pro Glu Tyr 2290 2295 2300  aat atc agc cag cct ggg acg gag atc ttc aat atg ccc gcc atc acc 6961  Asn Ile Ser Gln Pro Gly Thr Glu Ile Phe Asn Met Pro Ala Ile Thr 2305 2310 2315 2320  gga aca ggc ctt atg acc tat aga agc cag gcg gtg cag gaa cat gcc 7009  Gly Thr Gly Leu Met Thr Tyr Arg Ser Gln Ala Val Gln Glu His Ala 2325 2330 7057								6769
atg ggc tcc aag tct cca ggc aac acc agc cag ccg cca gcc ttc ttc  Met Gly Ser Lys Ser Pro Gly Asn Thr Ser Gln Pro Pro Ala Phe Phe  2260  2265  2270  agc aag ctg acc gag agc aac tcc gcc atg gtc aag tcc aag aag caa 6865  Ser Lys Leu Thr Glu Ser Asn Ser Ala Met Val Lys Ser Lys Lys Gln  2275  2280  2285  gag atc aac aag aag ctg aac acc cac aac cgg aat gag cct gaa tac 6913  Glu Ile Asn Lys Lys Leu Asn Thr His Asn Arg Asn Glu Pro Glu Tyr  2290  2295  2300  aat atc agc cag cct ggg acg gag atc ttc aat atg ccc gcc atc acc 6961  Asn Ile Ser Gln Pro Gly Thr Glu Ile Phe Asn Met Pro Ala Ile Thr  2305  2310  2315  2320  gga aca ggc ctt atg acc tat aga agc cag gcg gtg cag gaa cat gcc 7009  Gly Thr Gly Leu Met Thr Tyr Arg Ser Gln Ala Val Gln Glu His Ala  2325  2330  7057	var Tyr Pro I		r Arg Asp			Glu Pro		
Met Gly Ser Lys Ser Pro Gly Asn Thr Ser Gln Pro Pro Ala Phe Phe 2260 2265 2270  agc aag ctg acc gag agc aac tcc gcc atg gtc aag tcc aag aag caa 6865  Ser Lys Leu Thr Glu Ser Asn Ser Ala Met Val Lys Ser Lys Lys Gln 2275 2280 2285  gag atc aac aag aag ctg aac acc cac aac cgg aat gag cct gaa tac 6913  Glu Ile Asn Lys Lys Leu Asn Thr His Asn Arg Asn Glu Pro Glu Tyr 2290 2295 2300  aat atc agc cag cct ggg acg gag atc ttc aat atg ccc gcc atc acc 6961  Asn Ile Ser Gln Pro Gly Thr Glu Ile Phe Asn Met Pro Ala Ile Thr 2305 2310 2315 2320  gga aca ggc ctt atg acc tat aga agc cag gcg gtg cag gaa cat gcc 7009  Gly Thr Gly Leu Met Thr Tyr Arg Ser Gln Ala Val Gln Glu His Ala 2325 2330 7057	ata aan tan s							
2265 2270  agc aag ctg acc gag agc aac tcc gcc atg gtc aag tcc aag aag caa 6865  Ser Lys Leu Thr Glu Ser Asn Ser Ala Met Val Lys Ser Lys Lys Gln  2275 2280 2285  gag atc aac aag aag ctg aac acc cac aac cgg aat gag cct gaa tac 6913  Glu Ile Asn Lys Lys Leu Asn Thr His Asn Arg Asn Glu Pro Glu Tyr  2290 2295 2300  aat atc agc cag cct ggg acg gag atc ttc aat atg ccc gcc atc acc 69616  Asn Ile Ser Gln Pro Gly Thr Glu Ile Phe Asn Met Pro Ala Ile Thr  2305 2310 2315 2320  gga aca ggc ctt atg acc tat aga agc cag gcg gtg cag gaa cat gcc 7009  Gly Thr Gly Leu Met Thr Tyr Arg Ser Gln Ala Val Gln Glu His Ala  2325 2330 7057								6817
age aag ctg acc gag age aac tcc gcc atg gtc aag tcc aag aag caa 6865  Ser Lys Leu Thr Glu Ser Asn Ser Ala Met Val Lys Ser Lys Lys Gln  2275  2280  2285  gag atc aac aag aag ctg aac acc cac aac cgg aat gag cct gaa tac 6913  Glu Ile Asn Lys Lys Leu Asn Thr His Asn Arg Asn Glu Pro Glu Tyr  2290  2295  2300  aat atc age cag cct ggg acg gag atc ttc aat atg ccc gcc atc acc 6961  Asn Ile Ser Gln Pro Gly Thr Glu Ile Phe Asn Met Pro Ala Ile Thr  2305  2310  2315  2320  Gly Thr Gly Leu Met Thr Tyr Arg Ser Gln Ala Val Gln Glu His Ala  2325  2330  2335  age acc aac atg ggg ctg gag gcc ata att aga aag gca ctc atg ggt 7057			o Giy Asn		Gin Pro			
Ser Lys Leu Thr Glu Ser Asn Ser Ala Met Val Lys Ser Lys Lys Gln  2275 2280 2285  gag atc aac aag aag ctg aac acc cac aac cgg aat gag cct gaa tac 6913  Glu Ile Asn Lys Lys Leu Asn Thr His Asn Arg Asn Glu Pro Glu Tyr  2290 2295 2300  aat atc agc cag cct ggg acg gag atc ttc aat atg ccc gcc atc acc 6961  Asn Ile Ser Gln Pro Gly Thr Glu Ile Phe Asn Met Pro Ala Ile Thr  2305 2310 2315 2320  gga aca ggc ctt atg acc tat aga agc cag gcg gtg cag gaa cat gcc 7009  Gly Thr Gly Leu Met Thr Tyr Arg Ser Gln Ala Val Gln Glu His Ala  2325 2330 7057			a aaa taa		<del></del>			
gag atc aac aag aag ctg aac acc cac aac cgg aat gag cct gaa tac 6913 Glu Ile Asn Lys Lys Leu Asn Thr His Asn Arg Asn Glu Pro Glu Tyr 2290 2295 2300  aat atc agc cag cct ggg acg gag atc ttc aat atg ccc gcc atc acc 6961 Asn Ile Ser Gln Pro Gly Thr Glu Ile Phe Asn Met Pro Ala Ile Thr 2305 2310 2315 2320  gga aca ggc ctt atg acc tat aga agc cag gcg gtg cag gaa cat gcc 7009 Gly Thr Gly Leu Met Thr Tyr Arg Ser Gln Ala Val Gln Glu His Ala 2325 2330 2335								6865
gag atc aac aag aag ctg aac acc cac aac cgg aat gag cct gaa tac 6913 Glu Ile Asn Lys Lys Leu Asn Thr His Asn Arg Asn Glu Pro Glu Tyr 2290 2295 2300  aat atc agc cag cct ggg acg gag atc ttc aat atg ccc gcc atc acc 6961 Asn Ile Ser Gln Pro Gly Thr Glu Ile Phe Asn Met Pro Ala Ile Thr 2305 2310 2315 2320  gga aca ggc ctt atg acc tat aga agc cag gcg gtg cag gaa cat gcc 7009 Gly Thr Gly Leu Met Thr Tyr Arg Ser Gln Ala Val Gln Glu His Ala 2325 2330 2335  agc acc aac atg ggg ctg gag gcc ata att aga aag gca ctc atg ggt 7057		inz dia pe			var Lys		Lys Gin	
Glu Ile Asn Lys Lys Leu Asn Thr His Asn Arg Asn Glu Pro Glu Tyr  2290  2295  2300  aat atc agc cag cct ggg acg gag atc ttc aat atg ccc gcc atc acc 6961  Asn Ile Ser Gln Pro Gly Thr Glu Ile Phe Asn Met Pro Ala Ile Thr  2305  2310  2315  2320  7009  Gly Thr Gly Leu Met Thr Tyr Arg Ser Gln Ala Val Gln Glu His Ala  2325  2330  2335  2335	•	an aan ct		U		2200		
2295 2300  aat atc agc cag cct ggg acg gag atc ttc aat atg ccc gcc atc acc 6961  Asn Ile Ser Gln Pro Gly Thr Glu Ile Phe Asn Met Pro Ala Ile Thr  2305 2310 2315 2320  gga aca ggc ctt atg acc tat aga agc cag gcg gtg cag gaa cat gcc 7009  Gly Thr Gly Leu Met Thr Tyr Arg Ser Gln Ala Val Gln Glu His Ala  2325 2330 2335  agc acc aac atg ggg ctg gag gcc ata att aga aag gca ctc atg ggt 7057			T AAC ACC	cac aac	caa sat	<b>6</b> 26 665	~~~ h~~	C013
aat atc agc cag cct ggg acg gag atc ttc aat atg ccc gcc atc acc 6961  Asn Ile Ser Gln Pro Gly Thr Glu Ile Phe Asn Met Pro Ala Ile Thr  2305 2310 2315 2320  gga aca ggc ctt atg acc tat aga agc cag gcg gtg cag gaa cat gcc 7009  Gly Thr Gly Leu Met Thr Tyr Arg Ser Gln Ala Val Gln Glu His Ala  2325 2330 2335  agc acc aac atg ggg ctg gag gcc ata att aga aag gca ctc atg ggt 7057								6913
Asn Ile Ser Gln Pro Gly Thr Glu Ile Phe Asn Met Pro Ala Ile Thr  2305 2310 2315 2320  gga aca ggc ctt atg acc tat aga agc cag gcg gtg cag gaa cat gcc 7009  Gly Thr Gly Leu Met Thr Tyr Arg Ser Gln Ala Val Gln Glu His Ala 2325 2330 2335  agc acc aac atg ggg ctg gag gcc ata att aga aag gca ctc atg ggt 7057	Glu Ile Asn I		Asn Thr		Arg Asn	Glu Pro		6913
2310 2315 2320  gga aca ggc ctt atg acc tat aga agc cag gcg gtg cag gaa cat gcc 7009  Gly Thr Gly Leu Met Thr Tyr Arg Ser Gln Ala Val Gln Glu His Ala 2325 2330 2335  agc acc aac atg ggg ctg gag gcc ata att aga aag gca ctc atg ggt 7057	Glu Ile Asn I 2290	ys Lys Le	Asn Thr 2295	His Asn	Arg Asn	Glu Pro )	Glu Tyr	
gga aca ggc ctt atg acc tat aga agc cag gcg gtg cag gaa cat gcc 7009  Gly Thr Gly Leu Met Thr Tyr Arg Ser Gln Ala Val Gln Glu His Ala 2325  2330  2335  agc acc aac atg ggg ctg gag gcc ata att aga aag gca ctc atg ggt 7057	Glu Ile Asn I 2290 aat atc agc o	ys Lys Len	Asn Thr 2295 acg gag	His Asn	Arg Asn 2300 aat atg	Glu Pro ) ccc gcc	Glu Tyr	
Gly Thr Gly Leu Met Thr Tyr Arg Ser Gln Ala Val Gln Glu His Ala 2325 2330 2335 agc acc aac atg ggg ctg gag gcc ata att aga aag gca ctc atg ggt 7057	Glu Ile Asn I 2290 aat atc agc c Asn Ile Ser G	ys Lys Le ag cct gg ln Pro Gl	Asn Thr 2295 acg gag Thr Glu	His Asn	Arg Asn 2300 aat atg Asn Met	Glu Pro ) ccc gcc	Glu Tyr atc acc	
2325 2330 2335 agc acc acc atg ggg ctg gag gcc ata att aga aag gca ctc atg ggt 7057	Glu Ile Asn I 2290 aat atc agc o Asn Ile Ser G 2305	eag cct ggg ln Pro Gl	Asn Thr 2295 Gacg gag Thr Glu	His Asn	Arg Asn 2300 aat atg Asn Met 2315	Glu Pro ) ccc gcc Pro Ala	Glu Tyr atc acc Ile Thr 2320	6961
age acc aac atg ggg ctg gag gcc ata att aga aag gca ctc atg ggt 7057	Glu Ile Asn I 2290  aat atc agc o Asn Ile Ser G 2305  gga aca ggc o	ag cct ggg ln Pro Gly 23: ett atg acc	Asn Thr 2295 g acg gag Thr Glu 10 t tat aga	His Asn atc ttc Ile Phe agc cag	Arg Asn 2300 aat atg Asn Met 2315 gcg gtg	Glu Pro ) ccc gcc Pro Ala cag gaa	Glu Tyr  atc acc  Ile Thr  2320  cat gcc	6961
	Glu Ile Asn I 2290  aat atc agc o Asn Ile Ser G 2305  gga aca ggc o	eag cct ggg In Pro Gly 23: Ett atg acc	Asn Thr 2295 g acg gag Thr Glu 10 t tat aga	His Asn atc ttc Ile Phe agc cag Ser Gln	Arg Asn 2300 aat atg Asn Met 2315 gcg gtg Ala Val	Glu Pro ) ccc gcc Pro Ala cag gaa	Glu Tyr  atc acc Ile Thr 2320 cat gcc His Ala	6961
2 -2	Glu Ile Asn I 2290  aat atc agc c Asn Ile Ser G 2305  gga aca ggc c Gly Thr Gly L	ag cct ggalln Pro Gly 23: Ett atg acc eu Met The	Asn Thr 2295 G acg gag Thr Glu O tat aga	His Asn atc ttc Ile Phe agc cag Ser Gln 2330	Arg Asn 2300 aat atg Asn Met 2315 gcg gtg Ala Val	Glu Pro CCC GCC Pro Ala Cag gaa Gln Glu	Glu Tyr  atc acc  Ile Thr  2320  cat gcc  His Ala  2335	6961 7009
2340 2345 2350	Glu Ile Asn I 2290  aat atc agc o Asn Ile Ser G 2305  gga aca ggc o Gly Thr Gly I	eag cct ggg In Pro Gl 23: Ett atg acc eu Met The 2325 tg ggg ctg	Asn Thr 2295 g acg gag y Thr Glu 10 c tat aga r Tyr Arg	His Asn atc ttc Ile Phe agc cag Ser Gln 2336 ata att	Arg Asn 2300 aat atg Asn Met 2315 gcg gtg Ala Val	Glu Pro CCC GCC Pro Ala Cag gaa Gln Glu GCa CtC	atc acc Ile Thr 2320 cat gcc His Ala 2335 atg ggt	6961 7009
aaa tat gac cag tgg gaa gag tcc ccg ccg ctc agc gcc aat gct ttt 7105	Glu Ile Asn I 2290  aat atc agc o Asn Ile Ser G 2305  gga aca ggc o Gly Thr Gly L agc acc aac a Ser Thr Asn M	eag cct ggg In Pro Gl 23: Ett atg acc eu Met The 2325 Etg ggg ctc et Gly Lec	Asn Thr 2295 g acg gag y Thr Glu 10 c tat aga r Tyr Arg	His Asn atc ttc Ile Phe agc cag Ser Gln 2330 ata att Ile Ile	Arg Asn 2300 aat atg Asn Met 2315 gcg gtg Ala Val	Glu Pro CCC GCC Pro Ala Cag gaa Gln Glu GCa CtC Ala Leu	atc acc Ile Thr 2320 cat gcc His Ala 2335 atg ggt Met Gly	6961 7009

PTS-0012 -29- PATENT

Lys	Tyr	Asp	Gln	Trp	Glu	Glu	Ser	Pro	Pro	Leu	Ser	Ala	Asn	Ala	Phe	
	•	2359	5				2360	)				236	5			
aac	cct	ctg	aat	gcc	agt	gcc	agc	ctg	ccc	gct	gct	atg	CCC	ata	acc	7153
Asn	Pro	Leu	Asn	Ala	Ser	Ala	Ser	Leu	Pro	Ala	Ala	Met	Pro	Ile	Thr	
	237	0				2375	5				2380					
gct	gct	gac	gga	cgg	agt	gac	cac	aca	ctc	acc	tcg	cca	ggt	ggc	ggc	720Ì
Ala	Ala	Asp	Gly	Arg	Ser	Asp	His	Thr	Leu	Thr	Ser	Pro	Gly	Gly	Gly	
238	5				239	0				2399	5				2400	
ggg	aag	gcc	aag	gtc	tct	ggc	aga	ccc	agc	agc	cga	aaa	gcc	aag	tcc	7249
Gly	Lys	Ala	Lys	Val	Ser	Gly	Arg	Pro	Ser	Ser	Arg	Lys	Ala	Lys	Ser	
				240	5				2410	)				2415	5	
ccg	gcc	ccg	ggc	ctg	gca	tct	ggg	gac	cgg	cca	ccc	tct	gtc	tcc	tca	7297
Pro	Ala	Pro	Gly	Leu	Ala	Ser	Gly	Asp	Arg	Pro	Pro	Ser	Val	Ser	Ser	
			2420	0				2425	5				243	0		
gtg	cac	tcg	gag	gga	gac	tgc	aac	cgc	cgg	acg	ccg	ctc	acc	aac	cgc	7345
Val	His	Ser	Glu	Gly	Asp	Cys	Asn	Arg	Arg	Thr	Pro	Leu	Thr	Asn	Arg	
		243	5				2440	)				244	5			
gtg	tgg	gag	gac	agg	ccc	tcg	tcc	gca	ggt	tcc	acg	cca	ttc	ccc	tac	7393
Val	Trp	Glu	Asp	Arg	Pro	Ser	Ser	Ala	Gly	Ser	Thr	Pro	Phe	Pro	Tyr	
	245	0				245	5				246	С				
aac	ccc	ctg	atc	atg	cgg	ctg	cag	gcg	ggt	gtc	atg	gct	tcc	cca	ccc	7441
Asn	Pro	Leu	Ile	Met	Arg	Leu	Gln	Ala	Gly	Val	Met	Ala	Ser	Pro	Pro	
246	5				247	0				247	5				2480	
cca	ccg	ggc	ctc	ccc	gcg	ggc	agc	ggg	ccc	ctc	gct	ggc	ccc	cac	cac	7489
Pro	Pro	Gly	Leu	Pro	Ala	Gly	Ser	Gly	Pro	Leu	Ala	Gly	Pro	His	His	
				248	5				249	0				249	5	
gcc	tgg	gac	gag	gag	ccc	aag	cca	ctg	ctc	tgc	tcg	cag	tac	gag	aca	7537
Ala	Trp	Asp	Glu	Glu	Pro	Lys	Pro	Leu	Leu	Cys	Ser	Gln	Туr	Glu	Thr	
			250	0				250	5				251	0		
ctc	tcc	gac	agc	gag	tga	ctc	agaa	cag (	ggcg	gggg	gg g	gcgg	gegg	t		7585
Leu	Ser	Asp	Ser	Glu												
		251	5				•									
gtc	aggt	ccc a	agcg	agcc	ac a	ggaa	cggc	c ct	gcag	gagc	ggg	gcgg	ctg	ccga	ctcccc	7645
caa	ccaa	gga	agga	gccc	ct g	agtc	cgcci	t gc	gcct	ccat	cca	tctg	tcc	gtcca	agagcc	7705
ggc	atcc	ttg (	cctg	tcta	aa g	cctt	aacta	a aga	actc	ccgc	CCC	gggc	tgg	ccct	gtgcag	7765
acc	ttac	tca	gggg	atgt	tt a	cctg	gtgc	t cg	ggaa	ggga	ggg	gaag	ggg	ccgg	ggaggg	7825
ggc	acgg	cag	gcgt	gtgg	ca g	ccac	acaca	a gge	egge	cagg	gcg	gcca	ggg	accca	aaagca	7885
gga	tgac	cac	gcac	ctcc	ac g	ccac	tgcc	t cc	cccg	aatg	cat	ttgg	aac	caaa	gtctaa	7945
açt	gagc	tcg (	cagc	cccc	gc g	ccct	ccct	c cg	cctc	ccat	ccc	gctt	agc	gctc	tggaca	8005
										•						

-30-

gatggacgca ggccctgtcc agccccagt gcgctcgttc cggtcccac agactgccc 8065 agccaacgag attgctggaa accaagtcag gccaggtgg cggacaaaag ggccaggtgc 8125 ggcctggggg gaacggatgc tccgaggact ggactgttt tttcacacat cgttgccgca 8185 gcggtgggaa ggaaaggcag atgtaaatga tgtgttggtt tacagggtat attttgata 8245 ccttcaatga attaattcag atgtttacg caaggaagga cttacccagt attactgctg 8305 ccatcactcg caggaccaag ggggcgggga ctgctcgtca cgcccgctg tgtcctcct 8425 ccctcccttc cttgggcaga atgaattcga tgcgtattct gtggccgcca tttgcgcagg 8485 gtggtggtat tctgtcatt accacgtcg ttctaattaa aaagcgaatt atactccaaa 8545 aaaaaadaaaa aaaaaa

<210> 12

rs-0012

<211> 221000

<212> DNA

<213> H. sapiens

<220>

<221> unsure

<222> 77967

<223> unknown

<221> unsure

<222> 77968

<223> unknown

<221> unsure

<222> 77969

<223> unknown

<221> unsure

<222> 77970

<223> unknown

<221> unsure

<222> 77971

<223> unknown

<221> unsure

<222> 77972 ,

<223> unknown

<221> unsure

<222> 77973

<223> unknown

<221> unsure

<222> 77974

<223> unknown

<221> unsure

><222> 77975

<223> unknown

<221> unsure

<222> 77976

<223> unknown

<221> unsure

<222> 77977

<223> unknown

<221> unsure

<222> 77978

<223> unknown

<221> unsure

<222> 77979

<223> unknown

<221> unsure

<222> 77980

<223> unknown

<221> unsure

<222> 77981

<223> unknown

<22	1>	1213	sure
< 4 4	τ>	un	sure

<222> 77982

<223> unknown

<221> unsure

<222> 77983

<223> unknown

<221> unsure

<222> 77984

<223> unknown

<221> unsure

<222> 77985

<223> unknown

<221> unsure

<222> 77986

<223> unknown

<221> unsure

<222> 77987

<223> unknown

<221> unsure

<222> 77988

<223> unknown

<221> unsure

<222> 77989

<223> unknown

<221> unsure

<222> 77990

<223> unknown

<221> unsure

<222> 77991

_	2	2	3	>	•	'n	<b>b</b> -	n	_	<b>t.</b> 7	,

- <221> unsure
- <222> 77992
- <223> unknown
- <221> unsure
- <222> 77993
- <223> unknown
- <221> unsure
- <222> 77994
- <223> unknown
- <221> unsure
- <222> 77995
- <223> unknown
- <221> unsure
- <222> 77996
- <223> unknown
- <221> unsure
- <222> 77997
- <223> unknown
- <221> unsure
- <222> 77998
- <223> unknown
- <221> unsure
- <222> 77999
- <223> unknown
- <221> unsure
- <222> 78000
- <223> unknown
- <221> unsure

<222> 78001

<223> unknown

<221> unsure

<222> 78002

<223> unknown

<221> unsure

<222> 78003

<223> unknown

<221> unsure

<222> 78004

<223> unknown

<221> unsure

<222> 78005

<223> unknown

<221> unsure

<222> 78006

<223> unknown

<221> unsure

<222> 78007

<223> unknown

<221> unsure

<222> 78008

<223> unknown

<221> unsure

<222> 78009

<223> unknown

<221> unsure

<222> 78010

<223> unknown

<u>P</u>TS-0012 -35- PATENT

<221> unsure

<222> 78011

<223> unknown

<221> unsure

<222> 78012

<223> unknown

<221> unsure

<222> 78013

<223> unknown

<221> unsure

<222> 78014

<223> unknown

<221> unsure

<222> 78015

<223> unknown

<221> unsure

<222> 78016

<223> unknown

<221> unsure

<222> 78017

<223> unknown

<221> unsure

<222> 78018

<223> unknown

<221> unsure

<222> 78019

<223> unknown

<221> unsure

<222> 78020

<223> unknown

<2	2	1	`	,	ın	c	11	r	_
< /.	/.	.1.	~	ı	111	. =	u	ı	=

<222> 78021

<223> unknown

<221> unsure

<222> 78022

<223> unknown

<221> unsure

<222> 78023

<223> unknown

<221> unsure

<222> 78024

<223> unknown

<221> unsure

<222> 78025

<223> unknown

<221> unsure

<222> 78026

<223> unknown

<221> unsure

<222> 78027

<223> unknown

<221> unsure

<222> 78028

<223> unknown

<221> unsure

<222> 78029

<223> unknown

<221> unsure

<222> 78030

<b>~??</b>	3>	unknown

- <221> unsure
- <222> 78031
- <223> unknown
- <221> unsure
- <222> 78032
- <223> unknown
- <221> unsure
- <222> 78033
- <223> unknown
- <221> unsure
- <222> 78034
- <223> unknown
- <221> unsure
- <222> 78035
- <223> unknown
- <221> unsure
- <222> 78036
- <223> unknown
- <221> unsure
- <222> 78037
- <223> unknown
- <221> unsure
- <222> 78038
- <223> unknown
- <221> unsure
- <222> 78039
- <223> unknown
- <221> unsure

-38-

<222> '	78	04	0
---------	----	----	---

<223> unknown

<221> unsure

<222> 78041

<223> unknown

<221> unsure

<222> 78042

<223> unknown

<221> unsure

<222> 78043

<223> unknown

<221> unsure

<222> 78044

<223> unknown

<221> unsure

<222> 78045

<223> unknown

<221> unsure

<222> 78046

<223> unknown

<221> unsure

<222> 78047

<223> unknown

<221> unsure

<222> 78048

<223> unknown

<221> unsure

<222> 78049

<223> unknown

<22:	L>	un	su	$\mathbf{r}\mathbf{e}$

<223> unknown

<221> unsure

<222> 78051

<223> unknown

<221> unsure

<222> 78052

<223> unknown

<221> unsure

<222> 78053

<223> unknown

<221> unsure

<222> 78054

<223> unknown

<221> unsure

<222> 78055

<223> unknown

<221> unsure

<222> 78056

<223> unknown

<221> unsure

<222> 78057

<223> unknown

<221> unsure

<222> 78058

<223> unknown

<221> unsure

<222> 78059

<221> unsure

<222> 78060

<223> unknown

<221> unsure

<222> 78061

<223> unknown

<221> unsure

<222> 78062

<223> unknown

<221> unsure

<222> 78063

<223> unknown

<221> unsure

<222> 78064

<223> unknown

<221> unsure

<222> 78065

<223> unknown

<221> unsure

<222> 78066

<223> unknown

<221> unsure

<222> 106867

<223> unknown

<221> unsure

<222> 106901

<223> unknown

<221> unsure

PTS-0012 -41-

<223> unknown

<221> unsure

<222> 106903

<223> unknown

<221> unsure

<222> 106904

<221> unsure <222> 106905 <223> unknown

<223> unknown

<221> unsure <222> 106906

<223> unknown

<221> unsure <222> 106907

<223> unknown

<221> unsure

<222> 106908

<223> unknown

<221> unsure

<222> 106909

<223> unknown

<221> unsure

<222> 106910

<223> unknown

<221> unsure

<222> 106911

<223> unknown

<221> unsure

<222> 106912

<223> unknown

<221> unsure ,

<222> 106913

<223> unknown

<221> unsure

<222> 106914

<223> unknown

<221> unsure

<222> 106915

<223> unknown

<221> unsure

<222> 106916

<223> unknown

<221> unsure

<222> 106917

<223> unknown

<221> unsure

<222> 106918

<223> unknown

<221> unsure

<222> 106919

<223> unknown

<221> unsure

<222> 106920

<223> unknown

<221> unsure

<222> 106921

<221> unsure

<222> 106922

<223> unknown

<221> unsure

<222> 106923

<223> unknown

<221> unsure

<222> 106924

<223> unknown

<221> unsure

<222> 106925

<223> unknown

<221> unsure

<222> 106926

<223> unknown

<221> unsure

<222> 106927

<223> unknown

<221> unsure

<222> 106928

<223> unknown

<221> unsure

<222> 106929

<223> unknown

<221> unsure

<222> 106930

<223> unknown

<221> unsure

. <222> 106931

<221>	unsure
-------	--------

<223> unknown

<221> unsure

<222> 106933

<223> unknown

<221> unsure

<222> 106934

<223> unknown

<221> unsure

<222> 106935

<223> unknown

<221> unsure

<222> 106936

<223> unknown

<221> unsure -

<222> 106937

<223> unknown

<221> unsure

<222> 106938

<223> unknown

<221> unsure

· <222> 106939

<223> unknown

<221> unsure

<222> 106940

<223> unknown

<221> unsure

<223> unknown

<221> unsure

<222> 106942

<223> unknown

<221> unsure

<222> 106943

<223> unknown

<221> unsure

<222> 106944

<223> unknown

<221> unsure

<222> 106945

<223> unknown

<221> unsure

<222> 106946

<223> unknown

<221> unsure

<222> 106947

<223> unknown

<221> unsure

<222> 106948

<223> unknown

<221> unsure

<222> 106949

<223> unknown

<221> unsure

<222> 106950

<223> unknown

<221> unsure

<2	2	2>	1	n	69	35	3

<223> unknown

<221> unsure

<222> 106952

<223> unknown

<221> unsure

<222> 106953

<223> unknown

<221> unsure

<222> 106954

<223> unknown

<221> unsure

<222> 106955

<223> unknown

<221> unsure

<222> 106956

<223> unknown

<221> unsure

<222> 106957

<223> unknown

<221> unsure

<222> 106958

<223> unknown

<221> unsure

<222> 106959

<223> unknown

<221> unsure

<222> 106960

<2	2	1	>	un	21	11	re

- <222> 106961
- <223> unknown
- <221> unsure
- <222> 106962
- <223> unknown
- <221> unsure
- <222> 106963
- <223> unknown
- <221> unsure
- <222> 106964
- <223> unknown
- <221> unsure
- <222> 106965
- <223> unknown
- <221> unsure
- <222> 106966
- <223> unknown
- <221> unsure
- <222> 106967
- <223> unknown
- <221> unsure
- <222> 106968
- <223> unknown
- <221> unsure
- <222> 106969
- <223> unknown
- <221> unsure
- <222> 106970
- <223> unknown

<221> unsure

<222> 106971

<223> unknown

<221> unsure

<222> 106972

<223> unknown

<221> unsure

<222> 106973

<223> unknown

<221> unsure

<222> 106974

<223> unknown

<221> unsure

<222> 106975

<223> unknown

<221> unsure

<222> 106976

<223> unknown

<221> unsure

<222> 106977

<223> unknown

<221> unsure

<222> 106978

<223> unknown

<221> unsure

<222> 106979

<223> unknown

<221> unsure

<223:	> 11m	kn ov.m
S Z. Z. J.	- un	KIICMATT

- <221> unsure
- <222> 106981
- <223> unknown
- <221> unsure
- <222> 106982
- <223> unknown
- <221> unsure
- <222> 106983
- <223> unknown
- <221> unsure
- <222> 106984
- <223> unknown
- <221> unsure
- <222> 106985
- <223> unknown
- <221> unsure
- <222> 106986
- <223> unknown
- <221> unsure
- <222> 106987
- <223> unknown
- <221> unsure
- <222> 106988
- <223> unknown
- <221> unsure
- <222> 106989
- <223> unknown
- <221> unsure

<2	22	`	1	Λ	6	q	q	n

<223> unknown

<221> unsure

<222> 106991

<223> unknown

<221> unsure

<222> 106992

<223> unknown

<221> unsure

<222> 106993

<223> unknown

<221> unsure

<222> 106994

<223> unknown

<221> unsure

<222> 106995

<223> unknown

<221> unsure

<222> 106996

<223> unknown

<221> unsure

<222> 106997

<223> unknown

<221> unsure

<222> 106998

<223> unknown

<221> unsure

<222> 106999

PTS-0012

<221> unsure

<222> 107000

<223> unknown

<221> unsure

<222> 151389

<223> unknown

<221> unsure

<222> 151394

<223> unknown

<221> unsure

<222> 151412

<223> unknown

<221> unsure

<222> 151655

<223> unknown

<221> unsure

<222> 151656

<223> unknown

<221> unsure

<222> 151657

<223> unknown

<221> unsure

<222> 151658

<223> unknown

<221> unsure

<222> 151659

<223> unknown

<221> unsure

<222> 151660

<221> unsure

<222> 151661

<223> unknown

<221> unsure

<222> 151662

<223> unknown

<221> unsure

<222> 151663

<223> unknown

<221> unsure

<222> 151664

<223> unknown

<221> unsure

<222> 151665

<223> unknown

<221> unsure

<222> 151666

<223> unknown

<221> unsure

<222> 151667

<223> unknown

<221> unsure

<222> 151668

<223> unknown

<221> unsure

<222> 151669

<223> unknown

<221> unsure

<223> unknown

<221> unsure

<222> 151671

<223> unknown

<221> unsure

<222> 151672

<223> unknown

<221> unsure

<222> 151673

<223> unknown

<221> unsure

<222> 151674

<223> unknown

<221> unsure

<222> 151675

<223> unknown

<221> unsure

<222> 151676

<223> unknown

<221> unsure

<222> 151677

<223> unknown

<221> unsure

<222> 151678

<223> unknown

<221> unsure

<222> 151679

<223> unknown

<221> unsure

<223> unknown

<221> unsure

<222> 151681

<223> unknown

<221> unsure

<222> 151682

<223> unknown

<221> unsure

<222> 151683

<223> unknown

<221> unsure

<222> 151684

<223> unknown

<221> unsure

<222> 151685

<223> unknown

<221> unsure

<222> 151686

<223> unknown

<221> unsure

<222> 151687

<223> unknown

<221> unsure

<222> 151688

<223> unknown

<221> unsure

<222> 151689

<221> unsure

<222> 151690

<223> unknown

<221> unsure

<222> 151691

<223> unknown

<221> unsure

<222> 151692

<223> unknown

<221> unsure

<222> 151693

<223> unknown

<221> unsure

<222> 151694

<223> unknown

<221> unsure

<222> 151695

<223> unknown

<221> unsure

<222> 151696

<223> unknown

<221> unsure

<222> 151697

<223> unknown

<221> unsure

<222> 151698

<223> unknown

<221> unsure

<222> 151699

<2	2	1	>	11	n	Si	1	~	0

<223> unknown

<221> unsure

<222> 151701

<223> unknown

<221> unsure

<222> 151702 ·

<223> unknown

<221> unsure

<222> 151703

<223> unknown

<221> unsure

<222> 151704

<223> unknown

<221> unsure ·

<222> 151705

<223> unknown

<221> unsure

<222> 151706

. <223> unknown

<221> unsure

<222> 151707

<223> unknown

<221> unsure

<222> 151708

<223> unknown

<221> unsure

<223> unknown

<221> unsure

<222> 151710

<223> unknown

<221> unsure

<222> 151711

<223> unknown

<221> unsure

<222> 151712

<223> unknown

<221> unsure

<222> 151713

<223> unknown

<221> unsure

<222> 151714

<223> unknown

<221> unsure

<222> 151715

<223> unknown

<221> unsure

<222> 151716

<223> unknown

<221> unsure

<222> 151717

<223> unknown

<221> unsure

<222> 151718

<223> unknown

<221> unsure

<22	2>	15	1	71	9

<223> unknown

<221> unsure

<222> 151720

<223> unknown

<221> unsure

<222> 151721

<223> unknown

<221> unsure

<222> 151722

<223> unknown

<221> unsure

<222> 151723

<223> unknown

<221> unsure

<222> 151724

<223> unknown

<221> unsure

<222> 151725

<223> unknown

<221> unsure

<222> 151726

<223> unknown

<221> unsure

<222> 151727

<223> unknown

<221> unsure

<222> 151728

<221> unsure

<222> 151729

<223> unknown

<221> unsure

<222> 151730

<223> unknown

<221> unsure

<222> 151731

<223> unknown

<221> unsure

<222> 151732

<223> unknown

<221> unsure

<222> 151733

<223> unknown

<221> unsure

<222> 151734

<223> unknown

<221> unsure

<222> 151735

<223> unknown

<221> unsure

<222> 151736

<223> unknown

<221> unsure

<222> 151737

<223> unknown

<221> unsure

<222> 151738

<	2	2	1	>	1	ш	19	31	1	r	6

<223> unknown

<221> unsure

<222> 151740

<223> unknown

<221> unsure

<222> 151741

<223> unknown

<221> unsure

<222> 151742

<223> unknown

<221> unsure

<222> 151743

<223> unknown

<221> unsure

<222> 151744

<223> unknown

<221> unsure

<222> 151745

<223> unknown

<221> unsure

<222> 151746

<223> unknown

<221> unsure

<222> 151747

<223> unknown

<221> unsure

<223> unknown

<221> unsure

<222> 151749

<223> unknown

<221> unsure

. <222> 151750

<223> unknown

<221> unsure

<222> 151751

<223> unknown

<221> unsure

<222> 151752

<223> unknown

<221> unsure

<222> 151753

<223> unknown

<221> unsure

<222> 151754

<223> unknown

<221> unsure

<222> 151945

<223> unknown

<221> unsure

<222> 151946

<223> unknown

<221> unsure

<222> 151947

<223> unknown

<221> unsure

	<2	22	>	15	1	9	79
--	----	----	---	----	---	---	----

<223> unknown

<221> unsure

<222> 152020

<223> unknown

<221> unsure

<222> 152021

<223> unknown

<221> unsure

<222> 201562

<223> unknown

<221> unsure

<222> 201563

<223> unknown

<221> unsure

<222> 201564

<223> unknown

<221> unsure

<222> 201565

<223> unknown

<221> unsure

`<222> 201566

<223> unknown

<221>, unsure

<222> 201567

<223> unknown

<221> unsure

<222> 201568

<22	1>	unsu	ıre

<222> 201569

<223> unknown

<221> unsure

<222> 201570

<223> unknown

<221> unsure

<222> 201571

<223> unknown

<221> unsure

<222> 201572

<223> unknown

<221> unsure

<222> 201573

<223> unknown

<221> unsure.

<222> 201574

<223> unknown

<221> unsure

<222> 201575

<223> unknown

<221> unsure

<222> 201576

<223> unknown

<221> unsure

<222> 201577

<223> unknown

<221> unsure

<222> 201578

<221> uns	ur	e
-----------	----	---

<222> 201579

<223> unknown

<221> unsure

<222> 201580

<223> unknown

<221> unsure

<222> 201581

<223> unknown

<221> unsure

· <222> 201582

<223> unknown

<221> unsure

<222> 201583

<223> unknown

<221> unsure

<222> 201584

<223> unknown

<221> unsure

<222> 201585

<223> unknown

<221> unsure

<222> 201586

<223> unknown

<221> unsure

<222> 201587

<223> unknown

<221> unsure

-	2	3>	umk	nown

- <221> unsure
- <222> 201589
- <223> unknown
- <221> unsure
- <222> 201590
- <223> unknown
- <221> unsure
- <222> 201591
- <223> unknown
- <221> unsure
- <222> 201592
- <223> unknown
- <221> unsure
- <222> 201593
- <223> unknown
- <221> unsure
  - <222> 201594
  - <223> unknown
  - <221> unsure
  - <222> 201595
  - <223> unknown
  - <221> unsure
  - <222> 201596
  - <223> unknown
  - <221> unsure
  - <222> 201597
  - <223> unknown
  - <221> unsure

<222> 201598

<223> unknown

<221> unsure

. <222> 201599

<223> unknown

<221> unsure

<222> 201600

<223> unknown

<221> unsure

<222> 201601

<223> unknown

<221> unsure

<222> 201602

<223> unknown

<221> unsure

<222> 201603

<223> unknown

<221> unsure

<222> 201604

<223> unknown

<221> unsure

<222> 201605

<223> unknown

<221> unsure

<222> 201606

<223> unknown

<221> unsure

<222> 201607

< 2	2	1	>	מנו	Q.	. 1	~	_

<223> unknown

· <221> unsure

<222> 201609

<223> unknown

<221> unsure

<222> 201610

<223> unknown -

<221> unsure

<222> 201611

<223> unknown

<221> unsure

<222> 201612

<223> unknown

<221> unsure

<222> 201613

· <223> unknown

<221> unsure

<222> 201614

<223> unknown

<221> unsure

<222> 201615

<223> unknown

<221> unsure

<222> 201616

<223> unknown

<221> unsure

<222> 201617

_	2	2	1	>	٠,	n	œ	.,	~	_

<223> unknown

<221> unsure

<222> 201619

<223> unknown

<221> unsure

<222> 201620

<223> unknown

. <221> unsure

<222> 201621

<223> unknown

<221> unsure

<222> 201622

<223> unknown

<221> unsure

<222> 201623

<223> unknown

<221> unsure

<222> 201624

<223> unknown

<221> unsure

<222> 201625

<223> unknown

<221> unsure

<222> 201626

<223> unknown

<221> unsure

-20	2	_	***	1	Own

- <221> unsure
- <222> 201628
- <223> unknown
- <221> unsure
- <222> 201629
- <223> unknown
- <221> unsure
- . <222> 201630
  - <223> unknown
- <221> unsure
- <222> 201631
- <223> unknown
- <221> unsure
- <222> 201632
- <223> unknown
- <221> unsure
- <222> 201633
- <223> unknown
- <221> unsure
- <222> 201634
- <223> unknown
- <221> unsure
- <222> 201635
- <223> unknown
- <221> unsure
- <222> 201636
- <223> unknown
- <221> unsure

<222> 201637

<223> unknown

<221> unsure

<222> 201638

<223> unknown

<221> unsure

<222> 201639

<223> unknown

<221> unsure

<222> 201640

<223> unknown

<221> unsure

<222> 201641

<223> unknown

<221> unsure

<222> 201642

<223> unknown

<221> unsure

<222> 201643

<223> unknown

<221> unsure

<222> 201644

<223> unknown

<221> unsure

<222> 201645

<223> unknown

<221> unsure

<222> 201646

<221	> .	ıın	S11	re

- <222> 201647
- <223> unknown
- <221> unsure
- <222> 201648
- <223> unknown
- <221> unsure
- <222> 201649
- <223> unknown
- <221> unsure
- <222> 201650
- <223> unknown
- <221> unsure ,
- <222> 201651
- <223> unknown
- <221> unsure
- <222> 201652
- <223> unknown
- <221> unsure
- <222> 201653
- <223> unknown
- <221> unsure
- <222> 201654
- <223> unknown
- <221> unsure
- <222> 201655
- <223> unknown
- <221> unsure
- <222> 201656
- <223> unknown

<221> unsure

<222> 201657

<223> unknown

<221> unsure

<222> 201658

<223> unknown

<221> unsure

<222> 201659

<223> unknown

<221> unsure

<222> 201660

<223> unknown

<221> unsure

<222> 201661

<223> unknown

<221> unsure

<222> 202839

<223> unknown

<221> unsure

<222> 202840

<223> unknown

<221> unsure

<222> 202841

<223> unknown

<221> unsure

<222> 202842

<223> unknown

<221> unsure

<223> unknown

<221> unsure

<222> 202844

<223> unknown

<221> unsure

<222> 202845

<223> unknown

<221> unsure

<222> 202846

<223> unknown

<221> unsure

<222> 202847

<223> unknown

<221> unsure

<222> 202848

<223> unknown.

<221> unsure

<222> 202849

<223> unknown

<221> unsure

<222> 202850

<223> unknown

<221> unsure

<222> 202851

<223> unknown

<221> unsure

<222> 202852

<223> unknown

<221> unsure

<223> unknown

<221> unsure

<222> 202854

<223> unknown

<221> unsure

<222> 202855

<223> unknown

<221> unsure

<222> 202856

<223> unknown

<221> unsure

<222> 202857

<223> unknown

<221> unsure

<222> 202858

<223> unknown

<221> unsure

<222> 202859

<223> unknown

<221> unsure

<222> 202860

<223> unknown

<221> unsure

<222> 202861

<223> unknown

<221> unsure

<222> 202862

PATENT '

<221> unsure

<222> 202863

<223> unknown

<221> unsure

<222> 202864

<223> unknown

<221> unsure

<222> 202865

<223> unknown

<221> unsure

<222> 202866

<223> unknown

<221> unsure

<222> 202867

<223> unknown

<221> unsure

<222> 202868

<223> unknown

<221> unsure

<222> 202869

<223> unknown

<221> unsure

<222> 202870

<223> unknown

<221> unsure

<222> 202871

<223> unknown

<221> unsure

<222> 202872

<7	2	1	`	٠,	₩,	S	 ~	_

<222> 202873

<223> unknown

· <221> unsure

<222> 202874

<223> unknown

<221> unsure

<222> 202875

<223> unknown

<221> unsure

<222> 202876

<223> unknown

<221> unsure

·<222> 202877

<223> unknown

<221> unsure

· <222> 202878

<223> unknown

<221> unsure

<222> 202879

<223> unknown

<221> unsure

<222> 202880

<223> unknown.

<221> unsure

<222> 202881

<223> unknown

<221> unsure

<222> 202882

<223> unknown

<221> unsure

<222> 202883

<223> unknown

<221> unsure

<222> 202884

<223> unknown

<221> unsure

<222> 202885

<223> unknown

<221> unsure

<222> 202886

<223> unknown

<221> unsure

<222> 202887

<223> unknown

<221> unsure

<222> 202888

<223> unknown

<221> unsure

<222> 202889

<223> unknown

<221> unsure

<222> 202890

<223> unknown

<221> unsure

<222> 202891

<223> unknown

<221> unsure

<222> 202892

<223> unknown

<221> unsure

<222> 202893

<223> unknown

<221> unsure

<222> 202894

<223> unknown

<221> unsure

<222> 202895

<223> unknown

<221> unsure

<222> 202896

<223> unknown

<221> unsure

<222> 202897

<223> unknown

<221> unsure

<222> 202898

<223> unknown

<221> unsure

<222> 202899

<223> unknown

<221> unsure

<222> 202900

<223> unknown

<221> unsure

<222> 202901

<221> unsure

<222> 202902

<223> unknown

<221> unsure

<222> 202903

<223> unknown

<221> unsure

<222> 202904

<223> unknown

<221> unsure

<222> 202905

<223> unknown

<221> unsure

<222> 202906

<223> unknown

<221> unsure

<222> 202907

<223> unknown

<221> unsure

<222> 202908

<223> unknown

<221> unsure

<222> 202909

<223> unknown

<221> unsure

<222> 202910

<223> unknown

<221> unsure

<222> 202911

PTS-0012

<221> unsure

<222> 202912

<223> unknown

<221> unsure

<222> 202913

<223> unknown

<221> unsure

<222> 202914

<223> unknown

<221> unsure

<222> 202915

<223> unknown

<221> unsure

<222> 202916

<223> unknown

<221> unsure

<222> 202917

<223> unknown

<221> unsure

<222> 202918

<223> unknown

<221> unsure

<222> 202919

<223> unknown

<221> unsure

<222> 202920

<223> unknown

<221> unsure

<222> 202921

<223> unkno	רתעו	
-------------	------	--

- <221> unsure
- <222> 202922
- <223> unknown
- <221> unsure
- <222> 202923
- <223> unknown
- <221> unsure
- <222> 202924
- <223> unknown
- <221> unsure
- <222> 202925
- <223> unknown
- <221> unsure
- <222> 202926
- <223> unknown
- <221> unsure
- <222> 202927
- <223> unknown
- <221> unsure
- <222> 202928
- <223> unknown
- <221> unsure
- <222> 202929
- <223> unknown
- <221> unsure
- <222> 202930
- <223> unknown
- <221> unsure

<u>P</u>TS-0012 -82- PATENT

<222> 202931

<223> unknown

<221> unsure

<222> 202932

<223> unknown

<221> unsure

<222> 202933

<223> unknown

<221> unsure

<222> 202934

<223> unknown

<221> unsure

<222> 202935

<223> unknown

<221> unsure

<222> 202936

<223> unknown

<221> unsure

<222> 202937

<223> unknown

<221> unsure

<222> 202938

<223> unknown

<221> unsure

<222> 204299

<223> unknown

<221> unsure

<222> 204300

PTS-0012 -83- , PATENT

'<221> unsure

<222> 204301

<223> unknown

<221> unsure

<222> 204302

<223> unknown

<221> unsure

<222> 204303

<223> unknown

<221> unsure

<222> 204304

<223> unknown

<221> unsure

<222> 204305

<223> unknown

<221> unsure

<222> 204306

<223> unknown

<221> unsure

<222> 204307

<223> unknown

<221> unsure

<222> 204308

<223> unknown

<221> unsure

<222> 204309

<223> unknown

<221> unsure

<222> 204310

<221> unsure

<222> 204311

<223> unknown

<221> unsure

<222> 204312

<223> unknown

<221> unsure

<222> 204313

<223> unknown

<221> unsure

<222> 204314

<223> unknown

<221> unsure

<222> 204315

<223> unknown

<221> unsure

<222> 204316

<223> unknown

<221> unsure

<222> 204317

<223> unknown

<221> unsure

<222> 204318

<223> unknown

<221> unsure

<222> 204319

<223> unknown

<221> unsure

<222> 204320

PTS-0012

<223> unknown

<221> unsure

<222> 204321

<223> unknown

<221> unsure

<222> 204322

<223> unknown

<221> unsure

<222> 204323

<223> unknown

<221> unsure

<222> 204324

<223> unknown

<221> unsure

<222> 204325

<223> unknown

<221> unsure

<222> 204326

<223> unknown

<221> unsure

<222> 204327

<223> unknown

<221> unsure

<222> 204328

<223> unknown

<221> unsure

<222> 204329

<223> unknown

<221> unsure

<222> 204330

<223> unknown

<221> unsure

<222> 204331

<223> unknown

<221> unsure

<222> 204332'

<223> unknown

<221> unsure

<222> 204333

<223> unknown

<221> unsure

<222> 204334

<223> unknown

<221> unsure

<222> 204335

<223> unknown

<221> unsure

<222> 204336

<223> unknown

<221> unsure

<222> 204337

<223> unknown

<221> unsure

<222> 204338

<223> unknown

<221> unsure

<222> 204339

<221> unsure

<222> 204340

<223> unknown

<221> unsure

<222> 204341

<223> unknown

<221> unsure

<222> 204342

<223> unknown

<221> unsure

<222> 204343

<223> unknown

<221> unsure

<222> 204344

<223> unknown

<221> unsure

<222> 204345

<223> unknown

<221> unsure

<222> 204346

<223> unknown

<221> unsure

<222> 204347

<223> unknown

<221> unsure

<222> 204348

<223> unknown

<221> unsure

<222> 204349

<221> unsure

<222> 204350

<223> unknown

<221> unsure

<222> 204351

<223> unknown

<221> unsure

<222> 204352

<223> unknown

<221> unsure

3

<222> 204353

<223> unknown

<221> unsure

<222> 204354

<223> unknown

<221> unsure

<222> 204355

<223> unknown

<221> unsure

<222> 204356

<223> unknown

<221> unsure

<222> 204357

<223> unknown

<221> unsure

<222> 204358

<223> unknown

<221> unsure

<222> 204359

-89-

PATENT

<2	7	3	_	,	٠,	'n	٠.	n	_	T. 27	_

- <221> unsure
- <222> 204360
- <223> unknown
- <221> unsure
- <222> 204361
  - <223> unknown
  - <221> unsure
  - <222> 204362
  - <223> unknown
  - <221> unsure
  - <222> 204363
  - <223> unknown
  - <221> unsure
  - <222> 204364
  - <223> unknown
  - <221> unsure
  - <222> 204365
  - <223> unknown
  - <221> unsure
  - <222> 204366
  - <223> unknown
  - <221> unsure
  - <222> 204367
    - <223> unknown
    - <221> unsure
    - <222> 204368
    - <223> unknown
    - <221> unsure

<222> 204369

<223> unknown

<221> unsure

<222> 204370

<223> unknown

<221> unsure

<222> 204371

<223> unknown

<221> unsure

<222> 204372

<223> unknown

<221> unsure

<222> 204373

<223> unknown

<221> unsure

<222> 204374

<223> unknown

<221> unsure

<222> 204375

<223> unknown

<221> unsure

<222> 204376

<223> unknown

<221> unsure

<222> 204377

<223> unknown

<221> unsure

<222> 204378

-91-

PTS-0012

PATENT

<221> unsure

<222> 204379

<223> unknown

<221> unsure

<222> 204380

<223> unknown

<221> unsure

<222> 204381

<223> unknown

<221> unsure

<222> 204382

<223> unknown

<221> unsure

<222> 204383

<223> unknown

<221> unsure

<222> 204384

<223> unknown

<221> unsure

<222> 204385

<223> unknown

<221> unsure

<222> 204386

<223> unknown

<221> unsure

<222> 204387

<223> unknown

<221> unsure

<222> 204388

<221> unsure

<222> 204389

<223> unknown

<221> unsure

<222> 204390

<223> unknown

<221> unsure

<222> 204391

<223> unknown

<221> unsure

<222> 204392

<223> unknown

<221> unsure

<222> 204393

<223> unknown

<221> unsure

<222> 204394

<223> unknown

<221> unsure

<222> 204395

<223> unknown

<221> unsure

<222> 204396

<223> unknown

<221> unsure

<222> 204397

<223> unknown

<221> unsure

<222> 204398

<223> unknowr	<22	3>	unl	kn	റയന
---------------	-----	----	-----	----	-----

<221> unsure

<222> 205499

<223> unknown

<221> unsure

<222> 205500

<223> unknown

<221> unsure

<222> 205501

<223> unknown

<221> unsure

<222> 205502

<223> unknown

<221> unsure

<222> 205503

<223> unknown

<221> unsure

<222> 205504

<223> unknown

<221> unsure

<222> 205505

<223> unknown

<221> unsure

<222> 205506

<223> unknown

<221> unsure

<222> 205507

<223> unknown

<221> unsure

<222> 205508

<223> unknown

<221> unsure

<222> 205509

<223> unknown

<221> unsure

<222> 205510

<223> unknown

<221> unsure

<222> 205511

<223> unknown

<221> unsure

<222> 205512

<223> unknown

<221> unsure

<222> 205513

<223> unknown

<221> unsure

<222> 205514

<223> unknown

<221> unsure

<222> 205515

<223> unknown

<221> unsure

<222> 205516

<223> unknown

<221> unsure

<222> 205517

<221> unsure

<222> 205518

<223> unknown

<221> unsure

<222> 205519

<223> unknown

<221> unsure

<222> 205520

<223> unknown

<221> unsure

<222> 205521

<223> unknown

<221> unsure

<222> 205522

<223> unknown

. <221> unsure

<222> 205523

<223> unknown

<221> unsure

<222> 205524

<223> unknown

<221> unsure

<222> 205525

<223> unknown

<221> unsure

<222> 205526

<223> unknown

<221> unsure

<222> 205527

<221> unsure

<222> 205528

<223> unknown

<221> unsure

<222> 205529

<223> unknown

<221> unsure

<222> 205530

<223> unknown

<221> unsure

<222> 205531

<223> unknown

<221> unsure

<222> 205532

<223> unknown

<221> unsure

<222> 205533

<223> unknown

<221> unsure

<222> 205534

<223> unknown

<221> unsure

<222> 205535

<223> unknown

<221> unsure

<222> 205536

<223> unknown

<221> unsure

<222> 205537

<223> unknown

<221> unsure

<222> 205538

<223> unknown

<221> unsure

<222> 205539

<223> unknown

<221> unsure

<222> 205540

<223> unknown

<221> unsure

<222> 205541

<223> unknown

<221> unsure

<222> 205542

<223> unknown

<221> unsure

<222> 205543

<223> unknown

<221> unsure

<222> 205544

<223> unknown

<221> unsure

<222> 205545

<223> unknown

<221> unsure

<222> 205546

<223> unknown

<221> unsure

<222> 205547

<223> unknown

<221> unsure

<222> 205548

<223> unknown

<221> unsure

<222> 205549

<223> unknown

<221> unsure

<222> 205550

<223> unknown

<221> unsure

<222> 205551

<223> unknown

<221> unsure

<222> 205552

<223> unknown

<221> unsure

<222> 205553

<223> unknown

<221> unsure

<222> 205554

<223> unknown

<221> unsure

<222> 205555

<223> unknown

<221> unsure

<222> 205556

-99-

PATENT

<221> unsure

<222> 205557

<223> unknown

<221> unsure

<222> 205558

<223> unknown

<221> unsure

<222> 205559

<223> unknown

<221> unsure

<222> 205560

<223> unknown

<221> unsure

<222> 205561

<223> unknown

<221> unsure

<222> 205562

<223> unknown

<221> unsure

<222> 205563

<223> unknown

<221> unsure

<222> 205564

<223> unknown

<221> unsure

<222> 205565

<223> unknown

<221> unsure

<222> 205566

<221> unsure

<222> 205567

<223> unknown

<221> unsure

<222> 205568

<223> unknown

<221> unsure

<222> 205569

<223> unknown

<221> unsure

<222> 205570

<223> unknown

<221> unsure

<222> 205571

<223> unknown

<221> unsure

<222> 205572

<223> unknown

<221> unsure

<222> 205573

<223> unknown ·

<221> unsure

<222> 205574

<223> unknown

<221> unsure

<222> 205575

<223> unknown

<221> unsure

<222> 205576

<223>	unknown
-------	---------

<221> unsure

<222> 205577

<223> unknown

<221> unsure

<222> 205578

<223> unknown

<221> unsure

<222> 205579

<223> unknown

<221> unsure

<222> 205580

<223> unknown

<221> unsure

<222> 205581

<223> unknown

<221> unsure

<222> 205582

<223> unknown

<221> unsure

<222> 205583

<223> unknown

<221> unsure

<222> 205584

<223> unknown

<221> unsure

<222> 205585

<223> unknown

<221> unsure

<2	2	2	>	2	n	5	5	R	հ

<223> unknown

<221> unsure

<222> 205587

<223> unknown

<221> unsure

<222> 205588

<223> unknown

<221> unsure

<222> 205589

<223> unknown

<221> unsure

<222> 205590

<223> unknown

<221> unsure

<222> 205591

<223> unknown

<221> unsure

<222> 205592

<223> unknown

<221> unsure

<222> 205593

<223> unknown

<221> unsure

<222> 205594

<223> unknown

<221> unsure

<222> 205595

PTS-0012 -103- PATENT

<221> unsure

<222> 205596

<223> unknown

<221> unsure

<222> 205597

<223> unknown

<221> unsure

<222> 205598

<223> unknown

<221> unsure

<222> 205699

<223> unknown

<221> unsure

<222> 205748

<223> unknown

<221> unsure

<222> 205789

<223> unknown

## <400> 12

ctgtctgctg ttggactgac tggctcatat tgatttgtg gtgtccccc tgtattctgg 60 gtactagcta tcattgcact acttttgact ttgtatggta actcagaaat tcttaaatga 120 ggctgggcac agtggctcgc acctgtaatc ctagcacttt gggaggccaa ggcaggagga 180 ttgcttgagc tcaggagttt gaaaccagcc tgggcaacat ggtgagaccc tgtctctaca 240 aaaaaataca aaaattagcc gggcatggtg gcacgtgccc atagtcccag ctacttagca 300 ggcttaggtg ggaggatcgc cttagggttg gggctgcagg gagccatgat tgcaccccag 360 cctgagtgac agagcgagac tatatccaaa acaaaaacaa aaacaaaaac actccaaaat 420 accaaacaaa caaaaataaa ttcttgcatg agaatagtag acacccccac ccccggaccc 480 catccttcag gtgtccgtcg accaatctcc ctgtttgtgg ggtcctctgg gtagttaatg 540 gggcagtttc ccagtagcct agccgtgtgg cccggggccc ctcggtggtc ttgccaggg 660 ctctgagaac ctgggcatga gatttgattg tctgagcgtc agcccctc tctgtcaaat 720 aggtagcagt acccstca cagggttctc atggagaat acctgcca gtgcttacga 780 cacatgggcc ctgacggca acatggtct ttttcctgca tgtcggttc gtcatgcca 840

PTS-0012 -104- PATENT

actgcataca tgcgatgtca actaacaaaa cccgtgtttt gtctgcaggt ctccctgagt 900 ctttgaggac acagcctcgc tggaggcagt ttctggtagg ttcatgtctg tctccacttg 960 gtgtccccag gaggttcatc ctgcctggac tttctcacgg gaagtgggtc tggaattact 1020 cggagccagg ttcggcctgg agtgtgtggt gggggcctcg gggggcgtgt ggggtctggc 1080 acatcagagc tgtccagggc agggagcaac ttagggcagt ttgcggggtc ccccagtgat 1140 gggccgtttc ctggctgagt tggtgcagtg attttttgat gacacctgag aggtgggagg 1200 gtccctgaca gtgtcagtgt caggagggtg ggcttccccg ggctccgggg ttcttggtca 1260 cattgctttt gtgctttggc ggtgggcccg caggtttggc cagggtgggg cctgtcgatg 1320 ggcccaggtg ttcgggtgtt gggtgctgga ggaagccctg aggctgaacc accactgtgg 1380 teccegtgee tageaggeaa agaggtggee tgggteetgg tettateact getacttetg 1440 tgctgggcac tggggccagg ttgctttatc tctctgtatc tctgtttctc catctgtaga 1500 ctgggcgggg aggcaataac agtttcccct tatagggttt tgctgcggtg attaatgctc 1560 atagagagca gtgcctggcc tgagaaggtg cctggtgagt cataatcaca ggtcgtgctt 1620 ttcacaggtc accccatttt gtgaccctca cagcaacact ccagaatggg tggtgcctca 1680 ttttacaagt ggggaaactg aggcacaggt tggtcacctg tcccagatct ttcagctgga 1740 agcaaagagc cagaagcaaa gaaccccttc tcacccttcc cagggaatgc agcaagtttc 1800 tcctggagtg ctcatttccc agccaggcag atggtcgctg agggcattgc agggctcgtg 1860 cgcatggagg ctggggcaca tggcgggcac acagcgtgtt ctggctcatg acaggctgtt 1920 gtcgggagat ttcattcttg ttccaaatac agtcatgtgc tgcataacga cattctggtc 1980 aacgatggac cgcatatatg acagtggtcc cataagatta taataccaca ttttttttt 2040 tttcgagaca gagtcttgct tggttgccca ggctggagtg cagtggtgtg atctcggctc 2100 actacaacct ctgcctccag gttcaagcta ttctcctgcc tcagcctcct tagtagctgg 2160 gattacaggc gtgcgccacc acgcctggct aatttttgta tttgtagtag agatggggtt 2220 tegecatgtt ggecaggetg gtetegaaet eetgacetea agtgateete etgeetegge 2280 ctcccaaagt gctgggatga caggtgtgag ccaccaagcc cagagaatac cacatttgta 2340 ctgttccttt tctgtgtttg gatacctagt gtaccactgg gttctagctg cctgtgggag 2400 tcagtccagc cacacgccgt acaggtggta gcctgggaac cgtcggctac accagggttg 2460 tccaatcttt tggcttccct gggccacatt ggaagaagaa ttgtcttggg ccacccagaa 2520 aatacactag cactaatgat agcggatgaa ctaaaaaaaa aaaaaaaatc acaaaaaggt 2580 ctcataatgt tttcagaaag tttacaaatg tgtgccaggc cacattcaaa ggcatcctgg 2640 gccggggttg gacgagcttg gatgacacca cacaacctgg gtgtaccgct ggcactgagg 2700 tctaggtttg tgcaagtcca ccccatcgt gctcccacag ccacggcacc agctcccgtg 2760 cgtttctcag aacgtgtccc cgtggttaag cagtacatga ctatatattc gtttatggaa 2820 tggctctttc taaagcacct actgtgtgcc aggctctgtt gtgggtgctg ggaatagacc 2880 tgtggacaag acggccaagc acctagtcct ccctgcgggg agacagacca tgaccaaaag 2940 tcagtaagtg cgacgcttag cgggtctctt ggtggtgagc accaggctga ggaacaagtg 3000 gtgaaggggt ctggggagcc tgtgggtggg ctgggggttg cagtttcaaa gtgggggtca 3060 gggtaggcct ccctgagaag gtggcctttg agcaaagacc tgaagtaggg gaggaaggaa 3120 gcatgtaggt atctggggga agggtgaccc aggctgaggg aacagccctg ccaaagcact 3180

PTS-0012 -105- PATENT

gaggcagett ggaatgggcc tecegggttg egegattetg agttaceteg ggggagtttt 3240 cctggaggag gcctctttac ttcttcctga gcctttgggg gcccccact aggcaggagg 3300 gaagatcagc cctgcaggtc atctgcttcc tggggctggg ccttgggccc taagccctgg 3360 gcctcacaac caggttttgt cttggaggga gcaggggaag gaggattggg atttggaggt 3420 aggagaagga ggagtgggac tggggtgggg gaggaggagt gggatttgga gggaggaggg 3480 gaaggaggag tgcgatttgg aggtggggga aagaggagtg ggatttggag ggagggggga 3540 aggaggagtg ggatttgggt tagggagggg gaaggaggag tgggacttgg agggaggggg 3660 gaaagaggag tgggatttgg aggtggggga aggaggagtg ggacggtggc ggtccccac 3720 aaagtgatga actcagcagg gctttctgcc taggctcatg gggctttgaa gttggaagga 3780 aageggeetg gtetgggetg ttttteecag ceteeteete etetgeeteg etgteeceeg 3840 tocatoggog totocgtoto oggoctaatg gggagcotto otoctgtggc tgagttatot 3900 gcttgtcatg ccagtggccc acccgaggac gataaaaggg ctttttgtct gcaagcactt 3960 agetteetet geeggggega teeateacat etgagggagg eegggaagge agacagaegg 4020 tggagtgggg cetecteete eeetgetgag ggaacetgat geteecagga geceeettge 4080 aggacccaag tggctcctca gcccgaaggc aaggcctgtc tggggggccag caggggtgag 4140 · tgggagtggg gccatggggg cacattgagg caggcagatg ctctgcactc ccctgacaga 4200 · ggacagacgc tgcccggatg ccctgccca ccacacccac ttggcagctc tgtggggccc 4260 ctctgggacc ctccatgctg gagagggtgg gtgggggtg cagccttttc tgagtaagaa 4320 ccgtgatggt agaagggggc atggggggaga caagggggga cagacctcag ggccgacact 4380 cgctatgcgt gcactaagca ctttgtggaa ttacctcctt aaatctcagg gcgaccetgg 4440 aggtgggcac cgtccttatc cccattctcc agatgaggaa actgaggtac agggaggcga 4500 tgtggcatcc ccagggtgca gcagcagagg gagggcttgg ctccaggctc ccagcggtac 4560 actetteect geggaectag gaeettagaa gggggetgtg ggageecetg geeceaaaag 4620 tgggttgccc gtgactcgaa actctgtgag tggattcttc agctgggagt ggggtgggga 4680 ggtgggtgtc tgggattgtc tatacattgg ggtgaggggt ccggtgtggg tgggggctgg 4740 ggtcacgggg taccctgggc gggtgatcgg ggacaccgaa ggtgtgtagg gggaggtttt 4800 agggccctgg cccagtggga tctcacctct cgggggctct gggaggaccg gctttaaccc 4860 cagttggacg gggccctggg ccctgcttgg gtggggagga gagcaattca gggcccctg 4920 ccettecetg tetgegeeac caecettece tetetgeeat ceteetetet etecttecea 4980 gcctggatgc tcagccctgg gcgggggctc cctgcaatcc cttcctcccc tcccccttcc 5040 ttcctgctcc ctacccctcc ttctccccc tccttctccc cacaggccac cctcaaatga 5100 cagcaattaa tggtgcctgt gatggcgggc tgagaggagg aggctgacag ttgagcgtgt 5160 ctgcctgcgg ccgcccgcta atcgggcccg ggggatgccc ctcctgccgt tggctccagg 5220 egectgeect gecateacte agaggggage aggageectg gacaggeetg tgggagetgg 5280 tgcagagccc ccatccctgc agccccctcc ctgtccttct attattatta tcattttctt 5340 tcataaacgg gtgggctctg gctggactct tgttcagcat gagttggtgg atgcctccca 5400 gacgtccttc tcctgaaatg acctctcatg tgcctgtgtt gtcctcaggg ccagccatcc 5460 ccacagggcc ccatcetttt gtccctgctt ccctgggaga ggcgggttgg gtggagccca 5520

PTS-0012

-106-

PATENT

ggaaccgtgt	cctgtccgga	cagcaggcat	cagttaaatg	cccggcctg	agtcctcggg	5580
gcctgggggc	agctatttga	gcccagagcc	ttgtctggtg	gggtgaggaa	gtgtgttgtg	5640
tttgtcaggg	ttacaagaat	cctggccagc	tctgtccaca	gtgggcctgg	gcttgaccat	5700
ttatcacctg	gcagcagcaa	taatgaagcc	cctgctgtat	gctggggcct	gcagctggta	5760
tgttcacttt	ggttcatttt	acttggcagt	tttctgagga	gtgtggtatt	tctcaccttg	5820
cttttgtaga	gggggagact	gaggggcaga	gaggcaaagc	gatttgccct	aaggggcaca	5880
gtgccctacg	tgacctagct	agcataggac	aaagctgggg	ttcaacccag	acccaaactg	5940
tccaatgctc	atacatcagg	ggactttggg	aaacttgagg	gccagtttag	gaaccagcag	6000
actgatttag	aagtgaggaa	atagtccctg	ggtactggga	atggagtgag	tagtgttaat	6060
atatgcatct	ctctccctgt	tccacttaag	atcatcttca	ttgagatgta	attaacctat	6120
aatgatgcac	ccattttaag	ggttcaattg	catgtgtttt	gacaaatgta	aacatttgca	6180
tcacctccac	aatcagaata	aagtgtttct	gttccccca	aatccccacc	agtcccttgg	6240
cactaaatct	ctagcaccca	cctccacccc	ccaccccga	ctagaggtac	ccactgatct	6300
gctgttatag	aagcttttaa	ctcttctaga	attttataat	aaaattatca	ttttattata	6360
tactatactt	tgttgtgtct	ggcttctttc	actctgcata	acccatgttg	ctcatgtatc	6420
aattcattct	ttctcatggc	taagtagtat	ttcattctgt	ggatatatta	cagtttatcc	6480
attcatcagt	tgatggacat	caaagtttcc	agtttttggc	tattgggaat	aaagctgctc	6540
tgaacattct	tgtgtaagtc	tttgtgtgaa	catgttttct	tttttcttat	gtgaatatct	6600
aggcattggg	ttgctaggtc	acatggtaaa	tgtgttattt	tagtttataa	gaaaccacca	6660
gctgttttct	aaagtggctg	tcccattttg	catgcccacc	tgcagtggat	gagagttcca	6720
gttgctcccc	atccttgtca	gcacttgcta	ctgtcaatct	tttaatgtta	gccgttccag	6780
gagaccctaa	tgcacatgcg	attacatttt	tcagcttttg	ctgccttttg	ggcaaagctg	6840
tggttctgtg	ttttgatttt	atgtgtctgg	ccagctggtg	ggagtctaaa	ggatggtggg	6900
agataatctc	gtgtctgcca	acgctagctc	tgtgttttcc	tttctagtct	ttatgctgct	6960
gactgactgc	ttctcgtccg	gctgcagtgg	ttgagaccac	agtgcagtgc	cggattgcac	7020
cagttgggtt	gtttggggtt	agttagctgt	gagtgttgtt	atttatttt	ttattttta	7080
tttttttga	gacagagtct	tgctctgtcg	cccaggctgg	agtgccatgg	catgatcttg	7140
gctcactgca	acctccgcct	cccgggttca	agcgattctc	ctgcctcaac	ctcccaagta	7200
gctgggatta	caggcatgcg	ccaccacatc	tggctagttt	ttgtatttt	ttttttagt	7260
agagacgggg	ttttgccatg	ttggccaggc	tgttcttgaa	ctcctgacct	caggtcatcc	7320
acttactttg	cctcccaaag	tgctaggatt	agtgagtgtt	ttttttt	ttttttt	7380
tgagtčggag	tttcgctctt	atcgtgcagg	ctggagtgca	atggcacgat	ctcggctcac	7440
tgcaacctcc	gcctcccggg	ttcaagcaat	tctcctgcct	cagcctccct	agaagctggg	7500
attataggca	tgcgccacca	cgcctggcta	attttgtatt	tttagtagag	acggggtttc	7560
tctgtgttgg	ccaggctggt	ctcgaattcc	cgacctcagg	tgatctgccc	gcctcggcct	7620
cccaaactgt	tgggattaca	ggcgtgagcc	accgcgccca	gaggtgttgt	tcttaacact	7680
catcttacag	atgaggaaac	tgaggctctg	acaggtcagg	tgacttccat	tccgataaga	7740
aatgaaactc	atgactctga	gttgtgtgcc	ctttctcctc	cttcaggcta	ggaggtgcca	7800
gctccgtttg	ttgcagtgat	gtgtttgcca	gtccagaggg	tcatgccaag	aattggtggc	7860

PTS-0012

-107-

PATENT

					•	
tggttggggc	caggaccacc	tttttcctag	ggtttcctct	gctggagaga	tgagggtgtg	7920
gaggagacgc	tgtgccttcc	ggatcaagca	ctgtcctttg	gcactgagca	ctgttgagtg	7980
aatgtcaggc	gttggttctg	ccaagggtct	tccttgttca	atcctgttgt	cttgggcaaa	8040
accacacctg	ccttccgggg	agctattttg	gggcaaggga	ggagcatggc	atatggaagc	8100
ccaggaatgg	gctgggatgg	aagagggggc	ctccttctcc	tttttccttg	cctgaggggt	8160
gtcagctaag	atgacttttc	ggggaaggag	gcctgtaaat	taaataagca	atcccgtaaa	8220
taaataagta	atgaagtcag	cggggtgcct	aattacatca	gattcatcat	tgtggatgga	8280
tgcctgcccg	gtcattgtac	ttgtttttaa	tcttcggctc	tgacatgtgt	ctccttccgt	8340
ctcatagtca	tccccacccc	agctggaggg	aggaggcggg	gaggcgctgc	tgtaggggct	8400
tccagagagc	cttggtggtg	gaggtggtgg	tggggtccct	ggagggttat	ttacccagtc	8460
tgcctgttta	tggcagtcgt	ggaagggatg	acgtctgttc	cacagtgaaa	cctcaggagg	8520
cctcgggcca	tcctgattca	gcaaatccct	catcaggctg	cgctgaaggg	tagatgacaa	8580
acatggtgcc	ccgcacagat	ggggccacag	cacacgcagc	acgccctgga	gggcgagatg	8640
ggaaggacac	ggacgggggc	agatgacctc	agtgcaaagt	cccagggatc	caggtggacc	8700
cgtctttatg	ctgcagttgg	gtttgtaaac	ctactggagc	ttcgaagtgg	gagcacccca	8760
·tggcagtgac	agcagcagtc	ctaacagggt	ttgtgatcgt	ccttgtgtca	cacttcacat	8820
gttataattt	atttaattga	ctgggcacag	tggctcacgt	ctgtaatgta	atcccagcac	8880
tttggaaggc	cgaggcaggc	ggatcatctg	aggtcaggag	ttcgagacca	gcctggccaa	8940
catggtgaaa	ccccgtctct	aataaaaaca	gaagaattag	ccgggcgtgg	tggcgggcgc	9000
ctgtaatccc	aactactgga	gaggctgagg	caggagaatt	gtttgaaccc	aggaggcaga	9060
gactgcagtg	agctgagatc	gtgccactgc	actccagcct	gggcaacaga	gcaagactcc	9120
acctcaaaaa	aaaaaataaa	taaaaaatta	tttcatcacc	taaaagctct	tgtaaagtag	9180
ggattatcat	catcccctct	ttacatatga	ggaaactgag	gcacagagag	gttccgcatc	9240
ttgcccgagg	tcacacagee	agtgaacttt	gcactcaagt	catctgcccc	cgtctgcgtc	9300
cttcccatct	caccctacag	ggcgtgctgt	gtgtgctgtg	gccgcgtctg	tgcggggcgc	9360
cgtgtttgtc	atctaccctt	cagcacggcc	tgttcaggga	tttgctgaat	caggatggcc	9420
tgaggcctcc	tgaggtttca	ctgctgaaaa	gatctcatca	tcccttccac	gactgccata	9480
aacagatgcc	attctgaact	gtaaaataaa	atcatgtttc	actaaggaca	aagcaagccc	9540
atttgctgaa	attaaaatag	cttctttcca	gatcttctct	ttctctttca	gcggccctga	9600
ttggctggct	cttgggggac	tctctgtcct	gcctgagata	atggtcctta	gacccattgt	9660
acagttggag	aaactgaggc	tcagggaggt	ggaggagcat	gagtgagacc	acacagctgg	9720
gaggtggtga	agctgggatt	ctagctgctt	cttactgttt	ggtttgggga	gcgggggcca	9780
cctcatgtgc	ctgacgtgga	aggggctgcc	tgtcctctcc	gagaagcgca	gggagctgtg	9840
tgcaccccag	gctggctttg	ctggggttct	tgctgtggct	gattggttag	cgtcctgtct	9900
gtccgcgggg	gagaggagac	cagctgcccc	acctcgtggt	ttctcctcag	gacctgagca	9960
tgtgctgggc	atggacagag	gatgggggtg	gctgggggca	gtcttgtcct	cgttcgctgt	10020
ccatgcagct	ccagggtgcc	cagccacagc	ccacacctgt	tccctccatg	gtgcctctcc	10080
atatctccag	actccaggtc	ctgtacgagg	cagtggggcc	t'gaacccttg	ggatgtctgg	10140
gcctctactg	ggggcccagg	gagggaacac	cctttacttt	acagggtgta	cttgtgcagc	10200

PTS-0012 -108-

cggacagggc	ctgcgttgct	gggccgtggc	ttggatggga	gtgggggttc	acacattccc	10260
ctggtgctga	cttcaggctt-	gcggggtttg	gggctctccc	tgcccctcac	tgtcacctgg	10320
ggtggagaga	ggagttgagg	aaagacccac	atgaagaatt	gtgtgtgtcc	atggtgttcc	10380
tgggggttgg	agcaatccaa	ggaggctgcc	tggaggagct	ggaacactca	cattgaataa	10440
tcataagccc	atcttggagg	gactaatgtg	tgtacatgct	tcaaacagga	cctggcacag	10500
agcaaatacc	atatttacca	taaaagctaa	catttcctga	tccttttctt	gcctcagtgc	10560
tgtgtgtgag	ttgccagtat	tattattatt	aacattaact	acaatttcta	acgtgcaccc	10620
catacataca	cgcatgtact	ctttgcagca	gccttagaag	gtaggtgcta	ttatgatcag	10680
ccctgtttc	tagttaaggg	gattgagggc	agagagaggt	taggggactt	gtccaaggtc	10740
gcccagttgg	cagagctagg	atgtgaaccc	agaacgcctg	actccacggc	agctgctttt	10800
catcgtgtgg	atggtgcagg	tgccacctgc	agccctccct	ctgcccgtg	ggtacgccga	10860
tcactgccgc	agccagcctg	gatctcttgg	cagggccatg	ccagctgtgg	gacagcctcc	10920
atgtgccacg	tagggccctc	aggcacgcag	cagctgctct	gggcagtgtg	ggatggtcag	10980
gacgtgggac	atctgcttcc	tgcctccctg	cagccagatt	ggtgtcccca	cggcctcctc	11040
ctggttgagg	ggatggcaaa	cagcaaacaa	gatgcggcgc	tttgccttat	ggatcacaca	11100
ggctgatggg	gagatgggca	gtgccaaaaa	acaaacacga	ttttgcaagg	caagaaaatg	11160
ctgcctgtga	aataatacag	ggtggggagg	tagggatgac	ttcagtttcg	ggggactcat	11220
tttaggtaag	aattccaggg	tagcttctga	ggaggtggca	tctgagctgg	gccctggaca	11280
ataaggaggc	acccactatg	tgaaaggaag	ggggatgagg	gaacagcagg	cgcgaaggcc	11340
ctccggccac	catgtttcag	gcatgctgat	tggggttctg	tgcctcagtt	tcccactctg	11400
taatggctgg	agcagagcag	gggggcccca	ggagggcttt	cctggatctg	agactgtcct	11460
gcagacctcc	agggctgggc	tgtttttcac	atttaaggca	gaagtcaaat	ttaatgactt	11520
ttgcctttcc	cttttgttct	tttgctccat	agttaatttc	catgtattta	catggtttta	11580
atttacatgt	attgggcacg	tggcatgttc	cggactcatg	tacgtcactg	ggatgagaat	11640
ggtggagaag	ttggacattg	cctgtgcctt	cgagtttagt	atccagaggg	ggagtgtcag	11700
ttaaacaagc	aagtgctatc	gcgggtggtg	agggttgtga	ggacgaggtt	caggcattca	11760
cctgggtgag	gcaagagctg	aattagtctt	ccatcaggcc	aggcgtccag	ggacgagtca	11820
ttcaagggga	gacctggggg	tgattagtta	ggggcagtta	gttagggctc	ctgagttgtg	11880
gcagagacac	actcgagccg	agttaggcta	tgacggggag	ttgatgggtc	ctcagagtgg	11940
ccagggtagg	acacgttcag	gcacggctgg	atctaggtgc	tcaaacaatg	cctctgggag	12000
ctggctttgc	ctcagctgtg	cctccttcca	tgcgggcctt	gttctcagac	aggctcatgc	12060
caccagccca	gcccagccag	ccaaggagaa	ggagagtcac	ctggcatccc	aggagggaca	12120
ctcctttctc	ttgtttgagt	gaggtcctcg	acatttgttt	cactgtttgc	aacagcaaga	12180
ggaggtggcc	aaagaaggga	taaggggatg	tcccaaactc	agacacaggg	aggaaaggag	12240
					ggcatgctgg	
gtattctgat	ggttttccaa	gagaagctgg	aaatctggat	tttataagga	atggcctagt	12360
					tggctgtcac	
					tgtgatctgg	
gtagaatgtc	ccatgggctg	ttccagaagg	tctcaagtct	tgggaagtca	cgtctgacac	12540

PTS-0012 -109- PATENT

cattggagat gccatttctg aaagtcaagg cccacggcca cagcagtttc tcagagaaca 12600 ataccatgtc tccagtgggg cctgacattc ttggagacag tatagtctag tggttagtgt 12660 cgtagatgcg ggtttcacac ttgctgagtt caaaaccgac attgccactt cccagccccg 12720 tccccttggg caagtcactt cactgctctc tgcctcagtt tcccagtatg tattaatgga 12780 atgggtatga cagcacccca taggattgtt gtaaggcaag cttgtccaac ctgcggctca 12840 ggacggtttt aaatgcagcc caacacaaat ttgtaaactt tcttaaaaca gattgttttt 12900 cggttttttg tttttttt ttttttagtt catcagctat ggttagtgtt agtgttatgt 12960 gtgatccgag acagttcttt tagtgtggcc cagtgaagcc aaaagactgg acacgccggt 13020 tgtaaggcac agtggaggcc gcgtgaagcc cactgaccct ggcacactga gagcttgagt 13080 gatgctggcc ggcgtgatgt gtccttcccg ggttaggtcc ctgggatcca gctggctggc 13140 gtggagcatt cetgggcact cetettteet etgeegetge eeetgeeace ggggtgtggg 13200 · ttcccaggag ccccagaaca ggcagccacc tgccccctgc ccccagccgt ccttgccagt 13260 tgctgggtgc ccatggtatt ctggcgtgcc ggatggtgct gcagttggaa gtgagtcttg 13320 agtgagcaat taactctgcc agctgccagc tcacagctgc tgtgggtggg ggcggcccct 13380 ·tttaaaaata aaaacaacat gcagaaaaac agccctggag taccgttggc ttcccttagc 13440 caacgtggtc agggcttcat tttgatgctt ttgtggagaa gaatcccggg cctggatggg 13500 gaaataggat gcattttggt ctggggagtg tctttattta ggggcagagg tgatggcctg 13560 tgtctggcct ccccatccag gaggcaggcc cctttcctca agctgcccac gagtggctgg 13620 ctcatggatg cctgccacag ggaaggggat ttgggttcct tggggccagt ttttagcagg 13680 ctcaggccgg agagggtggc tgtgggacct ctcaggtctg tttccagctc tgtcggctat 13740 aggggggccc tggggccatc ccggagatcc ctggagctct cctctgcagc ttccagccag 13800 ttttctggaa ctagcgggaa aggaaagggg caccaaaggt gtttccgggc atgcgactgc 13860 tgccactttg aggtcttggc tttggtagtg ggttgagtca tggcccatga aacataggta 13920 cacttggaaa ctgtgaatat gaccttggcc ttatttggac cacaggtctt cgcagatgtc 13980 actaaggtaa gggtctcaag atgggatcat cctggaatag gatgggccct aaatccaatg 14040 acaagtgttc taagagaaga cacacagcag agaagtccac gtgaagatgg aaggaacgcc 14100 aggagecaet gggaactgga agacacagag aaggeteece etgeagagte tittggagggt 14160 gtgtggccct ggtgacacct tgagcttgga tttctggcct ccagaactgt gagaggatag 14220 gtcgctggtt tcagccaccc aatttgtaat aatttgttat agcagccaca ggaaacgaat 14280 acagttgtga actttatttt aatcactcat gtattttaaa attaaaatgt aaaatgtaat 14340 tttgtcttgt tcactgccat atttccagtg ctcagcacat acagtagggg ctcagcagat 14400 gettetegaa tgtetgatag etecaggeet gggtgaggaa etectacetg etgggagttg 14460 gacccagctt tcaggaagtc ggtaaactgg gctggagtgg tgtgcattca gcaacaccat 14520 ctttttgttt attfatttgt ttatttgaga tgcggccttg ctctgttgcc caggctggag 14580 tgcagtggca tgatcttggc tcactgcagc ctctgcctcc tggttcaagc aattctctta 14640 cctcagcctc ctgagtagct ggaattacgg gtatgcgcca ccacacctga ctgaattttg 14700 tatttttagt agagatgggg ttttgccatg atagccaggc tggtcttgag ctcctggcct 14760 caagcgatcc actgcgcccg gcctatttat tttcagttga ggtgaaattc acatcacata 14820 taatttacca ttttaacatg aacagttçat gagttcttag tacaatcaca atgttgagca 14880 PTS-0012

-110-

PATENT

cccacccctt	ctatccaaaa	aatgtcctca	tcaccccaaa	aggaaccctg	taccggtggg	14940
gtcactccac	gttgccgcct	cccgcagccc	ctggcagcta	ccaatctgcc	ttctgcctct	15000
gtggacttac	ctattttggg	tatttctcct	ggacggaatc	gtgcactgtg	ggttttggct	15060
tctttcactc	cgcacaatgt	gtttgaggtt	gatccgtgtt	gaatggtgtg	agtccttcat	15120
tcctttatat	ggcggaattc	cattgtgtgg	catacatcaa	tagaaccatt	tgatatctaa	15180
gtggcttttc	agatgaggaa	actgaggctg	cccaggtcac	ggagccctgg	ggcccgggat	15240
tgaggaggtg	cagatagcca	gacgtgtctg	gctcacggtg	ctgtctcttt	ctcctgcccc	15300
caccctgctc	cactcgtatc	tgtgcctggc	caggaagcag	cagtgtgtgg	ggaggaagtg	15360
agtgggggtc	tcttccagct	ggagccggat	gctgaagcgt	agctgcggct	gtgggtctgg	15420
atctggtcct	cagagttctg	gccccacct	ccccctggg	ccccacacat	gtagtttctg	15480
ttgacctggg	ttgcgagaga	ggcagcaggc	aggagctccc	ccattcgcca	gctgagcctt	15540
ctgatgcctc	gagaggctgg	gggccttgcc	tggggccact	cagcttaagg	tccccctgcc	15600
cctttccaga	cccctttgg	cccaccgtcc	tggcccctgt	ggcctgcggt	gaatcatatt	15660
cŕaaaaaatc	ttcaccgatc	tttcccaccg	tcaaagctct	gctcagcaga	cgggctccag	15720
gaagcggcct	gtcggcagat	tttggccagg	ggatgctttt	tcgaagtatg	gaggggtggt	15780
cgccgtcgaa	ggcttgcgtg	atggggagtt	cttttgctga	gcagataacc	agacactggc	15840
ttattctgaa	tatgagtttg	gttttggcca	caggctctgt	ctgggggctg	ctgcctgtgg	15900
ctgtttctgg	tgtttgatga	tttgtggtct	tcattaagtc	actcaacaaa	caatttgctg	15960
cggagtatct	ggcggggaag	gcacaggaag	cagaacgagt	ggccgtgaag	agacatgccc	16020
agtgtcaaac	ctgcccatag	cacacagtcg	ctctgagggg	gtgggaggag	ttaccgtgga	16080
ttccagggcc	agcctttggc	gaaggtctgg	atgcaggtct	gtgtccaaaa	caaacaaaaa	16140
tgaacagaag	gaggtggtga	ggcctgactc	ggccgctctc	aggcaccgct	tcctggtggt	16200
gtttgcatgg	ggccagtttg	gcctgggtgt	catggtcccg	cctggtcttg	gcgacggtct	16260
gggcgggaag	atggtgctgg	atctttgggc	taaaaatatg	cccgtgcctt	cctgtgcctc	16320
agtttcccta	cctataaaag	aaggcgtaag	agtagcagaa	tcccaccttt	ggctttgggg	16380
caggtctacg	gaaacccccc	aggggtgttt	cctggggaag	gctagagggc	cagctgttca	16440
caggagacat	ctggcttcca	ggggcctccg	cagccactat	gctcatcccc	tcgtggccag	16500
tctgggcccc	ctgccagtcc	agtggccacg	ggcccctgtc	acaggcaaat	ctggtcttag	16560
tcctgaaacc	ctcctgtgac	tccttgtggc	tgaattacca	cgtggatagc	ggagacaagc	16620
caggettgee	cagttcaagt	cccagctcag	ccactagctg	ttgaccttgg	gcaagtcacc	16680
taccctctct	gggccagcct	cctgctctgt	ctgtgtgtgg	cggctcaggg	gcatacctgc	16740
ctatgctgcg	gtggtgtgag	gccagctggt	gaaccagggg	acccgcttag	cacagtgctg	16800
ggcacacagt	ccgagctgct	gggctcggtg	tgtgtggcca	ctgttattgt	tattaatatt	16860
attactctca	agatgctcct	gagagtaaaa	aggatgacaa	tgttattgct	ggagttgaag	16920
gccaggccca	gagtccatct	gaccacttcc	cctccactcc	tattagctcc	ctgacctcat	16980
cgtcaaactc	teceegeete	gcccctgcgc	cccggccaca	ccagccttct	ctctgctttg	17040
acaacacacc	cgcgtggtcc	agcctccaga	ccttcacatc	tgccatgctt	ctgccagggg	17100
tgccttcctc	acatctgcac	ccccagaccc	ttgtcatcat	gtgggctgct	gtccagggac	17160
acattcttag	gcccaactct	tggctgctag	gggcagggaa	gtgaatctgg	agaccctggt	17220


PTS-0012

-111-

ggagcctcct	ctgcctcctg	ggagctccag	cagcttcctc	tggcgcctca	tctctgcttt	17280
ccagagcact	tggagaagca	gagctcagcc	tgccccttct	acggatggaa	agttgacacc	17340
cagagaagct	cagacttgtc	tctgagtcac	acagctaatt	gcagccaagg	ttcagactcc	17400
tggctgacta	ccaagccatc	attgttggcc	tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	17460
tgtgtgtgtg	tgtgtgtgtg	tatgtgtgtg	tgtattattt	ggccacgtct	tcttttctag	17520
gcctgtcacc	gagatgaccc	cagatcagaa	tgccagtgtg	agggggtcac	gctttcttt	17580
cctaggatta	aaaggaggac	agaaatattt	gcaagggaga	gcctgctcct	ctggccatct	17640
ggccctcggg	acagaggacg	ggggagggat	gggccgaggc	ctgggttcgg	aaccaggccg	17700
gagccaaggc	gccagagcta	cgctcaggtt	ggaggtgcag	gtgcggctcg	aagctggaca	17760
gtccgggctg	ggaggaagcg	ggttaaagtg	ggagaagcgg	ggctggagct	ctctttcgcc	17820
tgccagcgag	cgaagagccg	agctataaaa	aggcctcaca	gtgtttcagc	tcccgagtgt	17880
cggctggaag	cccgccaggg	ttaccatggc	gatgaggaat	tattacttac	tgccaaggct	17940
gggagaaaaa	gctcgtactt	ttggcttcca	aacaagagga	gtggacttat	gtaattccct	18000
gtgtttatag	gcccagagtg	gcagaggcga	gaacggatcg	ctggaggccc	gacgtctcgt	18060
tcącggccca	gccgtggggt	caggcggccc	cgcacttgtc	gccggtgggc	cttggcctgc	18120
ccgggtttgg	ggggcatcgg	gctgggagcc	tggggggcct	ggcctggccc	tgcagggcct	18180
ccagggccgg	gatgggagtc	gtagtctcgc	gggaaggtga	ggccgccctc	tggggccgcc	18240
cctctgcggg	tgtcatcctg	gaġgaaggat	gggtctgatg	ttggctgtgg	tgtgcctcct	18300
ggaagccggc	agcacagcct	gtgtgtgtgg	actctgctgg	cccgctggct	ggcacttttt	18360
ttcttttct	tttttttct	tgtgagagag	ttacttcaag	ttgtgtttgg	agctgacgtg	18420
agcgaggttg	gtcatgtgct	cgggtaagag	aagtcgccgg	gcttggagtg	ggcagggagg	18480
tgcagtgtgg	ctgggtcacc	ccggccgggg	gaggtgggcg	cagactgggg	tggggggctg	18540
tggcctgcag	gctctatgca	ggggcgctga	ttgggggccg	aggaattcat	ctggaaagag	18600
ccctagttct	gtcgctggag	gtggtggcca	gggctggggg	ctgagtggcc	ggccgcaggt	18660
cagccaatgg	gggcagctgg	accctcccct	ggcagcgcag	tgttgtcggc	cctgagctca	18720
gcgggatggt	gggcagggct	gtctcatcgg	acgaagttgc	tgcagtcacg	gaaaagagcg	18780
ctcggaggcg	ctggccgggc	aggccggggt	gaggcttctt	ggccggcccg	cgtgggaggg	18840
gacccgggtg	ggcactgtgc	tcctctcctt	ggtgcacatc	cggcgtccct	ggggggagc	18900
atggcgagcc	ttgggggctc	agggggcttc	tgttcccgga	gttgacttca	ggagggcatg	18960
tgatcgtggg	cgctcccgag	gctctgccct	ggggctccgc	ggtgggctca	ggcaggggag	19020
agccaggtgc	aggcagcgct	gcagcccggc	cccggcgccc	ggctcccac	cgaggtggcg	19080
cttggctcgg	tgcccatgtc	tggtttgaaa	tcagcgccac	cggcccaggc	ttgcccaggg	19140
acttggcagc	gaggagccgg	gataaacact	ggaaagttgg	aagggcttcc	cgagctcaca	19200
aggagccttt	agttgcaaac	cggggggatg	agggagtgat	ttgtcctgag	gtctgggtgc	19260
gccgcggcca	tagggaggtg	gcgggaatgg	ctcctgggga	cctctgagcc	caggctgggg	19320
aagggagggg	gctgggcttc	caggcaatgt	tgctcctttg	ccacagacct	gggtttgagt	19380
cctggctccg	tcctctctat	gctgtgtgac	cttgggcgtg	ttgcctcccc	tttgcagacc	19440
tcagtttcct	cgtctgtaaa	atggggcaca	gtągggtcta	cacaagcatg	ggactgacgg	19500
	tgcagtțtta					

PTS-0012 -112- PATENT

tggacacttc ctggctgtgt gaccttgggc aagtcactta ctgtctctga gcctcagttt 19620 tcccatctgg caaatggaag ttgcatcttt ccccacctca taggctgtat ggcttaaggg 19680 agtgaatgaa acctgccttc tagctcataa taggctcaca gttgataatt cactggcact 19740 ttgttttctc gatgctgaca ataccggcac ctggtctgag ggtggggggc ccctgggatt 19800 tcagcatctc agggcgatgg tatttatgaa gttgtagtgg ccggactgag gttccagtcc 19860 tggctcgacc cctcaaggat ggtgtgacct tgggcaagtc ccggaatccc acagagcctc 19920 agtttccttg tcctttacca cagtggtagc actgcagcct gccggtgtgt ctcgggagag 19980 cctgagagaa gcctgaaggg gcccgcacag tgctggcctg ggtgggcctc cgtaattgta 20040 accacaaggt tggatttaag ttcgagttcc gtccattttt cttttcttct ttgcagagag 20100 ctctcatgtt ttgtagaaac ctgggtccag ataatgggag gtaggtcgag tgggtgcttc 20160 ccaggetetg cetttgtttg ggatececag gtetececec atgeetgeet gttetgeece 20220 gteteceact cageetgage eceteegtge cageeetggg ecaggeacee cecacagtge 20280 ctggtgtggc ctggggactg gcgcgggagg gccagttctc ctgcagaagg tggcagccgt 20340 cctgtgtttg taagtgacac cggatgctgg gccagtgact ggctcagggc ctccgctctt 20400 gggccagcag gagccagtgg ggagttcccc gggcgtccag gcccccgca ccagctgccc 20460 gctgtctcat tgtcatgggg cctctcctgg gacctcgaga atggcctccg aaggcggggg 20520 ggttctcatc catgtcccct tgtcaccccc agggccttgg tgtccacttg ggttggccac 20580 agagetgtgt cgtggctgcc cctgacettt gccaaagtcc tcagggactc gattttccta 20640 cccggtggag aagagtcctg ggtgaggttc agaacagaag tcagcaccag ggcctttgtg 20700 acgaggcagc tcagcatgga ctggttgtga tcactggagt ctgcacatgt gataagaaca 20760 catagaacta aatacgegca cacteacaca tgeacacaca taeatgeaca etcaegeaca 20820 cacccacatg tatactcaca cgcacacttg tgaacataca caccatacac acagtcacac 20880 gaacatgcac acgcatactc gcacactcac actcacatgc acacactc atatgcacac 20940 tcacagtcgt gcacacaca ccatactcac atgcagacac ccacacagat acatgcgcac 21000 atgcacacac acactcacac aagtgagtgc attggaaact gctgcaatct gcatacggct 21060 ggctatatcc atgctgcctt cctagttatg atatggatga tgaattgtcg ttgtctcagg 21120 tttgtctcag gatgttattc ttgggggagg ctgggtgaag ggcacacagg atcctgggat 21180 ettgattttt ttttttttc ettttttgaa accgagtete actcegteae eeaggetgga 21240 gtgcagtgca gtggcacgat ctcagctcac tgcaaccact gcctcctgag ttcaagcgat 21300 tetectgtea cageeteeca agttgetggg actacaggeg catgecatea ageecageta 21360 atgtttgtat ttttagtaga ggactccccc atgaagctgg cctgtaactg agcttggtcc 21420 cttggacatc ccagggggtc caggcagagt ttgctttgtg cctcaggatc acagagggct 21480 ccagagcgtc ccaggctggg ggacacgtgg tgcctgcagg gcctgtgggg gcctcatgac 21540 tgagctgctg taagggtgtt cctgtcatca gagtggcgtg gtggaggctt gtgtcccgtg 21600 ggcatgggtc gtagcttagg gtctggagag atgggggtgg gatagggttt gggggcatcc 21660 agceteatga geetettett tgetgttett tggggeeeet gateatggge etgeeteagg 21720 acctttgcac tggctataac ctttttttt ttttttttt gagacaaagt ctcactcccg 21780 caggetggag tgcagagetg tggccacett tettteaggt teaagegatt etcetgeete 21840 ctgagtagct gggactacag gcgcatacca ccatgcctaa tttttgtatt ttgagtggag 21900



PTS-0012 -113- PATENT

acagggtttt	gccatgttag	ccaggctggt	cttgaactcc	tgacctcaag	tgatccacct	21960
gcctcggcct	cccaaagtgc	taggattaca	ggcatgagcc	accacacccg	gcctggctgt	22020
aacctcttct	gggaacaccc	tttcctgaga	ccttcagcct	ccctgatata	ggcctctgct	22080
aatggcgcct	cctgagagag	gcctgatgtc	agttgtgact	ccctgtgaca	ccttcactac	22140
tccttgtaac	actgtcacca	ccagggtctg	cggtatgccc	atcacccctg	tccccacctt	22200
gttttagtct	atttggactg	ggtggctcac	aaacaataga	actttattgc	tcacagttct	22260
ggaggctgga	tgtccaagac	caagatgctg	gcagatttgg	tgtcacatgg	gacgagggcc	22320
cgtttcctgg	ttcatagatg	gtggcttctc	ccaggaagag	gggcagggcg	gctttctggg	22380
ggcaccaatc	ccactcatga	cagctcatca	cctcccagaa	gccccacgct	ctgacatcat	22440
cccgtggtga	ttaggtctca	acatgcagat	tttgggggga	cataaacatt	cacactccag	22500
cacccctcca	tccaggattt	tgttcatctt	tgtcaccgct	gtgtccccag	cactgggtat	22560
gtagcaggca	cttaggagac	agttgtgcct	gactcagtgt	cttccacggg	gcctcagcct	22620
gtcccctccc	cataaatggg	gcctctctgg	tgaaggaggc	cctgcatttt	ggggatgatt	22680
tggaaaacca	ggaaaagttc	tcatgctttt	tetetgaetg	ccactggggt	acccaccaag	22740
catcccaaga	gagctacccc	tcctagatac	agtcatgaga	aggaacccag	ggatgctgta	22800
ggtacgggga	gtgggggagg	ggtggtgaca	gcctcagcct	tgtgtgttga	ggaccaaggc	22860
gaggtgagca	ttccacatac	cttagttcat	tgtgtccttc	ccatagcctt	gtaaagtcgg	22920
cacagagtca	ccctctcctg	ataaggcaca	gagagggtag	gcagcttgct	caaagacaca	22980
cagctgcagg	cctgcagtat	taccaactga	atggcatttc	caaggcagtt	gcttctttgc	23040
tcaaggtcat	gcttagcatg	ttaaggggat	catcctgttt	catccccaaa	agtccctcta	23100
ctatccctat	cttccgaggc	gggtcctgtt	ttctggggat	ctggctcaga	actggcaggg	23160
acccgtttcc	caggctgaga	gagtgcgcct	catttagccc	agagcagagg	cccagagatg	23220
cccacacttc	tgaaggttgg	gggtcagttt	ccagtgtggc	ttagaagtta	gagggcagga	23280
ggggcacccc	agagtggagg	aactgccctc	ttcctccgga	gtcgttcatt	tgcatgacaa	23340
tgagcccttt	gttcctgagg	ccagcctcct	tcccaggcta	ataacataat	tectggeetg	23400
tgatgtcata	atgggccctt	tctgtggctg	gggtcagagg	ctgggtgggc	agctgtgtgg	23460
gctgggccag	gcctgctaat	aaccagggag	gtggtgattg	ccaggggcct	gtgtgccaag	23520
ctgcctcctt	ccagggtctc	gctgagtcct	cccgagagag	cagcgggagg	tgggatttgc	23580
teceetgttg	acactggagc	aagctgagcc	tccaggaagc	cctccctggc	cccaccgttt	23640
gtctggtccc	cctcgatgag	ctgcttcaag	cttcttggcc	tgtggagtgg	gggtgactca	23700
ctgtcagttt	ggccctcggc	cgagaggcgt	gggcgtgaga	gtcccttgtt	tcctgtaaac	23760
tggagggagg	ccaataccca	gcggctactg	tgttggggcc	actcggaaag	ccaggttcaa	23820
accttggccc	cacttggtcc	cctgggcatc	ggctgaactc	cctgtgcctc	cgtttccccc	23880
tctgcttcat	ggggttccgc	tggggcttgg	gctcagagct	aggcagggag	tgagctttca	23940
ggaaatgggc	aatgtcagaa	aaggcggggg	ctggtggagt	ggggtgagtg	gtgatacccc	24000
caagagttag	gtccatgtcc	tagtaaccca	gcccctgtca	gagagagacc	gtatttgata	24060
aaagggtctt	tgcagatgtg	ttttgagatg	agctcatcct	gggttaccca	ggtgggccct	24120
gaatçcaaag	accagtgtcc	ttagaagaga	cagaagagga	gagagcaaga	ctacatgaac	24180
tacaggaaga	caaaggcaga	gattggaggg	ctgaagccgc	aagccaagga	atgcctggag	24240

PTS-0012 -1

-114- PATENT

ccaccagcat ctggaagagg cagaaaggag cctccctttg agcttctgga gggagtaggg 24300 tectgetgae geettgattt tggaetteea ggeteeagaa etgttagaga ataaattget 24360 gtcgttggcc gggcgaggtg gctcatgcct atagtcccag cactttggga ggccgaggtg 24420 ggcgcatcac ttgagcccag gatttcaaga tcagcctggg caacatggcg agaccctgtc 24480 tctacaaaaa gcacaaaaat tagccggatg tggtggcggc ttgcctgtag tcccacgctg 24540 aggcaggagg atcaattgag cccaggaggt caaggctgca gtaagccatg attgtgccac 24600 tgcactccag cctggaccac agagtgagac cctgtcaaaa aataataaaa aaataaaaat 24660 aaatcactgt tgttttaagt ttcctggttt gtggtcattt ttatggcagc cctaggaaat 24720 gaacacaget ggcgacgeca gtctctggag gtgggggaac tggccctggc gggggttggt 24780 actgttcccc actccaagcc tgagggtgca ggacaagttt gggtggccga gaaccccttt 24840 gtgcctggga gtgcatgaag ccccattcgg ggagtctgga ctttccagga aggacgcctt 24900 gctcgaacct gcctttcttg ccgagaacca aatccacaag gccctagacc ccacctgccg 24960 cctgctgttc gctgtcccct cagacagccc tgctaagggg acaggaccca gaggcaggag 25020 gctctcggat tctaccccgg ctttgcccca ggccccggac gccctttccc cacgcgtctg 25080 gtgactcctg cagaacccgg gttgcactca tcccccagca agccccaggt ttgccgggtg 25140 cccttgacaa atggagaaac taggcccaga gagggcaggc tacttggcag aggccacaca 25200 geteettagt ggeactgacg geettacagt etegecacgg gggetggeac tggggettee 25260 aggagtgggg atcagagttc tcggccactt ggagacctgg agtggagctg gccggctgtg 25320 tggacctggg gtcagttacc tgatatttgg gacactcggc tgcctttgat ggacctggcc 25380 tggtgtaggt ggtaccccga aatctgggct ttaagcacac cctgtctgtg ctctcagcct 25440 cagtetetet gtttgeaaac tggtetttga getteagete caegtetgeg attttgetet 25500 tagcatgttc atgcattcag caaacattta ttgagcacct gccatgtgca gtgtgctggg 25560 actotggggg acacaaaggt gtgactottg ottcatggat ottgtgtttg gggetgtggg 25620 gggagaggaa atgcagcagc acaggttgga gtccagattc cgggttctga tgagggaggt 25680 cacggagetg ggccgtgagg gaggtgagga tgtggccttt cgtctcctcc tgggcccggg 25740 gtggacagtg tgcagcaggc tctcaagtgg acatggagat gcccacagcc tgtccgcggc 25800 ggcccatggg cacctctggc tggcaggacc tggcctggtc ttgtgagcag ggacatggga 25860 tgggaggget geaaggeetg geteeageet ggtgggagag acaacagtet cetetaacet 25920 aagcagcagg catgggtatg ctggtgacag ggtcccagga cacagtgggt gagctggaca 25980 caggaggtgg ctcgcctggg tttgcatcca ggctgtgccc ttgttggctg tgtgaccttg 26040 ggcaagttgc teggeetete tgtgeeagte tetecagetg tagaatgggg atgataacag 26100 aatccctcac gggggcgctg tgaggaagga gttggtgcca ccaagtgttg tgttggggac 26160 tggctgtgcc agtggctgcg aggtgttccc tcccgtggct gctcagggca gcggcgtgga 26220 agatggaagt ggcatttgct catcttcccg ctgccctgct cctccctgtg caaatagcct 26280 cagtetteca cetaggaaac gggagetgta acaagcacat ggeeecatgg aggtegggag 26340 gagaagegga getggggtge atcagtgeet gtggggtggg ggettggggt egeeacetge 26400 tecagattga ggeettgget geeceegagg eetggaacag ceaettgttt tacaacceag 26460 gaaactgaag gcctggcagg gatggcccca agacatgccc atgggtacag cccatgtggt 26520 ggctcctggc tgcagacaat gcctcttttt tctggcctgg cgggagcagc ccaggcttgc 26580

PATENT

PTS-0012 -115-

tcaacctggc ctaggtttat cagcacattt ggttctgcgg tgcggctagc agacattccc 26640 tccaagagag atcgtgatgt tcctccggaa accgaggtcc ggaggctcag gttactgtgg 26700 ggggcggccg tcggggggtg tgtctgcctc tgagaagtga cccagatcag agctgggctg 26760 tgctgggcag tgttcatctg caaagctgcc gcctgctctt tcacccatga gagccactga 26820 cageteagga agggaetggg agecaeceae ttteeettea gggtgaeaca ggaeaggeet 26880 ctcctggct cctgcctggc cccttccccc tacactgagt ctggcctggg tctcccattc 26940 catttctctg gcctcttctt ggctggcttt ggacctgtcc tcacctacat ggataaggga 27000 cctagcgggt ggaagagatc tgattccagg gagatcctat ctgagagttt gtgttttagg 27060 agggttgcta tcttaggtct cttggttgca atggacagac tccctctgcc tcctgcattt 27120 agcacaaata gttcaagtaa ctaaaaaacc tcagagaagc ttcaggcaca gttgggtcca 27180 ggtgctcccc actttcagtc cctgttagcc tgagactaat aattgcagtt cagtagcccc 27240 agtggaagga cagcttcttg ttcccaatat tccagcaaat atcatgggaa tgagttttgt 27300 tgcctcagct tgagagttca gagttaagcc ccccccgcc ccccaccaaa gccagtgcca 27360 ctttggctgg agggctgggt cagcctcct gagaccccag gactgagggt gcagggggg 27420 tggttgccca gggaaattgg ggtgtggcat gcacggagtg ggccgggtg ggcagagaca 27480 ctgtgtcttg ctccctgtgt tggagatggg gccaggttgg ggtccctgcc tggcctgcct 27540 ttcatggcca gtgtgtgtgt gtcccattgg ggtggagcag gtggcgccga tgagtcactg 27600 ggtaagtttc attcctgtta tatttaatag ttgagggcct cttgggtccc ccctccaagc 27660 : . egttgetgge getecacete etgtececee ateageeege tteageteee cageetteee 27720 tcacctctct tgtggcgtcc agtgaccacg tcataagcca caggtcatgt cctggcagcc 27780° cctgggctgt atttggctgt cagactgatt tattgggttg gttttatagt cagtgttttt 27840 ttagaaatat cgggagatgt ctcaaaattg ggcttcttgg ctttgctgga aagatttgga 27900 tgccgtggac cccctgcccc acgtggaccc tgttccagca gggtctggaa catcaggaat 27960 gtttgggggc cacattectg ggtetetget cagtgttgge tggggetgag etgeggteae 28020 gggtcttggg tatctacage tetectettg etttttgtee etgeeettet tegggtggat 28140 catccgatcc caggtagacg cttagcttca gccgtcgcca ctcctgggcg ctgaagcatt 28200 tgtttactgt ctgagctcct ggctgcaggg gccataggac cttttgggtt cttgatcact 28260 gtcccgtcat cagacattta ttgatcaatg cccctggggt aattgaatgg cccagatgcg 28320 tccacttctg agcattggac agagctgacg taaagtggat tcttcccgtt tagcctggga 28380 gcccaggcgg cagtggggtc ctcccatcca ggccctttgt ggtccagcct ggccacttgc 28440 tgggggctgg gatgggttgg ggaggcagga ggggaccctt gttgagtggg tgggctctgt 28500 cgccctggac gctgctgctg gcacagctat tcttagcagc agaaacattt gtcctcattc 28560 acatgtggtg gatgcctcca gggatctacc ctgaaatact agaggcgacc ccataaattc 28620 ctcagaaagc catccttgag ggcctgcgtg catggaggag aagcgggagg aggcgtttcc 28680 ggcagctgca cagctgtgga tgtgtttgcc agatgttgga ggcagggaag tcggtgggaa 28740 cettgeggag geegeettea cacteggggt etgggeatgg acatgagegg gtgggacaga 28800 gactgcagac tggtgggcag agagaagggc tctggccctg gcctcaagtt ttggggtcca 28860 ggggcccctc tgaagcagtc agcccttccc tgggccctgg ccttgaggcc acctgggttg 28920

PTS-0012

-116-

gaggcagctg	gcgaggggag	agctcagctt	atcoggege	t tccgagggat	. cadaddtaa	20000
				tgaggtgagg		
				gctgagtgc		
				ggccaccgcg		
				g tgttgtttaa		
				g gtaagtagat		
				acttttcate		
				; ctctccccag		
				ggccacctcc		
				: tcagcataat		
				: atgaagcaaa		
				aggtcccacc		
				ccctgagccc		
				ggttaagtgg		
				acagcagcct		
				ccagatggag		
				tgaggaagag		
				ctcccgtgc		
				cctgctgtgg		
				aggggaggag		
				gctgccgtcc		
				gaggctccga		
				gggccgtggg		
				gtcagttcac		
				gtgaatggaa		
				gtggaggtgg		
				cttgaagcag		
				ggaggggaga		
				gaagcaggag		
				cacttgagaa		
				catagtgact		
				gcgtggcaga		
				actgcaccga		
				aggtcaggac		
				tgatcagcac		
				gagggcactg		
				tcctacaggt		
				ccgaggagga		
				ggccgagtcc		
			•			

PTS-0012

1 -117-

cagggggagc	gggccatggc	accggggggc	cccttgggg	ttgggggaag	gttccaagga	31320
ggtgccagta	gaggcaggag	ctgaaggctc	aggagaagac	agactgaacc	tgccccattg	31380
agtccaacca	gccaggcagg	gcatgtaaac	aaaggtagct	gagtaggagg	ggacgtggca	31440
aatagggaaa	gccgagccta	tctggtgtag	atagcctctg	cccacttcca	gccggccatg	31500
gctggaacct	cagtttcccc	tgtcaaacga	ttttgtggta	aaatacgtac	aaaatatacc	31560
attttggcta	tactaaagtg	aacaattagt	ttgcatttag	gacattcacg	ggttgtgcaa	31620
ccaccacctc	tgtctaattc	caaaacagtt	tcatcctccc	agaaggaaac	cccaaaccca	31680
ttaaaccgtc	actcccctct	cctccctccc	cacaacccct	ggcagcctcg	ggcctttgtt	31740
ctgtcctggg	aatctgcccc	tcctgtgaag	ttaatggaat	catgcagtgc	gtggcctttc	31800
tgagcggctt	ctttgccttt	tgtgccatgt	cttcagggct	cacctgcgtt	gtggctgagt	31860
cagcgcttac	ctttgcgtgg	ctgaatcgta	gtccattgat	ggacagactg	cgtttgtttc	31920
atctgtttgt	cagtagatgg	acatttgggt	tgtttctgct	tgttggctga	tgtaaatagt	31980
gctgctgtgg	gcattctaat	cctttctgtt	tgttttgtca	ccagttttcc	gttccttggg	32040
gatgtgtagc	taggagtggc	atcgctgggt	catggggtaa	ttctgggttt	aacctagtga	32100
ctgttttcca	cagtggctgc	actgcacatc	tgacattccc	acccgcaatg	tgtgagcagc	32160
cctcattagg	agaagccaga	cattccaaat	ttcctgtgaa	atccctcttt	ataagagctg	32220
gtctctgggg	cttagctgag	ctgaccctgg	ggtgaggaag	caagtcccag	gaaactgccc	32280
agagggagca	agtctgggac	ctgacgagac	gctccgggca	ccccagcttt	ctggctttaa	32340
cctggcccac	gtatctctac	cctgtacatc	tacccggggt	caaggaggag	gattcccagg	32400
ctggagtcct	ctcggccttt	ctcctcgaac	ccagctcaag	gggaagatgt	gctggtttat	32460
gctgaaaagg	gagaagtggt	gccaggtggg	ggactcggga	gagttgagac	cctcccacgc	32520
tgagtctggg	tttgggactg	gaggcagttt	tccctagggt	ccttcttact	cagcaggctg	32580
ggacttgggg	agcagttata	tgggtttggg	ggttcctgaa	ggcgacagtg	cctttctgtg	32640
tccctcatgg	agctgggcat	gtgggagggc	ctgggaatat	tagcaggatg	aagacatgct	32700
tggccctggg	gattggttag	aaatgtaaga	ccagaaaaac	ccggaaaatg	aagcagctaa	32760
gttgatatcc	atctggtgat	gagtgtgtgc	atccatccgc	ccatccatcc	atccatccat	32820
ccatgcatcc	atgcatccat	ccgtccatcc	atccatccat	tcgtctgtcc	atccatccat	32880
ccatccatcc	atccatccat	ccatccattc	acccgtccat	ccatccatcc	atccatccat	32940
tcgcccatcc	atccatccat	ccatccgtcc	gtccgtccat	ccatccatcc	gtccatccgt	33000
ccgtcttcca	tctatccatc	catccattcg	tccatccatc	catccattca	tctgtccatc	33060
ctctgtccat	ccatccatcc	atccatcaat	ccatcatcca	tccatccatc	catcagtcca	33120
tgcatccttc	ctcctttctc	tatccatgca	tgcattcatc	catccatcct	cctttcctcc	33180
ctcccttcct	cctttctcct	ccatcctccc	atctctatcc	ctcttccatc	ttctccctcc	33240
atccagccac	cccctgctga	gcacctgggt	ggggagtctg	ccagttgggc	cagacctgtc	33300
actgggtgtg	ggccgtggtc	agcagggcct	tttgcctttt	gtctgacttg	gtcactgctg	33360
tagctgtgct	tgtacagtgt	ttgcacataa	cagatgctga	aataattctc	taattgatga	33420
gaatgggtca	gcaaccggag	tttgggatgg	gtttggcttg	cctggtctca	gctggagggc	33480
agaccgcacc	cttgtgggtg	gcacctggga	ttgagctctt	agtatttgac	cctcageccc	33540
tccggcagag	ccaacgacag	gctggggttg	ggtacctggc	tcttccttag	ggagtggaat	33600

PTS-0012 -118- PATENT

gacctttctg	ccaagtgagg	gccaaggagt	ctggcċtcat	tcctgcaggc	ctgccgctgt	33660
gcatgggtgg	aggcccgttt	ctctagggcc	ctgacaatcg	tggctgtcat	cattcagggt	33720
tacaggggcc	cttttacctg	tgccccacac	tcagacacct	gtgcccagtg	ctcctcgaca	33780
caggggcagc	tacagtgtcc	tttgaacaca	gagacgccag	aggcagactt	gccacaggag	33840
accgcacgtc	agccttgttt	aaagtgcacc	agctgtgtcc	ttcctagctc	ccttgcagtg	33900
aacaccccag	ctttctggct	atagccagaa	agagtgacct	cacatgcctt	cgctcacccc	33960
actctcccca	ttcaggcctc	cctgctgtcc	tcacacacca	ggctcggtcc	tgcctctggg	34020
cctttgcacc	tgctgtgcct	gctgtgtgga	ctcctcctc	tccccggcgc	ctttgcataa	34080
aaggcacctc	tggtgacgca	ccctgactg	cccactttca	aaatgtaccc	ccattccctg	34140
cctgccgcct	cctggttctg	tttttctcca	tcgtgctaac	accttctgcc	atcctcttac	34200
tcccgtctca	cctgctggaa	tggcagcttc	acgaggtggg	ggatttggga	tcagtaattc	34260
actgctgtat	ccccagcacc	tttcacacag	taggtgctta	acaaatcgtg	gtagacagag	34320
tgagccacca	ggccgggcag	caggagctct	ctcttcaccc	ccttcctcat	tggctgtggg	34380
ggcccctctg	gactgggctg	ggcgaggtgc	accettgeca	cgtcccaccg	gctttccgca	34440
tctcaggact	cactccagag	ctggattcct	gagcatccgt	tctgcgccag	gagtcctgct	34500
gaaggtggcc	atcagatact	tggccagttc	cccagttttt	actgcacgcc	agaaagtaaa	34560
cacccaaggt	gtcaacagct	cgacccctgg	agctggcgct	ccgcagcatc	ttgtgcgcac	34620
atcccagaac	tgctgtccca	gagttccccc	cgggccggct	tctcctcggg	ccagactggc	34680
tgcagtggtt	ttgtttagta	aatatttatt	agatgcctac	tgtgtgctgg	gctctgggga	34740
tacagcagtg	aacaaaacaa	gtatttctgg	agcacctcct	gaagtaggta	gtgttctccc	34800
ttaaggtacg	tctgcgtgga	acctgggagt	gcggccttgt	ttggaaaggg	tttttgcaga	34860
tcacattagt	taagatgagg	tcacaaccgg	ataggggagg	gccccaaatc	caatatgacg	34920
ggtgccctta	gaagaagggg	agacacagag	acaggagatg	cagtggaaag	gctgcgtgga	34980
gatagaggca	gaggatggca	cgatgcatct	acaagccagg	gaacaccggg	ggttgccggg	35040
gccaccagag	ctggaggagt	gaggaagtag	gaagggcctc	ccccagagcc	cccagaggcc	35100
gtggggccct	gatgacagct	ggatatggac	tcgaggcctc	cagaacagtg	agacaatcca	35160
tttctgttgc	·ttgaagccat	gcagtctgtg	gtggggcagc	cgagggcgct	aatacgcctc	35220
gtgtgtgcca	ggtgccgtgc	ctctcggtgg	ctgtcacaca	ataggtgctt	attccacagt	35280
gagtggagca	aatacctact	gagcggtgag	ggaggccgta	tgtggctgag	ctgcagggct	35340
cctggggcct	gcctģtcttc	gcagggccag	gctgggacag	tggaggcacg	gcctgtgttc	35400
ccgccgtggt	tccgcccacc	ccaggggggc	tttgtgcctt	gggcttctca	gagtatcaga	35460
gggttctgtc	gagtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gcgcgtgcac	gcgtgcgcgc	35520
tcgtgccgtg	ggcgctctct	gcctggcagg	ttggttttta	atcccgaggc	tccccacct	35580
gccacaggtt	cttccaatgt	cagcacccat	tagttcccag	aacatttcag	gcacgtgcgg	35640
cgcagagccc	cgcgtgcctt	tcatcctccc	cacagcccgc	ggctgagcgc	tccgggcaca	35700
tcctgtagct	cccacacctc	caccagcccc	cgcctgcccc	tcaccctgag	gctgtaattc	35760
caccctcccc	aggtctgaac	caggccgctc	aagacacaga	aaatctatgg	aatgtgtctc	35820
ggtgtggcct	catcctgccg	gagctggaga	ggaatgcagg	ggtgggaggc	cccatggaag	35880
cttccagggc	ctcccggaaa	ggcgcctctg	cccggccagg	tgggaagagg	acacaggtgt	35940

-119-

PTS-0012

					•	
ggtggtttct	ggcatcactg	cgttgctggc	atgcacctcc	gctgggcaga	gtcattcagt	36000
gtgcacctac	tgtgtgccag	gcaccagaag	gggctctggg	tccagcagga	ggcaaggcgg	36060
acagccagtc	agagctcacg	gcccgagctt	tccgctgtgg	atttggaaac	cttaccaaag	36120
cccgcagtgg	ccgggaacag	ggaatgtggc	ccacttggct	tctgctgctg	cccggcagag	36180
tgcagtgggg	gcggggggca	cttgtgtgtt	tgctacctcc	ttgcaggcat	ggcccaggga	36240
cagacccctg	cagccgtgca	tggggagccc	ctccacctgc	ctgtgtggga	tctgcagccc	36300
tcctccagct	ggttcagggg	ccagcagggg	ccctggggct	gtggttggtg	gcttggatgt	36360
gcagaggcct	gcttgggccc	ttggtgtccc	cgttgggtat	cccggccacc	tgagatctac	36420
aagtcccttg	acctcaccca	ggcaccgtct	tgttctcctc	ggaggcctga	ccctcctgac	36480
tctgcatggc	tgagcacctg	ctgttcccca	ggcacctctc	ggtatgccac	aggcacaggg	36540
tcctcgcagc	gggcctgtgc	agcgggactc	ctgcagcgag	ctgtttccgc	ggcctgcaga	36600
.gtcagcctcc	ctcctgactt	tcacccacct	gcccatttcc	ccttctctgt	cgctgttgcc	36660
ctgatcccc	agtgtcccct	ctcttggaca	tttgcaggag	cctccccagg	tctccctgat	36720
ccactcttgc	tgtccccagt	gcctgctcgt	aaaacactga	ccctttactc	gccccgcaa	36780
ccaccttctg	tggctcccca	ctgccctgag	aacaaaatcc	atccttaccc	gggcccatgg	36840
ggccctgaat	gactctgtcc	ccacttcccc	ccatattcac	tcaatgaatt	tctcaaacat	36900
aaacggcacc	tgtgctcacc	cccaggccct	cgctcacccc	tgggcctgtg	ctcaccgcct	36960
	cacccccaag					
tcttgctcag	cggcgcctcc	agctggagca	ctctccatcc	cctcgccttc	accctctgga	37080
	cctcgtatct					
	gcctggaccc					
	cacagtgtgt					
	cgcagcggcg					
	gaacctcctt					
	tgcccccatc					
	tgatgaaaag					
	atcaagtttc					
	cattcctgcc					
	gcctgttctg					
	ctctttggtt					
	g ttcctctta					
	tgccttttgg					
	ccctgtttcc					
,	a ttctatgttt					
	g agttggcagg					
	ggtgagtgag					
	g tgaggcgctg					
	c agccccatgo					
cagccagcca	a gctgcgggg	actttaggad	ggtgtcacc	c tecetggtet	ctggtgcccg	38280

-120-

PTS-0012

tgtgcaccat	ggtaagcgtg	tgccaggggc	ctgtcacccc	caggcagcat	ctcactgggc	38340
					gcaactcaaa	
atccaatagc	aatttggaag	ttgcccgtgg	tgcccttgaa	agaggggcag	acctcgggaa	38460
					gtttagcacc	
tagagagaag	ggaatagaat	ttgctttgct	gcatgagatg	accagggtct	gcagactttg	38580
agccgagctc	tagcaggaag	aattttagaa	cagggctggg	tcctggtggc	cacagctgtt	38640
ctctctccca	gggccagact	cttgtttctg	gctgcagaac	ggatgtctca	ttgctcttgg	38700
ggccgggcag	ggctagctgt	gccttgcctc	cccatcatag	cgtcactggt	gactgggctg	38760
cagctgcatc	attgacagtc	ctggtgacag	cagtattagg	cattctggtt	tgctgagcat	38820
ttactgtgtg	ctgggagctg	ctgagtgcct	gctgtccgcc	acccggcctt	tcctggggtc	38880
cttgcaggag	gacttaggca	gtcggaatat	gcacagacgt	cttcatgtgt	gtgggagtgc	38940
gtttgtgatt	ccgatgcctt	cctatttatt	ccacatagta	ctgggtttct	gtatacctat	39000
gctgataata	agcttctctt	gtatgtaaag	ttatgcctaa	ctgaatgaaa	gtgacaggcc	39060
cggggctaga	cggctgtcgc	ctgggtaatc	tctataaaaa	agtccctacg	cgggggtggc	39120
acatgaatgt	ctgatgttta	gggaacactg	tgtgtttgga	ggttcagaga	gggcaagtga	39180
cttgcccaag	gccacgcagc	ttagcgatgg	tggagcggga	cgtgttccca	tgttcacggg	39240
aattgcgcca	tacatcctgt	ctcggggctg	ggaaagccca	cgcaggcagg	accgaggtgg	39300
tggtagatgt	gtcagtcttg	gctccggaat	tccttggctt	ttctgtgttt	gaaggatgga	39360
cagcagccag	ttgaaggggt	ggcctcctct	gtgactcctt	ctttccctgt	gtgagcccga	39420
attcttggtg	gcatgtgaca	gaaacccagc	ttgggctgcc	aaagacaaaa	cgtgcagaag	39480
gagtgccctg	gctcccctaa	tgaagtgagc	aggcttcgac	ctgcctccag	ccaccatcgg	39540
acacaacctg	ctcttaccgc	cctttcgccc	tgccttcctg	ccggtgggcg	tgggtctcag	39600
gcaggctcct	gctgcatggt	ggccccaga	gctccaggct	ttcattccca	gcttagatcc	39660
ccagcagaga	gcacctttct	cctggttcca	gcagcaaaag	tctcaaggca	gattctcatt	39720
gactcctatt	gggtcacagg	ctcatccttg	agacagtcac	tggcccagaa	gcatgcagga	39780
ctctgattgg	ccaggaccgg	gtcacatgac	catccctggc	acctggggag	gġagggaggg	39840
tcaagtctac	actaatgaga	gatgaggtgg	ggcctgggag	gcagtcaggg	ccccaacct	39900
taaccttcct	cccaatgccc	ctccacatta	ggcctccaag	ggctttcctg	cttggagaag	39960
gacggttacc	ctcttcaggt	tgggggaggg	ggtgttctga	tgaaattgca	gggctgggta	40020
tgctctgttt	cccctcctga	cccctgacct	cgtgtggtgc	agcctcagtc	ctccgccact	40080
ggaggcccac	atccaggcgc	tgggtcccgg	tgccagggtg	catttccctc	agctctgggg	40140
ggtgtgtgca	attgtggggg	tgctggagag	ggctttgcat	gaggcaggac	ctgatggaca	40200
caccttttct	gagggactgg	ttcagggaga	gtgtggaggg	ggccttggtc	tgggatggga	40260
ccctgttgta	agcccagcag	gtggcgtgga	gctgtggctg	gcggaggaag	gggagaagcc	40320
ttgttggggg	tggggggtgc	ttaggggttt	cctggcaaag	gcagcttcgg	agtaggggtc	40380
cccgtggctc	ccttgctggg	ccgtgtcttc	tctgtggggc	tgtttttcca	tctgtaaagc	40440
tgctagcccg	cttcgtgtta	ttcctctggc	gtggccacga	gtagatcctc	tcccgtggaa	40500
ggctccagta	tctgccccag	gagccgtttg	gggtacctat	ccctaggctg	cagggcccga	40560
ctggctgtca	ttctgccctț	ggctcttcct	ggtgtagccc	ţçcatgtcct	aatcccacct	40620

-121-

PTS-0012

cctagtttgc	atctggctaa	cctcatatca	gtcctgtccc	atgtcatggt	gtcagcctcc	40680
tgcacagggt	catagccttg	cccaggtcat	gctgtggcct	gtggcccgtg	gcccgcctga	40740
gctggccctg	gtccctgctg	cccgggacag	cggtgtgtga	tgtccctgct	gccggccgcc	40800
cctcctggga	caggtgcttt	ctgggaattc	tgccctgtga	cttagaaacc	cgggggccat	40860
ggagtgaagt	tggatgggct	taggggggct	gggagccatc	tgggtggtgg	tgagggcagc	40920
gcagagtccc	tgtgcctgcc	gggtgaaggc	ctgggtgggg	aggaggcctc	tggtcccttg	40980
cgtggcttgc	atggctcgga	gggaccttga	atgccatgcc	tgtctccttg	tgctcccgga	41040
gaacaggtga	gtgtggcagt	ggatggagga	gggtccaggc	aggcccctgg	gtgctcgcgt	41100
gtcctcacgg	gaccacagga	acgactcggg	gacctgtgca	cggaggagcc	agctgccccg	41160
tggctgatct	tgtttttctt	ttcttgtttt	cccgcaggtg	ccagtgacgg	ggtggcccgt	41220
gagctgatga	cgaggactgg	cttttaatcc	ttggtggtga	ttaagagaaa	gcttattggg	41280
gcctgggagc	agctccccgc	cgacccccac	caccatgtcg	ggatccacac	agcctgtggc	41340
					acccagtgca	
					tacctttgag	
accettette	cattccactg	agtcttcacc	ccttcctttc	tcctgggagc	caggctcatg	41520
tggctctgag	cctcccaggg	cagaggggag	gccgccacag	agacccctgg	tgtctgaagc	41580
					aagatggagg	
					ttggcacgcg	
				•	gctcccccgc	
					ggataggtca	
					cggctcgagg	
					gagggtccag	
					ttgccctggg	
					taagccgcac	
					cactgcatgg	
					gcttgctgta	
					cccttgtgac	
					tgaagctgac	
					ctgcctggct	
					tttccatcag	
					ctgacacagt	
					cagtgggtgc	
					: ctcctgggcg	
					actgaggccc	
					gccacagcat	
					gagcacctac	
					: tttgtcatca	
					gagcacctac	
tatgggtca	a atgttgttca	a aagccctgaq	g tgtatatgg	t tgtgtgcati	ccctgatca	42960



PTS-0012 -

-122- PATENT

ccccagagtg ggactatcat gctctgtatt ttgtcaatgg gaaaatattt cacagggtag 43020 gaaactggac aagttacgta acctetetga geeteagttt tgteacceat aaagtggggg 43080 tactgagagt acctgtctcc tagattctca cgaggggtaa aggggatatg ccgaatgttc 43140 ttaagatggc gcctggctca gggccagccc gctctgtccg tttgctgctg ccgttccttg 43200 gtcttgttgc tgtacctgca gctgcccaga ggggaacctg cctgccctgg gggtgctgct 43260 ggcttctggt ttcttgtcct gtcctgtgga ggttcccact cttctcaacc gccctcaccc 43320 ggctcctagc cttggggagt cctcaggctg ctgtggcctc tgctctcca cccctcctgc 43380 cetttgeecc aactgggeec teggggteac tggetgaecc tagacacete ceattettet 43440 . cctgctgggc cgtcagtgac gcaggatgtg ggtggacagg gccaagcgct caccgccccc 43500 tccaggcagg aggctgaggc cagggagtga gtggggccca gcctggcggc cacaggtgag 43560 aacatgtctg teettgtgtg ggggcageag gggccaectg tgtgtgetee teeetggggg 43620 · agetgeecea tateggaece teetgeetea tggtaggget geccatecag agaateetge 43680 ttgtctcttg aagggcagga ggaagagttc tgggcactct gaggagggcc ctgctgccct 43740 gggcatattg cagggtggag ccgctttctt gctgtgggtt ggaggtgagc tgggggctgt 43800 gatctggagg cccctccctg gaagcccctc agccctcaaa cccttcctgt ccttttaaag 43860 ggcaagaccc agttcgaaag atactacccc cttcctgagc tcctcatcaa gccacagaaa 43920 · gacagatece ecegggtaag gggacagtea gtggegggaa eetggetgte etggtteete 43980 gtacagtage egaggeeatt etgetgggat ceaegggatg ceteagtgae etteceagat 44040 teaggteace tecaegeata etecegacag geetacetee tgggacaget ceteetgtet 44100 ggagagtect etteetggtg etttgggeac ggggetgett tgatggeagg tetteeetgg 44160 agcctgtgag acctcagtgt ggcttcgaac cctctccgtg ttcagcttgc tgagtggcat 44220 tggcccgctc acagccacgt ggaacggcct cagtttcccc acctgcagta ccggtgtcct 44280 ggtgggtctg tgcatcggtg gcaatgtctg cacgcagcaa gcgcggggta gtcatctctt 44340 tcctcctgga agggtggcag gagacccaag cagggcctct tccccctggg gaaccacagg 44400 accytygaty ccyayctygc gytygaatyy tycayyccyt gyaayccyct gcctctycct 44460 gtgctctgcc ctggcgtcat ctgcgggctg ctggtgagtg attcccagca caaatgggag 44520 gcttcactta gttgggtgct tgcagacaga ggcctggacc ctgagaccat ggaaagcccc 44580 caggitteet gactcageet cagecatget ceaggettet atatgeatea teeetgeeet 44640 cccgcttcct acctgccgca tccctctgtg cctcattctc tccatcctca ggggcccagc 44700 tteteteegt gacagtagea ggateetatg acteteetg agggteetgg ggaagegagg 44760 gtctccaggg ttgagggtcc agtaacaaaa tgctcacagc ttttgttttc ccggagatca 44820 acgectecte etetectgge etecttteag getttetgtg geceagetge attetgeett 44880 cttcttcaag tcctctggga cccctgaaca ctcctgagct cctccagacc ttgggctaaa 44940 cgaatgggct aaaggaatgc agttaaaagc agggacacag agtctgaatc ccagcgtgac 45000 tettttetge tgtgtggeet tgggcaagtt acttaacete tetatgeege agtattgaag 45060 actggttcat agcaccggtt ctggagccag gttgcttgca tttacatcct gccccagtga 45120 tgtcctagct gtgaaacagg gggcaagtgg ccttaccgtc ccgtgcctca gtttccctat 45180 cagttgagca aggatagttt taagattgtg aggatccaat tagttggtag gtgcagagtc 45240 cttcgcacag ggtatggaca gagtaagcag acatttgata taatcaataa tgtaatgatg 45300

-123-PTS-0012

acgatgctat	tattacaaca	tcgcctttag	tagctttttc	tgtcttgccc	caagggtaca	45360
ctttgggctt	tgcccctagg	gcaggggtga	gcacaacctt	ctctgtaaat	atttcaggct	45420
ttgcaggcca	tgcaaccgcc	cttcgcggcc	cgtatggtgt	gaaagcagct	cagccagggt	45480
gtaagggagt	gggcgtggcc	tgtgcctgtg	acactggacg	ctgctgcctt	ggccttgggc	45540
cctagtgtgc	tgcctcttgg	cctagattag	ctcttatcag	actccctatg	ggaaggaccg	45600
gtctgtttca	tttccagttt	gtcacaaatc	gatatggggt	cccactgcac	agacgcaggg	45660
gctcagccag	gcccagtccg	gcagggtcag	acagagttgg	ttgtgccctt	ggatgccagg	45720
gtcacgccaa	ccccagaggt	ctgcatgctg	tcatgttctg	tgcccacttc	gttgcagttg	45780
gcaacgttgc	agacctttgg	tggagtagta	ctgccctggg	ctaaggctcc	cagaccctgg	45840
agactgcctg	ggccaggctg	gggcaggtgg	gcgcgtgggg	atcactggaa	gaggctagac	45900
ttgggaggct	ttgcagtgtc	ctgagtgccc	tggggggggt	ctctccatta	gcttcatggc	45960
ccccttgcag	ctcagttcct	ggtgcttggt	gatggctctt	aagaggctgt	tgagggatgg	46020
tttggccctc	aaaagagagg	ctggtgggag	ctcccatgct	ggggaagatt	cattcattca	46080
ttgggagctc	ccatgctggg	agatccatcc	atccatccat	ccatccatcc	atccatccat	46140
ccatccatcc	atccatctgg	caaatactta	tcaggcgtct	cgggcccgtc	ctcttccagg	46200
cccttgcagt	gcagctgtga	acagaacagg	taagcatcct	tgtctcaggg	agctgacctc	46260
·cttgtgggga	atggcgagtt	gggaaggaga	tgaggggaag	ggctgaggtt	gggggagccc	46320
agatttaagt	agagagtcgg	ggaggagcct	cactgagaag	ctgcctttgg	agctgaacct	46380
ggaggaaggg	agagggccag	gcatgtggga	atctggctga	ggaatgttçc	aggcagcagg	46440
aacagtatgt	gcaaaggtcc	tgaggtggga	gctctcttga	ctgtagccgc	catcattccg	46500
ggagagaccc	gtgaatgcag	ccagggtcta	ggaatgtgct.	gaattcttcc	tttgctttcc	46560
catgaatcca	gggtccagga	acgggctgaa	ttcttccttt	cctttcagtg	tgcagtccca	46620
ggcattccct	tgacaccttc	tggagtaagg	agccctatgc	aggggccaga	gaggggcact	46680
cctctcccgc	aaaggaactt	ctcccagtcc	atgctcaaac	atccccccgc	atctagcccc	46740
tttctcctct	ctgcccccag	ccactcctcc	ccacccttgg	gacccagcca	agaaggcacc	46800
agctgggatt	ccctcctgga	tgaatggctt	tttctggtgg	cctctcacct	ttcccaggag	46860
ttttaagggt	gtaatttatt	ggtggccctg	atttccagct	tcagaggtgc	catggtcagg	46920
gagaaccctc	tgaggccagg	gggcatcacc	tgaatggctt	tttcctgcct	ccctttctga	46980
gcagctgggt	cagactccct	ctgcccaagt	caggtttgct	gctgtcctac	agggacaggt	47040
tcagagcctg	gggactgtcc	cctcttgtcc	ctcctcagaa	agccagctca	gcctttgcct	47100
tgcatctcag	aacgtacccc	ttattgctgt	gtgacgtgga	caagccactt	accctctctg	47160
tgcctctgtt	ttctcgtctt	tgtgtggggc	ttcttgtaat	acccacctca	cagggttgct	47220
gtagggatga	aattaactaa	tatatttaga	gcgtttagct	gcaggtacac	aaaggcaatt	47280
tattactgtg	gggtattatt	gttgttttt	atgattaatg	ttgtcgcgtt	ggggagctct	47340
cctgcttgga	gacgtggcga	ggtggtttcc	agcctgggcg	tattccagct	catgggaccc	47400
cttgggctcc	acctcaggtc	agtttctctg	gtggggcctc	cccaattctt	gccttcccct	47460
agagcctcca	ggtactcttg	ttgggggagt	ccctgggctc	aaccctggtg	acctgcttca	47520
agcctagtgg	tgggggccag	tgtggaccga	gtgtctccca	gggtttaggg	tccagtaaca	47580
aaatgcccac	agattttggg	cagaaacggc	acccaagatg	ctcctaggag	gatctcctaa	47640

PTS-0012 -124- PATENT

attgggaaac	gaaggccaaa	gggttcatgc	agaggcctcc	ccagccccca	cttcgggcct	47700
cctccaccat	ggttggctgc	cgtgggcact	atcgggccga	ggccctcttc	ccagggactg	47760
gaccgtccgc	cctgcttctc	tgcccacttg	gccttggtat	gggagagctg	ggtggagagg	47820
atcctcctgg	cagactgtga	ggcctgctgc	tttcttctca	cacctctgtg	tgtgtggcaa	47880
ggtctttgcc	tggcagctgc	gtcattgtca	gcccagtggc	ctcctccact	ccctccctcc	47940
agccccgtct	tctcccttct	cctcccactg	agagcaccta	gagtcttgtg	ctagacactg	48000
tgggatgcag	gaggaggctc	gtgccttttc	tgccttctgg	aggctgctct	cagccttggg	48060
ggaatccctc	agagaggtga	gggagatgag	tgtaggaggt	gcaggcctcc	tttaatctgg	48120
gctgggcacc	catttcaaag	aggagaaact	gaggctcaga	gggttagaat	aacagggcca	48180
aagacacacc	ttctgttgga	ggccttgcag	cttttggtat	ctacatcgga	ctgtccaggg	48240
aggtcctttc	cccagctttt	ccagcttctg	aggctgccag	ggtccccatg	gattccactt	48300
gctcatcctt	cctggcctct	gggctcccgg	gctcttatgt	gctgattttg	ttgggtctgc	48360
aacagataca	ttatcaacgc	acccacctgg	cattgtctct	gattctcttt	gcaaaaataa	48420
ctgccttgtt	gaaaaagcca	gacaacaaaa	gagtgactag	atttttatgg	aaaattggga	48480
aaattaaaaa	aaggtgccaa	gaagagacga	agtcccttgt	aatcccactc	tctaaagcct	48540
tacctgtcag	acatcactaa	ctgattgccg	caaacagcct	cactgagtgt	tccaggcaga	48600
cagaactaat	ctattggaat	tggtgcgtaa	gtgaagcctg	tcttgtttt	gtttgagagg	48660
cttgttactg	tctttttt	ttttttt	ttaaacacag	tttaatgttt	ctcaaatctg	48720
ggtgtacttg	gcaattggta	tacatctaat	ttgttgatat	tgagttttac	cccctatgat	48780
aatggataat	gtgttaaaga	aacaagtatt	tggactcttg	ttaagcagga	agaccgtaca	48840
ggacaattgt	gctatcagcg	tcaagactgt	cacgataagg	gagagagacc	aggctcagcg	48900
ccaaatacgg	. ccaagacagc	tggggcctca	tagcctagcc	gcagggcgga	gggaggggtc	48960
ggtggatgga	aaattactaa	gaggagcgct	tgagggtggg	gggttcctct	agactgactt	49020
agcaggatgc	ctgcagctgg	gcagagcccc	gcaaggccaa	ggccaaggcc	gaggccccgt	49080
agagagagga	tgggtcagag	gagcttgact	caggtgtggg	caaggagagt	ctttgtcaaa	49140
tggacgacgg	tgtgttatta	aaggaggaag	gtctgcctaa	ggcttaccct	tctggctgtg	49200
atacgagcgg	ggagttcctc	ttttacaggg	cggccttggg	gtcaggggtc	gctttgttct	49260
gaaacctggt	ctttgggcct	cgctggctgt	cgggtgtttg	tcgccatcac	ttgccaccat	49320
ccatccttct	cctggcgagt	gaggcccgag	cctcgttccc	tcgcgtgggc	atcacttacc	49380
caccctgcca	agagctgggc	atctaggttg	ggccttttcc	cagttgttgc	tgcaaatgca	49440
tttctgtttt	tacaaataat	gctgccccgt	atgcaccttc	agtcctgtct	tcccaggcct	49500
gcatttccaa	gcttcagctc	ctcaggctgg	agggacccac	agcctggcag	gggtaggatg	49560
gggtgggagg	gtagaaaagc	gaagacagct	tcctctactc	tggcccccca	gtcaacgcca	49620
gcatggccgg	cagacagagg	ccatggttag	gatggttcca	ggcctgtatt	agcctgtggc	49680
ctcagacagc	cccatcagac	ctcccaggct	tggcggtctc	atttggaagg	tgggcgtgat	49740
cgtgggtccc	tgggatgctg	tgtgggaagg	atgcagccca	gggccgttca	gctgtgttct	49800
ttctcctcct	tggtgttcgg	ccccaagggt	agcctctggc	cagacggtcc	ctgaggttcc	49860
ctgcaggact	tgggcttatc	tgcctagggc	aggagcgagc	ctgagcaggg	agtccacggc	49920
cttgcccact	gtgccctgcc	gtgccccgcc	atgcccgtgc	ccgcccacgc	tcaccactcc	49980

PTS-0012 -125- PATENT

tetgteeect cetgeaggae gtegggetee tggagtacea geaceactee egegaetatg 50040 cctcccacct gtcgcccggc tccatcatcc agccccagcg gcggaggccc tccctgctgt 50100 ctgagttcca gcccgggaat gaacggtgag gagagagttg ctgcctccct gtccagggcg 50160 tgagagctcc ttctcagatg gagaagcaga ggcccgtggc agagcaggag cacacagggt 50220 cctgtgaaat gaggggatgt cgggccgtgt gttcaccctt gacctggcgt gggcgtgact 50280 cggggtgagg atgggacgag cagggaagag ccacgtggcc ctcagacttc cagcgtggaa 50340 cttcagtggc ctctgtgggt ttaggcagca gtggggacct ccaagctggg ctgcagcagg 50400 gctgggcttc tgtgggaaga tttgagtcca cacctggtgc ccctggggcc cctgccctct 50460 cctcccattc ttccttcttc tccagctggc agaggacacc ctctggtgtg tgcctgtgct 50520 gggccagcct tactttcctt gatccaggtg ggaagggaat gaacaggtta ggtggtaggg 50580 tgagagggag gtggggtggg gagctggagg gactacagca aggggagggc cagggctggg 50640 teagagecag etetecatge atteacttgg gateggtagg ceaegttett teteceatet 50700 tctctaggag cttctgctgg agacggctga ggtgtgggga attgtgccta tttctcagat 50760 ggggcagctg aggctgcgag gttgagggat gggctcttgt ttactcagcc aggactagaa 50820 gtcgaggcac caggccccag cccttcatgg taccacggag gtgtcccagg gccccagatc 50880 gtgccttctg tacctggatt ggtttcctgg gcctgccgtc gcaacgtgcc acaaactggg 51000. · cggcttcaag ccacagaagt gcattcctgt gatctgaagt cagggcgtcc gcagggccgc 51060 gccccctcag aaggctcaag gggaggatgc ttttctgtct cctccagctt ctgggggcta 51120 caggogttoc toagotgtgg otgoatoggt coaatototg cototgcotc tgcctotgto 51180 . tcacgtggcc atttccttgt ctgtctctgt gttctcttgt tgtgttacaa ggatcccagt 51240 gatectaate caggatggee teatettage ttaatteeat etgeaatgae eetaggteea 51300 aagaaggtct tattttgagg ttccagtggc tgtgcatttt gggaggatgt tatatttgga 51360 ggttccagtg gccgtggatt ttgggaggac attatttgag ccactgcagt gccactatca 51420 tgtttaagag aaaacaccat gcgcttcctg ccaagcccca tgtaatggtg aagccctggg 51480 ttctgggcct tgaagagggg gatgtcttgg ggcccagctt tggagggaca aggacttgag 51540 ggccctccag ggaggtgagc acagagggt ggctgccccg ctccccgggg gggccagcaa 51600 cacggccca gcccgtgctg cagtgggcag cattcagtca gtctacaggc actgattgaa 51660 cacctactgt gcgccagtac ctggggacag ccatgaacaa gacaggtgaa ccacctgcg 51720 ttcattcatg ggtggggag gtggccagga aacacctgtt gtcaccaagc gcgtgggagg 51780 gcagtggaga gagagcagac aggcgggtgt agtgtggtct ggcctgggac aaggaggcgc 51840 catctgcacc atgacaggaa ggggaggagc tcacatggag ggcctgaggt ctcagtgctc 51900 caggcagagc ccagcaggtg caaaggccct ggggcaggag tgcagtggcg ggacagcgag 51960 ggccaggcca ggcagggctt gtgcaggagg ggaacagctg tggattccct gcttagcctc 52020 tgggaaaagc atttcagcaa ggcccatatt caggctcttt ctggtgggtg atggttggag 52080 cctcagaggt ggaggccagg agtcccagct ccgtggggtg tgcttagtta ggcaaggcca 52140 tgccctctct aggcacactg cggaggaggg ttcaggagag ccagtcgctg gggaaactgg 52200 gcagctccag tctctgcacc aggctgctag gctgagttga gaaggtggtt aggccaggtt 52260 cagcagcaag agttctgcga tcggccagcg atgtctgccc tgcgtgggtg agagggaaat 52320

PATENT

-126-

PTS-0012

ggcatcacgg gtgctgttat ctgtgttagg ctcacagcgt ttcccggatg gactgtgcct 52380 gtgaaccacc caatgatctt gttaaaatgc cgagtctgac tcagtaggcc tcagatggta 52440 ctggagattc tgcattgtag ccagccccag gtggggacgg tggggtggtc cgtagcaagg 52500 gaggggcagt cactetgggg tgttccagtg ccaccgtage acactecete cetgtaaatg 52560 tcctcggtga atgtggacct gaaggaaggc agcgctgcat tggagtcctg ccctgctgtg 52620 ggaccgtggg aggtgggctc ctgtgagcac cttcctggca ggatcataca gagcacggcg 52680 cgcagtagat gctcggcgca gagggtggtc ggggcctcgg gagttctcag agccacaatc 52740 tectatgtga egttggatge etcaeeteet geaggteeca ggageteeae etgeggeeag 52800 agtcccactc atacctgccc gagctgggga agtcagagat ggagttcatt gaaagcaagc 52860 gccctcggct agagctgctg cctgaccccc tgctgcgacc gtcacccctg ctggccacgg 52920 gccagcctgc gggatctgaa gacctcacca aggtaagcct gggcccccag ctgggagctc 52980 ctctcccgct tgaggttctg ctgctggttg ggctgggtgg gaggtggtgg gtaggggtgc 53040 agggaggggg cagctcgggc aaaggcttgg aggtgggcca agcaccgggt gcacagagct 53100 gggtggcagg aagagggcag gcgctgggtc tctggaggtg ccagagtgtg ggaagaagtg 53160 gggaaggtgt tccaggtggg cagagcagca agtgcaaagg ccctggggca ggaataggct 53220 tgtggtcacg gggtagctgg cgtgagggag gggagagctg ggatgggagg gcctggggtg 53280 ccgtggagca gagagctgcc attcgatggg ggtcaggacc gtcctgtggt cggtgggcag 53340 ctttcagcac attctgagag cttcctcgag ggtgggttgt ttggttccat gcttgcttgg 53400 aacagggggc tcagtgaccc ctgcctcgag ccctgcacag caggcagccc cctgggcctt 53460 gaaccccggc ccgcgaggtg gacagctcag ggctctgcca ggcacctgag gcttctggat 53520 tettaagggt cagggagggg agactecaga gtecegeaaa gtgagatgag acagagttgg 53580 ctcagcacta aaggggcggt gcttggttag gacatggcct ggacccctag aatgacaaag 53640 ccgccttcta ctgcccagtc tggctgctcc ttgggccacc gtgtggcact gggctagcgt 53700 gggttgagtc tgcagccacc caggcctgag ggaccacgga tgcactttgg gcaggggagc 53760 cagacaactt caggetegte tgcateteca tggggggetg cetggeattg caggtgggee 53820 caggeeteae etgggeaeae teaettatee cagggeeete egteeatetg eeeteaggtg 53880 acceaggtgc gatttccacc acceccact ccacagetgt getgeetttg tgcctetetg 53940 atccccattt cttcctcact gatctgggac cttgtgggca gggtgtcacc tggtcatgtg 54000 ggtagagggc tcggctgtgg gccccatgcg tgggaactat ttggcacccg tgagccggca 54060 tgggtggtgg tetggetgeg gggeeaggee acetgggeea gaeteggeet tetetegggg 54120 agagaggata cctgcgtgga acctgggata tccctggggt gggcttgggc tggcaggagg 54180 tgggggtgcc gtcctggggc tgggatggct gggcttcccc tcctgctctg agtggctgtg 54240 gccccgacac ctgcacacct gccagatacc cacagggctg cctctggggc caggggaggg 54300 aggggctggg gtgtctgtgt ggtcgttggc tggcttggcc tccctgccac tggggcagtc 54360 cccgcctcac caagttgtca caggaaagtg gaggtcagtt aatgaactcc tagccaacag 54420 accacatgcg cctgagagcc cactcaggaa cctcccccgg cggatgcagc tgtgttcttg 54480 ttggcactca gggactccac cctggccacc tccctgctct cctgcgtact tccagtccat 54540 cagcaaatcc tgacacctct gccctaaaat atctcaattc cagccttctg cccacacctg 54600

aggcaacccc cggcctgagc tcgtcattgc tctccagtaa ctttgcagta gcctcctcct 54660

PTS-0012 -127- PATENT

gggtctccct gctcctgcct ccctctactc ccttcagttt atcttccaag cagcagccag 54720 agggetetta taaaggeaga egaetgeate eeeetgtgtg tteeeeetg tgeteeaaac 54780 catccatggc tcctgtctca agcaggaaaa agccaaaatc cttgccatgg gctgcaggtc 54840 eggegtgate eageceegte acetecetga ceteatetee etgeageage ceteteaace 54900 qctcacgtac agcctcccag gccaccctgg agttcctcaa acacgccagg cacattccca 54960 cctqqqqacc tttqcaccqq ctqtqccctc cgcaggagcg ccctcccca ggcacattcc 55020 tettteeteg eteetteeag eeetggetge eeteeaggge etgeatggea ggggagaeet 55080 gtggctagcc ctgtggggac tctcgaggcc actcatggct gaggctgcag ccccaccacg 55140 tcctcctggg gtgtgagatt cagccacagg ggccctgccg gccttgaagg gggtctctgt 55200 ggcctggggc ttggccgcct gcacttgggt ctgggcttgg gactggtgtc gatgccagtt 55260 ecteteggge actgecette gggtacecea gecageatee etgeceegae geceaaceet 55320 tecageaeat cetteetgee ettecteece tteettetet eettetaeae ettecteeet 55380 cettettect cectetett etttecacce aaacageece cetgteetge teacteecet 55440 tcacccctg cttcctcagc tcctgccaac tctccctgct catcccctgg ggcaacctcc 55500 ctaccacaga gccactccca gccaccaccc agcgccaccc agcccatctg cctgcggcca 55560 tetgteettg cetteattac etgeceetec ceeteacete ceageegeec etcaccatg 55620 ggttetgeet gecateatet cecaccagtg geettgeece tececcatec acteacetec 55680 cccattccct tgctcccca cccctaccc ccatccgctc cccctccttc ccccactcgc 55740 ctggagtcca gggtcctgtg agcccagtca gcccttgcag gaactcacaa ctcacagccg 55800 gacaagggcg cctgggggtg cttggcccgt ggccatttct tggctggaga acgacacctc 55860 ccacgtgtgt gtccagcctg gggcctgcca cgcctccagt gccctccaca gccctttgat 55920 · ttcactcctc tttgaaacag aaagtggaac ctagacggtg gcggtggtga ggatgtgcac 55980 agattaagca cctgtggttt gctgctgtgg gagtttgctg tggtttcagt aaagctcagg 56040 acataccagg ctggaggctt gttctctctc cagcttccac agaggatgcc gatggcaggg 56100 ctggtggggg aatcgcaggc agtgtcccca gaggcttcag tcccccaggg tcactcagcc 56160 acceagetgt gtetgaetge ceaggeeagg gtggggetgt ggeeaggtgg eatectaate 56220 cttgttgtag cctggtgccc ggccagctgt gacacgggcc cctccctgca cagccctggg 56280 gcaccctaag ctccttagca gcctcagggc aaaggccatc ctcctcctgc agcgggagta 56340 ggggtgggcg gtggggactg ggagacagcc ccggggaggg aagtggccac tcaggcctac 56400 agggtcccct tttctgccca gtgcggccgg attggattga atggttgacc cctagggtga 56460 ggcacctcct ttatcaggag gctggcacgc aggaggcatt cacgcagtgg taagaatgct 56520 gcagtgatgg cgggtgccat taagtgagcg ccgactgcct gccacgtgcc aagtcatgcc 56580 cagccagtgt cattecetga tetetteeca geccaaggag getgggtetg tgaccccett 56640 ttgtagacgg ccccaggctg agcgagctgg acgtgggggga acggggattca ggcccaggca 56700 getgggagtg caccecatge etgeeteeag gttgacetge tgetgtgggt etceeetetg 56760 gtctccctgg tggggtgccc tcctccctct gcctggcatc ccccattagc actggaatct 56820 gctttctcct cttttgtttt gttttgttgt tacagaaggc aggagagaat tttagctcag 56880 cctcctggga gagatgtttc catttgaaca actcccctga agtggggcct ggatggatag 56940 

PTS-0012

	tgtgcgtgcg					
tgtgtccctg	cgtgtgtgtg	tgtatgcgtg	tgtgcacaca	tctgcctgtg	tgcgtgcatg	57120
tacctgtgtg	tgcgtgcgtg	tgtccatgcg	tgtttgtgtg	tgtgcgtgag	tgtgcatgtg	57180
ttgcacgtgt	gtatgtgtgt	ttgtgtgcgc	acgtgtgtgc	atgtgtccgt	gcatgtgcgt	57240
gagtgtgcat	gtgtgtatat	gcatgtgtgc	gtgtgtttgt	gtgtgcgtgt	gtgtgcatgt	57300
gcacgtgtgt	gtgcatgtgt	ttgtgcgcag	gcagctcagg	gcccagcctt	ggagggtgac	57360
çaacccctga	gtgggcagtt	gtcccccagg	tgcgcgtttt	gtctctgcgc	agagagcagg	57420
cccgaggggt	gagttgctgc	ctgcccgcct	ctccagcacg	tccgtgcgct	ctggcctgtg	57480
ggttctggag	ggtctccatc	ccttaccgtt	gctctgtggg	ttctggaggg	tctccgtccc	57540
ttaccgttgc	tctgtggttc	tttctgcctg	cctggctttc	cctcttcttg	tcaggaatgc	57600
ctctgcctgt	ggtgcgccct	ctgggatctc	tcttagtctc	tgtgtctgtc	tctgtctgtg	57660
tctctgcctc	tccatctctt	tctctttgtg	tccctctatc	tctatctctt	tctctttgtg	57720
tgtgtctgtc	accacgtctc	tgtctttctg	tctctgtttc	tgtcttcatc	tatgtccatt	57780
tctgtttctc	gatctgtctg	tctgtcttcg	tctctgtgtc	tgtctctctc	tectetetge	57840
ttggaccaca	aggtggaggt	gtgatgagct	tggtgctggg	gcctgaccag	cctggccgca	57900
gtaattgctc	caggccgtga	agagatttgg	aaagtctgag	caagggaaga	tgcctgggag	57960
agcgagttga	gaggttttct	gcatctgctg	tgtggaattc	agctgggcgc	ctgaggcagg	58020
aatttgatgg	gatttttctg	tgtgtgcccc	ctctgcccca	ccgtgttcct	gttttctgat	58080
gettetetge	tcttcagcct	ccggagtttt	gtggcatcag	agacttcctt	gggaattcac	58140
·cgaactttgt	tttggggact	ttagaattgt	cacaaatagc	actatctctg	aaaatcccta	58200
agggggacag	acagccccta	tcaaatataa	acatgaattc	tggctcacat	aactgaagtc	58260
	tagcttcagg					
gtcccttttc	atcccttggc	tctgccatct	ttcacagggt	cttggtgtgt	tagcaggaag	58380
	actccaggcc					
	ccgcatttct					
	agaacctgtc					
	ctttttcctg					
	ttgcataata				•	
	agtaagaggt			•		
	ttccctgcag					
	tgaccgccag					
	ggcaatccgg					
	: attaaagtga					
	tctagttcta					
taatcagtca	ctccctgtgt	tagtctgttc	ttacaccgct	. aataaagaca	tacccgagac	: 59100
	. ataatagaaa					
ctcaggaaac	: tcacagtcgt	ggtggaaggg	gaagcaaaca	cgtccttctt	: cacatggcag	59220
	, tgctgagcaa					
aactcactca	ccatcatgag	aacaggacgg	gggaaaccgo	; çaccatgatt	caatgaccto	: 59340

PTS-0012 -129- PATENT

cacttggccc ctcccatgac atgtgggaat tatgggaact acaattcaag atgagatttg 59400 ggtggggaca cggccaaacc atgtcaccc ccacttcccc ctcctcttt ttcctggcaa 59460 ccacgaatca ctgtccatct ctctggattt gcctattctg gacatttctt gtaagtggaa 59520 ttgtacactc tgcagccttt tatgtctgtc cacttccact cagcatcata ttctcggggt 59580 tcatccacag tgtagcctgg gtcagtgctt cattcctttt ttttttttt ttttaataaa 59640 gatggggtct tgctatgttg cccaggcggt cttgaactcc tgggctcaag caatcctcct 59700 gcctcggcct ccatgtccag cccttcacat tgcttgtatg gatatgccat gttttattta 59760 tetgtteate aggtgatgga ettaettgtg caattttget gegaataaaa getaaaceeg 59820 aacttaaaga agaacccatt aaagacaacg gcttttatcc atggagagtt taaaggaagt 59880 aagttttcag caacttttcc aagtgttgct agtggttgcc agccgctgct tttactcctg 59940 gtgctgcctg ttagccctgg ggatggaaat cttctttttg ttaatgttgc tttggagaat 60000 tattcccagg ttggacgagc agtttgctct cagagtttta gggtggcctg gcccccatag 60060 cccttccttc cacatccttg tccttgctct gttatctctc ttcttggtcc aggtggaaga 60120 gcagagatag gatagcggag atgtttcttg ccaccagtag tgcgaccggg ctctgggtgc 60180 catgtttgct gccacctttt gtcttaagaa cctcaagaaa tgacatgggc tgtagggaga 60240 gaccagccaa gcacccaagg tggaccgcag tgagggcctg ggcggtggcg tggggatgtc 60300 tcacgtcagt tggcacagaa ggggtgttgg gcactctggg tagcggagcc agcctgtgca 60360 · aaggeeeggg ggtgeeagae geatgagetg teeatggttt getgtgggtg gggteagatg 60420 cccatggccc cctgcctgcc ttcctgttgg ggagcagtga gggccccaca cccactggta 60480 cgtgcataca cactcctgag gctttttcta gggagttttt cttccacaca cacttttgcc 60540 ttgagtttct ggaggtcctg cactctgggt ccctggaagg ggtgctgctt tggcgcttat 60600 gctcagccct atggttctgt ggggtgaacg gatgtgtggc tgggacccca cgtggagtcc 60660 ccacatggct cagccccacg gttctgtggg gtgaacagat gtgtggccat ttctgacgtg 60720 ggagcccctg cagcctcccc cttcaagcac cttccaaggt aggatgctga gtggccttgg 60780 gcatgtcgtc aaacagaaat cccacttccc acggtggtta tgacggttac gtggattaag 60840 atttgtgaat tgcttagagc aggaggccag caaactccag caagctccaa atctggccct 60900 cagtgtgttt ttgtaaataa agttttattg gcacacagcc atgcccattt gttccccgtt 60960 gcctgtggct gcttttgcaa tacaatggca ggggtgagta gatgagacag agaccttgtg 61020 gccctcaaag cttgagctat ttttaccatc tggcccttta taggaaagtg ccggcctctg 61080 gcatccagcc ccagtggcct ccaggctctg tttctgcctc tgcgtaatgg agatggagca 61140 gcagtcccct cggagggctg ttgtgggatc cacttcatgg ggtgtgcaga ggacttcatg 61200 gggtgtgcag aggactggga taggctgagc tgtgagcagc cccaggtgtg atttctaggt 61260 gtccctgggg gaggtggcct gaggagcatg gaggactgca ttggggggat tgagggatat 61320 gagecetttt etetgtttee etegaggagt eegtgtgtgt ggagggagea eegggttgte 61380 caggeeeetg etgteettge ecceacatet cacatggtaa cagaggeeag aggeaaacet 61440 aatgtgactc caagactett ggeeeetgtg ggtettgetg gggetetgtg gggtgagggg 61500 aggacagagg ccctgaggat ggcaggagtg gacagaagat gatgcagcct ctgtgaatcc 61560 tgaggttggt ggggcactcg gtggcccccg ggctgcagtt gtccggagaa taatgcaccc 61620 tgtgtcctct gggtgcagct gctgcggggg cggggaggtg gtggcctggc gctgctctgg 61680

PATENT

PTS-0012 -130-

gccttgtctg ccagcagctg ccggcttggc cccaaggatg gcacagggcg ggggctgggt 61740 tctggagccc agctagggga ggaccatccc agccaacatt tattgaggct tacggtatgc 61800 caggeteaga gecattaact catteaagae teacaaggae eggggaggtg ceagetgtte 61860 tccccattgg gcagatgagg aactgaggca ggaagcagtt gaatgacctg ctggaggtca 61920 cggaactgga gagtggcaga gggggctggg atttgaaccc agggctgcac aggtgaggcc 61980 tgggttgttt tttctaacct ccttatcctg agagtgtttc cagcacagcc tgggtgcacc 62040 agactttagc tggtgggatg aaggcgtcca tggataactg aatgcaggct tcctttgttg 62100 ttaagcacat tttcaaaaac agctgtatta cacaaagagt gactctcagt gaaagaagat 62160 cagaaaaaat aacgggcaaa taaaaagaag aaagtaaaaa taccctcttc tgccctgctg 62220 ccgagataac tccttttagc ttaactgtag cccgttctga tggcttttcc gtgtgtttgg 62280 gaacatatgt tttctgcaaa gccacgtgtg tgttggctgc atggttctgg aacttgcgtg 62340 tttggactga gcttcatgga tgaatgttta cagagggtat gcagaggcca ggccttggga 62400 gaatggaggc tgtgggtctt ggttccttgg gctggtgggg aacacacaga tggggtaagt 62460 ggaagaagag aggtgtgtta cgcgaacagg gagttggaag acttcacaac ttgaggagag 62520 gctgggaaac cattcatgta gcaagagcat ttgaaccgca tcttgaaggc tgtaagggac 62580 tctgaatttt ggagaatggg tgatggctgg gatgggaatg ggatccttga acaggtgagg 62640 · actgtcctga cagatgtcca ggactctggg cctggagtca gggatggaaa cccggggtgt 62700 attggggagg gggtgtgtat tagtccgttt tcatgctgct gataaagaca tacccaagac 62760 tggtcaattt aaaaaagaaa gaggtttaat tgtactcaca gttccatgtg gctgtggagg 62820 gctcacaatc atggcggagg gcaaagagga gcaagtcaca tcttacatgg atggcagcag 62880 gcaaaaagtt ggcaactaca ttagtcaggg ttctctagag ggacagaact aatagaaaaa 62940 atatatat atattacata aaggggagtt tattaaggag tattaactca cacgatcaca 63000 aggtcccaca acaggccatc tgcaggctga gaagcaagga agccagtctg agtcccaaag 63060 cttgaagaac ttggagtgtg atgttcgagg gcaggaagca tccagcacgg gagaaagatg 63120 taggctggga ggctaggcca gtctcgcctt tgcacatttt tctgtctgct ttatattcgc 63180 tggcagctga ttagatggtg cctacacaga ttaagggtgg gtctgccttc tccagcccac 63240 tgactcaaat gttaatctcc tttggcaaca ccctcacaga cataccgagg atcaatactt 63300 tgcctccttc aatccaatca ggttgacagt attaaccatc acagggttgt acagactggg 63360 gggtgtcccc tgtgctgacc ccatgcccgt tttttttctg ccacaggacc gtagcctgac 63420 gggcaagetg gaaceggtgt etececeag ecceeggac actgaecetg agetggaget 63480 ggtgccgcca cggctgtcca aggaggagct gatccagaac atggaccgcg tggaccgaga 63540 gatcaccatg gtagagcagc agatctctaa gctgaagaag aagcaggtgt gaatgggcag 63600 ggggaggggg agtgtttgtt ctgagtctcc attctagcag cagtgacagc ggtgtcacag 63660 acatgtgcca agcccttccc aagttcctgg gtgctcactg gtttttatgc cctttacgtt 63720 tattggacag gagcacatcc acagaacttt ctgccatgat ggaaacactg tgtatctgca 63780 ggatagccat gttccactgt tgagcatttg aaatgtgcct actgcgactg aggaactgat 63840 ttttaatttt tatttaatat acgtattaaa tgtgcctttg aatagccaca caggctgccg 63900 cattagacag cacaagaatg gagggtgaaa attcaggatt tctagccagt ctgtccaggt 63960 tcagatcctg tttcttccag taccaggcaa cgtggggtgg gcagtccctt ctctgtgctt 64020

PATENT


-131-

PTS-0012

cactttcctt atctgtaatg tggggaaaca gcccctggct ctggaatctg aatggactgg 64080 cctcctaact gctctttact agctgtgtgg ccctggaacc ttcatctctt ggagccttgg 64140 trtccttgcc tgtaaaatgg acaacttgta gaggagggag caagatcccg agattaaaaa 64200 taaatcctca ttgtcactgt tgaaaccaca caaagacaag cggagaaaaa gctgatataa 64260 atatttataa cattcatttt ataactttgt tttaaatatg agttaatata caattctttg 64320 ataatctgcc ttttcccagc tcttcatggt ttgctccctg gtatcattca ggtctctgct 64380 cagatgtccc tgacaccaag aggccactgt cagccttgta caggaacaca cacccccaac 64440 cctcctctat cccgggttca gccaatccag ccaattctag ctgctgctgg tttttgtaaa 64500 taaagtttta ttggcacagc cacgaccact tatttgtgta tctgtataca catgtgtgtt 64560 tatatgactg cttttctgcc acagtggcag agttaagtca tcacaacaga gacctgtgtg 64620 gcctgcaaag tcaaaaatat ttgctgttta ggcctttaaa gaaaagcttt gggctgggca 64680 tggtggctga tgcctgtaat cccagcactt tgggaggctg aggctggagg atcacttgag 64740 cccgggagtt tgagaccagc gtgggcaaca tagcgagacc ctgtctctac aaataattta 64800 aaacattagc caggtgtgga ggcacatgcc tgtggtcaca gctactcagg aggctgaggc 64860 aggagtgcct gagcccagga ggtttaggct gcatgagcca tgattgccac tgcactcttg 64920 cctgggcaac agagtgagac tctatctcaa caaaaagaaa ttttgctgat cactgatctg 64980 tctcatcacc ctgctggtga catcattatt tgaattaata tagacccagc tttgttatac 65040 agtggtcctc tccttgtctc cctgttaact gctgtgttct gagcagcatg gggtacatag 65100 taggtgctca ttaaaaatgg ttgattgagt cattgtgaca ctgtctgggc cccagggagc 65160 gtctagacta atgggagaaa caggctcata tctagtgccc tccagacaag gaagtagggg 65220 ctccaaggag gatcaagggc tcattttagc cactgtaggc aggtgggtga aggctggtga 65280 gagtaggett ccaggaagag gtgccctggt agctgggttt tgaaggacge tccaggggga 65340 gagcattgat ttcaagtgtc catcgtggct gtcacgtggt tggggggaacc aggatttgag 65400 gatagtccag cagtgagacc cggtcctgga gactctgcca actgtcctag gcttcagtgg 65460 gcagtgggta ggtctcatgt tggtggcaca ggcatcccga gaggggccgg gccccagcgg 65520 cgtgggcagg cattgccagg gccagcctgg taccgcaccg ttaggcttcc aggcctggcc 65580 ttggggtggg gctgaagctg cgggtcactg gcacacattg gtgactgcag ctggaagcca 65640 ggtggctcaa ggcagccctc aatggttagg tttttgtttg tttgttttt cccctctaaa 65700 ttccactttg gcatttttta aaagtgaaat tctcaagcat aattatttta aagtgcacaa 65760 ttcagtggca tttcgtacat ttgcagtgtt gtgcagctgt cacctctctc tggttcccag 65820 ccatttcaac aacccacagg gaagcctcat aggagctaaa gcagccactc cccgttcccc 65880 tactctctgt ctctatggac tgacctgttc tagacatttc ctatataggg catcacacag 65940

tatgcgtcct ttctggcttc ttccacatag tgtcatggtt ttggagttta tcatgttgtc 66000 tcttgtctcc atccttcatt ccttttatg gctgaaacat attccgttgt atggagatgc 66060 ctccttttgt ttattcatc atctgtggcc atttgggctg tggctgttgt gaatagtgct 66120 gctgttgaac atttgtgttg aagtttttgt tgggacacct gttttcagtt ctcatgggta 66180 tatacctagg agcagaattg ctgggtcgtg tcgtacagta actctaggtt taatttgctg 66240 atgaagattc ctggtttct ggttttccac atcctcaccg accgccccc agctttttt 66360

-132-



PTS-0012 -133- PATENT

gaaggtaagg cttagagagg tccaggagct tctcaaggct acgcagtaag taggagtggg 68760 agttgggctc cagtctcacc agtgcagctg tggagtctgc acagcctctc ctagcactga 68820 tgctgcctgt aggaaccgta atgggtaata atgccggctc ggagcaggcc tgactgtgcc 68880 tgcctgtgta actcattcag ttctcaccac agtcagaatg gcggcacggc aatcagcccc 68940 gtttactgat ggggcaactg agggctagca gggtgaggct gcttggctgt gcttccctgg 69000 ctggcaagtc acgaaggcag gatttgaacc tggctttgga gcttggaggc tgcagctggc 69060 cctggagctg gggcctctcc cgggtgcgga gtccctgggg tgactcacag gaaatgtgta 69120 gcagcctgac ttcctgtgcg cggccgtggc ccgggctgca agggggcctc cccgcgccct 69180 gggggctgca gccctccttc cgcccgctgg ggtgctcatc cctcacgttc tgcctctccc 69240 cacagcaaca gctggaggag gaggctgcca agccgcccga gcctgagaag cccgtgtcac 69300 cgccgcccat cgagtcgaag caccgcagcc tggtgcagat catctacgac gagaaccggg 69360 tatgtgtccc cgccctggcc tgctgccccc cggtgctggc catgaggcgc ttcacagggg 69420 gcaccatgaa tcaggcctca gtgtttccat ctatgtgggg aggggacctc gccaccctct 69480 ccccagaga cgcagggttt atgagtgggt gggggaaggt gaccggtgga aagccatcct 69540 ggtgtggcct ctgggctgtt ctgctcagac actcagatgg gtgtggactg tggctggtca 69600 gcaggatgca acacaaaaca gaggttttgg gctccaggag agcaccaggg tccagctcat 69660 ggccaagggt aaggggctgc cactttaggt gctggtgcag aagaaatccc tttaaggcaa 69720 aagataatga cattatgacc gcagcagtga ggtttcatgg agcagcccct cctgtcagtc 69780 ctggaagggc aggtacaggt gtcatttcca ttttcctaag gcccagagag gttaagtgac 69840 ttgtccagag tcacacagct aggaagcatt ggacctggat ttgaacctgt gggctgtcag 69900 accacagggc ctgagttctc agcactggct tccactgaca ctgggccctg gaaggggcct 69960 ttgagatgat tgaaacacag agtctggagc aggctgtgga ggcccatgga gatcccactg 70020 ggggcagcta tagtgggtct ggtcttgctg gaggggcttg ggatgctcag agcagtgtct 70080 ccaggggctg gaccctaagg gtctgtgcac ccccaaggtg gaaccttgtg tctggtgagg 70140 tggtaagete eccatettee cagteaagee actaceaget gggetttaat gatttacagt 70200 gtactttttc taaatgtact caggatctgt ggatgttgat cccctccctt attttctgga 70260 tgaggaaact gaggcccaga gagggactgg tccttgtgaa gcatgacaga tgaggaacct 70320 cetetecetg cettggette tetggtteee etectgeetg tagteecage caccetțeee 70380 agctgccttt tctgtaatat cttccttggc caatcagtgc tcagagttga ggtgggggtg 70440 gggaggcctc gagtcacgtg gtgggtgcct gcagtggcag cctgaggcag ggaactactg 70500 gatcaacctg tttggctatg cctccacctc tagaaacagc gatgtcatgc agaatgagac 70560 aageetgttt ggggeetggg aactgtgtge eeggeteact eteceacace etgaceete 70620 accecaagea ceactagtaa cagteatagg agagecaagg ggecacacat cetteageca 70680 gccatcctgg gttcaaatcc catttctccc acttcctggc tctgtgaccc tggagcgttg 70740 tacttaaacc ttcctgtgcc tcatgctcca cagctttaaa acaatgacaa cgacggcatc 70800 acctagtaca gttggtgtgg ggactaaagg ggtaatttcc tagtgccctt aggacagaca 70860 gtgtctggca ccaaagaagt gccagctggt gctattaatt gtcattatca tagctctcat 70920 ttcttcttgt gtttgtttac cttgtgcatt taatagaata ctatttgcat ttagtagaac 70980 tactgttatt ctctcaattt tgctcatcaa gaaaccaaag ctcagagagg gaaggagacc 71040 PTS-0012 -134- PATENT

tccctgagat tgcagagcaa gtgagctttg agcctgggac ttggagccaa gattgagatg 71100 gctccaggag cccaaagtgg aggggacatg ggcagggctc ctgagagtgt cacctctacc 71160 tgccctctct gatcctcggt ggagagcaga cacggttctc tccagcagct gtggaggcca 71220 ggtcagtggc ccagcacatt gctgcagtgc cttggccctc tgcctggagc tcctctcctt 71280 gcaaggetea tactgteact tecetettig etgaagtgge eeetteteag caagaeeegt 71340 ttcaaccete tacttaatae tgaaaaceet tttttcagga aaaggagttt tcaggatgae 71400 acceptttte etecttigtg gettetgatt etecttagee ettgteecea tgggacatga 71460 tttctgtttt acttatttat tctgtttatt atgaatggaa actccgtaag ggcagggatt 71520 ttattcctgc ccacttttat ttccagtggc atctccagca cctaaaacag tgctcaccac 71580 acggcagatg cacattaaat aattattgtg caaatattca ggcggcagga agggagggga 71640 gatggaggcg ggtggccagc tctggcctgt ggaagaggcc tctggtttgg gggcgtgggg 71700 gctggtgggg atcctcccgc ccgggctgag tctctgagcc tccaaagcct gcagcctaat 71760 gtgcgggagg cccccagccg cctttggcag gagcagccag gacttaccgc cccttggggg 71820 atcagtagga ttaaatttta atctgccttc cttccctgct ggttcctgga gagatggagg 71880 acaagggtct gtttttcgag ccagccggaa aacgcagctt ccctgccggg cagggcccgc 71940 ctggcagttc tgagtgctgg agtctggctc attatccatt cggagcacat tggtgaggca 72000 cccgctgagc gaggcttttc ccgcctcccc gcctcctggg agctgcctgc gtgggtgggg 72060 gccgggcagg tgtgcacaga tggcagggca gccatcaggg tggctgcagc ctgagagcag 72120 gagcagacgg ggtggcctgg gcccaggagg gcagaagcgt gacctggaag tgggtgctgg 72180 gaaaggette ttggaggeag egggtgggee ggaaggaggg egttagggtg agggggeatg 72240 gcacaggcca agtcccagag aggggactgg cgtctccttt gatcttcaaa ggtggtgggc 72300 acgaggtagg agcctgttgg ttccgggaca aggcacgcac ttggaatctg gataaaacat 72360 acacagaggc agegetageg atgtgtggat acataagggg catttgtgca gcacaggttg 72420 ctggtaccgt aggaattcag gacactgggg aacagtcagg atgggcttca tagaggagac 72480 gggccttgag ctaggtcgac tggggaaagg tagaaggctg cttccaatag agatgtagat 72540 ggctcattca caaggtggag aggaggcagg attgatggaa gcggcaaccc cagttgctga 72600 qtaatqcqqa aatcaqcaqa aqactcaqqt ccttqtcttc cagtttaagc gtcttaaaag 72660 gaaagtgttt atatgatgtg attaggactc agtgtgtgca cagtgtgatc gggactgagc 72720 agggcaaaga agaataatac cattaacagt caccgtgaac gtgaagcatt cagtagagcc 72780 ttttgggggt tttggcactc ctcatgcttg tttgtagggc ccagcatcag atcccctgat 72840 tgaagatttt cagagcagtg cttcagaccc cgtcctgtgg cctcagcatc ctgggccagg 72900 ccccacctc tggcctccat gcccggccac ctggtcatca aaactgcccc cagggtccag 72960 gggttctttc agattgtccg tttcagcccc gcgaggctgc tgcacgcgtc ctctgacctg 73020 ccgcttttcc tgctcgtcac ccaccctggg agagctctgc acggggctca tgggcatggg 73080 gctctgtttg cagatgagga agctgaagct ccgggtaggc cgttgccctg aggcactgct 73140 gcagccagcg gaggggcttg ggtgcaggac tgggggctcg gggcttcttg ggtgagtagg 73200 tgctgcccc aatctgcaga tgaggaagcc agtgtggcag agaaggggct aggatggggc 73260 ttccaggcag gggagaggct agggagtgat gagtgtcagg tctgtttctg tgctctagag 73320 gagageegea tgtggatgta tgtgtggttt gtgtgeetgt gggtaeaegt gtgtataegg 73380

PTS-0012 -135- PATENT

gtggatgtat gtgtggtatg tgtgttagat acacgtgtgc ctttggatgg ctgtgcatac 73440 ttgtatgtga atacttagag taagagtcag cttgtgtggg acgagcatgt ggtgattcgt 73500 gcattgatac agcacacttg ggtgtgtgta tgcgggcatg tgtgtatgtg tggacctctg 73560 gatggctgtg tgcacatgtg tataagcgta tatgagtcag catgtggggc ctgtggttat 73620 ctgtgcactt acacatccat gcatacacac gtgggtgcgt gtatgtgtgc aggtatacct 73680 gtgggtgctg tgtgcacatg cgtgaacatt catccacgaa ttggcacatg tgaggcatgt 73740 atataggtat tegtgeatet gtgeaeetgt gtgeataege atgtgtteae atgggtaeae 73800 gttaggetgt gtgeatgtgt gtacaggtgg atgtgegtga gatggegggt gtggggeggg 73860 tgtggttaca tcatgtgttc acttgggtgc acatgtgtat gtgcgtgcgc cttgatgtgt 73920 gtggacatgt gtgtatgtct ttgcgtgttc ctagatcttg gcatgtgcac ttggtaacgt 73980 gggtctggtg ctcccgtgga cccgtctgca taggtgacta aggacttgtg tgccccagca 74040 cageteetag getttttggg catgggagge etggeeacge agaeecagag tetetgeagg 74100 ggtgccactg ctcgaatgag aacgtgcccg gatctcagtt ggctggcgag agcccctaca 74160 gggggtggac gccacggtga gcggggccgc tcattggctt gagtccctag gttttccttt 74220 cctctcagag ccaggtgagc ttgggcagtg gcttctctca ggcttggcca cctcccctgc 74280 ggcgtcagcc ccaccacca cgatcagagc agagacctcg gccccaaaag gccaggaacg 74340 tgggaggacg tgcgtggggg cagtcgggtt tcagcgggat tgagaaaggc ctgtttccct 74400 tctcccccag gttggggctg agtcccctga attccagcct cccagccgga aggtggcagc 74460 ccagcctgaa gccctccttt gggccggagc agtccctgag ttttgccacc cttgggtgga 74520 gttagttcag ctctaacaag tgtgtcctgg cgtccctgc aagctgggcc ttgggcccgc 74580 atggggaaga tgcagacagg agctcctgtt ggagcacttg ctgtttgcca ggaccagggg 74640 cagccaggga gacagtgtcg ggaggtggcc cccaaagggc cgaggagatg tggagatatc 74700 agccacggga atattggggt tggggaatgt tctagatggg agaggttcag gtgggaaggg 74760 tttgggattt tgcctagaac tgtgtggatt ggtgacctcc tatccaagtg tcctctccga 74820 gcctcagttt ccccatctgt aaaatggggc agccctgca ccccagaaac aggttactgg 74880 gaggettgge aateetgatt gtggettgga gageagggag acagggeetg ceeteteate 74940 cacctctatg gagggggcag agaggactcc gtgtccttgg aaaggccagg cacatccggg 75000 atgtggactg cttcccccat ggccctggag aaagtgccca ctgccctcaa ccctgtgctg 75060 ggccctgctg gacgatagca gcttggtggc cagcgctggc ctcttctggt cctggtggag 75120 aggcagggag gccctgggcc agctgcagcg acgtggagag aggacagggt tctgggctgg 75180 gaccggacag cctgcaggta caagaatgct ttgccccaga gaccgcctga gcgagggagc 75240 cagccgcact ccatttccag gtatttagac cattcctgag catccactgt gagccagaca 75300 ctgtccaggc actgtgggtg cagcagagaa cagagcaggc accttgctcc tcatggagtc 75360 ctcatcaggg gaggtggcca gtaagataaa cagtgggacg cagaccctta tccctgaccg 75420 catgtgctgt gaagacagcc aggtgggaaa acgagtggtc gagggaggtg gaccgccctg 75480 ctgcgggggg tcagggaagg cctctgtggg gaggggaggc tgagtcaaga catgagcaag 75540 aggcaggcga gagcatgtga agatgtgggg aacagcattc caggcaggga acggtaggtg 75600 caaaggetea gaggeagtag tggettteag tgtgeagggg acagtgaggg geeageagag 75660 gtcaaggtcc tgtgagggct gggaccetgt tgaccetgge gaggagtttg gatttggtgc 75720 PTS-0012 -136- PATENT

tcagggtggc	aggaagacag	cagccgagga	ggtgaggggg	aatttttggc	atgaggctga	75780
atctgtggcc	tgcgtccacg	ttccccagcc	atgccacgtt	ctagagggta	tctcctctgc	75840
attcaaagag	ggaagggatg	acatgcactt	cactttgctc	cctgcagaac	gtccttgcag	75900
aggtcatggg	agtttggtac	cctgggtgag	tgtggccgtt	tcgtgaatgg	ggagactgag	75960
gccagactca	gtcaggagac	tcagattgct	gagggttaga	gcacagccga	ctcccagatg	76020
ttgggcaggt	gtgttgagaa	aggccagccc	atcttgggac	agggctccac	aggcccacct	76080
ccccaggagg	ctgacaagca	ggaccagaga	agaccgtgga	gcaggaacaa	acccaacact	76140
gggagcaggg	gatgtggggg	caggaggtga	aggaaacacc	ccagagagac	aggaggaggt	76200
ggggctccct	gtggctttgg	caggtgaaga	aggggtcttc	cttgctctct	aggtgctagc	76260
tgtgtggccg	tgtagtttct	agtggcttgg	ccctttccgt	tggtatcact	cttttatcta	76320
gatggacagt	tgctgctgat	cccacagat	catacacaaa	ctcctattca	tccctcaaaa	76380
cccagcctat	atagccctcc	tgttaccttt	ttgggagagt	gacttgtgcc	ccactttcac	76440
acataccttt	atctgcctga	gcatactaat	ctgctgttac	tgctcttaac	caacagccat	76500
tgtttgggtt	tattccaggc	aggggccagg	tctcattcat	tccatgtctc	tccccaggtc	76560
ccagtgtttg	ggagctgccc	tgcccccatg	ctaccccata	cccagtcctt	cactgggcct	76620
ggcttagggg	ttctcccatc	ttcagtaccc	cagggcagac	tctttcctgc	ttcgagggtg	76680
tggctgggac	attgactctc	cgggtgatgt	ctgcccccat	ccaccggaaa	tactagtccc	76740
aagcctaggg	gtggtcctgc	atgggacctg	gcccttggct	tectetgtee	gtggatcctg	76800
gaggtcataa	gaagggcttc	ttccctgtgt	tttgtttctg	tgcctcagtt	tcaccatctg	76860
tgagatgggg	ctactcctgc	ctgtacctcc	catggcgctt	atgcgcaatt	gacatgttaa	76920
gaacacaccg	tatgcccgac	gcttggctca	tggcaggtgc	ttggagaagt	gaccatcgct	76980
'gtaatagttc	teceetgete	ttctggcccc	cagccgcacc	ttgaggctgc	aggtctcggg	77040
gttttggctc	agcctgaagg	tggccaagag	catggctctg	ctcttggtgg	gccgggctct	77100
gggctgtagg	cggaggcagc	tctaggttcc	agcttgagcc	cacctacata	cctgctgtct	77160
ttctccgggg	gctggggagg	gggagtgatg	ctgggctgcc	acgccctcct	ctctctgctg	77220
cagcccggga	gcctgggcac	ctccgccctg	cgaggagatc	ttggcaaagg	ctgcgtcaaa	77280
tttttgttgg	cagccacatt	tcccagggct	tggggtcacc	tccttttggc	caatctggtt	77340
tggggtcact	ggggacagtt	tcagtatggt	gatggtgact	tctgcggcct	gtccgcctag	77400
tccttgccaa	atactgagtg	gctgccccaa	tgcagctgag	tcacagcagg	ggctcgcccg	77460
cgtgccagcc	tgtgaacacc	catttgccag	cacacacgca	gtttagcctg	gtgcaggggg	77520
cacccaaacc	cacgcaaatt	ctgcccctgc	cctccgccac	agcccccatg	aagccacctt	77580
caggagcccc	tccgccccc	acctccctgt	acccggctgg	cctgggctgc	cctccaggcc	77640
tcctgtgagt	ggaccctggt	ggtcccaggc	tgcgggctgg	tgggcctggc	cgaggcacaa	77700
tgtctgcctt	cacaccgagg	gccggggtgg	gggcccggag	gtccagccta	ttgatggagc	77760
ggccaccgag	ccctgcgcca	catgttcctg	ttttcctaat	aagtccccag	ttgtgagtgg	77820
ggaggaggcg	gggaggcccc	ggggcagccc	agaaataatc	acatgattgt	gaaacacaag	77880
aatcctagaa	agggtatctc	cgagcgcctc	tatctcaccc	tgcctcctcc	tectectect	77940
ccttccctcg	ctggctgcac	tagctcnnnn	nnnnnnnn	nnnnnnnn	nnnnnnnnn	78000
nnnnnnnnn	nnnnnnnn	nnnnnnnnn	nnnnnnnn	nnnnnnnn	nnnnnnnn	78060

PATENT

-137-

PTS-0012

nnnnnngtat atgagtcagc atgtggggcc tgtggttatc tgtgcactta cacatccatg 78120 catacacacg tgggtgcgtg tatgtgtgca ggtatacctg tgggtgctgt gtgcacatgc 78180 gtgaacattc atccacgaat tggcacatgt gaggcatgta tataggtatt cgtgcatctg 78240 tgcacctgtg tgcatacgca tgtgttcaca tgggtacacg ttaggctgtg tgcatgtgtg 78300 tacaggtgga tgtgcgtgag atggcgggtg tggggcgggt gtggttacat catgtgttca 78360 cttgggtgca catgtgtatg tgcgtgcgcc ttgatgtgtg tggacatgtg tgtatgtctt 78420 tgcgtgttcc tagatcttgg catgtgcact tggtaacgtg ggtctggtgc tcccgtggac 78480 ccgtctgcat aggtgactaa ggacttgtgt gccccagcac agctcctagg ctttttgggc 78540 atgggaggcc tggccacgca gacccagagt ctctgcaggg gtgccactgc tcgaatgaga 78600 acgtgcccgg atctcagttg gctggcgaga gcccctacag ggggtggacg ccacggtgag 78660 cggggccgct cattggcttg agtccctagg ttttcctttc ctctcagagc caggtgagct 78720 tgggcagtgg cttctctcag gcttggccac ctcccctgcg gcgtcagccc cacccaccac 78780 gatcagagca gagacctcgg cccccaaagg ccaggaacgt gggaggacgt gcgtgggggc 78840 agtcgggttt cagcgggatt gagaaaggcc tgtttccctt ctcccccagg ttggggctga 78900 gtcccctgaa ttccagcctc ccagccggaa ggtggcagcc cagcctgaag ccctcctttg 78960 ggccggagca gtccctgagt tttgccaccc ttgggtggag ttagttcagc tctaacaagt 79020 gtgtcctggc gtcccctgca agctgggcct tgggcccgca tggggaagat gcagacagga 79080 gctcctgttg gagcacttgc tgtttgccag gaccaggggc agccagggag acagtgtcgg 79140 gaggtggccc ccaaaggggc cgaggagatg tggagatatc agccacggga atattggggt 79200 tggggaatgt tctagatggg agaggttcag gtgggaaggg tttgggattt tgcctagaac 79260 tgtgtggatt ggtgacctcc tatccaagtg tcctctccga gcctcagttt ccccatctgt 79320 aaaatggggc agcccctgca ccccagaaac aggttactgg gaggcttggc aatcctgatt 79380 gtggcttgga gagcagggag acagggcctg ccctctcatc cacctctatg gagggggcag 79440 agaggactcc gtgtccttgg aaaggccagg cacatccggg atgtggactg cttcccccat 79500 ggccctggag aaagtgccca ctgccctcaa ccctgtgctg ggccctgctg gacgataggg 79560 cgacggctgg ggtcgcggcc ggcgcgcgc tcgcggctgg ggggtagggg ctggccccgg 79620 ggagggggtg tgggacctcg cggtgccttg gggttttagg gcggtttggg ctggttgagg 79680 ctgggtgtgt gaccacgtcg tttttcttgg tcgactccgt cgctgagcgc gcgttgaggg 79740 ttgtggggtt gcccggcggt gctgccggtt cgcggggggt gtgtgcgctg gggcgttggg 79800 tatgctacgt gccgcggcac gaccactatc tcccgtttta tcgcgggtgt ggcctgtggt 79860 ttatttggcg gtatgcgggt gtgggggggt tcgtccccc ctcgcgtgtt gggtgtgcgc 79920 gtgtggcttc ctgacggtgc agtaggggtc tgcgggtctg cgcctgggca ggtggtctct 79980 ctcccagccc gccctcgccc ctcctcaccc cagcccgctc tccgcacgcc ccacgtcccc 80040 cccagcattt cagtcagtct ccggttcgct ctaagtttca cagtcagtag tggctttcag 80100 tgtgcagtgt tcagtcaggg gccagcacag gtcaaggtcc tgtgagggct gggaccctgt 80160 tgaccctggc gaggagtttg gatttggtgc tcagggtggc aggaagacag cagccgagga 80220 ggtgaggggg aatttttggc atgaggctga atctgtggcc tgcgtccacg ttccccagcc 80280 atgccacgtt ctagagggta tctcctctgc attcaaagag ggaagggatg acatgcactt 80340 cactttgctc cctgcagaac gtccttgcag aggtcatggg agtttggtac cctgggtgag 80400

PATENT

-138-

PTS-0012

tgtggccgtt tcgtgaatgg ggagactgag gccagactca gtcaggagac tcagattgct 80460 gagggttaga gcacagccga ctcccagatg ttgggcaggt gtgttgagaa aggccagccc 80520 atcttgggac agggctccac aggcccacct ccccaggagg ctgacaagca ggaccagaga 80580 agaccgtgga gcaggaacaa acccaacact gggagcaggg gatgtggggg caggaggtga 80640 aggaaacacc ccagagagac aggaggaggt ggggctccct gtggctttgg caggtgaaga 80700 aggggtette ettgetetet aggtgetage tgtgtggeeg tgtagtttet agtggettgg 80760 ccctttccgt tggtatcact cttttatcta gatggacagt tgctgctgat ccccacagat 80820 catacacaaa ctcctattca tccctcaaaa cccagcctat atagccctcc tgttaccttt 80880 ttgggagagt gacttgtgcc ccactttcac acataccttt atctgcctga gcatactaat 80940 ctgctgttac tgctcttaac caacagccat tgtttgggtt tattccaggc aggggccagg 81000 teteatteat tecatgtete tecceaggte ceagtgtttg ggagetgeee tgeeccatg 81060 ctaccccata cccagtcctt cactgggcct ggcttagggg ttctcccatc ttcagtaccc 81120 cagggcagac tettteetge ttegagggtg tggetgggac attgaetete egggtgatgt 81180 ctgccccat ccaccggaaa tactagtccc aagcctaggg gtggtcctgc atgggacctg 81240 geoettgget teetetgtee gtggateetg gaggteataa gaagggette tteeetgtgt 81300 tttgtttctg tgcctcagtt tcaccatctg tgagatgggg ctactcctgc ctgtacctcc 81360 catggcgctt atgcgcaatt gacatgttaa gaacacaccg tatgcccgac gcttggctca 81420 tggcaggtgc ttggagaagt gaccatcgct gtaatagttc tcccctgctc ttctggcccc 81480 cageegeace ttgaggetge aggteteggg gttttggete ageetgaagg tggeeaagag 81540 catggctctg ctcttggtgg gccgggctct gggctgtagg cggaggcagc tctaggttcc 81600 agcttgagcc cacctacata cctgctgtct ttctccgggg gctggggagg gggagtgatg 81660 ctggcctgcc acgccctcct ctctctgctg cagcccggga gcctgggcac ctccgccctg 81720 egaggagate ttggcaaagg etgegteaaa tttttgttgg eageeacatt teeeaggget 81780 tggggtcacc tccttttggc caatctggtt tggggtcact ggggacagtt tcagtatggt 81840 gatggtgact tctgcggcct gtccgcctag tccttgccaa atactgagtg gctgccccaa 81900 tgcagctgag tcacagcagg ggctcgcccg cgtgccagcc tgtgaacacc catttgccag 81960 cacacacgca gtttagcctg gtgcaggggg cacccaaacc cacgcaaatt ctgccctgc 82020 ceteegecae agececeatg aagecacett caggageece teegecece aceteeetgt 82080 acceggetgg cetgggetge cetecaggee teetgtgagt ggaceetggt ggteceagge 82140 tgcgggctgg tgggcctggc cgaggcacaa tgtctgcctt cacaccgagg gccggggtgg 82200 gggcccggag gtccagccta ttgatggagc ggccaccgag ccctgcgcca catgttcctg 82260 ttttcctaat aagtccccag ttgtgagtgg ggaggaggcg gggaggcccc ggggcagccc 82320 agaaataatc acatgattgt gaaacacaag aatcctagaa agggtatctc cgagcgcctc 82380 tateteacce tecetecte tecteetect cetteeeteg etggetgeac tagetetgag 82440 gtaattgtag acaacccaac cagcttccag ggtgagggaa ggcatctcag ggctggcagt 82500 gtcggctggg ctggtgggga gcggtgccca cgtcgctggg ccctggggga gcgaggcctg 82560 cgcgcctgcc ggggagcagg cttcagtgga cccggcgcat ttgctaaaat cgaaacttgg 82620 ctggcttgct ggggccgctg tgggggtatt gaggctcctc tgtgtttttt tccagcgtgg 82680 ggagggcctg cagggggccc cgggcctccc tcccccgtgc tgaggatcag catgctggac 82740 PTS-0012 -139- PATENT

tgggctgggc aggtgcccgc tgctccggga agcctctatt tataatctgt gtttttttgt 82800 tttttaaaaa aattcctcct cttcgccatc accctgcaga agaaggctga agctgcacat 82860 cggattctgg aaggcctggg gccccaggtg.gagctggtga gctggggtac agggtcaggg 82920 gctcagggga gggcgggggt ggctggagag gtgggcaggg aggcgggagg gtgcggcgga 82980 ggaggaagtc atctattacc aagcgctgcc caggcggcgt ccgcggagga agcaggaaac 83040 ccaccttcct gatgagagga cggcagatag cgggtgggcg ggcctggctg ggctgggtgg 83100 gggtggggag tettggeage gagegeetee ggggeeacet gegeaeteet gtgeataceg 83160 tgaagcccgg ccgctcgggc tgtgaggaga gtcacacatc cgtaggccgg tgcgcttgct 83220 ccagctgagc gcggagagcc ggttctctgg gtcacacaat ctcggtccac tcccaggtgc 83280 accgcttcat ggcggtgtga ccctgagcgg gtctgttacc ctccctgtgc. ttcagtttcc 83340 tcatctgtaa aatgggaatc ctaacagcac ctattccact ggattacagt gaggaggagc 83400 tgtgttaata tttttccaac atcgggtgcc gcgcctgcct tgtaaacagt aagtgctggg 83460 cattagctat gatgatgatg atgatgatga tggcgatgat ggcgatgatg gctgtcacta 83520 gtgtcctttt gctgcggaaa gatgccatgt cagcagcaga gctggaaagc aggccccagg 83580 cctcctggag tccctgggct gaggatgggt ggatgcagaa gccctagccc ccagagaatg 83640 ggccgcagcc cctgcctgcc ccacagccat ctgtgcccac tgagctggtc agcatggatg 83700 gccgtggtgg gcactgaagg tatatgctac ccacatgtgt gccggatgag ggagagtctc 83760 tgtgtgcatg gtgggctagg gtgtgcgtgt gagtgcgccc agggtgcaga taaaggctta 83820 tgccttcgcc atgtgtagtg gctcatacct gtaatcccag tgctatggga ggccaaggca 83880 ggaggattgc atgaagccag gaatttgaga tcagcctggg caagatagca agaccttgtc 83940 tctgcaaaaa attaaaaaat tcaccaggtg tggtgatgca cgcctttcgt cccagctact 84000 tgggaggctg aggcaggagg atcgcttgag ccctggagtt caaggctgcg gtgagctatg 84060 atcacaccac tgcactccag cctgggcagt agagtgagac cctgcctcat aaaaaaacga 84120 aacagaagte tgacacette agageeteaa tetaaaetea geteeaetge atgtttgeea 84180 agtggcctta ggaaaggggc tgacctccca gtaccacagt gctctctcat ctgggacagg 84240 cggaggetet agggeeteet tecagggtet teccagggtt aaaggeagtg etgeetgtta 84300 aaggeteace tagtgeaget cetggteect aegaageget cagtagttgt gaacaatttg 84360 gtgatgaget getececetg aagtttetge aggetgetea gttttgeagt gagageteee 84420 caaagcccgg ggtccgtctt ttgaggccac tcaggaacta caagccccgg gctcccaggc 84480 ccactcagaa ggcagaagca gggaggagat ggcaagggct cctccagctc agaagcaggg 84540 cccagctgcc cacctggctg gactcaggaa cctcgctggg ctcccccacc ccttcagggc 84600 tctgcccct ccaggcacat cctcgggcct gggcgatctg ggtggtgagc tctggcctag 84660 ggtcgtgctt ctctcagtgg aagtgatatc tggggaagtt ttcagcagca gcagctgctg 84720 cttgcttgtt tttttgtttt gtaaacagct ttattgaggt acaattcaca cgcatgccat 84780 tcactcaaag tgtccagttc agtgggtttt agtgtattca cagatgtgtg caactgtcac 84840 cacggtcaat tttagaacat tccatcatct caaaaagaaa cccttctgtc tctatggatt 84900 tgcctattct ggacatttcc tataaatgga atcttgcaat atgtggtcct ttgtgtctgg 84960 tttctctcac tcagcatcat gttttcgagg ttcatccgtg tcgagcgtgg gtcggtcctt 85020 cgttcctttt tgtggctgaa tcatatttca ctgtaggggt aggtcacgtg ttgtttaccc 85080 PTS-0012 -140- PATENT

actcatcagt cggtggacgt gagattgttt gcatatttgg ggtattgtga ataaagttgc 85140 tgtgaacatt agtgtgccgt ttccatgtga acgtacgtct tcatttctcc tgggtgtgta 85200 cctaggcgtg gaattgctag atcctctgtt aaccctgttt agccccttga ggaactgccc 85260 aactgttttc caaagtggcc gaaaagtggc cgtaccattt tacatctcca ccagtaagct 85320 gcctcttgcc tcggtttctc cttttctgcc aaatagggat ggcagggttg gatgaagttc 85380 ccaagcattt ccagatttcc gggtcctccc gctcccgttt cctgattggt ccccgggggc 85440 ctcctggggg aaagggcctg tgtcttaggg cccgaggaac acaggcgagg aagcccctgt 85500 ccgtgggagt ctgtgggcag atgggggtgg gcagctgctg gtgtcagaag ctttggaacc 85560 agggacccca cagtgagtct tctctggttc tttggagaca aggggacggg gttgtcttcc 85620 acttggggat ctcagagcag aggcttccac aaggctgatg gcacaggagg ctaagatcta 85680 gtgtttggac tcttgaaggc ccctggcttg gtgccagtca gtggggacag ggaggacgcc 85740 tcacagagct gttgccgtcc cattttctgg atgaggctca gtgagaggag tgccttgtgc 85800 cgggccacac agcaagagat gaggcgtgga ggtgtgctga gcccctggga gagcggccgg 85860 ccagttctgc acagatctgc caggcccgag tggccacagg catcctccaa gcagaggcag 85920 ctgcatggtg caccetetge agggteetgt ctaccaactg ggtgccagaa gcccgggcca 85980 gggacggcct gaggtgctgt gggtcacaga gtccagttcc cagggtgtct tccatcagaa 86040 gctgcagttc caacgcccct cccctcggca gggacggatc cctgtggcct tcctggagga 86100 atttgcattg gaaaggatga aaatagcacc agaggtgcta accaggggtc gggggcactg 86160 agatggtggg gcacggcccc tccagcccag ctgtggggac tggaccaggc tgggagcggg 86220 cgcagtggtg gagggcgtgc ccagcagccc cgacctctct gccgctttga gtcattgctt 86280 cetteetgtt ceaaggegtt attttaagaa getggtgtea ceagegggtt gagggetggg 86340 gctgtcactt catttattgc cagctcaggc cgcctgggac tctggctctt cctggtggcc 86400 ctgctggctg gctcaaagcc cgagggggc cgcctcctcc ctggcccctg ctggctttct 86460 tagtcaccac catgcctcat ctctgcctgc gccctgcgtc tggcacctgc tcccctttgc 86520 cctctttctg ccctctgagt ggctgtgcct ctgattttag aggagacgga ggctgagcaa 86580 gagagagetg gacettgggg cetectgggt geegeeeta ceaceceagg etecacaege 86640 atctaggeet egatteeete actggegtga gteececeag gggteattte teeegggagg 86700 ataaggcctg ggggtgaggg acaggggcca gccatgcccc ccagcctgtg tggctgtgga 86760 ggtgcctcat ggccccatgt ggggaccccg gctagcctgg gctgggagcc gccaggcctt 86820 tgtgcagccc tctctgcaga ggatgagggg gatgttgggg agtcccctcg ggccctgcgt 86880 cccctcagca atgcacctgc caggacatgt cactgtccct ccctccccc actcccttct 86940 gggctttcca agatggctgt cctcagcctg ttgccatggc ggtgcacggc attccaggca 87000 gctctgggcc cagagcctcc cctgggctcc tggggttcag gggcctcggg gagtggctgg 87060 tgagtgcctc ccaggggggc agttcctgtt tagaggccgc agcaccccac agtatcctca 87120 gtccttcggg gccttcgcct tgtgggcccc tcaccgatgg ccgccttgag aagcaggggc 87180 tgtgtcccta tctacagggc aggggaggag gccaccaagt ggaagtggcc ttcctcccct 87240 gtggctttgg tgggttggag gctgaccggg ctcttgctgc ccccgggagc cggtcctgca 87300 tttctgcacc cgccctgtgc cgcagaagca ctgtcccctc tgcccacctc gccctcccag 87360 ggctgcgtgc tgtgggcttc cagccccttt ctggccccct tcggctgttt gctatcttta 87420 -141-

PTS-0012

PATENT

aaaccaaaac aagacaaaca ccaaatttca ccaagtctga aattttctgg gctatccaaa 87480 atttccgtga agtaggtcct ctttgaccta cacccatatt ccagatgagg aaaccgaggc 87540 tggagtgttg agggcacttg tccaagctca cagctagtga gggaggaggc accatttaaa 87600 ttggggccta tctgtttcca aaacccgaac ctttaagtga tgtccgcttg cacctggect 87660 gcatttgatt ggcatgtggg gaacataaag gagccagtgt ggttgcccgg gttacagcat 87720 gggcatcttc acagggcccc ttgccattcc tgagacgagg attcgcaccc tctgcaggga 87780 tgctgcactg caccccttcc ctccactggg aagttctgca gtgagtctga ccgtgggctc 87840 tcttgttcct ctgcccactt ctccctcttg ttcaaacttc cagggtcagg gtggggaaac 87900 tgccctctgt tcagggctga gaaccttggg aggggagcct gacccggcac ggggagaaat 87960 ggcccatggc agctgcagga tgacatctct gtccccagga gagtagctga gcaggagcct 88020 ggaattgccc gagcccagtg gtgaattctc taggagggga tctggggcta cagggggaaa 88080 ggcgacattg tcaccagccg agactgtctg tgaggctctg tagagctgca gaggcccttc 88140 cctggggatg ggtgggcggg ggtctgggtg gcccactctg ccggcgtcat caggaggtgt 88200 gttcagctct atccccaggg aagagacttg tgtgtccctt ctgtcgctgc agccctgccc 88260 tgaggctgca ggactccacg tctccatcct tccctgttcc atctgatcac tcacactctg 88320 tacctgatct teccaceata gteacecatg gecaecetgg gaggeteetg etgtgtgeat 88380 cacacacaca cagagactca ggcagagagg ggagcagact ccttcctcca gcgctggggc 88500 tgagaggcgg gctgtcattc aggctcatct cttaccagct gtgggcaaat gttgtaacct 88560 cttaaggact caatttttct ttctgtacag tgggggatga ttgtatcagt tacccggtat 88620 ggttacatgg ctactgctgg ggaacaaagc agccccacat ttagaggctt gaagcagcaa 88680 ctgttcactg tttctcacct gtctggaagg cagctgagca tttctgctgg tgtgggctca 88740 gctcttgcac ctccgtggcc agcgagggag tcggggggcc ggcgttgtag atcagcccag 88800 getgggttge accaegetge teettgeete tetgeeeget teetgeagge caggetagge 88860 tcattctctt gacagaaaca gcagaaatgc gaactcgcat cttcaagcct ctgcttttgc 88920 taagtgtgca gcaattccac tggccacagc aaggtcatgg gtggttacag ggaggcgtga 88980 aaggtgggtg ccattagcac agccactgct ccctgatggc ggcaatgtga ctggcacctc 89040 tgggcacttc agcctgcagg taccagcctg agagcttagc atgcactgtc tcgtttgatc 89100 ttcacaaaat cctatgagtt taaccccatt ttatagatga ggagaaatgg aggcacagat 89160 ggaataagta acttcccagg gagacccagc tagaaagtat cagaaccggg acttgaacct 89220 aggctgtgcc cttggttgct aagcaaggtt cttccatctg ggaggggaca cgtggcagct 89280 ggcttggtcc ctgcaccatc acagatgctg ccgtgctttc tgcgtctcct ggtacgctct 89340 ttgaagccct gtgcttgcta catgtgggcc ctgcctccct ttctcactgc tgtgtgggat 89400 ttgtggtgta accgagtcct ggtctcctta gctgctcttc tggtggtgga cggctagctt 89460 gcttctcact ggccgctgtg agcagtgcgt taggaacatc ctagcgcccg tctcctggtg 89520 gagcacagta ggcaactgca ggagcatggg ggtcggaagc gggggcgtcg gtgttcgtta 89580 ccaggtagtg gctgttgtct ctctggggga tgtgtgccca tacaccatgc tcccaccagc 89640 tatgtgccag ccttcctgtc accccagacc tcaccaacac ttggcattca acgtttttgt 89700 cttttgctgg tcagtggggg tggagtggta tcttgcagcg ttgggacgcg cgtttccatg 89760 PTS-0012 -142- PATENT

gtgagctagg aagccaagtg gctttccacg tttggtggcc agggccaatc tctggggtgt 89820 gtgtgggttt gtccgggtgt gctctgggct gtggcccctt ccaggccagc actgctgaat 89880 gccccgcaga gcagccatga cgaccttggt gggggtggtc acagtaccca cagctgttcc 89940 cgaggaacca gtttcagcct gttcctggct ggggctgcgt gctgggtccc tgtgttctgt 90000 ttcatgcctg cctgcggctg agccctcacc cagaggacag ctcctccgtg ccagggctgt 90060 ggctcctacc ggtgggctct gtagtggcga gtggccagcc aggctctgat gtgcttctct 90120 ctctcccttt gcagccgctg tacaaccagc cctccgacac ccggcagtat catgagaaca 90180 tcaaaatgtg agtgctcgcg ggcagccgtg cagacacaca gaggcagggt gggcgagcag 90240 gctctcagca gcctgcatgg gatgtgggac gtgggctctc tgttcccatc aggggctccc 90300 ggccagggcc aggtgctccc ggaggggaca ggagacagtc ctaggtggca cctggggtgg 90360 gggtggggag cagagagagt gtccccctga ggttttggga gacaggctgg gtttgggagg 90420 gtgggcgagg gagctgctgg tgcacaggtg ggtctggaga gacggaggtc agaggtccca 90480 ggctgtacat ctgcatcctg ttcgagcagg agggagctgt tgcgggcaga aggcagccgg 90540 ctcagggaga tggggagtgg ccccagagca ggcgggggcc tggtgttttg ggctctggca 90600 taagcatgtt tgggaatcac ctggtgtctg cacagagagg tccctctggc acagcccact 90660 atggggcaga tcagagcact catccaggcc ctgaggcttt ggaggtggcc aatgtgatgt 90720 attctaatga tgggggcctt ttcccagacc ggtgctagga gggaagaaaa tgtcaattaa 90780 gtgccactgc cattgggtga ggcggtgctg gaggctggta gcattgtatc ttcaagcggg 90840 gtacaaggca ttggaggtgt ggcagctgga agggggctgg ctttttcttg ggatgcatta 90900 acgggagcat agactgttgg gccgaggagg gcatgttatc tcatgttagt gcccaggaac 90960 ccaaaaggta aaaggggctg cagatettge ccettgagga acatatggce acgtggtggg 91020 ctggtaggtt ggaggtgaga ctcttcagga tcatagctgt tgaatgttca aggttcgtca 91080 tggtgagagg gtacaggcgt ttgagtgtgg ctgcaaaggg aggcgtttag ctgattcggt 91140 gggtagttca gcccggtccg attgttcaag cgttcctggg atggaactac agagtgtata 91200 tgcggtggtg agctccccgt tcctgaaagc gtgcaaacct tccagtgttt tcacacatct 91260 gctggtgctg gactagtcga cggggagatc gctgctgttg tagtttccag agttgcgcga 91320 ctggtccaag ctcaggtgat caacttggcc acctggtcat tgttgcagca gcctagaaaa 91380 teteteettg etagttgagg ceettggeet tetegggtte aggageacet gacaaagata 91440 cttcaccagc gtggctggcg ggggggtcat cctcagccag tggccagcag gggctgcaga 91500 gtgtgtcagg aaggggcatg tgttctgcgc caggggtccc gggctggtac agaaggccca 91560 tgtcagatgc agcctgggct cctcatcggc ctggcgggct cattcattgc ccaggtccca 91620 gatccctttt gactcgacat agtttgtctt ccaattgggc tacccctgtc ccttctgcag 91680 cttcctggga cctgccttgc tctggggccc ctgtctgggg tgggaagcca cagatggagg 91740 ggtgctgaaa gcaaggggga cattcttagg acctcatcac aggtggttta ggggatgagg 91800 gtggggtgtt ctcaactgag tccaggctgt ttggggcatt ccctcattca ttcatcccat 91860 ctttattgag agcctgctgt gtgtcaggtc ccgttctagg ccttggctat tcagccttgg 91920 ataaaacaaa ggcctcatcc ctcatcaaga tttgtctagc agtggagaca gaaccagaat 91980 gagttaagta aacaaaacaa gagaatgtca gctaatacag ccgggtgcag tggctcatgc 92040 ctataatccg agcactttgg gaggctgagg tgggaggatt gcctggggcc aggagttcaa 92100



PTS-0012

-143-

gaccagcctg	gccaaacata	gcaaaaattg	acaagaaatt	agctgggtgt	ggtggcacgt	92160
gcctgtggtc	ccaggtactc	aggaggcgaa	ggagggagaa	tcgcttgagc	ccaggagttc	92220
agggctgcag	tgagccgtga	ttgcaccact	gtactccagc	ctgggtgaca	gagcaaaacc	92280
ctgtttctgt	taaaaaaaaa	aaagaaagaa	agaaaaaaga	aagaaaatac	cagcgaatct	92340
aaagtactat	gctgacataa	ctatcttaag	ctctttacgc	cttcatatac	ctagttatga	92400
ttttttt	tgacataata	atttttgata	gccatattat	tatactgaca	attttacata	92460
ggttttttc	acttaaagtg	agtgatattt	taagctgaat	actgtggttg	atttcaggta	92520
ataaagacag	ccatagaatc	taaacaaaag	aggagcaaga	tgctcatata	gatgacacca	92580
gcaaatagat	attgcttcat	ctttgtgtaa	gtagaataaa	actgtaagca	tattaaagcc	92640
agtgctgtat	ttgacatctc	ataatcttcc	tcagagaatg	actgtggtcc	gttgaagtgc	92700
attttgacta	aataggtaac	cgcctcactg	aatttgttcc	aaatctaaat	cacaaacaaa	92760
catgtttcta	tttaaaacaa	ctagatgtgc	tgggcgcggt	ggctcacgcc	tgtaatcccc	92820
					accagcctgg	
ccgacatggt	gaaaccccat	ctctactaaa	aatacaaaaa	ttagccggct	gtggtggcgt	92940
					acctggaaga	
					cagagcaaga	
					gaataattaa	
					taaattgttg	
					ttatcatccc	
					cattcatttt	
					gggtgacatt	
					tgagcagcag	
					gcaaaggcct	
					ggcaagggag	
					ttatctgttg	
					aatgtgatca	
					ggggtagggg	
					gcaccctgtc	
					gcccaggaag	
					: tgtgaccgct	
					ggaggccccg	
					cgcagctcgt	
					agggctcagt	
					tgggttttg:	
					atttactgag	
					a atgaggeetg	
					tgccgccatg	
					ggagcagcct	
ccctggcgc	t cacggeeted	tegeçeceg	tgctgtcat	t gcttctagg	gggaggtcgt	94440



PTS-0012 -144- PATENT

1	tccctcccca	gagaccttgc	cccgtcactt	taatttctct	gcgtctgcat	gctggggccg	94500
		gttaatttca					
		tagccgcctc					
		gcaggaggga					
		tgggggctcc					
		gtctatggag					
		tggcgctcag					
		tcaggcctgg					
		tecetectge					
		aggcggaaag					
		tcagagacat					
		tgcacatcca					
		gggtgacctt					
		tcagtgatca					
		gccctgcata					
		caccccttct					
		tgctcatttt					
	ctcaaacctc	ccttcctcca	ggaagcctcc	cctgattgcc	cccaagcttt	ccttttccag	95520
	taccccataa	accccaggac	cagtcccagc	tagggtccaa	ccggactccc	ctggaatact	95580
	ctcataatto	: ctgcctcctt	atcctgccct	cctatgtcct	gcttctcctc	tccagtgccc	95640
	tggcagatgg	caagactagg	tttccttata	gggtgtgtgt	tttaaaccc	tgacttcttt	95700
	gcaccccatg	g agtgcctcta	ccagcaaact	catcacatgo	tgcttacccc	atgcctccag	95760
	agccctccta	a cagactgtgg	tccttatgct	tgccggacag	, aagctcagca	gaaaagattt	95820
	gtctgcagta	a agctatttgc	atcttcattg	cctaaacact	gcttggaaca	aaataaacac	95880
	ttaaaaaaaa	gtttgccaga	ggaatgttga	acacgtggg	atcataaacc	: aggagtcccc	95940
		g cctccaggag					
	atagggagta	a gtaggggctg	aggaacgggg	agctgggcga	a cctttgaaag	, gagcagccaa	96060
		cccagcctgt					
		t aggtttggct					
		t tagaaagcac					
		g aggcaggcag					
		c gtctctacta					
		t acttgggagg					
		c gagattgcgc					
		a taaaaaataa					
		g tctctggcct					
		t gacgtgtcct					
		g ggaggaaac					
	atçggtggc	a aacagacgg	c tgcatgcaca	a tcaccacca	c cccgaggcc	t catgctcac	96780

PATENT

-145-PTS-0012

			gcggtttgtg			
			tgaaccgggc			
			ttggaaatca			
			ttgccggttc			
			gtcactcccg			
			ctccgtgtgt			
			cccaccccag			
			ggţcatgttt			
			ggttgggggt			
			attttgtatg			
			aaggtggaac			
			aatacgctcc			
			tataacagca			
			tcccagcact			
			ctgggcaaca			
			tgtacctgta			
			ttcaaggatg			
			accctgtctc			
			tggcacatga			
			aacgtctgtt			
			ctctttagtc			
			acttttgaag			
			gatggtgggt			
			agggggctct			
			tttactaggg			
			cctggaggga			
			g agattctttg			
			cattcatccc			
			tetgttteed			
			ttctcctcca			
			tttgtttat			
			gttccagctc			
			: ttcttttgtt			
			tggccgagcg			
			g tetttgetga			
			g ccttcacago			
			a ccctgcagga			
			t ccccagcact			
tctgtctgt	g cttccgata	c acagagttt	g ttcctgtcto	c ctgcggtgc	c ctccagctg	g 99120

-146-

PTS-0012

		<b></b>	caaateette	taataacata	gateceaget	99180
agttcccttc	cttctggatc	ttcccagage	caggicate	tctaaaataq	ccctcacac	99240
caaggccatc	ctctctggga	gatettete	taccacygaa	ttcccaatc	caggattate	99300
cccgtcccc	agcacccact	ageceaecat	tatatasaaa	ccctcaacta	tatattacta	99360
ttggtcatct	tgcttattgt	cagtgtcacc	cetgegagag	agragatect	cagtaaacag	99420
cctgctgtgt	ccccagcacc	Eggaacagtg	cetggcacat	tagataga	aaactgaggg	99480
ttattgaata	acagaagatg	aggetgegat	gecatagatt	ccayacyagy	cctacctat	99540
cttctgaggt	gtgctcagag	acaccctgtt	atgagatgaa	gggrgccggc	traturator	99600
gggactgagg	acccccatgg	cccaccctgg	eeggggggeg	geggeeagae	cattccacc	99660
tggggaggcc	ctggccaagt	caccaccaga	atgacccggg	gactyaggtg	cttttcctat	99720
ccttgagccc	catgaggctt	cactcgtccg	tcagagectg	gggtteette	agtagette	99780
ttccaatggg	getggggtee	cgggggctgg	acatagegeg	geteedagte	tagatage	99840
gaacttttga	gggggtttgg	acactgctga	gaatatgaaa	aagttgggga	paget gage	99900
agaaaagcgg	gtgccactga	atgccgcgga	ttggggacag	acagcaagtt	aaggtgcaca	99960
gcaggctcct	gaggtcgctg	tggccccca	ggccctggga	ggccagctgc	ageaeeetge	100020
.tttgtgtgtt	ggagaccgtg	gggaggggcc	: tgggaagaga	agaggacggt	cetggggtet	100020
.cggtgcagca	a gtgggtgggg	gtgtcttcca	gccctcatgg	cgtgggctcc	agaaccccc	100000
gcctctacto	c tccagggcto	cctccctttg	cctgtctcag	ggtccctgtc	CCCEECEC	100200
gggtcttgto	c tctttcccto	tccccactto	tetetette	cctctcctag	tttcatcttc	100200
ctctgagtc	t ctgtcccct	cctttggato	ttgtctctct	gtgactgcct	ctetetetet	100200
ctctgatcc	t ctctttctca	a tctctctcac	tccagtctca	cctctcagto	tcatctcctg	100320
tccatctcc	a ggtctctgt	c ctttcttgga	a tctcatctgt	ctatctatct	: ccgtctctgt	100380
gtctcccct	t ctcccagtc	t ctgtctctt	t ctcacctctg	g tetecetgte	: tgtctcccta	100440
gțctctggg	t ccctgtttc	c ctctctggg	t ctctgtctco	gtctctctct	ctctgggtct	100500
ctgtttccc	t ctttctctg	g gtctctgtc	t ccctctctcl	gggtccctg	ttccctctct	100560
gggtctctg	t ctctctctc	t ctctctctg	g gtctctgtc	t ccctctgtc	t ctgggtctct	100620
gtgtctccc	t ctgtctctg	g gtctctgtc	t ccctctgtc	t ctgggtctc	t gtatacata	100680
gtctctggg	t ctctgtctc	c ctctgtctc	t ggatctctg	t ctccctctg	t ctctgggtc	100740
ctgtctctc	c tgtctctgg	g tcactgtct	c cctctctct	g ggtctctgt	g tetecetet	g 100800
tetetgggt	c tetgtetee	c tctgtctct	g ggtctctgt	c tecetetet	c teagggtet	2 100860
cgtctccct	c tgcctctga	g tctctgact	c cgggtctct	g tctccctct	g tetetgggt	c 100920
tctgtctct	c ctgtctctg	g gtctctgtc	t ccctctctc	t gggactctg	t gactccctc	t 100980
gtctctggg	gt ctctgtctc	c ctctgtctc	t gggtctctg	t ctctctctg	t ctctgggtt	t 101040
ctttctcc	et ctctctggg	t ctccatctc	c ctctctctg	g atctctctc	t ctctctctc	t 101100
gggtctctg	gt etecttete	t ctgggtctc	t gtctccctc	t gtctctggg	t ctctgtctc	c 101160
ctctgtctc	cc gggtctctg	gt ctccctctc	t ctctgggtc	t ctgtctctc	c ctctgtctc	t 101220
gggtctctg	gt ctctctct	et ctgggtcto	ct ctctccctc	t gtctcaggg	t ctccatctc	t 101280
ctctctct	gg gtctctgtd	ct ccctctgto	ct ctgggtctc	t gtctcccto	t gt¢tctggg	t 101340
ctccgtct	ct ctctctct	gg gtctctgtt	t coctototo	t gggtttctg	ıt ctccctctg	t 101400
ctctgggt	ct ctgtctct	gg gtetetgte	et etecetete	jt ctctgggtd	t ctgtttctc	t 101460

PTS-0012 -147- PATENT

ctctgggtct ctgtctccct ctgtctcagg gtctccatct ctctctctct gggtctctgt 101520 ctccctctgt ctcagggtct ccatctctct ctctctgggt ctctgtctcc ctctgtctct 101580 gggtctctct ctccctctgt ctctgggtct ccgtctctct ctctctgggt ctctgtctcc 101640 ctctctctgg gtctctgtct tcctctgtct ctgggtctct gtctccctct gtctctgggt 101700 ctctctgggt ctctgtctct ctctctct ctggttctct gtttccctgt ctctctgggt 101820 ctctgtctcc ctctctttct gggtctctgt ctccctctct ctctctgaaa ctcccgtctc 101880 ccaggacgtg cctccttctc ttggagcctg cagtggtgtg tgtaacctgc ttggttgaga 101940 ccccatgggc cctgccctga agtctgagac cgccccgcc cgggggtttc ctgaagtcca 102000 tgcctggtgg ccccaccagc tgccccacac tgcttgtgtc cctcccccg cagcaggact 102060 gggtgtgctg gaggtccatg cacagcacct ggttggagcc aatcctgggg ccacacaggc 102120 cacactetga cacceggeet gtgggeggea geaggteteg gggteteggg etetgtggee 102180 tgtattccta gttggaggct gtggctgttt ctccgtggcc atctttccgt gggcagatgt 102240 ggctgccggg gtgcatgtgg gcgggggcgg gaagccacag gcccctcggc tctgggaacc 102300 ctcttgcctg cacactgggc tcaacctaaa cgttggcggg ggctgcctcg cgcgcggggg 102360 agtaaggatg cacgttggca gctcacaggt ctctctgggg atacagcacg ggtgggtctc 102420 atctccctga gaaccaataa cggggcaaat ttggggctca ctctcagcaa acaggatggc 102480 acggggtgca gcgcctgagc ccggccgggc tgacctgtct gccgcttccc tcctgcacag 102540 aaaccaggcg atgcggaaga agctaatctt gtacttcaag aggaggaatc acgctcggaa 102600 acaatgggta agtccacacc gtggccccca tcagctttcc ttgagatctg gggagaatcg 102660 . agegeacagg gggeeacace tgeeggggee etgteagtte egeagetgtg teeteeetga 102720 gtgtccaggc tgcggaggaa aagccaaggc cggccaggaa aggaggaaag acaacagctg 102780 cttccagaag gccccagggt gggtggggtt gggggggctc tatggcccct cttccagcct 102840 ggaagggaag aaagcaaaat gttggcctgg aaaattagtt gctaagccct ggtcacggga 102900 cctgtcctgg gcttttcagg cagaaagaga ggttttggag agaggtggag gatcagggtg 102960 ggctgtgtgc cgggcagcag gggccgcagg cgcaccctta caaatgagcc tttcctggtg 103020 cactgggccc aggtccaggc tcagggaaac tgagacagtg gacaagcatt gagccccctt 103080 tccctgagcc tgcatttgtg gccagtggcc tcatccaaac agaaaaggat gctgattcct 103140 getteteact gtaggetgtg gateteagee caeggegggg aggetgggte tgccagagge 103200 atgtggtggt ggtttcaggc ggccgtggcc atcacccatt ccccggagga gatcagggtt 103260 gagtattctc ccagctgtca ggggaagaag cgcggactca gatgggcttc aacaggaaag 103320 gaatggctgt agctggaaat gtctgttggg tgtagatggc aggaatagtc tttcaactca 103380 agtettgeet teattteatt teattacatt teattteatt ttatttgttt atttatttat 103440 tatttatttt tgagatggag tttcgctctg tcacccaggt tggagtgcag tggcagggtc 103500 tctactcact gcagcctccg cctctcgggt tcaagcaatt ctcctgcctc agcctcccaa 103560 gtagctggga ttacaggcgc ccgccaccaa gcccggctaa tttttgtatt tttagtagag 103620 aaggtttcac tccattgacc aggctggtct tgaactcccg acctcaggtg atgcacccgc 103680 ctcggcctcc caaagcgctg ggatcacagg tgtgagcact gcacccagcc ccttcattcc 103740 tgtgcagttt tttcaactcc ttatgttaga acattgacaa actgaacctg aattcccata 103800



PTS-0012 -148- PATENT

gcaggtggga gccggagaga gctgtgcttt ctcggatggt atcacagatg ctctgattag 103860 gccaggagag ggcctgcgtc ctgtgaacca gtggctgatg ccggggagat ggagtgaggc 103920 tgcctggttt tggctcatgg gactttctct acagttgggg atgatgtcat tgactccacc 103980 caagccacgg ggctgctggg acatggtagg gaatgggata aggctgggga ggccctgaaa 104040 aggtccccac ctggggaaga ggcgggctgg atggggactg ctgccttggg attcttggat 104100 aagagacgcg gcaagggctg ggaactaggt ttgctggagg ctggaggggc tcccctcata 104160 cetgeagece cetgeeceae etectete ceteagetgt gttgaggeag ggeetgegag 104220 gcagctccct gtatcctttc tgggcctcca gagaggccct cccaggcgca ggcctggctc 104280 agtcatgccc agcgcctgta ggtctgtggt acacagtagg tgatgaccaa gtcctgcttg 104340 aactgaaatg ggccgggaca gggtgttagc tgatccagtg cetttggggc ctggatgcca 104400 gtagtcacgg agcacctact gtgtgtgagg ctcgcagttg ctgtgacacg ggccctgtcc 104460 tcagacctgc aggctgcagg gacaggtcgt gcgtaaggac gaggaggatg cccgcacacc 104520 ctgcccttcc ggtgcctgtt gtgttgcagg cgctcttctg agtgctctcc atacattagg 104580 gcatttagtc ctgcgaggtg ggcgcttggt cagccacatg tttcagagga ggaaatcgag 104640 gcacagagag gttaagtaac ttgccctagg tcacacagct gggaagtggt ggagctgaga 104700 tttgaaccca gaccacctgg ttcctgagcc catgctctga acccccaagg ggcagttccg 104760 gagcagtgcc tggggagggg gaccctgggc aggcatgggg tcctgggcag gtgtgtgggc 104880 acgtggggcc aggtgagggg cttagctggg gcaggaggtc ctggctttgg aaggaggggc 104940 . tgtgctatat gggaggaggg tcttcccttg gccctgcctg cctgctctgg ccccgaactt 105000 ggttgggtac tagagggagg agacacttcc agccagatgc tggtgcctgg gaagctgcgg 105060 gcagccctcg ggacccaagc cctgctcata ggtgaggaga ggtgggctgc ccagcagtgc 105120 cttgcccagc ttcctcagat ccccacctt gactggatgg tgcccacagg cacttgggct 105180 ggtgcgagag gctcttgaaa cgagcgtcca atctgtttat caagttaaga gatacccaca 105240 cagggctgct gggtgcccgg gagtcacagg ccaggaaaca gaccggtaat ctggggagaa 105300 gagctgcaca gagggctaga ctctcgagat gggctgggga cctcagtgct gaggtgggaa 105360 tgaccagaaa ggactggctt tgtgcggatc tgggagtcag ggtgtcaggc agagggcata 105420 gcaagtgcag aggccctgag gcaggaacca gcttgggaca gaacctggca ggccagcagc 105480 aggagccagg tcgcgtggaa acatctgccc tcaggctagg atggaacatt caggttttat 105540 tccgaatgca gtgggacacc gaatttattc ttaatacatg tatttgtagt aaagaatcca 105600 aagteettat tetaagaaat ttgacagaag agtacaagge acatetatat acccaccace 105660 tagaatcagc cacggttacc attgccttgt atttgctctg tgtgtataac atgtttgttg 105720 ttgcactatt ggaaaatagg tgcagaggtg ccgaccttca cccctaataa atactccccc 105780 tctgtctcct gcgaggaagg aaatcctctc attttcacct aaaatgactg ccaattcagc 105840 gcgatcttgc cgcctccttg acagcccccc atggttcccc ccttggggtg aaggctcctc 105900 tcgggagggc aggagggat ctgatttcca tttaaaagga tcgctgcagc tgctggaagg 105960 agctcaggct ggaggtggag ttggggtggg cttgagttct ttaaagatcg ccagtggctc 106020 cttggggggt ctgtggaggg ggtggaggga gaaattggct tatttaaagc tagagaagag 106080 gcaggcagaa accaaggact tccaagaagg gtccggtgtg gctttgtggc ccatcttagg 106140

-149-

PTS-0012

PATENT

agggatggaa	acaaattcaa	caccccctga	agctgcggtg	gcgattggga	tggtctcttt	106200
gttgtggtat	aagaagccga	agtccctgac	ttcattgatt	tcagtaaggc	ctggggaggg	106260
gggcttggcc	gagaactctg	atgtgcctgc	ctcaccccca	ctggggagtc	agacccccct	106320
		ccttagcagg				
		catgggatcc				
		ctggaccctc				
		tggctggcct				
		gcgggggtgg				
		tgtgtgtgtg				
		agagggaggg				
		ttgtagaaaa				
		cctgcgctgt				
		caggtgttac				
		nnnnnnnnn				
		ctgaaaaccc				
		tgcctcttga				
		ccacccagca				
		tggagggcac				
		gtctgggctc				
		tgtggaggct				
		gggttgtgtg				
		gccacttgct				
		ggggatctct				
		ttccttgtct				
		tggtccttgg				
		ctgcccctcc				
		cagtgggctc				
		g acactggaag				
		g atttcagttg				
		ggccaggtct				
		: tgtgggttt				
		: tctgtcgtct				
		gtatgtgtgt				
		g cgactgtgtg				
		c ctgtgtgac				
		catatgtct				
		g tetgtetge				
		t gtgtatata				
ctatatgac	t gtctgtctg	c ctgtgtgac	t gtgtgtctgt	: ctgtctgtct	gcctgtgtat	: 108480

PTS-0012

PATENT

					gtaccgtgtg	
ggtgactgca	tgtgtgtatg	tgactgtgtg	tgtctgtgac	tgtatgtgtg	tgtatctgtg	108600
tgtctgcctg	tgtgacttgt	gtgtgcctgt	atgtatgtgt	gcctgtgtat	atctgtctga	108660
ctgtatgtat	gtgtgcctgt	gcatatatct	gtgtgtgtgt	gtctctctgt	gtatcttgtg	108720
tgtgcctgta	tgtatgtgtg	cctgtgtata	tctgtctgac	tgtatgtatg	tgtgcctgtg	108780
tatatatctg	tgtgtgtgtg	tctctctgtg	tatctgccta	tatgactgtc	tgtctgcctg	108840
					tgccatgtga	
ctgtctgtgt	gactgtgtgt	ctactgtgtg	tgtaccgtgt	gggtgactgc	atgtgtgtat	108960
					gtgacttgtg	
					tgtgcctgtg	
					tgtgtctgcc	
					ctgtatgtgc	
					gtgtgcctgt	
					tgtgtgtgcc	
					tgtgactttg	
					ggaggcggcg	
					agcagaagtt	
					gcatcgagaa	
					agcagttccc	
					ggcctgagcc	
					gatggcctgg	
					cctaccagac	
					taaatacatt	
					cactcatttc	
					ggacaaaggg	
					ggactgggtg	
					ttttctttg	
					ttaactgaag	
					tgccactttt	
					ggcccagggc	
					: cagggtgttt	
					: tgggttgggg	
					ctggccgctg	
					g gtctgctagt	
					g cagggtgggc	
					gtcagagato	
					cageteett	
					ccgggtggtt	
tacgtcgag	g ggctttgcc	a cçgaagcgc	g ggtggaatc	a aggtgggta	tgaggtacco	: 110820

PTS-0012 -151-

gtcccaggcc tgcaggggcg agcagagaga ggggtgttaa tgtgtctgag agggagggta 110880 gcaggacccc ctgcagggag ggccctggcg ctcccccatc cagatgccac aacagggagg 110940 gggttggggg acgaggaccc tgcctctcac tcttcccatc tcctgcctcc ttttggaact 111000 tcccattggc tgagtccagc cagaagccca aggggcggga gtgcctgtgg gttccagggt 111060 cagcetteca gggeecagag cetggeaggg tggggggage atggegeagg cegaagagtt 111120 cccagcacgc cagctgtcca cgcagccacg accttctcgc aggcacctca gccctcctgg 111180 ctggagcagg gccggtttcc cctcaggcct ctttggggtg ccaggacacc ctggggtcag 111240 cctaggtgac cctggctgcc gtcactgggg cccacagatg gccaggaagc agagaggcag 111300 ccttttctcc tggggaggaa gttggtgtca gcctgttccc tcccgggtcc tgtgggtcag 111360 gtacccatga tgagactacc ccctgctcct aacaccacag cagacacgag gcagccacgg 111420 cacgtttctt ccttctgggg acttttgtcc agggagagct tttgtccaga tgggagatta 111480 tagcccttta gctcagcaca gcagagccac gcatggctat tgaaatcaaa attaattaaa 111540 atgggataaa attagcaatt cagtteeteg gttgcatetg acacatetea agagetegae 111600 agecgettgt ggttggeage teceeteetg ggeggageag acagegaaca ceteeetgge 111660 tgcagagtgc tctgttggac aacagaacgc gctgccctgc gatgctgatg ctcagattag 111720 acagatggaa ggggccccag ggagggggcg gctggtttaa gtagcagttt ctcaccagag 111780 actctgattc agctggtctg gggcagagcc caggaatccg catttttacc cagccaccca 111840 · cttgattctg acgcaggcaa tccaaagatg aatctggcca ttaaaacata atttttcatt 111900 ttaaaacttc tcgtggtacg tttttgttta caacaacatc cagttgacag aaaacagagc 111960 ctgggccgtg tcagccctg tctcaccgat gctgtgcact tatggacatc ccgcagagag 112080 gctggctgtg ggtttagtct gcactggaag gaggaggccg gtggccctct cctctgcatt 112140 cctcacctga tggccaaggg tgtggcacct gggctgattg ttgcatgtac acacacac 112200 acacacaca acacacaca acacacaca actggccaca tgggaatgca gtcatcagag 112260 tcctcaggga catcaaggat gctgtgtccg gggtgaaggg tggaagtgga atttgggaca 112320 gaaacttccc cagccagcct ggggtgacct gaggttcccc cgggagtgtg caagggaggg 112380 ggctgggccg gaggacaggc acttcccatc cttctgggag cttcctgtgg tcagagcaca 112440 tggccgtgcc gggggtcctg ccattattac atccctggga tacccgagga aggtcgccgt 112560 tccgtatcag gggtgtaggg gacageteca agggtetggg agacagatge cageetettg 112620 gggggattct ctcccaccc ggggtcagag ctgtgccccg cacccgacct gacccctggc 112680 tgggagtcct gcacattgag tgaagaggtt ggatgtgggc ggccgggcag ctggatcgtt 112740 tgaactggct gaccttggct acgcggagtc ctcgcctacc tccggagatg ggtaattaat 112800 cgccagtaat tggctggctg cgagatttgg ggaagtgagc ccagctgagt ggcggctcag 112860 agcctcttaa tagtcatccc agtgcattag gagcggccgc ctgactcctg ccgcatgcag 112920 ggctgggcag gccagatccc aggtgggccc tctgaaggag cggggtgccg ggagggggcg 112980 tgtagtgtgg gggcaggaaa gacctctcca ccagcgaggc gctgaccctc tctgcgcccc 113040 tgggctgcct gcatgctgtg gggccagctg gaccccaggg cccactcttg cctgcggaac 113100 ctggaaggcc agcctgtctc ccgggctccc tgggcccagc tgggctgagc atccttcctg 113160

-152- PATENT

PTS-0012

cagtgcttta tggcgcttgc atttccaaag ggaagattca tggctcccct cccactgcag 113220 agaaggegge tgetgetete tgeattgaat etacagteet geceaceata aacetgtegg 113280 ggaggccttt acattctccc ttcccccagc atgagctatt attatttta aactcatcat 113340 tetecttete ettggttteg egtttteeet getetggege agaceateeg teeeetetgt 113400 gtetteeetg ggteeeetge geeggeegga geacetegte eetgggeete tgaeeetgee 113460 ctccgtttcc ctgcagaacc tggagaagca gatgcgccag ctggccgtga tcccgcccat 113520 gctgtacgac gctgaccagc agcgcatcaa gttcatcaac atgaacgggc ttatggccga 113580 ccccatgaag gtgtacaaag accgccaggt catgaacatg tggagtgagc aggagaagga 113640 atcctgttga ggcctgcgct gtctcccggc agccaccaca aatgagcatg ccggggggtg 113760 cttaaaaccg cagggattta ctctctcctg gttgtggagg ccggaagtcc aaatcctggt 113820 gtttcgtggg gttggttctt tctgggggcc gtaagggaga gcctgtccct gacctcttcc 113880 cagctggtgc tgccagcatc cttggccttc cggggcttct agatgcatcc ttccatgctc 113940 tgccttcgac cccacatgac ctttgtctct gtgcttctcc tcttcttata aggacacccg 114000 tcacactgaa tttagggtct agcctaaccc aatacaacct cacttcaact aattacatct 114060 ggaaagaccc tgtttccaaa taaggccgca ttctgaggtt ctgggtggcc atgaatttta 114120 agaggacaca cttcaatatg gtacaaagtg taagggcagc tggatgtaag acggggcact 114180 gcgagtcgga agaacaaggc aggagggact tagaggctgg gccgcagcct tgggcagggc 114240 ggcagctggc cagtggcttt tggtggtttc tattttgttt tgtctttgac aatagctgct 114300 ggctgagtgg gttcgtgatc ccatcactgt gcctgtgtct tctcagcttc atgcattttc 114360 cccctcctgt cccttatgac agctcagcca ggcccacccc agtacacagc tgatgacacg 114420 gaggeteaga gaggtteaga eagtgeacaa aggeeacaca geatgeacae aatggaggea 114480 gggttcagac tcctccagct ggaatggaga ggctgtatag ggaatggttt gtgaatgggg 114540 ccagggaggg gggctgtgca gagcagagac gggagtcgag ttctctcaaa agctgtgtct 114600 gagggggcca aaccccacag tgagaatctg cgatgtgaca tccaggcaga aggagacctc 114660 catecetgge eeggggteee cagaggagat egtgggeeet getgageeae eecaegeett 114720 agggacagtg tgctataatt ccggggaatc taatcttttg gcttccccag gccacactgg 114780 aaaaagaaat gtcttgggcc acacagaaaa tacactaaca ttaatgatac atgatgagct 114840 aaaaaaaaa tcacaaaaaa aatctcataa ggtttttttt tcctttttt ctttcttctt 114900 ttcaagacag agtttcgttc tgttgcccag gctggagtac aatggcacaa tctctgctca 114960 ctgcaagete tgccteeegg gttcaegeea tteteetgee teageeteee gagtagetgg 115020 gactacaggc ggccaccacc atgcctggct aattttttgt atttttagta gagatggggt 115080 ttcaccatgt tagccaggat ggtctcgatc tcctgacctc gtgatccgcc cgtctcggcc 115140 tcccaaagtg ctgagattat aggcgtgagc caccacgcct ggccaaaaat ctcataaggg 115200 ttaaagaaag tttacgaatt tgtattgggc cgcatttaaa gccgtcctgg gctgcatgtg 115260 gcctgtgggt tggacaagct tgctctaatc acttgcacgt agagggctgg gttccctgcc 115320 caggacatag agcacctcct caggacctca gagctctggg aggcaggaga gtgggaaact 115380 gaggtgtgga cggaggcctc tgtgcttggc caggagggga cgcagggaag agactttgtc 115440 actgecegae gttcaceegg caggetactg agetgeettg gggaagaeee tgeeteegga 115500

PTS-0012 -153- PATENT

caagagette	ctccaaagca	atgacactcc	ttccccagtg	ccctgggctt	tggtccaggg	115560
			ctaagggatg			
			ccgaactcag			
			agagtagctt			
			gagccctgga			
			cctgagcagg			
			cgatctttct			
			aggtgatggt			
			tcacgttccc			
			aaaaggtgtt			
			gcaggtctga			
			gggctgctat			
			tggccacttg			
			tgatagcact			
			gccatgtgac			
			cagggcctcc			
			gtgcaagtga			
			ctggtctctt			
			aggaaatgtc			
			gagaagggcc			
			ggaagcctgc			
			atcctcggat			
cggggcctgc	tggcctcctg	cccagccato	tggagggcca	ggcaggtcgg	gcactggtgc	116880
tcactcagco	tccctccgtg	ggagcccaca	gtccagcctc	actagcagcc	agccgctgct	116940
			gtcgccggga			
			ggccttgacc			
			r cctgggccca			
			gecagegace			
			agececetee			
			g cccagcagcc			
			c cctgtgtggg			
			g gattttaaag			
			g aagccgccto			
			c tccaaggaad			
			ttcccacac			
			a gtggggatgg			
			c aggtctcac			
			c tgatcgcato			
gtcgctgcc	c gccccatac	c ccttcggtc	t ccacctccg	t gggcaactg	gtggactca	g 117840

PTS-0012 -154-

ggtggaggcc ctccctcctt gcccacaagg ccctggcctg cctggcccct tgctccagct 117900 gccatgctcc cctcctcct ccctccttc cttccatctg ggagatagat cagtgcaggc 117960 cccgccctgg cctcctgggc ccatggagga ggagcctcag gttgctgagc acctgggaat 118020 cccgagaacc ccagggagag ctgcacggcc aggcttcctg gagccccgtg tgcccgacgg 118080 gtctcctgcc agctcctcaa aggccacgtg gagcgtcctt gcaaactggg ggtggattct 118140 · ggaagcacta cgtgcctggc atcccagtga agttttcgta ggcaggagtg gcgtgcctca 118200 aagggactgg agggaccagc ttttctaggt ccctctgagg gtcactgact gctttctgac 118260 acctctaatg ccaaaccaga cgtgtggcct gcaagtcccc atcttctttg gacaaacctt 118320 tgtgtggacc tgaggcctaa agcccacttt gtgtcaagcc caggcccgga gcagctccag 118380 gtggccggta gacacaaagt gtccccagag aatggtaaag ccgttgtttt gcacccacaa 118440 ggctggttgg actgtgcctg gagaggctgc aggtgggaga aggtggctgg atgaggctgc 118500 atgttggacg tggcccctgg gccttccccc agcatcttgg ggtcagagga gaaaggctgc 118560 cgtccgtgtg tcttaagcag cattcccctg aatcacgttt ctcagagatg gggacctgcc 118620 cacccagct tggtggacac cctgctcggg cttcctggtt gtaggaggga ggccaggagg 118680 atgaggcact tattttaaag gacagctgtt cccagcgcct gcccctcatg agctgataac 118740 cgtagaagga gagagaccga gcagagtggg gaaaaatctc tccatgcctg aaaaaccagt 118800 gtggagaaac aagccctata aatagcccat cttctgagtg acgacgtctc cctcagggag 118860 tggacggcac ggcggactct aggttagggc tccccaggat ggaagcattt cagaaactgg 118920 ccatcgagca gtcctccttc aggatgaggg gattagaagt etttgtgctg gggagtaaac 118980 ttcatgatgt tctttggctg agaggcagcc caggacaagg cttcagtaga gcttccagag 119040 gggtctggag caggagctgc caacggagag gccggcgggg acagtcaggt cttgacagtg 119100 agtgaggctg acgtctggct gggagccagg tggaccagcc agtctgtgcc cgtctgcggg 119160 ggcagctgct gtccggagcc gggctgccat tgctgagcgc aggaaggagc tctcttgaat 119220 tgttaaagga gaagtcgggc acccacatcc cctgaattgc aaatattggc atctgattat 119280 aaaacgtett tetegattge catgtttgtg ggetgggttt ageetgggge egeetgggag 119340 ccccctggc ggtcgtactt ggcaggaggc tgccagctgg gggctttctg ttgagggcag 119400 tgagatttga ggcccagctc agaggcctca cagaatgccc attggaggtg gggtcctggc 119460 ttggcactgg ccagagcatt gcagaaacat tttacattgt aaggggaacg gctgtgggca 119520 ttggcaagct gggctccatg cccgcaagtg ggggcatcgt ggcatcactt tctgaggctg 119580 ccccttttac tcgtcccatt tggccggggt tcatggaggg ctggttgctc cggctttcag 119640 acccaatcta catggaaaag accaaggcag agaaaagaag gaaacccagg aagaggcgcg 119700 tggggcgtgg ggcgtggggc ggtcccgatg cacaaggctt ggaagaggct attcaggacc 119760 tcaaatatca gggaagagaa ggctgaagcc agggaaaaga gaacccggac ctatgtttgg 119820 ggaaggettt gagtttgeec ggetgtggge tggagteett gttteecata agggetgggg 119880 gtgacatggc gacgtcagcg ctgtcattaa ccatagcaac agcggtgact gtgataacag 119940 gaaagacttc catcatgttt gctctgggcc aggcctcgtc ccaagtactt tacctatgta 120000 ttaactgatc tgatctttgt gataatcctg tgaagtatgt acaattagca ttcccatttt 120060 acagatgaga aaactgagac acagaggtta ggtcatctgt ccgaggtcac ccagccggta 120120 cgtggaagag gcaggatatg agcccaggat gtgagctcct ggctcctgcc ctgaatgcct 120180

-155- PATENT


PTS-0012

gtgctgtacc ctgctcagcg tcctctttct ctgtcccaca gacagtggct gagtgcgtcc 120240 tctattacta cctgactaag aagaatgaga actataagag cctggtgaga cggagctatc 120300 ggcgccgcgg caagagccag gtaagaggca aggtgggggt gactgtcctt gcaggctccc 120360 tgcatgctca gcggccactt gcttggtggc cagcaccccg catggctggc ggtaactgtc 120420 tccatgagtt gttgttgctt ggccaccggc agtgtgagtg caggctcccc tccgtggtag 120480 cagcagatgt ggggagaccc cctctggggt gctcaccctg ccaggctatc tcgagcctcc 120540 cgtagtggcc aggaagatag ctggggagaa/acagccacgg gcctcctcag cctgtgaaat 120600 cccagactcc tgactgggtg acctgtgatc tctgtgcgta aaaaggctac attccaaaag 120660 taagagette eeaggatgae ttggggtagt teacaaaett catgtttaaa atgttaatgg 120720 ttgtgtgtgt ttatcttaat acatacttga aagaaaaaat agccagtact tcagctcgcc 120780 gttttttcag acgccgttgc ttgggatgag actgaaagat tatttacgct agagcagagg 120840 ctggcagact gggactctgg ggctaatccg gcccaccatc tgttcttgtg aataaagttt 120900 tattggaaca cagccatgcc tgtttgttta catattacca tggcagcgtc cttgctgctc 120960 tggtggagtt gcatggttgt gaccaaaagt gtatggcgta cagggtctca aatgtttact 121020 agctggccct tcatagaaaa agtttgcttt ttcctccgag ttagaggaaa aggagttggt 121080 ttgaaaaaat atccagtaaa taatggtaga gatgagaggc tcagtggcac gcctttgaaa 121140 gggggatcct gggcgctcgg tgtttgggag aatttgtttt gcatccgggc tcttgaagca 121200 tcgtctcaga gcagatgctg ggagcaccac acagaggagg cgggtggagg cagtgggcac 121260 tetggeaget getggattgg agteggtega ggeattteet teetggggte eteagtgget 121320 ggggtggggg ccgggtgaga gtgacaaagg ccaagaatag cacgagccgc gtggagcgtc 121380 cttgcaaact gggggtggat tctggaagca ctacgtgcct ggcatcccag tgaagttttc 121440 gtaggcagga gtggcatgcc tcaaagggac tggagggacc agcttttcta ggtccctctg 121500 agggtcactg actgctttct gacaccccta atgccaagcc agacgtgtgg cctacaagtc 121560 cccatcttct ttggacaaac ctttgtgtgg acctgaggcc taaagcccac tttgtgtcaa 121620 gcccaggccc ggagcagctc caggtggccg gtagacacaa agtgtcccca gagaatggta 121680 aagccgttgt tttgcaccca caaggctggt tggactgtgc ctggagaggc tgcaggtggg 121740 agaaggtggc tggtactccc tatagtggca ccctctagcc cctccccaga gctgccccgc 121800 cttccctttc ccaggctgcc agaggtcgag acccataagg tgttgagacc agccatcacg 121860 ggttgggggc ggggtcccag tgtctgccgt gaaacagcca ctttcctaca gcctaagaaa 121920 acteceatga gggaaacgag getgttgtea ggageatgag eeaceeeteg eegeatteee 121980 aacatccagc cacgatgcct ggggctgaac tcggtcctta tccgcaggga tcgtggaagg 122040 gtggctgcgt ttgtggagag ggttttcttg tctagttttc tgtagccaga gttgaccagt 122100 ctgcttgccc ttctaacaga tgtgtaaaac caaggccgag tggcacagag catgtattcc 122160 aaagacgtag ctatgttcta tttttgtttt tttgggattt gtttttttt ttttttgaga 122220 tggagtttca caccgtcgcc caggtcagag tgcagtggcg cgatcccagc tcactgcaac 122280 ctctgcctcc tgggttagag tgattctcat gcctcagcct cccaagtagg cggcattaca 122340 ggtgcgtgcc actgcatcct gctaattttt tgtatttata atagagacag ggtttcacta 122400 tgttgcccag gctggtctcg aactcctgac ctagatgatc cacctgcctt ggcctcccaa 122460 agtgctggga ttacaggcat gagccactgt gctcagccgc tacggtgttt ttgaaattga 122520 -156-

PTS-0012

ACT FULLIANT PATENT

agtgcattca ggaattttct agactgagag gcaaaaaggt aagtgccagt cagggagtat 122580 atagatgctg aggtatgaga ggcagcaggg agcggtgggg attatgacaa aggaagggtg 122640 gctaacggcc tcaagaggta tttggaaaac atcatcaggc gtctgttggg cccctactgt 122700 atgctcattc tcttgctggc cttcccagtt cccctcccat gacctgtttg ggggcattga 122760 ggctgggctt gtggtgggag cccttcctgg tagctgggct gggggctctg aagagcagag 122820 gcccatcccc tccccctgtg tgagagccac atttgcacag agggaggtgg ggagaccatg 122880 gtaatttaag aagggtgggg ggtgtcggtg cccggcatat cctgttgtag aggcctggcc 122940 tgtactgtgg tagagtgagt gtccagtaga gtgagtgtcc ggcttgctct tcgtggagtg 123000 agtgtccggc ctgctctccg tggagtgagt gtccggcctg ctgtccgtgg agtgagtgtc 123060 cggcctgctg tccgtggagt gagtgtccgg cctgctctgc gtggagtgag tgtccggcct 123120 geteteegtg gagtgagtgt etggtetget eteegtggag tgaetgteeg geetgetete 123180 cgtggagtga ctgtccggcc tgctctccgt ggagtgagtg tccggcttgc tctcaggagt 123240 gagtgtccgg cttgctctgg gcggagcgaa tgtccagctt gctgactcat ccattgattg 123300 agcatttatt gtgtgcagga catggggagc ttcatgctgg ttgttcagag ccattgtaaa 123360 caggtggctt caagacagtg ccgcgggtct ccctgtgcgg cgggtctatc tgtgccacgg 123420 ggtctccctg ggccacgggg tctccctgtg ccgcggggtc tatctgtgct gcggggtctc 123480 ectgtgccac gggtctatct gtgctgcggg gactccctgt gccgcggggt ctatctgtgc 123540 cgcggggact ccctgtgccg cgggttctat ctgtgccgcg gggactccct gtgtcgcggg 123600 tetecetgtg etgtggggte teeetgtgee aegggtetat etgtgeegeg gggaeteeet 123660 gtgccgcggg gtctatctgt gccgtgggga ctccctgtgc cgcggggctc tatctgtgcc 123720 gegggtetee etgtgeegeg gggteteeet gtgeegeegg teteeetggg aggtggeatt 123780 ggtggcacat ccttgaagac tccgtagaat aaaaggcccc aaagatgagg ttgaggagca 123840 gccccacagg cggacaggga tggggccctc aagtgcaaag gcagggagca tgagagacag 123900 cgcgtgtctt caggaacagc agggggcctg agtctttgga ttcgtggggg tcccggtacc 123960 teccagggee ttaaaggaae aaagaaaggg agattatgtg accetette ttttgeteat 124020 ttttgatggg taaatagaga tgttttttt taccctgtga aaaatagaag tgcaaactcg 124080 ataaataaca gctcacactt gccttcgtgt ctggggaggg agtagggagt ggtgaggcct 124140 gtggctcact gcagagcttg ggccccgtct cagctccagt ggacgcttgg ccattggccc 124200 tgaattgcca ggtgttctga tctttgatga cgagctggaa atccagtttt atgtgaaact 124260 gcctgatttt aaatcttagg tcacattttt taaaaaggga aaaaacagct caacactgta 124320 tatgccacac aactettaet tgetgttgaa atcaceeeca geeecaagta gaagaeetet 124380 gggttagact acagtgagac caggggagga gggcattaga tgtctggggc caggctgggg 124440 caccggggaa gccctagaat gttccatagc agggaggaaa catgccctc tttacaccgg 124500 agatgtcctg gtttagccgt ggtatctgcg gtgcctggga gttggtgggg ctttgctggt 124560 gagtttttat cccctgctga agctgccgtt ccaggcaggg gctcccagga tggggaaatg 124620 atgcttgtct gctctgcgtc tctcagaaag atggcagaaa gcaagccggg caggaggtcc 124680 ctgtctgtct ccagggctcg ccccttcctc ggatcagctg cgtttgctaa ggaggtggtg 124740 gegtggeetg ggeeetgeea eeceecaeag geetggttea caaceaeggg gtaaaeaggg 124800 gttetcaagt getaaetetg gggetgagag teetetetge eecatggeag caaggaaaat 124860



PTS-0012 -157-

cageggeage tteaggetea geetgtettg ttaagtggag atgeagtgae tgeeggeage 124920 tgagcgtctc tgtctgtggc tgtatttgtg gagccactga cactgctgat cagtctgccc 124980 caggtgaggg cacagcaggc ctggggtggg cccagcaccg ctgcttggaa ggctgcggtg 125040 acggacggga ggtgcaggca gtggtggtct ctgagtgcgc caaggctgtg agcacacaga 125100 acctgcaget cettaaggag ggtggggagg tgaactgaga ceaeteecca eccaetacce 125160 cgctgcctca gcatggctgg cacctgcagg ctgggacagg catctgggac tcttggtgac 125220 tgtgggctgg ggagccactg ccctgtgctc caggcaatgc aggcacccag ggtacctctg 125280 tgggccggtt cttctttctg acctatcctg gcagctcagg ccttgtgatc agatgggaat 125340 ccctggccat ggagcacacg agcccctgcc cagccccact cccctcacag ctgccccagg 125400 acacttgtcc atgettetet eteceteata ggtttetgag tgageagaca cageccette 125460 cccctaccgt gacatgggcc ccctccccag gcaccacggg aagatggaga acccgggtct 125520 tcccagccag tgagcccacc caccctcagg ggtagggtgc ccactgccag gagatgctgt 125580 ctgcctcttc cccgatgtcg tctagtggga gggagctcaa gctcccttct ccgtgatgtt 125640 tacctggagg gcagcaggtc gggttctccc tcccttcctg ggccctctag ttttggaaga 125700 agacttaggt tatctcagcc aatatgcatt ggaccccttg atggctggtg ggggatggga 125760 cetgggagte cagtgagaca tgggageett gteaaaatte caggggeace tggeeetget 125820 gtgtgatggg gatgggtgct gctggccgct atggtggcga tggcgatgat ggtgatgatg 125880 acggcgacag tgatggtgcc ggccaacagt catgcagcac tatcgccaca cactgtgatg 125940 atttcaacct cactagtgtt ggggacaggt gtgtaattat ccccactggc cagatgagac 126000 agaggcacag ggaggtgagg aagcttccaa ggagcctgct gagtggcaga ctgagggttc 126060 tagcctggca catgcagccc ggggagttgg agggaggccc agccgtcccc tcggcagcac 126120 actggccata aagccagcct tctggaagcc agccctgatc cgccaggtag gacaggcctc 126180 tcctgtggtc tgtgcaggag ccctgcgagg gcaggcggca gaggggctca tgatgaggct 126240 ccatgtcagt ggggagtcgg atgctggatg cggggacccc aggtgagcca ggctggatct 126300 gtgctgtgga gacaccctct gatatggggt gggtgggagt cctggggttgg ggggggctca 126360 gtaccccccg ccaccacctg tgtctcttcc cctgccatgt gtccctcagc tcctggggac 126420 agcagetgge caetgtetet ttetetetea gtgeeteege egttaceata tatgtetttg 126480 gggagttget gagggetett ceteatetee eteteteeg cettgtetet ceteceeate 126540 totgtotoco gototgogto tottgogoto totcagoaco cocactocoa gtgcacageo 126600 cctctctcct gggttgctgt ggaggctgct gtgggtggcc gcagagaggc tgtggtgctt 126660 gtggtcctgg cgcggtgccc gtggctccag gccacatctc tgctgaagac aggcacgagt 126720 ggcctctctc atgtcaccag gacagaggcc gctcgcaggg gccttcctgc ctcgtgtccc 126780 caagettget egececacag accececagg aggtgeceat eggatgeaca gtatatgeat 126840 gttcatccgg gggcatttat tcagtgccta ctgtatgcca gggttgtcag actctacctt 126900 cagatgcgaa tccgacctta atccttccga aaatagggta aagggatcag ccgcgcctgg 126960 cccatctcaa caccccagac tgccctgatt ccacgctgca gaggtggaca cagggtagga 127020 cttccgaggt gtcggggagt gggcacgacc gccctccca gggtcaacag cgcccacgtg 127080 cctcctgtgg gtttcctgag ttggggggtg catggcccag gaccaaggac atgggtgccc 127140 ctcctttcgc catttgtcaa ggtgggattg aaatggaggc tgtggtggga tcccgaggga 127200

PTS-0012 -158-

ggggaageet gtgggetggg ggtgagaagt gacteeaggg acaetggaee gtgeaettte 127260 cccggcagcg aggcttccga cttcctcaga caccactgac cacgctggga tggctgtagc 127320 cagcatcctg gggctgtgcc ctcctggagt tccccctgtc tgaggccaag gtctgctttg 127380 tgaggggacg tgtcccagtc tgagtcctca gatgtgagtg catgtcggaa tcaccggaag 127440 ggctggggaa acccagtcac tgggccgcac ccctcacccc acaataaggc cgagatccaa 127500 gactetgeat ttecaaggag eteceaggeg ttggtetagg aegetgetga gaaceteggt 127560 gctgggggtc agcccctgag cagggagcag ggtggctgaa ggggttgtta agcccgaggt 127620 gggctacccc acagcccaga ccacccatgg gagtacactc aagctggaac ggcccttccc 127680 aggtgtttgg ggtgggcaac ggcctccctg gccagggccc aacttggatg aggcagctct 127740 gagetgagtt attgtcageg egeetgacag eegatggeag ecageeeett etagaaggga 127800 ggtctggcca gtccagccca ggaggcagcc tgtgcatctg catgtttgca aagccacgct 127860 tcatagatgc tgtggccacc cgaatgctta accacagccc agcagcaaga cgccagtgcc 127920 accepted ctcaaggaca ccteccetet cteaagtect tecaccagec ccttctccec 127980 cctgtcaccc cgacaccatg tgccctgtac caaagcagtt tgtgtgtcat ttcgatggtt 128040 acgtttctga aacttggatg gttataaagt ggaatatgaa agtccttgat taaaagtgct 128100 ggccatggga cgtctctgga ctcagacccg cgctgtgtgc ggccgccttc actctggccc 128160 accttggcat ccatggcact ggtgcttagc cttgtggccg gctggaggcg agggatgtgc 128220 atggctgttt agagtggtgg gattgccttc ttgtttaatg gagggtgcca tcctctttct 128280 ggaagettet etgtgttetg acaeggggat geaggeeegg geataggett ttggaatget 128340 agcccctcca cacccaccc catgagaccc cacaggcctg agctttggca agggagggcc 128400 gagececcae eteceggaae etggeceetg agateggeeg tgageggett ttgageetgg 128460 aggetgggtt gaggeeegag cateetetet tgggeteega geeceateae caecaceetg 128520 aggtgaatca cggactgtgg ggcggtgcgg ggaacagctc aagcgctggc acagtggttt 128580 atagtccatg attcattgat ggaagggccg cgttatccta gtgaattgca aaaccagagc 128640 ccaggaatgc tggggcctga ctgcagaccg ttggggagcg aggatgtgag gctggctagg 128700 ccaggtggca gggcccggcc cctggtagcc aatatggcct tcccgcagcg atgggggttc 128760 atgtggccaa gggggcctct ctttctgcag agatgggaca ctgagacggg aacagcccgt 128820 cctgggctcc agtcatccgg cctgggtcca agaaggaagc ccagggaggc cgaggctccg 128880 eccegactg etgecgteea etetecactg trececater etgreeeter gggtetgete 128940 tgcccaagcc cctggctctg aatctcctgc atttttctag gtttctctct ctctctct 129000 ctctgtgtgt gtatgcgcgc acacgggtgg ctacgtctgt ttctcttccc atgtcttcct 129060 ccctctttct atttctctgt gtctttatct ctgtgtccac gtctcgtctg tttctctgca 129120 tgtgctttcc cgtctctctc tctttccccc atctaagtct tttaactctg tctctagctc 129180 tetetetete teteceette tetetetece ceatetetee tetteeteet eeceegeece 129240 ctcccctcct caccctgtcc ctgggtctct cctctcaccc ttcctcctcc aggtctctgc 129300 tecteccea ectttetece tttetetete etecetecca etacagecce etgteccetg 129360 cctcctccgt ctgtcctctc ccagctcttt gcggagggac tggtgacctt gttccccttg 129420 ctgtggcact cggacagttt gcacagggaa cagtatgacc gggaaggctg ttccagggca 129480 ggagcagcca ggcttggtcc ctggggaggg gcagccgctg tgcggtgggt gttggtattc 129540

PTS-0012 -159- PATENT

agggctagct	gcctgcccta	ggtgctgaag	tcacttgatg	gtggggaccg	gtggcagggc	129600
gggccagatc	accccaggct	gtgtttcagc	tcccaggccg	agggcttgta	tcttgtttca	129660
aacctgctgc	ctgcttgggg	ctgggccagg	atgggcccac	agccttccgg	tggtgccgac	129720
tttcccaggc	ctgccagagg	aggtggctgg	gtcctctcca	gtcagggcca	gctgggctgg	129780
gcaggattgg	gtgcagtttt	agggttgaag	tgagcagatg	tctctggttt	cctgcccagc	129840
tttgtgctag	gtggggagac	agttgggggc	tccccacgtc	ctgcagtcag	ggatgttgct	129900 ·
cccagggaag	gcagctggtg	agtgggccgg	agcccaggga	tggagcagac	cgggctgcag	129960
gttgaggaaa	agaccaacat	ggcctttgca	tgggccagga	tgcagtgcag	gggcgatcgc	130020
atcagagagg	cagaaggagg	tggaaaatgt	gagcgctccc	caggcagcag	atcggtcagg	130080
atcgaggggg	cctgggggac	atctcaagct	gggctgctgg	agtcaggaag	tagttcccag	130140
aacagcagcc	ttggtgtctg	tggcagctgg	aggcactgag	ggaggggccc	tggcaggctc	130200
	ggttgtccct					
	attccctcgt					
	cagcactttg					
	gggcaacatg					
	·cttgctgctg					
tgagcccaga	aagtggaggc	tgcagtgagc	cgtgatcatg	ccactgtgca	cctcagcctg	130560
ggcaacagag	caagaccctg	cgtccaaaaa	aaagggcaaa	caaggtccct	ggagctgaca	130620
	acttggacca					
	catgggggac					
	ggcaaacatg					
	gagctggccg					
	agggactggc					
cacgtgcaaa	ggccctgaag	caggaacatg	cgggccatct	tccaggagac	aggtggtggg	130980
catggggaga	gctgccctga	gggaggtggg	ccagggccag	gaatcctggc	ctcagagcag	131040
	tgtggatttg					
	gctggcacag					
	: tcacgttctg					
	g ctttctgtag					
taaataaato	c ctctcaccgt	gcccagtgcc	e acgtgacaac	gtgctgccgc	tgacttggaa	131340
ctggggaaag	g atgcccctag	caccaggcto	f tettateetg	ttctcaccct	gtgcatggag	131400
	g tcacctccac					
	g cccttggagt					
attttttag	g agatggagtd	tcgctctgtc	acccaggeta	gagtgcagtg	gtgcagttga	131580
agctcgctg	c agccttgato	tcccaggtt	aagctttcct	cccaccttag	cctcctgagt	131640
agctgggact	t acagggatgo	accacctaat	taaaattago	: accaccagct	: aatttgtagt	131700
gacagggtc	t cactgtgtt	g cccaggctg	g tctgaactco	gagccctaga	caatcctcct	131760
	t cccaaagca					
	t aaggttaag					

PTS-0012 -160- PATENT

gctccagcac	gccttggtat	atctttttt	atttatttt	gtttgagaca	gagtctcact	131940
ctgtcaccca	ggctgcagtg	cagtggcgcg	atcttggctc	actgcaagct	ccgcctcccg	132000
ggttcacacc	attctcctgc	ctcagcctcc	tgagtagctg	ggactacagg	cgcccgccac	132060
caagcccagc	taattgtttg	tatttttagt	agagatgggg	tttcaccgtg	ttagccagga	132120
tggtctcgat	ttcctgacct	catgatccgc	cggcctcggc	ctcccaaagt	gctgggatta	132180
caggcgtgag	ccaccgcgcc	ccgccacgcc	ttggtatatc	ttataaaaag	acaaccctta	132240
aacgcactga	gatggcctcc	cctgactgca	ttttccccag	caaggacagg	agactgaatc	132300
cgagggacag	agagcaggtg	ttagggaaga	gctgccagca	acagggaacc	ctgttctgcc	132360
			accaacccca			
			aggatgcgcc			
atggtagatg	ctcagtgaag	tgtttgttga	atgagtgcat	gagattgagc	cacagacggt	132540
gttgctgggt	tttgggaagt	tctcctgaca	catttgtaag	gacttagcat	ctgagaatta	132600
			agcaccttct			
ttcccggaat	ccaccgtctt	ccttcctgcg	acctgctatt	ggattgctct	ttaacatggg	132720
gtgggtcatg	tgactccctg	cgacccctgc	accttttgag	aaaggtcccc	gggggctccc	132780
accgccctca	gaatgcctcc	tgtatttctg	agcatgggtg	ttagccctgg	ccaggccctc	132840
cagccatgcc	ccaaagtgcc	acttggtagg	cacaggggcc	attttcccat	tgccatgccg	132900
cagaggcctc	ctgctctgcc	aaagcccctt	ccctcgccct	gcatgtcagc	acgccttgct	132960
gcctcatctg	catcatgaat	gtgccttttg	aatgtgtcct	cgtcaccggc	gcctccatct	133020
			ccatacagtt			
			gctggcggaa			
			ggctgtgaac			
agggcacctg	gctgtaggac	cttctaggaa	atgctgtgtg	accttggatg	agttacttaa	133260
actccctctg	tctttgcatt	ctcatccata	aaactgggat	gataccagtt	gttgggagga	133320
ttcaaataac	aggtaggaag	tgattaggag	g aagaaggcct	catcaaatgt	gctcagcgag	133380
cttttgctgt	tttaattaa	gatattttt	tgcatagccc	ccagtctggg	gcttctgcad	: 133440
aggcccagto	atgtgctgct	tgtctggcag	g gctgagggtt	atgggttcag	tgtccagato	: 133500
			c cagtggctct			
gggtttgtca	a cagagttgta	ctgtggtttg	g gggggatgtt	tctgaccacg	g cacagggcad	: 133620
			a tctgaaaggo			
agggcgggg	t cctttgagat	agtggagct	g gcttctagtt	ctttctgatt	ctcctttcag	g 133740
teceteac	g ttgagggaat	ggtgcccaca	a ggcgttttct	gctgcacaga	a gtcctttate	133800
			c tcactcct <b>c</b> a			
			t gcagagtcco			
			c acctgcaggt			
			c aaatccggc			
			t ttgttgata			
			a gacggcatad			
			t ggttctcaa			

-161- PATENT

PTS-0012

acctggaatt taacatacga acgcctgggt ctccgcccag agatttggat gtcattggtg 134280 tggggtgcgg cctgggcatc aggacttcgc agggctcccc acgagatctg agtgtgcagc 134340 caatgtcatg ggaccttgag aaccatggcc cccagtggcc cgggaagccc agcaggtgca 134400 gttctgccgc tctatggaca ggcccaagac ccagcagccc agcctcgcca gtgtcggctg 134460 ctgcacttgc tgccctaaaa catagaaggc tttgggggct gagccggctg ccgggtcccc 134520 ccagctecte agggggagtt gtgagetggg acetecetet ecetgeataa teteccagea 134580 gegagtatga geggeeetca ateagteeet eggeeteeeg ggtggeeaet gegagaeeet 134640 gcagatgttc atcattaagg ctgccggggt ctgtcccact ggaaagcata ttttaaggcc 134700 agggctgctc tgctattcct ccttttcatc ttcccccacc ggactcactc agcgtgggct 134760 gcagggatgc ctctcccaca ggagatgttg aggccacagg aagtgaggag cctgtgcaca 134820 gggccctagg ccttggctgc agggtggccc agaaggtgct gtgctagtgg gtgttgctgc 134880 acccactcca accagagggt gagggtggaa ggcacccctg ccctgggggc ttgttaacat 134940 gtcagggaag aggaggcggc aaggcttggt gccaggattg cactcggtgc ctcagtttcc 135000 tgttctgtaa gatggacagg tgggtgggta ggggagacca tgtgggacgg agccaggcac 135060 · gtggtgccat gagcgatcga atatggagac atagggggtg acgttccagg agcgaggggg 135120 ttgtgggcag gccctggcgg ggcttgtaga gtctggagtg ggaggcaggt agggataggt 135180 agatggggcg tgctggcaag tctgcagaac acaaactgta gatcctggct gggggttggc 135240 tgagactete ageggggget etgggggeag eagggeecea teeceeacae tetgggeegt 135300 cageetttge teegagaeet egaagetttg cetetetgag eetgttteet eetetgeaga 135360 atgtgaccag tgatcactgc tctcctgttt ctgaggctgg gatagtgttt gcaaagcact 135420 tggcatggtg caggggtgtt actcgtggcg ttttcatctc catcaggact tcagaggggc 135480 caggageegg eccatagaaa atggaeagea eagtgetggg cacatagtea getetegggg 135540 atctgtgggg attttctcct ctgtaccagc ctcttcttcc ttggggcttt tctgaggact 135600 tggaggagag ctgcggtggg gaaggctcgt agctcagggc ctggcccaga tgcatccctc 135660 teccaactgg eccetgeetg eggeetgatg ggtgtggage tgcatttact ggeeatgeeg 135720 gagcagacat tagcctgatt cgttggtcca tgggtgaggc cccagggggt catggagccc 135780 ccaccagect aggtgcaggg gctgatgggc agatgctctg ggaaggagge tccgtggctg 135840 ctgctcccat cgggagggac gccacagccc aggtggggac ttcttggcac agacgtagct 135900 gaatgtggtc tcaggagaca ccaagcccgt gtgattcaaa agccccggcc ctgcccagac 135960 tctggccctg ggctgttgcc agggacatct gacccgggga gacggcatcc atgccgggca 136020 gcccaggggc caaggetete tecccageca gccacateae tectecetee eegggteeet 136080 acctctgccc acatcgggca aatgtggaca gaaaggatac tgtgtaggaa caagccaaaa 136140 aaaccetece tgccccaget tecaceteca aaagaggett cacetgeegg etgtttaaac 136200 gttacgtttg agggttcgag gtcaggagag ggagaacagg ttgatcccag gatgccgggc 136260 acctgttggg gaatcagcag caacctgggg gccggggggt ctgttccagg tcgggcaact 136320 ctgccccttc ctggctcctc ttacagaaca tggtggcaag ggattcctgg ggaaaagagg 136380 cagatgcagg cccgaggctc tgccctggac ctggcagcag cctcagggag cccacggttg 136440 cctgcagcag tcagacactt gctctgtttt tctgccccat cctaaatgaa aagaggctgg 136500 agagagcgtt gtgtgcgggt caggcacctg ttcctggcag gaaggaaagg caagagaagg 136560

-162- PATENT

gagtetetet caceteceg atecetecte ttecatetge ttggagttet tgetecetgg 136620 tttgaaacat tgccgtgact gtgcccctgg tacacattaa aaggctttgg ggtttatttt 136680 tatttcgctt ggctcagagg gatggaaaga tggtctggtt tggcagctgc ctgcagggag 136740 gaccttgggg tgtccaagaa aatcagtgtg tgctttaaaa gaaatcaggc gggatgacag 136800 gaaatcggga ggcggtgcca ggaggagctc acactccctc ctctatctcg gtgaggggag 136860 gggcggtagg cccagagtgg ctgggacagg tcggggaggc agatgacagg aagaggccca 136920 agtaaggagg ctggcttggc tcccagcctc tctgatctgc tctgtaaaat gggcttgttc 136980 tgtcccctg gggtgctggc atgcgaggga gaccaggccc aggcagcaga gcagccacct 137040 ccacgcaggc ctggggcctt cctgggctct ggggaatcag gggcatcccc ccacctcccc 137100 gttttacaga ctcggagacc gaggcttaga gaggtggcct gagctctgtc gggggcaggg 137160 cagggctggg gcatcagggg tgtgtcccca gcttcccaga tgctcaggca cccctgccga 137220 ggctcaccag ggcacctctc tcaacccaga tcacatctgc ccctcttaaa tatccgggcc 137280 agatgcggat gtaagcatgg tgaggattct ctcatttcaa cctcccagcc ctcagctgag 137340 gcacaggcat gctgaatacc cccattgtca aggcgaagga gtcggcacag agaggttaag 137400 acceteatee aageteacae agecaetgtg tggaaaggge aggaattgaa gecageaett 137460 ctgacaccaa tgcttcctgc ccctcacccc gactccgcct ccccaggccc ctagggcggc 137520 aagaccccag geegtgeete teeccatete atgecagtgg ggeetggett eeeggttgtt 137580 tatgacctct tctgggtgga ctccacgggt tttcctcctc ctcccccagc tcaggctgag 137640 cccaggtgca gagattcacc tgttcacggt tttcttccct ccccactccc ctctgccctc 137700 ccccggggtc tgacagcagc agcaacaaca gcagcagcag cagcagcagc agcagcagca 137760 gcagcccatg ccccgcagca gccaggagga gaaagatgag aaggagaagg aaaaggaggc 137820 ggagaaggag gaggagaagc cggaggtgga gaacgacaag gaagacctcc tcaagtaagg 137880 cagcctgctg tecectgcag ggeeeggeeg etgaeecaae eegggtggea eaeggttetg 137940 ggggaccctt tgtagagacg ggtggggtgc ccaccaattg cctgtgagca ggggggaggg 138000 ctttctgctc gtttgcccct gacagccccc cttccggaag cccacccatc gccctactcc 138060 tectecetgg etececete tecteegee tegettett tetecaacee tetggagaet 138120 ttagagactg atagctcatt tgagctccac tcctgagcta ataaatccag gcaatgactt 138180 tggaactete tgeeteeetg etteeteeeg etettteete etgaggegee aggaaggggg 138240 aaagggggat cagaggccct cctggaagga ctaggtgtgc aggcggctgc tgtcaccttt 138300 agaatcatcg atggcagtgt gagttcttgc agatcaaggc acagcctcac cgcgggggcc 138360 gtgacagcct cctgtgcctg ccaggggctg caggagtgca gccagctgga gaaagggggg 138420 cggcacgact tagcgccagg tacctgtaat gggctcagga atttggcttc agagaacatc 138480 tggcttcctc accccgtctc ccagacgctt ccagcaaggg cctttcagga agatgaatgg 138540 gaaggcagag gtgatcaatc tgagcctccc gcagtaaaac tctccccagt cacttctgcg 138600 agagccccag ctcgggtatc gaggttgtga gcacccccac acaccacagc taggcctgca 138660 ggctaggcct gcataaaacc agcaagagag tttcctcctg ccaatgtcta agatgatgcc 138720 cggcccttga taatactgaa ggccaatgta ttgcctctta tagagcccct ctggaaatag 138780 ctcctctgtg gcgaataaaa tggccctata aattgctgcc agcccacgcc cccatttagt 138840 tcaccaaata gtcttgcaga cagtatctct ctatttggtg cataaaatgg tcttgcagat 138900

PTS-0012



PATENT '

PTS-0012 -163-

aaccaccagc ccagaagaaa gtagccttgc aggaaagctc ccagtacctc ccatttgggg 138960 aataaaatag ccagccaatt aactacctgt ccacatggcc ttattggtga attaagttga 139020 tagcccaggt tacaccccca tcctttcttt ttctttttt tttttttgag acagggtctt 139080 gttctgtcac ccaggctgga gtgcagtggt ataatcatgg ctcactgcag cctcgacctc 139140 ccaggctcaa gagatccccc taccttagct tcccaagtag ctgggaccat cagcatatgc 139200 caccacgcct ggctaatttt ctgatctttt tcttttgtag agatggagtc ttgctgtgtt 139260 gcccaggctg gtcttaaact cctgggctca agcagtcctc caacttcggc ctcccaaagt 139320 gctgagatta caggtgtgac ccagcacacc tggccgcaac tcccttttga gaaatagcat 139380 ggtgttgtcc tgccagctgt actcccactt ctggtgaaca tggagcccct gcagacttgc 139440 ccctggccac cctcacctca ggcctctccc cctctttcct agcgtccgat tagtgccatg 139500 getggcagee agtgcaaate cagetaaaga aacagtetee tecagtgget gtttgattte 139560 ccggctcggg tgaagccatc ctatctcccc tctctggcct gtagggagaa gacagacgac 139620 acctcagggg aggacaacga cgagaaggag gctgtggcct ccaaaggccg caaaactgcc 139680 aacagccagg gaagacgcaa aggccgcatc acccgctcaa tggctaatga ggccaacagc 139740 gaggaggcca tcaccccca gcagagcgcc gagctgggtg agctgggggc cagggatgcg 139800 ggtggggaag gggctggaga cacggcgggt tgcgctcata tgaaagtttc gtgcaatttg 139860 agttaattgg caacagccaa ggggttggtg taagtcatgg ttggagtcaa atcccagcgc 139920 tacctactgg atgtgctgtg tggcccagca tgaattcctg aacctctctg tgcctcaggg 139980 tcctcatgtt ctcagtggga ggaatcggtg gttacctcta acgtgggggg acagttgtag 140040 tcacttgcta tgtgagaagc acctagaaca gtgcctgggg tgtaggaaga gttcagtggc 140100 ttcaaccaca gtgatttcag agcagggaga tgtcacaaaa aattcccagt gaccagttcc 140160 ggattttttg gttgtcgttt ttaaaacaga agatctggcc acgcttggcc caggttccca 140220 tgaggtggct gttgttggga gccgagtaac caccactcct tcttagaatg tcatgggctc 140280 tacttgtccc cacccagcct ctaccctggt aggcatctgg ttttgtacct tcacttccgt 140340 gggcctcagt ttccccttct gttgagaagg gtgttcatcc ctcactaccc tcccagaaag 140400 tagaaaaaaa tgagatgatg tgagtggcag ttcccaagat tcgccgcagg gggcagcggt 140460 gtgcgtctgt tgtctctact ttgtttagct gttagggtcc agccctccag ccactgcggg 140520 aacccaccca ggggcccaag cgctcaggcc gaagccccgc ctgccagggc tcattctcag 140580 ggtggagatg ctgcttcatc tcccacagac ccccaccgtc ccctggggtc cgggtcatgc 140640 acctgtetet tettetegtg ggatgtagtt tggacetatt teataaatgg eccaetegaa 140700 gctcagagag gaaacgttcc ctctctaaaa atttcattgt agctggggtt agaactcagc 140760 cccattggcc acagagccta tgcagctcct gcagatattt tccagctgcc tcttggtggc 140820 ggtgtacttg gaggcccagg gtgaaagggc tttcttcctg cctgatctct gggggatagtc 140880 ctctcggacc caaggctgat gctgggggct cagccgcagg gtggaaaaca cactcctagg 140940 ccttccatgt ctcttctggc actgggcacc ctcagcaccc ctggcacccc tggcttctgt 141000 aggetteete tgggagteet gtggggagga atgggageat egatgaggte ecagagagge 141060 ccaggctgtg gctgcagaga tgggggaggc tggggtggct ctggcctgtc ggggctgatg 141120 gggctgccca tgggggtggg ggccgtctcc cctcttctgc tggaaccttc cgccactcct 141180 cagccagcct ctgttggaca catactcccc ctggcgcagt tccaggtgct gagtccatgg 141240



PTS-0012 -164- PATENT

adctdacdtc	cctcccaccc	accccactca	tgggtcttaa	gcaactggaa	aggaagggcc	141300
	tccagaggag					
	cagccaaccc					
	ctggatgagt					
	ttactcccc					
	gagtagggtt					
	gggacagccc					
cogcogcogat	cccggcccac	ctgaagettg	tatcccactg	tegecaegte	accaggtgac	141720
	acagagtgca					
	ataaaatggg					
	ccaacggcac					
	ggtgccacgg					
	cagagccgtg					
	aaaagggcag					
	tttcagcctc					
ggeatettet	ccaagaaagg	taaggagees	atagagagatt	taagccttgt	tggtttgcat	142200
	tgaagctcac					
	g aggcctctgg					
ggergrggrg	tttaccttc	cacaaaatco	atctatacaa	ctacactate	aggettgtet	142380
ggagcereas	g agggcgcago	. tagaaaaaaa	: acadettata	ctatacatat	agtcagcgag	142440
ttgtgacttg	g gtgacctctc	. tagagagaga	: ctctqqqcct	tagagacaga	gcagtggcag	142500
tggettetgg	g tatctcggga	gegeeageac	ttaccaacaa	ccatctcggt	agagtcctgg	142560
cacacctgg	g acctgcaggg	cayttagage	accettagag	cccaaagg	cctatcctgg	142620
ggtcagggag	g accegeaggs t getggggett	tagaaaget	tereseatt	dadcacccca	atctgggtga	142680
gctcaagtg	g agtggatgg	. cygadacccs	, ccctaggeee	cagtcatag	agtggctcac	142740
cgggttctg	g agtggatggg a gccagcagg	g gacacccays	, ccaccadaac	r ccatcccgag	r cagatggcct	142800
acggcaggg	a gccagcagg	- accepted	geageagaag	, ctaacccgu	tecectete	142860
tgtgatgtg	c agcaccgtg	g gggccgggg	- ttaacaaca	. ecaageegge	chetagaeet	142920
getgtgetg	t ctcctggcc	a agatetta	atotageac	agegaeeege	atcagataac	: 142980
cggtttgcc	c gtctgttga	g tgggagggt	- gradagat	g tectecete	cheagecate	143040
cctgtgtga	g ggcccatgg	t gggctgagt	g ggagegaard	- ~~~~~~	r ctaagaccas	143100
cctggcctg	g ggcaggggc	t greggager	g gegeateact	gycaycact;	g gaacctacta	143160
ggcagcacc	t ggctcccac	g gcacgctca	e teteggita		g gggcccgcc	143220
ctgtccccg	c ccatgtccc	t gtttgtggg	c aaggagccas	g gaagcagag	a actorogati	- 143280
ccacgggtt	c cggagctgg	t gtgtggggc	r gggagcagg	- ceaggeeee	acceptions	143340
cctgtcccg	t gettggtee	c gtggccctg	c tggagtcgag	g getgtetgt	acytycygu	= 1434NA
tetttgtge	a gaaagetee	a ggtcgtgac	t tatggaggg	a acaaaggcc	- coccesses	~ 1434EU
acgctcttc	g cacataagg	g caggtgtat	c tgagaacag	c ctggatcac	g gggeteetg	a 183530
gcccggccc	c gtcctccac	t gtagttgtg	g ggggtgctg	a gggtcccca	e ageeergage	~ 14326U
agaccccca	e agcccccgc	c ctcaccccg	g gaccetgee	c ctcgccctc	a yayeteete	C 147700

PTS-0012 -165- PATENT

•	gggggcagtc	tgccctccgc	ccccaggct	gaggtgaacc	tggacccaga	gagaccctcg	143640
(	caccattcag	gaaggagggc	ctgcctgccg	ctgcaggtca	ggctctgtgt	gtggtgagtg	143700
1	agaggcatgc	cageggggcc	tgggcactgt	atccagctgg	tagggcctgg	gcactgtatc	143760
•	cagctggtag	ggcctggggc	tgctgtcagc	cccagagag	gccacattgt	tgtttctctg	143820
	tctttaatgt	ccacttggtg	gtttctggca	tgtatttcat	tataggctgc	aaaagaagct	143880
	ttattgaaat	tgtgtgattc	ccgccgcctt	ttatttaatt	ttgagatgat	acacatggca	143940
		cattctaacc					
	attggtgtgc	aaccctcacc	actgcctagt	tccagaactt	tttctcaccc	cagatggaaa	144060
	tcccataccc	attagcagtc	cctcccaggg	ccccgcccca	gccctaccag	cccctggcag	144120
	ccactaatgc	actctctgtc	tctgtggatt	ggcctgttct	gggcgtttcc	aatgaatgga	144180
	atcctacagt	ttgtggcctt	ttgtgtctgg	ctcctttctg	ggagcatgat	ggttctgagg	144240
	ttcatctgag	tagctttgta	cggctgaata	atattccctc	acctgcacgg	accacatttt	144300
	gtcggtcgtt	catctcttgg	gggatgtgtg	ggttgtttcc	atgtggctgt	tgtgaagagt	144360
	gctgctgtga	gcatttgtgt	aaaattgtgt	gagatttta	atcacaggtg	agtccctggg	144420
	atctcagcct	gttggctggg	agatttccca	gagcacccac	ccatcggagg	actccgcgtg	144480
	gacatececa	aacggtcagc	ccagggtccc	accgcctctc	catecettet	cgtgtctcgt	144540
	gttgtcacta	ccacctcctc	accggtgacc	accccgccc	ccaccgccca	ttgcctgaga	144600
	actgggaaga	cagtgcctgc	cctctgtttg	ccttctggaa	gggcagatcc	ggaggctggg	144660
	aggacggctg	gggatgactc	accggcggag	aggagcccgt	gtcccaccat	ctcaaggttg	144720
		gatgacagtg					
		gccgtgcacg					
		ttegtetgee					
		tgtgtgttcc					
		ggccccagca					
		ccgcccagaa					
		tggtctctgc					
		g caggggcact					
		agccaggttt					
		g tagcatggcc					
		caaccccctg					
	ctctgtgcct	cagtttcttc	atctgtacag	tgggattcaa	a ggagcgccc	a ctgtatgtt	145440
		g ccataataaa					
	actgttctgg	g aggccagaag	tccaagttga	aggcatccaa	a gaggctgca	t tccctccaga	a 145560
	ggetetgggg	g aggageetge	: cttgcctcc	ccagcccctg	g gegeetgee	t gcagccttg	145620
		g ctcatgacca					
	ccctgcgtgt	t ctctgtccac	: attttcctct	tcttacaag	g acccacccc	a atccagtat	g 145740
	accccacgt	t gacttgatca	catctgcaaa	a catcctttt	t ccaaataag	g tcacattca	t 145800
		t ggacacaaa					
		g gtgaaagtac					

PTS-0012 -166- PATENT

ctccccatca ctttgtagct acaagcagct ccttagcccc ctgaccttgg cctggcccat 145980 ctgtttcacc ctcagttacc atcgttctct cagatgaggc agggatgcta cctcccaggg 146040 gcactttaaa gacggagcga gccacatagg aacagtcctt ggtatacagt aggcactcag 146100 aaatggcagg ccgctagctt agggcgcagt ctccagaccc tgctccctag gtttgggtcc 146160 cagetgtgcc tectgcagag tetgaceetg ageaggtace tacaetttgg ggceteggce 146220 cccgccacct ctgtcttcgc cccggcgatg ggggtcggag gtaagtcacc tgccaagcaa 146280 atgtacagtg acaactggag gaacttccat ggtgctgggg gccaccagtc agagggctac 146340 cccgaggaag gggccgacac ccagagcacg aaataatagt gaatatcacc cagtaacacc 146400 gtggagccca tcctgcgtgc tgggcactgc tggaagcttt gtgtgtatga agtcacttta 146460 tctctaccaa cctgactagg aggcaggtgc tgttaatact tctgttattc aaatgaggaa 146520 accgaggeet agagaggett agtgageage ctagggteae acagetgtga agtggtagag 146580 ctgggatttg aacccaggca ctctacttgc agagtaggaa tggggttggc atgagagctg 146640 aacaggttag tccatgggcc aacctgttga ccaggtaaca aaggcaggac aggcatgtgc 146700 aaaggcccca tggcaggggc agtgtggccc catgagaagt ggttgaatcc cagaaggtag 146760 aggggccacc gggagcctgg ccttgccagc atgggatgga gtgtagctat tactctagag 146820 cgtgggaggc cactggggag gggctgggga catgatggcc atagggtttc tggtgggcaa 146880 gtgagcaacc tecettettg tgtgcatgeg getgtggetg cetgeeetgg ggettgtget 146940 gcctgaggac cgagaatgtt caggaggcag cttccccagg aaccgggcag ctccggggag 147000 ctggccgcct gccctcgggc ccagcgccaa gtggggaagg aggggcaggg caggagcagg 147060 gctgggatga gggactcggt tcccctggga aaggtcagcc tggcctggct tggaagcctg 147120 acceagetgt gegagaggee egaggetetg etggeagete etceaggece eagecetett 147180 ctctggcggg cagagaacct gctgtggagg gggttgggag gctcccggtc acaccattgt 147240 cacaccattc tagaccggga gttggctctg gcccgcctcc gggctgccag tccttcccaa 147300 tctccaggga gcggccaaca gtgggaggat gtgcaagacc aggccctggt ggctcccagt 147360 aagcccgggc agaccccaga ggcctccccc aggactccag ctgccttgtc tagtggcctt 147420 gccacttctc acaggagcga ggcaggaacc acccattgct gtgcacatgg gctggcctga 147480 cgggctttta tagatgaagc gtctaaggca tgggaagggg aggggtgagc ccccagcctg 147540 gagcctggag agcaggacct cctccactac atgtccactg ggaaagcctt gggctgtgcc 147600 caccatgggc cccccaaaag aggagcgcct gtgtgctctg ccgcacaaag ctgccagagc 147660 ttacagtggg gtgggcgggc cggtaggcag tgctgctgct cctgggtttg ggtctgcccg 147720 gctacttcct ggtgcagctg tccgtcaggg cccagcagga ggcgacactc gagctgtgtg 147780 gagactgtca ccacgtgtgg tctggagaga gaccactagg gagggtgcat gtctggggct 147900 ggttggcctc ccggccggat atgtgagaaa cagtctgttg tgatggtttg gagggaggaa 147960 aaaattgggg tttctgcagg aacttggggt acagccagac acaggggcag ggtctggacc 148020 acactettge teetgteage accettgaag atgaaateag geateaacaa geecceette 148080 cctcctaggg gagacccatg aatccgcatc cacatggctc ctgactcagg gaaggagcac 148140 ctggcggtcg atgcggtagt aatgatgcct gtcgtcacgt ggcgtggctg gtgctcacga 148200 acaaggcagg ccctccacac gcgtgtgtac acacgcacgc atacacacga cttctgcttt 148260

PTS-0012 -167-

gcacaggaga agaccaaggc cagagggaga gccagtgctc acccagccca ctgcggtgga 148320 gtaggaaaac gtgacattga aaggtgtaac gtggcacttc cggaaatggt aggcgagaca 148440 gcgccaggtc gtatgcaggt gactttattt catcttaatg agtctgggtt tttttgagag 148500 ctgggagaag acgtagcttt ttcacatcgt acctatgatt tacgggtata attgctgatg 148560 cggaggctaa ggcagatagc gaggctgatt tttgaaagag tagatggaga gaaaagagtg 148620 gggaggtgca agtccaggtg tgatgttatc cagccaacat cctgatagga tttcaggatg 148680 gcaggagttc gggaagtcct gacaagacac gcaggagtgc ccggcctgtc aagggtgtca 148740 atgcggaggc accgtccctg tggaaccccc ccccgccag ggcttggggt ttctgaaatg 148800 aggaagtggc atgactcagg cccaagacgg ctgggttctt ttcctcccaa ctttgatagg 148860 gttttaggca gagcatgctg agtttctcgg ggaaaatggc aggtgggggg cggtggtcga 148920 tgcacccctc tggcaggcag cctgtgagtc ttcatggaag gggtgggaaa cgtcaaggct 148980 ggaggtgact ggctggggtg gggagagcga gtgtgtttcc agggttgggg gctgacttcc 149040 agagaaaaca gctgcaacat ccccagatgc aggtgggcgg tggtgtggtc ccctcggagt 149100 cctagctgtg gatgcaggtt tgcagaccct tggagaaaag cagcttggag gcatctgagc 149160 ggcagcacag gcctccctga gggccagagc acctgagccg aggaggctga gtcctggccc 149220 ccacaagaac agctcgtcat gggcccgcgg atggcatgtg ggacgctgcc ccatgggtgc 149280 ccagaggagg attagcccag cggggcccca agcacccact cccgtggccg ccgggcccct 149340 gcgcctggct ctccactcgg cgtctgtgac tcagacctcc tggctggact tcctgtcttg 149400 gtcaatttca cttcctagtt cctgcctcct gactcttcag aacgaaactc cttccttaga 149460 aattagaagt ggggtcgggg aatccagacc acagggcatg gtggcagaat ctgccatctc 149520 cgccctggca cagagtgttg ggggcgtgtg cctggatgtc aagggggata ccccagcctc 149580 ttttgggagg gttcggggcc ccctgcagag ctaaacgcac agccccctct tcctttgcaa 149640 gctccttacc agggacccag acgggtggca gagatgccca gggtgctcag caggccccgg 149700 acacctgccg atgagcagtg ggacgaggga gctaatttca gaggcggtga aagctatgaa 149760 gatgatcaaa ccctgggatg gcagggcgac ggggggggt cactttggag gggcgggcaa 149820 ggaaggette tetgaggage cateaettga gecaagacea gagggaagae aaggeacate 149880 tgtgagaaaa cccgtggagg cagcaggagc agctggtgca aaggccctgg ggcacacacg 149940 agtgacccag agagaggctg ggcgggttca tggagctggc tcctaagggt cacctgggcc 150000 gtgctagggc ctttggattt tattccaaga gcttcatgtg gtcactggaa gattttaagc 150060 agaggagtga tttcacgggg ttggcatcct taaaagtgca ctgagacctc ccctgcagag 150120 ggcagagggc aggactcagg tggagaggcc cagatccctg atgtggttga ggtttgttgc 150180 cctccctgg catcgtgccc caggacgagg gctgggggtg cagggacatt ccagagacgc 150240 cttctgctcc ccagattttt agggggcagg atggaagggc tgggagttaa agggaaaagc 150300 aggttaatga tcccagagtc agggaagtcg gtcgtgacct gaatctagga tccaaagttc 150360 ageteagtta aettteaace ttetgggtgg eteceeggea ttteecacag tgtteettea 150420 cggctgcagg ggctctcgga ggaggacgaa aggggcagct gtggtcccga gaccccccca 150480 gcagcagagg gctctttggg gaccccaaat ccccaaaccc ttccccctcc cctaaatggt 150540 tggcggtctc atgtgcaccc tgcaaaggct cctcaaatcc cgggatccct ccggaatgcg 150600

-168-

PTS-0012 -10

PATENT

aggctagccc	tgcccaccca	cagtccccga	cagagggctc	ggtcagcctc	ggcagcatca	150660
					acgggcggcg	
ggggatgatg	gcggaagaag	ctgtttgctc	cctgtctgcc	gggggtggag	aagctctgtt	150780
tttctggaac	cctcatctgt	tcttaccact	gctgacgccg	ccaccgccgc	ggatggggag	150840
agagggaggg	ggagccagtg	ccaagttggc	ccgccccttg	tgaacctggg	cctctgccac	150900
gctcccccgc	ccgcctgccc	gcccgccgcg	agcctccgtc	tggaggtcac	attcagtcct	150960
gccgcgtctc	gctgggtcag	gcagcaagaa	gatcagagct	gagcccggct	gcgggggaca	151020
cggctgccct	gctgggcctg	ggtccttgga	ttttgcccgg	cccgggggtc	tgtgggctct	151080
ggccggcatt	gctcgctgag	cgtccgcact	gggcacattg	gtgctggagg	agctcggcac	151140
gctgcgcccc	ggtgatacct	ggcccagggg	catcccacac	gcaccactga	caacttcccg	151200
ccacccacca	ccctcgggga	agggcacctc	gcgcgcccac	agcggctggg	ggacggcgtc	151260
agaggtggca	ccgcccgctg	aaggagcccc	ggccaccacc	ggcaggcgga	cttgggagag	151320
ctgcctcccg	gccggccttt	tgaaccaagc	teggeeegeg	ggggcctttc	ctcccttgtt	151380
cccttcctnc	cttngttcct	tccttcctta	angggggacg	gaaaaagaat	ggaggctaaa	151440
ctgaaccccc	aaaaaaaccc	aaccagaago	ccttaaaaag	cccccgggg	gcgcgcccaa	151500
ċtggcgggcc	caaattggcc	ccggccctgg	ggggattttc	ccccccct	tgtgttccgg	151560
gaaaaattgg	cgccgggggg	gagaccccaa	agaagaaggg	ttggggttgt	ggggcctccg	151620
ggagggggg	agggaaatco	: cgttctccgc	cacgnnnnnn	nnnnnnnn	nnnnnnnn	151680
nnnnnnnnn	nnnnnnnnn	nnnnnnnnn	תתתתתתתתת ו	nnnnnnnnn	nnnnnnnnn	151740
nnnnnnnn	nnnntcgctg	g agcgtccgca	a ctgggcacat	tggtgctgga	ggagetegge	151800
acgctgcgc	ccggtgatac	c ctggcccag	g ggcatcccad	acgcaccact	gacaacttcc	151860
cgccacccac	caccctcggg	g gaagggcac	c tegegegeed	: acagcatggg	g aaaaaggaga	151920
agaaaaaaa	a gaggggggg	g agggnnngg	g ggggggagg	ggggggaaga	a gggagtaana	151980
aaaagcccta	a aagaaaaaa	g gaaagacca	c agagaaaatr	ntaaaaagaa	a aactccctcc	152040
ctccctccct	ceetecete	a ccgtgggac	g gagaaggat	g tgaggctgag	g ctgagccgcc	152100
agcagacgc	c aaccagcag	c ctcgcagag	c cgaccgcgg	c cgcccagcct	geeggeecae	: 152160
ttcggcccg	c tccctgggg	c atcttccca	g ccctatgtt	ccggaaaact	t tggccgaggg	152220
ggagacgcg	a atgagagga	t gtgagtgag	t ggtcctggg	g aggggatgg	g ggactgcggg	152280
tgcagggac	a gggaccgca	a cgtggccat	c tgggatttg	a ggctgggca	g ctggggagto	: 152340
ggagttctg	g gcccctgga	g tggatgggg	g teceageee	a teettteee	c catgccctct	: 152400
cctctctct	c cctgctggg	c tgaagctct	c ctggaagca	g gggtgggac	c tggatctgtq	152460
cctgggaag	g tctgtgatg	c tgtgtgcac	a gggggtctc	t ccaagtgga	c gggggcttca	a 152520
agctgggtc	t ggcggggtg	g tctccaagg	c acggtaggg	t agaaagtct	t teteteegt	3 152580
cctggcagc	c tetgeetgg	g cttcccaga	a caggaacca	g aggaagcca	g tgccagcct	g 152640
cccctaccc	c gcagccctg	g ccggcacta	a tgggacacc	c actctggct	c ctcacacgg	c 152700
agttaagga	a actgaggco	g gagagcaga	a gggctggcc	a agactgcta	g cgagctctg	g 152760
ccaggcgcc	t ggatgacto	t gcccagcto	c tttgggagc	c gtatgtttt	c aggaagggc	t 152820
gggtgaccc	c cacccccac	c tecatece	t ctcctctgc	c ctcaaccca	c tcccactgc	c 152880
cccatgato	g gagttaatt	a gggtcccca	ag ccccagco	a ggctcctag	c tacctcctt	a 152940

PTS-0012 -169-

tttattgact	gagtttggaa	atgtcaacct	cccagtgtt	gttgggccac	cctcacccca	153000
		caccccaccc				
		gccgggtctg				
		ggaaatataa				
		gegegggegg				
		ccttctgcgc				
		gggccacggc				
		agaggacccg				
		cctctaagct				
		gggaaaatgg				
accaagtctt	tgaagggctt	tgcaaactct	gtgtgtcagt	tagccgtgcc	acgggctgat	153600
gtgttgatgt	ttctgctgct	gttgttttat	ttgcattaga	gccttgtgtg	tagcaggcag	153660
gcagccagca	cgtgggtggg	tgggtgggtg	gatgaatgaa	tgaatgaatg	aatgaatgaa	153720
		gacggctgcc				
		ttgattttat				
		cttacaagtg				
		tggggcctgc				
		tccctgtctc				
		gccacacaag				
		ctgtgtgtgc				
		actgcctccg				
		ctagaacctg				
		ttttctgccg				
		cctcctggtt				
		gggccccgag				
		cccagttaac				
		c ctcccatccc				
		a cccgtctccc				
		caggeeete				
		cacagecet				
		t ttggctcct				
		a accagaccc				
		g gcccatcac				
		t ttctgctcc				
		g cctggcctc				
		c tggtcggcc				
		c ttcaactac				
		g gtgagcccc				
gggagagga	g cccagactg	c ctcaggaga	t gtctctgca	c cccaggagg	c atgggccag	g 155280

PTS-0012 -170-

gaggggctat tatgccgcct tgttagaact cagcttctgg gggttcaagc ccgggagtac 155340 cccgagatgg ctgcaggcgg caatgctgct atgagtgtcc ctgccttgga gacgggccgg 155400 gccaggctgc cctccacccc caccctgcac cccactcctc tcagacagac acctctgggg 155460 gccctcagcc ctgtctcacg gtgtggggga aggagcgcgg tggaccagac tgactcagcc 155520 aggaattcgg gctgtcagcg cgttggaatg aggacccgga ggcaaatggg tcctgagcga 155580 gtggctcccc tgccccattt gacctcacag ctttagggct gccgtggttg gggagggaca 155640 ggtctggggg ggcgggggcg gacgtctcag ccccagcatc ctggagggct tgaggcaggc 155700 agcgtgtaaa tggcctctga ggagcagccg cttcttccac agctgtttct gggaattgag 155820 gagcattttg gggagacctc tgctgccttc cctctctct tcccttcctc ctccttccct 155880 tcctccctcc tttctccctc tttgacacac ttgccaagca ttgtcccctt tttggagctg 155940 gggaaactga ggcttagcca ggctcatgtg cgactgaatt gcgatatgca cccacagtta 156000 tgagatcagc acccacgete tteategeta ggetgegtgt tteeteateg atacagaage 156060 actgagggag gggttgcata gctccctcc cccaggacta ctcctcccc cgccactccc 156120 aaaccatgac atcgggctgc cttgtgcctg ggtgtaaagt gtgtgcagtg ggttccgggc 156180 aggccatgct gaattgctcc ctcagtgcaa cctgctgagg cccagagagg gtgagcaggc 156240 tgtgaggtca cacagcctgc agtgggagga ccaggtatag cctcccctg tttgaactcc 156300 geccaageae tgtgcagaat ttaaggacat cettecacee teeegagtgg gttettagtg 156360 agtcatgtgt gegegegee getggtgget eegggacega ggggeeaegg teecaeggee 156420 ctgtggtcag ggctgagate caccetetgg ceteagggag geceeteece ateaetteea 156480 gttaagcagt geeeegegtg ceeteeacat tggeeeetgg gatttgteee eagageteag 156540 ggcttcaggc agcgcctttt ccttctggat gcttcgggcc ttctggttgg gtgtggagga 156600 aggcaccgca tetggetgaa tgtgcagaac eccgteeeta acaettgetg aagteeettg 156660 tggcaaagag ggcctgagcc agagcagcct gggggcgcag aagggggcct gggccggggg 156720 atgttgtggg ccattgattc tgtcagccag gtcaggagtc tgaggtggtt catccaggat 156780 . gacttggggg cagggctttg gccctgagca tctccccagg aacaaaaagg gcctcctgct 156840 ttetececag etgteettte aetttetete teetececee geetececte tetggggete 156900 cctccgcctg tcccctcac cccacgacca tggacgtctc ccccgctgc agcctgctgc 156960 cacacageet ggetttecag getteegeag ggtgtggeee cactgtacee ctagagaete 157020 caaaacctga gagtggcttg gaggaccaga gaccccagca cggtgaacca tcccattagg 157080 cccagggcga gactggggtc aaggcccagc ttgtggattt gggcacccct gtgaccttgg 157140 gcagtgaatt cagccttcta agcctcagtt tccccatctg taaggtagga gaataacagt 157200 tgttatccaa gaggtcctat gaggagtgaa cgagtgatta cctgtgaggt ccttagtgcc 157260 tgccagaggg gcagcgctcc gggagggcga cgtgccctag ttactcttac tgctgtggtt 157320 attgttattt tatctggatg ccatctaccc ccttctcagg gccacctgag gccccctctt 157380 tttttttttt tgagttggaa ggttttatta gactaggaga tttgtgggag gtatgagcac 157440 tgggccaagg tggcacgggc catgcttaag gcaccctgtt gagtgtggtg accaccagtg 157500 aagccgctgg cgtggacgaa catgcagcca gagatcccac tgacgagggc gcctcttgaa 157560 cggtgcgtgc aggcacagcc acagtgtgct atgggttggg agcagggact gggcccagga 157620

PTS-0012 -171- PATENT

gagctgagtt	tgaacgtagg	ctctgccacc	tactagctgt	gtggccttgg	ggaagtgacc	157680
tgtgctctct	gtgcctcagt	ttccccatct	gtgaaatggg	gacaataatg	gaacccactt	157740
caaagggctg	ttatgggaat	acactgggtg	gctgcctgca	gagtgctggg	aatgcggcct	157800
agtatgcccc	agacactctg	ctagtgagag	ctgtgatggt	gctggtggtg	gcacactcac	157860
gattgattga	ttcattcatt	cattcatcca	ttcattcaaa	gaggcatccc	agaaggatgg	157920
tgcagagcag	ggctttggag	ctggtggctt	tgtaccccag	ctctgccgct	tagtgactgg	157980
gtccaaggat	actgggcttc	acctctccgt	gcttcagttt	ccacctctgt	aaaatgggga	158040
taagaatggg	acccagtcgt	agggctgttg	aagaacaagt	gtgtttcttt	ttgtaaaggg	158100
.tggtgcctgg	tccttggtca	gccctcaata	agcattcagt	attatcctca	ctgtccattc	158160
agcagcccca	tattcagcgc	ctgctgtatc	ccagggaagc	aatggcagct	gccctgaggg	158220
cagagacatg	gatggggttt	tcctgctggg	ctgtggagct	aacacttcgt	tagtggaccg	158280
tggagggagt	gggggctgca	ttgaaggatt	ctgagctgag	acacagecee	catccagggc	158340
tggactcaaa	gtgggtcgtc	ctagtgtcga	tgaaagtgat	tctgatccga	atgacacagt	158400
caaagctgat	aaagaaggtg	gcccttctgt	ccctgacgc	tgaagactct	ggaggcgtgg	158460
acaggagggg	accccgagat	ccaggttggg	acctggatga	gaatgagtga	tttgggagtg	158520
tggggttggt	tctcgctcct	ggccgacctt	gaaggagcac	cctcatatcg	cgggctgcag	158580
agaaagcgga	gcagatgcag	ggacccacta	caggaagtgg	ggctcaggcc	aggccatccg	158640
tcttgacagt	agccgttctt	ggtgtagtgg	tgagctcccc	atcgctgcag	taagcaagca	158700
ggtctcacca	ggagaggtgc	cgctgaacct	ggtgacctcc	acctcctgcc	cctccctgt	158760
gcctttcagt	cccagggagg	agggcatatc	ccagtgaatc	ctaacgcagt	atcagccacc	158820
tctggctgct	ggcccagccc	tgtctggagt	acaggaagac	atgtcaccct	tggccagaga	158880
aggaaggagt	ggggaagcag	agggtcagtg	ggtgtcccct	cccgccttgc	actaggtctg	158940
gcccgagtgt	ggccgcaggc	gacgtcagca	ggaagcagga	teeggeggee	agacagacaa	159000
ggcatgtccc	ggagttatgt	aacacttggc	atcagtgtct	tctacgaggt	ttccctcccc	159060
ctccttatgg	ccgaaggtta	cccttttctc	ccatctgtga	attcaggccc	ctggggctcg	159120
gcttccacgt	tcctcagtct	ctgtccgcct	cagccttggc	ccagccccgc	cttgttttct	159180
gctgttaatc	tcttctacct	gaggctgcac	aggcctgcag	agagatggtc	cagccacgaa	159240
atgtttgaag	ctggcctgca	ttcaaatctg	agctcctcaa	ctcatgagct	gtgtggtctt	159300
gggcaagtgt	ctttgcctct	ctgagccatt	gtcactgtct	atcaggttca	ttcatctaaa	159360
gacatagtta	cagagcgtct	gttctgtgct	agacactgtt	ccaggtatgg	tgggaataca	159420
gcagagaaca	aagatcccag	cccttgagga	gctggtgcga	gagacaggtt	cacacactca	159480
atttcagaat	ggagtctgaa	gatgctatga	gaagaatgta	gtagaaagtg	attgatggtg	159540
ggggtgggag	ggatgagcta	atgatggagt	gatcagggaa	gacctctctg	atgtctgagc	159600
taaggcccga	aggaggtgag	gaagtgagtt	atgcagatat	ctaggggaag	ggtgtccagg	159660
caggggaaca	gccagtgtag	aggccctgtg	gctggggcag	cgagcaggga	gggcagtgtg	159720
tttgtagcac	agtctctgag	gaggggagag	gggagagcag	cttggagagg	caggcagggt	159780
ccagggctgg	atcacacagg	gccatatgga	tagggggagg	acttggggat	tgtatccagg	159840
tgttggagag	tttgaagcag	ggggtggcat	gcgctgattt	gcagagcagc	tgtgcaggtc	159900
cagtaaatta	ataccagaaa	ccgcttggcg	catagtaggt	gcttaataaa	cgtcaggcat	159960

<u>P</u>TS-0012 -172- PATENT

aatgattaat gccatcacta gcatctccta ttctacacac acctcctgat cccacagtgc 160020 cggaccatgt gtgtaaggat taactgtaac tcctgggact ctctctgaga cccagctttg 160080 tggggattca gggtgttggc accateceeg tecaetgeet cagagaceec acgeegeece 160140 ccgcagagac accttgcact ccaggatgct gggcgccacc accaggccga caggagaccc 160200 ctgttccctg cgagactctg agcatctccc atgtcccagc caccgcccgg gcagctcagg 160260 gcacccagcc ctgagtcttt cctgagcctc tgtctgccaa aaatagattc gggaagcagg 160320 gggagcctc ggccgcagcc gcagaaccca catgccacca ctttctcagg ccgccacagg 160380 etegaactet cetgggagag geteaggatt eggggeaggg etgggaetgg geceaggaeg 160440 tgtgcggggt tgcagagctg ggcatccctg tgggccctgt gggcactggc aggggcaggg 160500 etgtggccct ctggccgact gttggtgtcg gaaactgtga ctaacggacg agcagtcgtt 160560 tcccttttcc tccctgcgtt ccaaggggct gtgctcagag gaaccctgtt tgctcaggaa 160620 gaaggcagga caggaagtga tcccactccc tgcctgtggc tggggcttgg agcccgagac 160680 cccctctcct cccctccatg aggcccagct ccagcctggc cacggtgaag ggctggggtg 160740 ggcggggccc acctggcatt tgcccgagag caggctgtgt ggtctggacg tcagcagctt 160800 tttcttggaa tccgggtgca ccagcgcaga gggatgtgtg attccccctg gctgccgcaa 160860 ggaagtacca cagaccggtg gcttcaaaca acagagatgt attctcttcc aattctggag 160920 gctagacgtc tggaaccaaa gcgtccacag ggctgtgctc acattcaagg ctgcagggga 160980 gcctcttccg tcttccagcg actgctggca gttcgtgaca ttctttggct tgtagctgca 161040 tctctccaca tgtgcctcca ctgccacagg gccttcgtgt ccctgaatcc gtgtttccct 161100 tttcttccaa ggctgtcagt cctgttggat ttagggccca ccccactcca gtgtggcatc 161160 atcttaacta atgacatatg caggateceg tttetaaata aggtetgagg tteegggttg 161220 atgtgaactt tgagggacac cattcaaccc agtacagggc tcttggctga gagctgcggg 161280 cacctccagg tgtggcggag ggcccacctc tttctcagca accccagagg gatcaggctg 161340 ccgcccccc gtcacaccag gctgtggtgg gcaccccca gtgtctttcc agtccccctg 161400 ggagtcccca gtcacttcga gatgctgcct ccacgatgcc cctgctctct gctgtctatg 161460 cgttcaagcc cacgaaggct ggcctttcac agttgctcag caagtcagtc aacaaacgct 161520 ttctgagcct ctgcctggct cagcgtgggg acaaagagac acccaccca gtgagctacc 161580 aagacgagtg gtttgatgat ggtgcctaag ctgggggaag aagagtgggc tctgtgtgtg 161640 aggagctggg gttcccagga gcagggtgcg gtgcggggaa agtggaggcc cgacgatgag 161700 ggettettte catteetgga cacaccegge atgtteecca caetggggee tttgcacctg 161760 tgactccccg cacctgccac tctcgtccag agcctggcct ggcccattcc ctccgccgtc 161820 aaatcttggc tcaaatgtca cttccttgca gaagctcttc cagactgttc tgtccagagg 161880 agcccctgcc ttgtgctcct tgtcccatcc tgtttcaccc acgcgaccct ctgatcctct 161940 gagtgctgct tctgtgtgag gagcacgttg ccagtctccc cagcggcagg gcagcctcca 162000 agggcaggac cttgtctacc ccgtgccttg tgtccccaca gccctggtat gcagagctgg 162060 gcacacagta ggtgttctgt aaaggttcag ggaatgaaac gcgagcttcc caggctggcc 162120 tgttccccca gggacaggtg agacttgcat agcaaggaaa agcttcctgt gttcattcac 162180 tccacgtgtg ccgatgaagc tgacagggtg tccccaggag gcgtggtcac tcgctctgac 162240 taggagactc ctgggcaatg tcaggcaggt tctctcgtgc tcaggaagga tgtcagggtg 162300

PTS-0012 -173- PATENT

gctgaggggc cagcctgtac ccagagtgta tctggggctc aatggaagaa taaagccccc 162360 ggtaaaaata aaccctggca cgcttggctg ccgaggtggg gtgtgagggg gacggtcacc 162420 ctcattgcta catggccggg atcactgccc tttgcacctg cggcgaggcc ccaggcatgg 162480 ggagtccccg agctgacagc ccaggcccca gtcctgatct gctgcttccc tgtgccccag 162540 gagaaggaga ggaacgcgcg gaggaagaag aagaaagcgc cggcggcggc cagcgaggag 162600 gctgcattcc cgcccgtggt ggaggatgag gagatggagg cgtcgggcgt gagcggaaat 162660 gaggaggaga tggtggagga ggctgaaggt gagggctggc gcggcttgga ggtggctggc 162720 agctgtgggt ccgagctctg agggagggca tagcgggaac tgatcccggc agcctcctct 162780 cccctgagtc atctgggtcc tccttagaag gggcctcgac tccctggaag gtgcgggcct 162840 gacttgccag aaactcacca gtaatgggca caaggatgaa ggccataaca atactgagaa 162900 taatcagett etetgggage eccaageete geteagetet tetgatgeee atgagteeag 162960 tcttatgctt gggtgaccag acgtccaggc cagccctgtg ggtgcctgct gtctttcacc 163020 ccatccgatg tcacagttta gaaaaaaatt tactttggaa aagtttttt ttgtttttt 163080 ttttttcaga cggagtcttg ctctgtcgcc caggctggag tgcagtgacg tgatcacggc 163140 ccagtgtaac ctctgcctct cgggttcaag caattctcct gcctcagcct cctgagtagc 163200 tgggattaga ggtgcccgcc gccacacccg gctaattttt gtatttttag cagagatggg 163260 gtttcgccat gttggtcagg ctggtctcaa actcctgacc tcaggtgatc tgcccacctt 163320 ggcctcccaa agtgctggaa ttacaggtgt gagtcaccac gtcaggcccg aaaattgttt 163380 tttgaccaga actcttttac aaggtaacca gcataaatag aacctatctg tcagtcggta 163440 aatattgtac aagttatata gttattttca gtgtctcctt ttattcccaa gtgtccctat 163500 ttgagtgata aataattcag tccccttctt tggtgtcccc gttttctcta tggggaaacc 163560 gaggetcagg caettaaagg eetgggeeca ggegeeccag gtaccaegga gtgtgttgtt 163620 tgcaccagct gtagactaga caaatgcccc accaggtgag tgctgctgaa gagagggcgt 163680 aaagccatcg tgtgcatggt gctggtgggt ccccccgagt cccctcaaat gcaggactgt 163740 gaccacatga gctgtgtgtt gtccagggct ccggataaca cacggctcaa ctttgttatc 163800 agtgtgtata gacccgggaa ctgaacacgg gctgccgaca cctggccccg cactctcggt 163860 cacgagtgca tecacetteg acceecacee tgtgcetett tttecetgte aaaggggaag 163920 ctgggggtct agactgctcc ccctgtggcg tgaccgaagg cccctggagg acctcagccc 163980 ttctctgctg agtgtccctg actctccttt ctgactctct gaaggagaaa caagcagccc 164040 ggcggagccc aagtccttgg tgaattcaac cctccttcct cctgccccgt ctggggtcct 164100 tettgttgtt cetgttgtee etecetetet geetttgaae geeetggett etecetggea 164160 gaaggtgcaa gtcacctcct ggttccataa gcccagcctg cagataaatc caggctcctc 164220 cagcccgcag ggtttcacca gcccgaatcc ccgcttcccg ctggaaatgg gcaactgggc 164280 ccttgggtga ctcatctcaa gttgggggcg ggtcagggac actgagtctg gcctccccac 164340 cagctttggg tctctctgac ccaagttgac cagaagcctg gctagtgtct gatggaagga 164400 aggcctgggc cacgagtccc ttgggtcgtc ccattttggg tcctgggtct gtagccagga 164460 gaagaccccg ggagcagaaa cccagtcccc tctgtaaata tccctccagt gtctgaatgg 164520 gegggatgea ggettggtgg gageatttea ggaageeaag ceatggeeac acattaaaac 164580 cggagcagac gccacccagg actgtgtggc aacgaccccc gcatcgcttg cagagcttac 164640

PTS-0012 -174- PATENT

	gtagccccgt	agggacgggg	aggggcatgc	tctgctgggt	gggggaggag	ggagggctga	164700
	ggtggctgga	gctgaggctt	ctgtgacagt	ggtggtcttc	cgtggctgct	ctgagagatc	164760
	agggacggca	ggtgagaggc	cctgattaag	cctcctggtg	cccagggtgt	tagcccatct	164820
	taaggacgag	gagcccaggg	gagaggagaa	ccctcccat	ggggtgtccc	agcacatagc	164880
	cggtaggctc	ggggtctgcc	ggcccagcca	gcgcacgctg	cgtgacctgt	ctcttgtgct	164940
	caggatgggg	aggtgaggca	ggtgctgggt	tggagcctga	ggttgccctg	cctgaatctc	165000
	cccggagacc	cagccagccc	cagcggcact	gcaggcccct	cccgggggc	agtggaaagc	165060
	gtcttgttgc	atctgggctg	gaaatacacc	agcgcggggc	tgggagtgat	accctggccc	165120
	agtggtttct	ccagtaataa	taatagtatc	ctcatagtga	atgaagccat	gctgttctcc	165180
	gcatttgaca	gatggggaga	ctgaggcata	gcggggttat	ccaaggcgca	tttggtgacc	165240
	ggggttcaaa	cccaggcagc	ccggtactgg	ggacctccag	gcagaaagga	aaggaggcca	165300
	tctggtggtg	tgtttctatt	ttttatttt	ggtggttttt	tggtcactct	tgttaagcac	165360
	ctactgtgtg	tcagatgctg	cacaaagcac	ttcacctgga	ttctagggca	gcggtggcag	165420
	agtgttccct	gggatttgtt	agaagtgctg	attcttgggc	cccagtccac	acgtactgaa	165480
•	tcagaaacct	cggggcatag	tgcagccacc	tgcactgtca	caagcccttg	gagtgcttct	165540
	catgcaggct	cctgcccag	acccccttga	taactgtgag	accgagaagt	taactgccca	165600
	ttttgtagat	gaacaaactg	agacccagaa	gtttcatccc	tggtcctggg	gccctcagcg	165660
	ttggcctccc	aacgtcctgt	actctgactg	tggaaggaag	ggaatgacat	tgctgaagtc	165720
	accaggcaga	ggaaggccag	gggttaagga	cacaggaagc	tgggctcagt	gctctcccct	165780
	ccacagcgtg	gccttgggca	agctgattaa	cctgtctgcc	tccatttcct	catctgcaca	165840
	tgagagttgg	tggtcccagt	cttagaggtc	ttaaaggagt	cgtgtgtgaa	gaactcggca	165900
,	cggagcctgg	cctgtatgca	gccagcgttg	ctgctgttgc	tattgtttct	aaaaagggtg	165960
	gcctctgctc	tggggcctga	agggaggtga	gaagcaggag	agactggagg	gttggtgggg	166020
	gggcaatgaa	ggctgaagag	gccccagcag	ccccaaaagc	ctctccctgc	aaccttgccc	166080
	atccctgagg	tcaacacctc	ccactccagg	catcctggga	gcctggttcc	accaggaggc	166140
	tgatgactta	gggcaaggac	acccagagtg	gctgaagctc	acttttcacc	ctgaacaacc	166200
	ccattattgg	ctggccttga	acaggccatt	ggacçagcct	gctcagggct	attgcaggtc	166260
	acctgtggcc	gctggccaga	gcccagaggg	agagggctca	teggtecatg	gagaagggca	166320
	gtcggggcag	gagagcgagc	agcagcgagg	cctcactgct	gtgcactggg	cttcaggccc	166380
	ctcttggcca	cgttgcctcc	tccctcccct	cccactactt	ggtgctgcct	cacttctaac	166440
	tcttctctga	cttccttcca	gccttacatg	cctctgggaa	tgaggtgccc	agaggggaat	166500
	gcagtggccc	aggtacgaat	gtggccggct	ggcctggggg	gtagggccgg	gccggggcgg	166560
	gcatcccaag	gtccccggtc	ctccacaagg	aaccccgctt	ctgagcacat	gcctctttct	166620
	gtgagcgcca	ccgtttgtgc	tccgcggcct	ctgggcttcc	ttcccagcac	agtggctgtt	166680
	ccccatgctg	gtcccgggct	cactccagca	gaccagtttc	ccgtctccac	tgctttgctg	166740
	attttcactg	gtacgcttgg	gtctccgacc	gggtttgatt	tccctgatag	caaatgcagg	166800
	ggttttcaag	tatccccatt	ttacagaaaa	tgggagacat	tgagactcaa	agaagagccg	166860
	ggtgtgggtt	tgggggctag	agagccagga	atgcggctgg	gctctccttg	ccatccttgg	166920
	gtgcgtgctt	tcatcctgcc	actccgccag	cacagatcgc	gctcctgctg	tgtaaaaccc	166980

PTS-0012 -175- PATENT

atgctgaggc	cgttggtgtg	ggctgtgccc	ggggcccctg	cacacgcact	ggcctcgttg	167040
tccaccgtgc	ccggggcccc	tgcgcacgca	ctggcctcat	gattgtccac	cgtgcccagg	167100
gcccctgcac	acgcactggc	ctcatgattg	tccaccgtgc	ccagggcccc	tgcacacgca	167160
ctggcctcat	gattgtccac	tgtgcccggg	gcccctgcgc	acgcactggc	ctcatgattg	167220
tccactgtgc	ccggggcccc	tgcgcacgca	ctggcctcat	gattgtccac	tgtgcccggg	167280
gcccctgcgc	acgcactggc	ctcactgccc	actgtgcccg	gggcccctgc	gcacgcactg	167340
gcctcactgc	ccactgtgcc	cggggcccct	gcgcacgcac	tggcctcact	gtccactgtg	167400
cccggggccc	ctgcgcacgc	actggcctca	ctgtccactg	tgcccggggc	ccctgcgcac	167460
gcactggcct	cactgcccac	tgtgcccggg	gcccctgcgc	acgcactggc	ctcgtgattg	167520
tccactgtgc	ccggggcccc	tgcacacgca	ctggcctcat	gattgtccac	tgtgcccggg	167580
gcccctgcac	acgcactggc	ctcatgattg	tccactgtgc	ccgggcccct	gcacacgcac	167640
tggcctcatg	attgtccact	gtgcccgggt	ccctgcaca	cgcactggcc	tcattgtcca	167700
ctgtgcccgg	gtcccctgta	ctcacactga	gcgcattcta	cactgtcatg	tgacgatgat	167760
ggtggcgatg	gtggtgcagc	agcaggcagt	caccaggcag	ttgcccttgc	cctcacaatt	167820
gccagcttct	ccgccctgtg	agatgggaac	tattgttctc	ccgttctgca	gatgggaaaa	167880
ctgaggccca	agaggtaacc	tgagtttccc	gtggcacgca	gccagtgcgg	ggcagagccg	167940
gggttagagc	tcagatgaga	acatggagac	ccccaggacg	aaggcctttg	cccacggcca	168000
cectcaggct	ggctccatct	gtcgggggtg	ctgaccacca	ggaggtcctg	gggttgggaa	168060
ttaaccaggt	tatgccagca	gggtcagtct	gggagaaagg	cggccaggcg	agggcagcag	168120
ctgtgggtag	gggcctggtc	aggggctttg	tctcaggggt	ggggctctag	gcagcagccc	168180
aggtgtgtag	gagcctcggg	gctgttttgg	catcaggcga	cagagcggcc	tcatccggag	168240
ggtcagggcc	atgcatctct	tctggaggcc	ccgccagacc	ctgctcatcc	cctcttcctt	168300
ctcgccctgc	acagccactg	tcaacaacag	ctcagacacc	gagagcatcc	cctctcctca	168360
cactgaggcc	gccaaggaca	cagggcagaa	tgggcccaag	ccccagcca	ccctgggcgc	168420
cgacgggcca	ccccagggc	cacccacccc	accaccggag	gacatcccgg	ccccactga	168480
gcccaccccg	gcctctgaag	ccaccggagc	ccctacgccc	ccaccagcac	ccccatcgcc	168540
ctctgcacct	cctcctgtgg	tccccaagga	ggagaaggag	gaggagaccg	cagcagcgcc	168600
cccagtggag	gagggggagg	agcagaagcc	ccccgcggct	gaggagctgg	cagtggacac	168660
agggaaggcc	gaggagcccg	tcaagagcga	gtgcacggag	gaagccgagg	aggggccggc	168720
caagggcaag	gacgcggagg	ccgctgaggc	cacggccgag	ggggcgctca	aggcagagaa	168780
gaaggagggc	gggagcggca	gggccaccac	agccaagagc	tegggegeee	cccaggacag	168840
cgactccagt	gctacctgca	gtgcagacga	ggtggatgag	gccgagggcg	gcgacaagaa	168900
ccggtgagtg	ggcgccaggc	agccctaacc	ttggcttttg	tctgcagaca	ctgagcagcg	168960
actacctact	tagacagccg	cacccagtct	ggctctgcct	gctttggggg	agcccgaggt	169020
gtggttaggg	aggcagactt	ggagtagagt	ccaggaatga	gagatgcagg	ccaggaaggg	169080
gcggaggtgt	ggccgggagg	acctccccag	gaggtgacat	ccaagctgag	acccggacag	169140
aggaggcagc	cctgggcagc	gctagggaga	gagtgtgcca	ggcagcctgc	tegetteeta	169200
gggccgccct	cącaaggtag	ttcgagccag	gtggctttta	acaaatacag	tcctggaggc	169260
caggagcctg	ggggcaccat	gcaggccgag	acgcagcctc	cgagcctctg	ggcagatcca	169320

PTS-0012 -176- PATENT

tecegeetet tecageteet ggeegetget ggeggtegtg attgetggea tgeeacteeg 169380 tetttggete tgetgteaca tgacettege cetgtgeate tetgtgteca caetttette 169440 ttctgaggac accaggcatt ggatgggcag ctgtcctaat ctagtgcagc ttcatcttaa 169500 cttgattata tcagcaaaca gtctatttcc aaataaggtc acattcacag agaccctggg 169560 ttaggacttg aatgtacctt ctctgggggg acacagttct accctcagcg tggtgggaac 169620 agcaagtgcg aaggcccgag gtgggaatga gcttggtgga ttcaggtgcc aaagggtggc 169680 tcagggaggg ggcagcctgg caggacgggg ggcagctctc acgggggtgg gggcactgag 169740 tcacgccctg gcaggtgggg gctgcatttt gttctcaggg cagtgagaag gcctttacga 169800 gcctctccca agagagccag atgtgattta cccatgaaac catgtggggg atttgctggg 169860 agtgagaggc acagtcagga ggcagctgca agtgccctgg ggctggtgat ggagatgcga 169920 gcgtggtggc cgtggggttg gggaaaagcc acaggttcaa catgtttttg gtggctcatc 169980 tcccatcagc caagggtcca gggctcagga tcacaggtga tcaccttgga tcacaggtgc 170040 agaggttccc cttgcaaatt cctctccagc tggggtggcc tggaggaccc cagtgtcgtc 170100 ctgtttgggt gttgatgtct ctgaggtgtg ttctttcctt tctggcctct gtctttgctc 170160 ctggcctggg tgaccccaca tccctgagaa tgccaccttt tacccatttt cagcacagat 170220 gctttgggcc tcaaggcctc cagcccagaa ccaaagatgg ctacccaagt tagggccaat 170280 ctcggttggc agagggcaga cccgcggaga ctgcgtcctg ctcacatctg gatggctgga 170340 ggaattgttt tctggtgggg caggcaggcc attttatttc aactacagtg tggtctgttt 170400 tctccctcc caagtccctt ggaatggtcc tgggcagagc aagcgaggga ggaaaatcag 170460 accegcaggg teatgegggg ceettgtete tgeeetgggg tteaccetgg geeatgttaa 170520 agggggaagt cctaggacat tecetaggaa etgaggttea eeeggatete tataggttee 170580 acaaaacaaa atctcagggt ccccaggaac cactgccaac aggaaccgcg cccatgcgtg 170640 tgagaagtgg acggcctgac cctgaccctg tgatgagcaa aggcctggcc tgcgggtttc 170700 tgagggcacc aaatccctga gcttcttgcc cgacagtccc agcttggaaa acagtgttca 170760 tggtgtggct gggtctgccc tggaggcagg cagccagggc cattgtgcct ggatagcggg 170820 gtcagggcag acggctcccc gccccgctcc tgctggctgt ggggacagag tcatagaaac 170880 acatgtttct gccttcgccg ggggaccgct gaggtcatgg ggcagcccca ttgataagct 170940 gcctcccaga gtctgtattt tgggtccatg tggctggccc cggactgggg agccggggga 171000 tcagcttgca tcctgtccgt ccccagaaca ctcaggctag gcctgaggcc ccgcagggca 171060 cttgcagcct cccgtcctct ccctgcagc cccgcccagg gccgtgtcct ccctccccga 171120 gctgggcctg gcgtacgtcc accccttgcc cagtgtccag cacacagccc ccgggtgcag 171180 gagtcctcgg ctgggagtca ggacacctgg tttgtcccgc cctgtgcgac taggcccagg 171240 ccccgccct tggggcctgc tttgccctct cagtgaacga ggctggactc tggccagcct 171300 gctgacctcg tcctggccgg cagcccgcca ccctccctc tgccggccac gactgcgcag 171360 ggccgggcgg acgctggagg acgcggacga gatgcgtcag agtaggccct ggcagccagg 171420 gcctcccggg aagggctggt gggacgggcg ggcccccag gcgacccctg ctcctggctg 171480 cccgcccagt atcatccctc ctgcctggca gccccagtgg gggagctctg tgttcctgga 171540 tggacgcaag atgactetca tetggeecee egeceeggtg actttgggag agagaaate 171600 acattctcct teggeceget ggeaetttet tegaggtgge tetgeetggg tgttttettg 171660 PTS-0012 -177- PATENT

gcagacgacc agagatagtg gcttcaattg caaaaccccg agcctgcctg ccttccctc 171720 tcttactctt cagagaaggt gcctgggtgc tttttttggca gggcctggcc ttgggagtcc 171780 cctccccaa gcctcagttt tctcatctgt aaggtgggcg tggatggctt attgcaagaa 171840 taactcagtt aatgacgggc cacagtgggc gctcagagat tagctgccct cctttggatc 171900 tgctttggga caccccctag aggtcacccc aagagggggc tggagtgcag ctccttcagc 171960 tgtccctctg gcattttgga agatcataac agcaatttca cctttgttac tttattctgc 172020 aagtgactga tggcaccagc atgcgccagg cgccgggggc gctggaaact gcacagacaa 172080 ggccctgact ccaggcactt acattctagt gagggcatgg agaaggaaac cattgtttac 172140 gggatgagtg ggtgatgggc agatggggca tggggagcag gggagagtgg gctggtcagg 172200 cagggaggc ctctggggag gtgacattgg agggcaatga gagccttagt gtgagggaaa 172260 gccagaccc ctgggaacca ccagtgcaaa ggccctgtgg ccgcatgagc gtatgtccag 172320 tggacagcag agaggcctat agcagggtgt agagtggagt gagcagccca gggcagagag 172380 ggcggagagg tcagagaggt gggcaggccc cacgggtgga agtgacgggt cagggtttta 172440 tettggggee ttggagagge aagggatgee tgttcacaaa ecagecetee etetecetee 172500 tagccctagg atggtggcaa ggattgtccc agcttgatga ccatggggaa actgaggcaa 172560 gggctgggtg gagaggggat gtactgttgc aggcccagca tgttccgatg aatgtcccca 172620 ggcccttatt cccctctcg tgccctgccc cccaaccggc cttcatgagt gggaaggaaa 172680 atgacagtga ggagaaggtg gcccgaccca ctcggcccca cgtgctggtc accagcatcc 172740 ccacgcccac ccacggacag cccttgaagc tttcgtctcc actctccaga ttgagaaacc 172800 gaggcacagt tggctaagtc acatggtcag agaggggatc cgagcctttg ctcgcaactg 172860 cagggctggg taggcagggt ggggcccctc ccagacacat actctgtgcc aggccctgag 172920 agteccegee ccacceagge egecagaaag gaaaatagaa gtggetgeet tecaagaaaa 172980 caaaggagag aggccggtcg cggtggctca tgcctgtaat cccagcactt tgggaagcca 173040 aggtgggtgg atcatttgag gtcaagagtt tgagaccagc ctgaccaaca tagtgaaagc 173100 ctgtctccgc taaaatacca aaaaattagc caggtatggt ggcgtgtgcc tgcaatccca 173160 gctactaggg agactgaggc aggaggatca cttgagccca ggaagcagag cttgcagtga 173220 gccaagattg tgccactgca ctccagcctg ggcaacagag caagactctg tctccaaaaa 173280 aataaataaa taaataaaat aaaacaaaga agggagagtg gagggtgggg agagccagcc 173340 aggagggctt ctggaggtgg cgctcctcca gcatggctac gggacaaggg gcggtcagat 173400 gggccctgag ctctgagcgt tttccacctt cctcctccac tattggtggc cgctcctct 173460 gggggcttag gactctcgtt cccctcgaga acttgaaccc agcccttgtg ctggctgctg 173520 ccttctttac ccatgagaga gctctggctg ggatcagaag acctcttgta aactataaag 173580 tggtacctcc atgaccacag tccccacttg ctctgggggc tcaagaaggg tttgggcctc 173640 tgtgtgtgcc ccccagaggg tacctgctga gagcttctgg gcagcagccc ctgcccccgc 173700 tcacccctg ccaatctgac tgcccacacc ctactaggtg aggggccaca gggaaaccaa 173760 ggcacaggga gcactcaggc cccacataga aaacgcgagc tctcgggcag actgcatggg 173820 acagtggcac ctcatgtttt gtgtgtgtta taaagtcata tttttatctc tatagaatta 173880 tetttacaca tatacaaacg tttgcatttc aacettaaaa tttatatttt atttttctat 173940 ttgtacacac atataaaaat attattttta ctgttcatag agaaaataca gctgatacgt 174000 PTS-0012 -178- PATENT

cgaacccttt	atggctagca	tatagtatgg	tcctcatttc	attttgtaac	cgttattaag	174060
atatcattca	tataccatac	atttcaccat	tgaaagcgta	tcatttaggc	taggcacagt	174120
ggcacaćacc	tgcaatccta	gctctttgag	tggctaaagc	aggaggatag	cttgagccca	174180
ggagttcaag	accagcttgg	gcaacataga	gaaaccttgg	ctctaccaca	aaaaagaaaa	174240
aaatgcaaaa	atcagtcagg	tacggtgatg	tgtgccttta	gcttcagcaa	ttccggaggc	174300
tgaggtggga	ggattgcgtg	agcccagggg	gtcaaggctg	cagtgagatt	acagcactgc	174360
actccagcct	gagtgacata	gcaagaccct	gtctcaaaaa	aaacgtgtat	cattcagttc	174420
ttcttagtat	attcagtgtt	atactaagaa	agaaacccta	tgcccatcac	tagtcacccc	174480
tatcctccct	cctcccagcc	ctggcaccca	ctcatctcct	ttctgtcccc	gatggattgg	174540
cccgttctgg	acttttcaca	gaaacggaat	ctacactaga	ggccttctgc	gactagcttg	174600
tttcacgcgc	atcgtgtctt	cagggtccac	ccacgtcata	gcccgtgtca	gagcctcatg	174660
ccttttgatg	gccatgtgtt	ccatcgtgcg	gacagggcac	gctttgtctc	ctcattcgtc	174720
tcttggtgga	tgtcgggttg	tetetgeett	ctggctgttg	tgegetggge	ggtgctgcag	174780
tggtgggcac	gtgcaggttt	ctgcatagac	atttgctctc	atttgcctgg	tgtgtgccta	174840
ggagtggcag	tgctgggttt	agggćaatga	gggctcaccg	actgctttcc	aaagtggctg	174900
cagcattctc	ttttaaattt	cagcttgcaa	gtgcgagctg	gttgaaacgg	atggtggtag	174960
gtaaacctgt	ggggagggac	ataggggtgg	cggcagttga	agccgcaggt	ggagaatgtt	175020
gggacaggtg	ataccatctg	tgtttggacc	tgggtcaggg	taccttgtct	gtaccttgag	175080
gatggcgggg	agagcacagc	tgggcccagg	tccagggagt	gaggcatggc	agtggccaaa	175140
ggagaggctt	taggtggtcc	tgggagatca	agcagggtct	ggacaggtgg	agggaggga	175200
gggaggagag	tgggctggcg	gtgggggggg	tggaggtgca	tgcagaagtc	agggtgacct	175260
tcctcgtctg	gccccgtct	gtgcgccatg	ggcagcctaa	gcaggcatca	ccgagtctgt	175320
gtctgctctc	cccgctcagc	tgagcgtgtg	gcagatgcag	acagcaggct	ggtacctgca	175380
gaacaggccg	gtcacatgcc	ggtggcccca	tggtcctgct	atggcagaga	ttgaaggagg	175440
ggactgccgg	caggggcctc	agcaccctgg	gcatcggccc	tgctcatctg	caggaaggag	175500
atgggtgcct	ctgggcgcca	ggcatccagc	actggcagct	ggggactggg	gtggtgtgag	175560
ttgtgtccct	gttgtcacag	ctctcacctc	gaggccagta	ggctgtgact	tatagtctgc	175620
ataggacgtc	gtcactgtgg	tcacagcaca	gagtaggggc	tgtgccgaca	ggacctgcca	175680
gcttctggca	cccagaagtt	ttgccctctg	gctgaattcc	aggcccgtgg	ctgctgccct	175740
cacgcctgcc	atgtggtcat	ttcactagct	tggaagacct	aggacagaga	ctgggttctg	175800
cgtcgcctcc	aaatacaccc	aaatgcaggc	cgggctgctt	ccataccccc	aaacgtaggc	175860
cgggccatct	ccatacctgc	aaacgcaggc	caggccacct	ccataccccc	aaacataggc	175920
tgggccacct	ccatacccgc	agacgcaggc	cgggccacct	ccatacccgc	aaacacggtc	175980
caggctgcct	ccaaataccc	ccaaactcag	gccgggctgc	ctccataccc	ccaaatgcag	176040
gccgggctgc	ctccatacat	ccaaatgcag	gctaggctgc	tttgtgccta	gcaaatgcag	176100
gttgcaggag	ggagtcaaga	actgggcagc	cccgggcagc	cacactgggc	aggtgaaggg	176160
ttctcaggct	ggagcagatc	cagttcctgc	ccttggagac	ctcatgccaa	gtggggagcc	176220
agatggggat	tatggcaggt	gctatacccg	gtgctgggga	cttagaaatc	ctggaaggct	176280
tcctgaagga	aacggcaccc	accgaacagc	ttgggagcca	caccccaatg	cacgetetge	176340

PTS-0012 -179-

caggeacegt gtaccetgtg teggeetetg gtegegeate teagtageag acagaggaag 176400 ggactgcgac tgtggctaat gagtagacag tgggcaggcc ctacctgccc ctccacacaa 176460 agtetgtggc etgggeeett gttateatgt eetegteett egtggatagt gtgtgggaga 176520 gagtctagga agtgggtgca gctcccccac tcctgcctct ggtaaccgga gctcattcgg 176580 ctccatgccc actgtcttgc cctggcaccc gagcctctca gattcgagtg atgaggaatc 176640 tettggtgaa tetetteatt tetetgteee tgaateggge tgattetttg getttetgge 176700 agetteggaa gggecaegtg tggtgtggge eccaggtetg ggettetetg ggatttteet 176760 tgcctggaga tgtctttggg gatgtttgat cccagcctgg gcctctagca ctgcccggct 176820 ggcctctagg ctggggtggg aggctggctt ggcccctgat ggggcctgca agaaccaggg 176880 gagtgagtga ggaggcactt gcccgcccac tcgtgcctcc cctcccctgg ccccaaatct 176940 tggtctgttt tcccaagaga aaccgttgac attatctggg tgagctgcac agtcgcctcg 177000 tgtctcaggg ccttagcctc gtccccaggg cttgagacag gagaggccat caaaaccggg 177060 cagcccccc accctgggag agtccggctg tgggccccca gctgatggtg ctcgtgtgcc 177120 cgcaggctgc tgtccccaag gcccagcctc ctcaccccga ctggcgaccc ccgggccaat 177180 gcctcacccc agaagccact ggacctgaag cagctgaagc agcgagcggc tgccatcccc 177240 cccatcgtga gtgcccaccc ccagagcccc acagagtcca ccctgacctt gactttccca 177300 ttcattgaga cagagaatcc cacgggcggg agcatgcacc tgcagcctag ctcatccgct 177360 tctgtttcct ggagaaatcc ccgtggagct gaggtgggaa cagctgggga agctggcagg 177420 cgtaccgggt ggggctccca gtgaaggcgg gaactggcgg cctaaggcct cccccttcc 177480 accccgcagc acccttgaac ccccagatta gatactgggt catggggagg caggagcttc 177540 ccccacccac tcagctatag caacagcttg gccagggaag ggtggcctac cagttctgat 177600 cctggggccc tctgggaaca ccctcctgga aggttctctc agctgggtgc gtgggccctt 177660 ggaggtgcct tctccaggga ggtgagtctg gccttcccag ttgcaactgg gggctccggg 177720 ctaaaagacc ctgagctgac caggctggtg gtcccttggg actttgagtg atgggctcag 177780 ggcgtgtcag gctacacggc ccagtccccg aggcccacag aatcctgttg ctcagtcctg 177840 gcttccctga gacccagagg atttgggtcc acagaaggag ctggaggaga gagtcacagc 177900 aggetetage etectgteca ceaceagget getaggeeag getttttggg aggtgggete 177960 cccctgtcca tcaccaggca gctgggctag gctttctggg gaggtgggtt ccccctgttc 178020 actaccaggc agctggacca ggctttttag gaggtgaact cccctgtcc atcaccaggc 178080 agctgggcca ggttctggga ggtgggtccc cctgttcacc accaggcagc tgggccagac 178140 tttttaggag gtgagetece cetgtgeace accaggeage tgggeeagge tttttgggag 178200 gtgggctccc cctgtccatc accaggcagc tgggccaggt tctgggaggt gggtccccct 178260 gttcaccacc aggcagctgg gccaggcttt ttgggaggtg ggctcccct gtccatcacc 178320 aggcagctgg gctaggctgt ctggggaggt gggttccccc tgttcaccac cgggcagctg 178380 gggcaggctt tctggggagg tgagctcccc ctgttcacca ccgggcagct gggccaggct 178440 ttctgggagg tgggcttccc catgtgctct gtgctaagac ctccctttct tgccgcacct 178500 gggaccttga gcatgteget ggettteeeg ggeettggtt teeaggetgg tegegtgeat 178560

gtctctccct gaccctgtca ctttcagaca ccctctgtga atgctcactt ctgcctgctt 178620 ccctcagcag gtcaccaaag tccatgagcc cccccgggag gacgcagctc ccaccaagcc 178680

agctcccca	gccccaccgc	caccgcaaaa	cctgcagccg	gagagcgacg	ccctcagca	178740
gcctggcagc	agccccggg	gcaagagcag	gagcccggca	cccccgccg	acaaggaggg	178800
tġagtgcaca	ccagtggctg	agtggggctg	gggcagcagg	ggactgacgg	gcaagggatg	178860
tttgtgtgtc	tagagcagct	gctgcaaacc	ccatggccac	agtggcaggg	aaagcaaagt	178920
aaacgaatgg	aacagttgag	cagggggagg	cagttgggaa	tggtagggac	tgcggcaaat	178980
tggagaactc	ttgttttctc	taaagtgggc	acgtattggc	cttggccaag	agtcaccccg	179040
tggcaaatca	ggcctggggt	ggttcttcca	gcaaagccag	aaatccatct	tatgtgaaat	179100
cccctggtc	cctggtttct	caacactggc	aacttctcaa	aattttcaaa	agcattgtga	179160
acacgcaaaa	acatgtctac	agcccagcct	ctgattcggt	gtgaatcagt	ccacgcagga	179220
gcttctggaa	tcacagatgg	ggcccagcac	ccggctggca	gcagctctgg	ggcctgggca	179280
ggaagggctg	ccctccccag	ctggcatcct	gaccttgctc	caggcccagg	tctctgggtt	179340
caccaggagc	cagggttggg	ggtgactccc	gagccgctgt	gtcacaggga	ctgccccggg	179400
cacacctcac	tgtcatcacg	tgaagctcaa	ggtcaggaga	caggcgggcg	tgattgcttg	179460
ttctctggat	cttcaatctc	tgcccactt	cccactaggc	ccaagaaatt	ctgaacctgt	179520
gtccccaaag	aggcatcttc	tccaggtcag	cctggcacgc	agcaggtgct	gttgtgcctt	179580
gcaggtgttg	ggggctgctt	ccccagaggt	tccccaccct	gggctagccc	cggcgcttgc	179640
tggcaggctg	ctccaaaggt	ctgagggcag	caggacacca	ggccgacctc	ctgaccagca	179700
cagcccaggg	acaaatccgg	gtgactggag	ctaccatcag	ctgtcccctc	cccgctgcct	179760
tgggtgtgac	atcccccttc	tctttttt	tttttttt	ttgtttgaga	cggagtgtca	179820
ctctcgccag	gttggagtgc	agtggcacaa	tctccgctca	ctgcaacctc	tgcctccggg	179880
gtccaccgag	gctgctgggt	caggacattt	gttgaaaacc	caaggcccca	ggcaccatgc	179940
tggcagagcg	gggattaggt	agggagaaga	ggaagtctct	gctctgggga	gctgctgttg	180000
ttttgagtga	ggaggatgtt	aaaccaggga	acacgtaacg	aagcaagatg	gttttagagt	180060
cgttcatcca	ccatgagaaa	caaaacgggt	tgagtgaaga	geggeteegg	gaaggaccct	180120
gtggagtggg	aagcagcccc	gcagtgggag	ctctctgggt	gggcattgcg	ggcagaggga	180180
acagcacagg	gaaaggccct	ggtgtggaaa	cacgctcggg	gtgtgtgagg	agtcgccggg	180240
ggtggttgtg	gccagggaag	ggtgggcggg	tggacagtga	gggaagtggg	gaccggattg	180300
tgtggggcct	ctcaggccac	agcgggcagt	ggattttgtc	tcaggtgtgg	caggggctgc	180360
tggagggatt	tgaagtgagc	gtgtgttgcg	gaaggggaag	gaggtgcttg	ttatctgatt	180420
tgtatcttgg	aaagctctgt	ctggccgttg	ttgagtcaag	ggcagcagcg	ggaggtcaca	180480
gcgcagctct	tggcaggcga	cagaggctgc	ctgaaccgca	caggtggccg	tggaggtgga	180540
aggaagggcg	catcgggagt	ttgttttgga	ggcaaagcca	gtggggcgtt	gaacccggtg	180600
tggggatgac	gccagggatg	tctcgctgga	actgggatgc	cccatgacca	gggctgggct	180660
acctggggcc	agggtacagt	gtgcggccca	gggtgtggct	ctgggagacg	ttgcaggttt	180720
ggggcgccag	cccgggaagg	agctgtgtat	ccatgtcagg	ggccccagca	gctttggcca	180780
gcgtcagatc	tgatcagggc	tggaactgca	cggtgccagc	caggtcctgc	tgagccaggt	180840
cgcaggcccc	tgtcctggga	gaaagggagc	caccggccag	cagttcccgc	ggctggcact	180900
cagcccgttg	gtgtggccag	ggcctgtgcc	gtttcctggc	ctcattcccc	gtggggacgg	180960
tgcacctggc	gttaggccct	gcatgccttt	cttgcacagc	ctggcttgca	gctcagctcc	181020

PTS-0012 -181-

cgcagggaca cacatgaact tgacacccag cgctacctct ctggtctctc aggaagccag 181080 cctattctgc ccctggctcc cacacagagc ggctcagcca agcaggtccc tcggggcccc 181140 ctgggcccaa ctggaggaac aggttgtctc tccaggctct cggccgcccg cccagcctgg 181200 cctagcccca gtttgccttc cagcatcgaa cagctcccct cctctctct ccaactctct 181260 ggaactgggc tggaggaagc accagaggct tacagggctg ggtagccaga ggggccaggt 181320 ccagggcgtt tgcaggatct ccagatgtga ggcaggccct gtacaggtgc ctccactggg 181380 gactggttaa gaatgagaat tcccctgcat ctgtgccccc tgcctcctgt gggctgccca 181440 cctcgccagg gcacaagtcc aggggaaaca gtcttcaagg agagaattgg gggcaatttg 181500 gtacatagge ettettgece acetgetetg etcacageag gcatcattaa ttgatettag 181560 cactctcctc cgctgtcaca ccctgatggg ccctcagaac ctcctttgtt catctggagg 181620 cggcgtgata gatgacacct gcctgccatt cctgtcccag aacccagagg gctccgtcat 181680 teceaagttg tgtetetget caacttettg geeggttate tetecatagg attggteete 181740 agggagaggt tcagagctga ggacagattt cagcaaaggg cgagaggcca gcaggaagat 181800 gccatgaagc caggcctgag ccccggggcc ccgctgagtt tacaggatct ccccaggcct 181860 gaaatctagg acccatcatt gcttctctgc cgcaggccat gtggcatagc agtctggatt 181920 aaggccatgg tetgcageee cagtgeetgg gttegaagee getatetgee acttgetage 181980 tggggccttt gaccaggtgg cttaacctct cggcttccat tttcccgtct gtgaaatggg 182040 gacagtcagt cagttccttg tagggtgctg tgagaataaa tgagtgaaca cgcttacatt 182100 gctgtcagcc gtggagccct gagagagcat gacctctcgg taatgccctt tgcacactcc 182160 gcctggtaag tagccctgcc tgagcttggc ttctcagcca gccagcgcac aaccgctgct 182220 tgcactggct cagtgggctt ctgatcctga ctcggctaag tatttgctgg tgaactcaga 182280 tgagcccatt ggtgtgtctg tacctcagtt tcccctctgt aaaatgtgtc tggcagcagt 182340 ctctqtqtqa qcttaaccgg aggctcatgg aggccgtggg atgctgagca cagtgcctgt 182400 gctgagtacc actcagcaaa ctgaggctga cgctgtggtt gttacttgga gggtctgggc 182460 ttataacccc ccactgcccg ccacaacaca cacacacagg cgcacacaca tccatgcact 182520 cgcacacaca tgcacgtgca cgtgcacaca catcacaggt tacctccttc aacattgtgt 182580 acaggcacac acacatccat gcactcacac acacgcacat acacgtgcac gtgcacatac 182640 acacatcaca ggttacgtcc ttcaacattg tgtacaggca catacacaca tccatgcact 182700 cacacacaca tgcacatgca cgcgcacaca catcacaggt tatctccttc aacattgtgt 182760 acaggcacac acacacatcc atgcacacac acacatccat gcactcacac gcacgcacgt 182820 gegegegege acacacat cacaggttae etectteaac attgtgtaca ggeacacaca 182880 catccatgca ctcacacaca catgcacgca cgtgtgcaca cacacacac acaggttacc 182940 tectteaaca ttgtgtacag gtgcacacac acatecatge acteacacac acatgcacge 183000 acgtgcgcac gcacacacac atatcacagg ttacctcctt caacattgtg tacaggcgca 183060 cacacacatc catgcactca cacacacatg cacatacacg tgcacgcgcg tgcgcgcaca 183120 cacacacaca catcacaggt tacctccttc aacattgtgt agagcacagg ccagcaagct 183180 tttcctgcaa agagccggag agtgaacatt ttaggctttg tgggccagac aatctctgtt 183240 gcaaggattc agctctgcca tagacaatac ataaatgcac agatgtggcc acgctccagt 183300 aaaagcgtat tcacaaagtc agacggcggg gccaggcgtg ggggctcacg cctgtaattc 183360

PTS-0012 -182-

cagcactctg gaggccaagg tgggaggatc tcttgagccc agtagttcaa gaccagcctg 183420 ggcacacata acaagacctc atctctacaa aaacaaaata taaactagcc aagcatggtg 183480 tggtgacacg tgcttgtagt cccagctact tgggagcctg aagtgggaag atcccttgaa 183540 cccaagagtt caagacaagc ctggggcaac atagcaagac cccatctcta caaaagtaaa 183600 acaaattagc caggcatggt gcggtggtgg gcgcctgtat tcccagctac ttgagaggct 183660 gaggtgggag aatcacttga gcccagaggt gaaggctgct gtaagccgtg acagcaccac 183720 tgcaccccag cctgagtgac agaaggagac cctgtctcaa aaaaattagg gggcagacag 183780 accetetgag ataccatttg ceaceteetg gettagagge etgtecaggg accttggett 183840 gctgggcttg gttgagtgct tgtggggttg caaagccaga gggtcccgtt ctcgtcctca 183900 gcggcagctg agagccccca gctcagacct tgagatcccc tcccctgctg agcagaatac 183960 catggggtta cagagcagcg cccaggcagg cagacttggg gggcttcccg gaggagccca 184020 ggccgtcaca ggccaccact actgtgggtg caggaaggcc atttgtgtag ggtcagccag 184080 ggctcccgag gtctgactgc cccacctcct gccctcagca gagaagcctg tgttcttccc 184140 agcettegea geegaggeee agaagetgee tggggaeeee eettgetgga etteeggeet 184200 gcccttcccc gtgccccccc gtgaggtgat caaggcctcc ccgcatgccc cggaccctc 184260 agecttetee taegeteeae etggtaagta geteegeeeg agettggget tetteageea 184320 gtgcacaatc gctgtttgca ctgtttgcac tggctcagag ctgcacacag aagcatctta 184380 aagcettatg ggacetgget ggaggaacag eetggteagt ggagggaaag ggggagatet 184440 tttaagaaag ctgccccagg gttgagatgg aagccactgg caagagggag ccacagcagg 184500 tgcttgagct ggtgaggggc aggcttagag tgggagctat gttttccgtt gacggcttag 184560 agctagagaa tgggcagatg gtagaagagc ctggggaggg agcagaggcg ctaccttggt 184620 tcacagactc tgtgaggctg catttcggcc ctgttctagg tcctgcagtc ctgctgggcc 184680 tcaccagctg taaagcagca cagccggggg ctggtacaga ctgctgttgg taaaggctgg 184740 tcccgaggga tgcgtgggcc aagggagcca gaagaacagg gaaagtcatg ccaggcagac 184800 ggaacagcaa gtgcaaaagc ccagaggcag gagagagcag gcaaagcttg agaaactgaa 184860 tctggccacc actgccgaag ctcggtgccc agtgagctgg ggagacccag gggccaggtc 184920 aggcgagcct gaaggccaag tcgggggcta agactttctc ctgaggacag tgggagccat 184980 cgagggcaca cagcacaggg agggtgtgca ccagtagact tttccaaaaa ggtccttttg 185040 gttcctataa ggggaagggg ctactggggg ctacagtgga aatggggaga caggggatcc 185100 agatgagagt tgagggcgct tggatcaggg cctgggcagt gggtgaggtg ggaggcttcc 185160 ccaggatagt ggtgtctgca cctaggactc gggtcactaa tgaggacaga gccaggcagg 185220 gcaatagagg agtgcgcatg gatgggcact tcctggccag gacagggaag aggtggagtg 185280 cagcctggag tgtgtgtccg gcagggacgt gaccgctcct gggccccaca atggacagac 185340 atgtgctcca caggtcaccc actgcccctg ggcctccatg acactgcccg gcccgtcctg 185400 ccgcgcccac ccaccatctc caacccgcct cccctcatct cctctgccaa gcaccccagc 185460 gtcctcgaga ggcaaatagg tgccatctcc caagtgagtg gtagcccttc ctttcttggg 185520 ggcttagtct tcttatctgt aaagtggggg caatgggacc aatgaagtct gagtgggggc 185580 caggeteteg ggggeetggg teatetecae teaggeatet ggggtetgag etggetgggt 185640 cctgccccag gcactcaggg cctcgtccct ggggggtcac tctgtattgc agtcaagggc 185700

PTS-0012 -183-

atggctcagg aaccaggctg tgtggcctca ggcaagttac ttaacctcct gtttccccca 185760 ctgcgaaatg gaagggcaaa tgcaaggggc tcagagggca tggccccttc acaggggagg 185820 gggccgaggc ttgggagtag cagtgacttg tctgccgtca cacagctgga cagcagcccc 185880 agcctctgac ccacacgtgg gctttttgaa caggagcgtc aggcactctg gactgtgggg 185940 gagggaccag ggtgcccctg tgaccccaca actccgcccc tacagggaat gtcggtccag 186000 ctccacgtcc cgtactcaga gcatgccaag gccccggtgg gccctgtcac catggggctg 186060 cccctgccca tggaccccaa aaagctgggt aaggctcctg gcccatccgt ctgggtggct 186120 caggctgggc tctggctgtc ctgtgggtgg ggcgggggag gaaggggtat cttggcccac 186180 ggtactccag gtagcagctg ggaggtcccc cctcagcagc cctggctgga acatggtggg 186240 gaggggcage getteccage ecetggetea ggttgggtgg ggacaageet ecegggacee 186300 tgctccggca gcacgtgact cgctcctctt actggtcctc agcacccttc agcggagtga 186360 agcaggagca gctgtcccca cggggccagg ctgggccacc ggagagcctg ggggtgccca 186420 cagcccagga ggcgtccgtg ctgagaggtg agggcccttc tgccctgggc ccccagcatc 186480 tgcccctgtt cctcgggtgc ccaaagggcc ctttattcaa aacctgctgg gaagtgtcat 186540 ctcccagagg gtctgggggc ccctcttcac agctgtctcc ctcaccattt aggggtaggg 186600 ggactccctc tgcgttgaaa caactagcac aacttgtggg tctctcagtc agggtggctc 186660 tcaggactgg ggcctgggga aggaagggcc acagacacgc cctcagcccc acatcttgtg 186720 tcttccaggg acagctctgg gctcagttcc gggcggaagc atcaccaaag gcattcccag 186780 cacacgggtg ccctcggaca gcgccatcac ataccgcggc tccatcaccc acgtaggtgt 186840 cctggggtgc ggcaggaagg acggttggga ccagcacggg gccagcccat cttataaccc 186900 ctcattgtca ccaaaccatt agcctcagcc gatggggtga tgactggggg acagcagttc 186960 actocatgaa otttoatota gtotgoatgg aatoaggoac tgggattgoo aagoacagot 187020 caaaactctg ccttcaggga gctgccatgt agtggaagga aacagaccag ggtaaataag 187080 taggctggtg aaaaccgagc aggcaggcag aatgtgagcg taccgcggct gagaatgcct 187140 ggccacggac attgcttaga caggtgagga aggtgacatg tcagctgtgg.ccagaagaaa 187200 ttgagggtgc aagccatgcg ggaatctcag ggaacagcat tctaggctca gggaacagca 187260 tgtgcaaaga cagagcatga gagggttcct gaatcgtgcc aggactggtg ccccagcctt 187320 gcagctggtg agctgtggac ccaaggtttt gtgccacgtg tgtctggctc tagaacacag 187380 tgacagagcg tgggtccaca cacttgcaca cgtgcatgca tgttctaaca gtggagcttc 187440 gggcaacaag atggtccaca gggaggtgtt tttcactcag gcagcgtcaa atcccaccac 187500 agaggageca titacactit gecettetet gaaatetgea ggttttaaaa atetgagett 187560 tcaaaggcag ctgtgctgag tgggaagggc aagtgctttg gacaaaagtc aggctgaggg 187620 ccctcgggtg ccagctccac cacctactca gacaggcagc ggcctgccct gactccgttt 187680 cccctttgct aacagtattc ctgggagagt cattctcctg aagtcgtagg gacctttgaa 187740 gttcccaggc atccacctgc tctgggttcc tgagtggcca tgacccgcgc ccttcctcga 187800 acctcccagt tacacacatc tctttgattg cttttggcag acagccagct gccaaaacat 187860 gtgagatagg caagggtcaa acttccgtgc agtctcacta ccagatagtg aggaagtcag 187920 cgtgtggcct gcacgcacag agccgtttat taactgagta ggtgccatag gcagggacca 187980 cgtggttccc agctggcaag ggaggtcaag gaagtcccag ctccctgatc ctccagggac 188040

PTS-0012 -184- PATENT

ttcctgccca tcttgggagt agagttcatt ggggccaaga gcaagaggct acaggctcat 188100 ctcctggaag cagacgttat gcaaacagaa gcttccctgt taatgggagt ttgtccagtg 188160 tattctccca agagcagggg ccaccggctg gatttctgtt ctctgtccat gtccctgaag 188220 atggcacctc taaaatacta tagctcaaaa acatcaagct ggacacggtg gctcttgcct 188280 gtcaacccag cattttggga ggccaaggtg ggaggatagc ttgagcccag gagtttgaga 188340 ccagcctgga caaaaagagg cctgtctcta cagaaaattt aaaaattggc tgggcatggt 188400 ggcacatacc tgtagtctca gctacttggg actgggaggc aggaagatca cttgagccca 188460 ggagtttgag gctgcagtga actatgacag tgttctgcac tccagcctgg gcaatacagc 188520 aagacccctt ctcaaaaaaa aaaaatcaga tgcctcagtt tcaccatgga gagcccccct 188580 ttttaaatca tttattgtgg tgttcagtaa gccactgatt tctgcagtac aaacccagtt 188640 ctgacatgga ccatctgatg ttagggctgg atacagaaag gggtgcactt gtgttagctg 188700 cctcttgggg ggcttttccc gccaggatgc tgcaggaatc ctgtgctttc ctgatgggag 188760 aggtggetgc eccgagetgt cacetgacte ageacetatt gtgccacact gttagtgtac 188820 aggtgtctta aagcacagca gggagatgct gctcagagta tttgctttgg gaagtttggg 188880 gggageteat cagaatteag ggegtettge tgttgeete cgcaaagace aggatetgeg 188940 gtgaactccc cggggtacca ggtgctgccc tctgccaggg gatgtcccca gccaagcaag 189000 tccagccaga gactcagagc tcactggtcc aggtcttggg atatagtagg acctttaccg 189060 ttgaatctgc tcctggaacc ctagaaagag aagagggata ttgagatttg gggacccgtc 189120 gtctgtgcca gatgcctttg agaatcatca atgcagaagg tctccatttg tggatgtgca 189180 aactgagget cagaaaggag gtcccacggc agcttggtag taaagttgct gtttgacacc 189240 caacattetg ettecaaagt catattetaa etetgatget tgtgttettg aaagteacce 189300 aaggcaggat getgeeceae gtggeeatet eetetetget tgaacacate etecaaeggg 189360 aagctcattc cctatatggc agtggttctc aattggggga aattgtgcct ccaactctct 189420 agggacattt tcgattgtcc taacttggtg ggggacacac tggggaggcg tgtactcctg 189480 gettetagtg etttgaagee agggatgetg ttaacageee acagtgeaca ggacageeec 189540 acagcaaaga agggtccagc tccagctgtc aggagggccg aggtggaaaa cctgggttag 189600 aactaaaatt teeggtgtge tgeeetgaeg tgagteettg teetggtttt aggaaaceaa 189660 agtgcatgac gtggtcacgg gtacagcaca ggagcagaaa ccccagcgtc cccgccagtt 189720 accepttttcg gtaactgaat gtcaaggctc tgagtagacc ccacgcagtg gtggggacac 189780 agactecagg accagaatge etgggtteaa gteecegeet geecettatt agecaggtga 189840 ccccgggtaa agtcactgtg cctccctgtg cctcggtttc cccatctgaa acaggcataa 189900 tcaatagggt tgtcttaggg ttgtttcgag gattaaatga gcaaatccat agagagcacc 189960 cagaacagcg tecactcatg ggaagcactt gacaagggat cttcattctt caggttcctc 190020 atagggtttt gttccatgca aactcttacc tatttgagac agtgtgtgtg tggacacgcg 190080 tgtgcatcgg tgggcacatg ggcttttaag cacgtctttg cctgcatttg agttgagagg 190140 ggtcctgggc tgcagcctcc tgggcgctca ccctctgca cctgcagggc acgccagctg 190200 acgteetgta caagggeace ateaceagga teateggega ggacageeeg agtegettgg 190260 accgcggccg ggaggacagc ctgcccaagg gccacgtcat ctacgaaggc aagaagggcc 190320 

tgtgcttggc	ccactgaggt	agcttcacag	ggaggcaggg	ctggattgac	atcagaaagc	190440
acaatctgat	aggtggtgac	ctccttatcc	ctgcaggtat	gcaagccagc	agcagggaag	190500
cgttggcctt	agctgcctcc	cacctctgcc	cagttcttta	cagtttagaa	aacaaactca	190560
tggccaacct	ttttagaagc	ataggaggga	aactgaggcc	cggaacagaa	gcccgagctc	190620
acgccgccag	gcctccagca	ccgtactgac	aaaccacgca	ctctctcatt	ggccatgaaa	190680
gaggccatgg	ccagagtgcc	cctcgcccca	ctgtgtccca	ggctcttgct	gcggagcccc	190740
catcctctcc	ctctctaggc	tctgggttcc	agaacgagga	gaccctgcca	ggaaggagtt	190800
aagggaatcg	agtgccggga	aagagaattt	cctggcagcc	tagggcaccc	aggggtgtgg	190860
agatgaaagc	tgctaatggg	cgcctctctc	agcactgcag	ctgcgaggcc	cggaattgcc	190920
tctcctccat	ccacttccgc	ctgtgcccgc	agececetee	ccaggcctgg	gaggtggagg	190980
tggcaccgtg	tggcttagga	acataatgca	ctccctgctg	ccacagagat	agccttggag	191040
acaggcctgc	agctgtgtct	tgggtgccag	ctcatgccct	ggtgcccctg	gaccgagtgc	191100
cctgggggtg	gcgggaagcc	tgggaagggc	tggtggtggg	gttagtcaag	agcttgtctt	191160
gagaggtcac	tgggtagagt	cccaccttgg	gaccccagac	cagtgcctga	gcctttatag	191220
gccttcagcg	tatcgtcttc	atcatggġtt	tcagtcgggg	cctttaaact	ctcgtctgct	191280
ccctgggcca	ggtaggcagt	gcaggcagcg	gcaggtgtga	gactgtaggg	agtggggagg	191340
actgtaggga	atggggagga	ctgtggtgcc	tgctcacgcc	gtccactccc	ctgcggccac	191400
cggtcagcca	ggtttctcat	ctccgttttt	atctgaaatc	tcccgatgtt	taaacatcgg	191460
cgattaattt	ggaacgtttt	ctgaacagca	acctagtacc	ctcctgttgg	caacccctgg	191520
agtagctcac	gggccgtggg	ccacacgaag	caatggttga	aaagcccgag	agcctgtcag	191580
ttgctcattc	cctctgaggg	araaaacaaa	ggctcccggg	gctcatttct	gatagctctg	191640
gactcggctg	ccctggaagg	agagccctgg	ctagatgggc	aaagcccagc	ctttaccttc	191700
		cacctctctg				
		gaggccaccc				
		gacttgtggt				
tctgggtgtg	acacgtgtat	acatacaaag	ccgtgtactg	cctgcaccct	ggtacatgtg	191940
		tctcagcagc				
		gccagtgcac				
		acacgcgtgc				
		gcctgccaca				
		acacatccac				
		ccccatgtcg				
		accettgett				
cagggtgcag	gcagcgtgcc	ctgcatctcc	caccgtgcaa	cccctggaa	aagctcctgg	192420
		gggcctgcag				
		agcatggaag				
		gtcctgggcc				
		tgtgacccag				
ggacccccc	atgagacggc	cgcccccaag	cgcacctatg	acatgatgga	gggccgcgtg	192720

	ggcagagcca	tctcctcagc	cagcatcgaa	ggtgatagca	gggaggagac	ttcatctctc	192780
	ggtgcccct	ggtgggcggt	ggggggatgg	ctgaccccgt	tttacagatg	gggaaaccga	192840
	ggctgggctt	tctgaggctc	catctggagg	tagcgcaggg	accttcccgt	gctgggtcct	192900
	actccaccat	catcgtgggg	atgaccactg	gcggctgtaa	acactgaccc	ctgtcactgo	: 192960
	ccagtgtcgg	ctcagggagc	cacggaatga	tggcctcacc	ctctcctacc	caggtctcat	193020
	gggccgtgcc	atcccgccgg	agcgacacag	ccccaccac	ctcaaagagc	agcaccacat	193080
	ccgcgggtcc	atcacacaag	gtactgccct	gttccctgct	ccctcgttgc	ccccaacggg	193140
			gggagggaga				
			gcagcacaca				
			tcaaaacaaa				
			agcaactgtc				
			tcctggtgag				
	tccgagaact	ctttcaggtt	ctcgcggctg	gtccatggca	cagccagcta	ctgtgaactt	193500
	ggcagctttg	tgggttttat	tttttattt	tttattttgt	tgttgttgtt	gctgtttgag	193560
			ccaggctgga				
•	cctccgcctt	tcaggcttaa	acaatcctcc	cacttcagcc	tcccaagtag	ctgggaccac	,193680
			agctaatttt				
			actcctgagc				
٠			gagctactgc				
			gaggtggttc				
			gatttcctgg				
			aacccactgg				
			tgtcggcccg				
			ggaggccaag				
			gaccgaggcc				
	ctgaagccgg						
	gagatecege (						
	aaggagggct						
	ggggtggcgg						
	agagccctcg (						
	ttccagggct o	gcgcaggggg	caccaggete (	ctgacctgat	tctactgaac	tcacattgtt	194580
	cccattcttc a						
	ggactaaaca t	agtgacgag	taactgcctc (	cgttgaatct	ttgtgagggt	ccaggtgcgg	194700
	cctgaggatg t						
	ttaatgacct t	attttattg (	ctgagtaaat t	gaggttcag a	agaggttcaa (	cgactcaccc	194820
	agagtcacgc a						
	tccactgcac c	caccagcag g	yttgcaccac a	agaggcccc a	agtococcca (	ggcggcccca	194940
	gctcagtagg g	gaagtteeg t	gccgatggt a	ıcgaggacga (	ggagctgttc q	ggtggaaagc	195000
	ccctgaaggc c	actgtcctt o	cacatgggc a	igaggtggcc t	cttgtgaag g	gggaaggaga	195060

PTS-0012 -187-

atgggagcca ccacggggct gtggggctgt gaggcggaag gactggggtg ggtgtcccgg 195120 gaggggttcc agcttgtagg aaggttttga agccagggag aaggcagaag cagtaagatc 195180 cctgattgcc aggggaaggg tttggctctc agcccctagg caattatgga gtccttggaa 195240 gcatccaccg catgaccaag acagggtcca gattctagaa tattcttttg aaaaacaagg 195300 gcagttcccc ttcttacgac agtaatgaag acatccctaa atagagtttt gttgcttgca 195360 aagccctaaa gtcccaccat atcaagtgtc tccgaagcct gctgaaaaga ggcaggggac 195420 ctggtggcct ggctacgaag gtcccagtct ggactgtgac cccccattt cctcaccatc 195480 ctttctgtct ggagggcaaa cacctcagcc ctgacctcag tgtccctggg gctgaaagcc 195540 tcagggcggg tagtattggg tctgggtgct gactttttct gcttggcatt gggtgggcca 195600 tggagggtcc caggctgaac agaggaatgt tttttaccca catgagggtg ttgggcttct 195660 ttctcgcaaa ctccagggac catcagagag cccaccactc gcggcaggga gagttgactg 195720 ttgaactttt tacccctttc tgcagtcccc ccagggagcg tggggaccag ggtcaggccc 195780 agggtgcgca gggcagtaag taacaagtgt gccatctcag ggttagcaaa gccctctgtc 195840 tccctgcctc tggaggcatc agatgtcact tccatcttat agatgacaaa ctttttgagg 195900 ctcagaaggg ggatgcagct ggtctgggct atggctgtgg ccagggctag agcttacatc 195960 ccctctgccc cagggcaccc cgctcaagta cgacaccggc gcgtccacca ctggctccaa 196020 aaagcacgac gtacgctccc tcatcggcag ccccggccgg acgttcccac ccgtgcaccc 196080 gctggatgtg atggccgacg cccgggcact ggaacgtgcc tgctacgagg agagcctgaa 196140 gagccggcca gggaccgcca gcagctcggg gggctccatt gcgcgcggcg ccccggtcat 196200 tgtgcctgag ctgggtaagc cgcggcagag ccccctgacc tatgaggacc acggggcacc 196260 ctttgccggc cacctcccac gaggttcgcc cgtgaccacg cgggagccca cgccgcgcct 196320 gcaggagggt gagtggggtg tgcatgggcg tgagtggggt gggcgcctgt ctggagaagc 196380 tgtgcctccc catccaccat tagcttagtt tgcacctggg atatcctcgc cacccgcttt 196440 ccaccacate caaaccacet geaggeeegt gggetetgee teegatteea aaccetgtee 196500 aactccttgc cacctcccag accaccgtgg tgtctcacct agcttccccc acgcccctcc 196560 ctcttcctgc tgtaatccac tctgcaaaca gctacccgga tactttctaa aaatgcaaat 196620 catattattc cacttccctg cttccatcct tctagcaact tcacacattt tgctatggcc 196680 ttggggcgcc tgcctgttgg ggccctgcct gcctctcatt cagccggatt ccttcgtcct 196740 ccccaqccc agccctqqq ccctctttct ctttgttccc tggccatgct tagctcggtc 196800 cttccagatc tttacttagt gggtttcttt ccatccctca ggtctttgtt tacatattac 196920 atccttgggg aggcttctaa ccagacccc tatctccagt tcatatcaca tgctgtgaca 196980 ttttaaaatt gtcttccggc caggcatggt ggctcacacc tgtaatccca gcagtttggg 197040 aggtcaaggc aggcagatca cctgaggtca ggagttcaag accagcctgg tcaacatggt 197100 gaaaccctgt ctctactaaa aatacaaaaa aataaccggg tgtggtggta cgcacctgta 197160 ttcccagcta ctcgggaggc tgaggcagga gaatcacttg agcctgggag gcagaggtta 197220 cagtgaacgg agatcgtgcc attgcactcc agcctgggca acaagagtga aactcttatc 197280 tcaaaaaaaa aaaaaaatga aagaaaattt tcttctgagc gtgtttcact ctgtaattct 197340 catttgtttg ctagtttatc acctgtctct cgcattgaat gtcagcttgt gagggctggg 197400

PTS-0012 -188- PATENT

atttctgttt cgttcactgg ggtgacccca gttctcacaa caatgcttgc cacgtagtag 197460 aggctgcatc aatattttt aattgattga gtgagtgaat ggatgaaaga atgaattttt 197520 taaaaactat aacacaaaag caaatgagtc agtgagcaaa aagtgaacta aggcaatgaa 197580 gaaatgaagg agtgaatgaa gagacctggt ccttgggatc ccgaggtccc tatcctcaaa 197640 caactccccg taaatgccag ccccagaggc ccgatgcatc caccttgccc gtccacaggc 197700 agcetttegt ceageaagge atceeaggae egaaagetga egtegaegee tegtgagate 197760 gccaagtccc cgcacagcac cgtgcccgag caccacccac accccatctc gccctatgag 197820 cacctgcttc ggggcgtgag tggcgtggac ctgtatcgca gccacatccc cctggccttc 197880 gaccccacct ccataccccg cggcatccct ctggacgcag gtgattgccc tggggctccc 197940 agaaccctgc agtggtgctg aacagggcca cggacctcat cagtgttcgc tcagggactc 198000 cttaggcatc aactgtcagg ttcccctgga tggcgaaact gaggcctcgg gattggaaga 198060 cccaacagtg taatcatgag cttaggttgg agcagaattt ctcttagtag tttgcaggac 198120 atgtggggtt aaacatttca gtggttttct tttccggcag gacttatcag tgcctttagc 198180 aatgcaaagg tatagaatga ggacttgagt atatgcattt ttcaaataga catgatctga 198240 aagtettttt taaaagttge egggeaeggt ggeteaeace tgtaateeea geaetttggg 198300 aggccgaggc aggcggatca caaggtcagg agatagagac catcctggct aacacggtga 198360 aaccccgtcc ctactaaaaa tacaaaaact agccgggtgt ggtggcgggc gcctgtagtc 198420 ccagctactc gggaggctga ggcaggagaa tggcgtgaac ccgggaggcg gagcttgcag 198480 tgagccaaga tcgcgccact gcactccagc ctgggcgaca gagcgagact ccttctctaa 198540 aaataaaaga aattaaaaaa aaagaaataa aaaaagttgc atccctttgg agtgttaatc 198600 tgcattggga tgtcctatgt ttgggacaac tttgatgcaa aaagcatcct tcgtagaagt 198660 caccetetty tyteetygeg tyatyttte etgetyteeg acgeteagtt etgytttyty 198720 ctttgggcag ccacacatgt aggtgggaga agctgtccgg gtgcagaagt agggggcatc 198780 cagacaggtg gagcgacacc atcaggccta ggtatggctg gcctcacatg agctcccctc 198840 tgccccgcag ccgctgccta ctacctgccc cgacacctgg cccccaaccc cacctacccg 198900 cacctgtacc caccctacct catccgcggc taccccgaca cggcggcgct ggagaaccgg 198960 · cagaccatca tcaatgacta catcacctcg cagcagatgc accacaacgc ggccaccgcc 199020 atggcccage gagetgatat getgagggge etetegeece gegagteete getggeacte 199080 aactacgctg cgggtccccg aggtgagtgg gtgggcagac cacctccgct gggtttggcc 199140 ttattcccaa aggacatggg cgtgcccctg tggcctcgcg gaggcagcta gacctggtca 199200 ccttgtgggt caccttgtgt gaacggacct gagtgggtgg cctggggttg tgcgtgctgt 199260 gggtgctggt tggcatctgg taggtgagtg cacagcgtgt ggctcctggc tgcatcctca 199320 gtgggtgtgc gtgcatctgt gtatactctt aggatacagg ggcctcagga gtttaaagat 199380 caaaatgtgg ccgggcacag tggctcatgc ctgtaatccc agcacttggg gagggcgagg 199440 caggtggata acaaggtcag aagttcgaga ccagtctgac caacatggtg aaacccgtct 199500 ctcctaaaaa tacaaaaatt agccaggcat ggtgatgcgc acctgtagtc ccagctactc 199560 actaggctga ggcaagagaa tcacttgaac ccaggaggtg gaggttacag tgagtggaga 199620 ttttaccatt gcactccagc ctgggcaaca gggcaagact gtgtctcgaa aaaaaaaaa 199680 agatgaaaat gtgaggctgt ttggagtttg ttcctttgcc ttgtaaacag cccacagctg 199740

PTS-0012 -189-

ctttgcgtgc acacgttcca gggccatcct cagaaatgct tctggaataa ccaagttcta 199800 gctggggctc agctggaaaa gctgaagtca cacttaagta ttttgaacag tgaggattga 199860 atacagggaa tggattgtgt aggcgtcaga ggctgaaggg gcacagaggg cctgagatgg 199920 gaaccagtga gggcagctgc aggagatgcc ccggctcggg cttgggagca gaagaggagg 199980 tggtaccgag agaacctgag cattcagaaa agggttccat ggctggtgct gggagccgag 200040 gagggagtgc ctgccaccag ctctgctggc tccaggagtg tgtgccgtgc tctccaggag 200100 ggtgatctgg ccggtgggca gcctggcctc tctcctccct gtggctacag ccctggccca 200160 acaceteceg caggeateat egacetgtee caagtgecae acetgeetgt getegtgeee 200220 ccgacaccag gcaccccagc caccgccatg gaccgccttg cctacctccc caccgcgccc 200280 cagcccttca gcagccgcca cagcagctcc ccactctccc caggtagcgc cactgcccag 200340 tctggggtgg ggaccccggc atccatggga ggcggctggg ggatgggcgg gcagaagccc 200400 tgctctcttt cccaccccag aagacaaagc caggctcttc ttcggccctg gggctgagtc 200460 tctggccttt gggtttccta ggaggtccaa cacacttgac aaaaccaacc accacgtcct 200520 cgtccgagcg ggagcgagac cgggatcgag agcgggaccg ggatcgggag cgggaaaagt 200580 ccatcctcac gtccaccacg acggtggagc acgcacccat ctggagacct ggtagggcat 200640 cagagecece acceeeget eegggactee ttgtgggeeg caagaggeet eeeetgetg 200700 atgccactga ctgtcaccag gtacagagca gagcagcggc agcagcggcg ggggtggggg 200760 cagcagcage egeceegeet eccaetecea tgeceaceag caetegeeca teteceeteg 200820 gacccaggat gccctccagc agagacccag tgtgcttcac aacacaggca tgaagggtat 200880 catcaccgct gtggagccca gcacgcccac ggtcctgagg tgggccaggt tggcatgggg 200940 gagggggcgg gcaggtggat gggtggtcag taggaggatg agcagataag aggatgcttg 201000 gtgggaggta tatgggaggt gggtgggtgg gcagatgtgt gggggtagaa gaatagacta 201060 tgtgtgagta gtggatgggt gggtggtcgg gttaggtggg tgtgtgggtc agtgggaagt 201120 taggttagct gcgtgggtgg atggatggat ggatgggggg gtggtcgggt taggtgggtg 201180 ggtgggtcag tggaaagata gatggctggg ttagctggtt ggatgggtgg atgatcaggt 201240 ttggtaggta ggtgggtggg tggaaggata gatggccggg ttagccagat aggtggttgg 201300 gttaggtggg taggtgggtc agtgggagga tagatggtta ggttagctgg gtgggtggat 201360 tgggttagct gggtggatgg atgggtgggt ggtcacgtta ggtaggtaag tagatgggca 201480 naaacacttt gctgaatcca gaaacactga tgcaagaggt gggtttccat ggccttagga 201720 agetecacet etgtggettt geagagtaca geeceeteet geetgettte atgggetgge 201780 attgagtgtc tgccactttt ccaggcacat ggtgcaagct gtcaatggag ctaccattct 201840 ggggtttgga gaacaatggc cctcttctca cagcttcact agtccctaac tggggactct 201900 gtttgggggc tctgactcta catttccctt ctgcactgcc ctaacaaagg ttctccatga 201960 gggctctgcc cctgcagcaa acttctgcct ggatatcctg gcatttccat acatccactg 202020 atatctaggc tgaggattca aatccacaac tcttatgctc tgtgcatctg caggcttaac 202080

PTS-0012 -190-

accacatgaa agccactaag tcttatggct gacaccctat cgagcagtgg gttaacatat 202140 atctggagcc cttttagcta caactggcac ttgagtggct gggacacagg gagcaatgtc 202200 ccatggatgt gcagggcagc aggtccctgg gcatggacaa tgaaaccatt cttctctcca 202260 agacctctgg gcttgtgatg ggaggggctg ctacaaagtt ctctgaaata ctttcaaggc 202320 attttcccac attgtcttgg ctattaacat tcagcaatgt tacatatgca aatttctgta 202380 gatggcttga attactccca taaaatgggg tattcttttc tagtgcatgg acagactgca 202440 aatattctaa acttttatgc cctgcttccc ctttaaatat aactctcagt ttcagacatc 202500 tcattgctca cacatatgac catatgctgt tagaagcatc caggcgacat cttcaatgct 202560 ttgctgctca gtgtgtgggg gtgtactaca atacattcat gcttatatac aatgcatttg 202620 aggttgaggc atgtaaaaat actaaggcac tgtgtgtatg ttgtttgtgc atgatactgt 202680 aactccttgt ctctgaaaac agtacaagga acaggatgtg tgataaggag tgctgaagac 202740 agcatcctaa gaatgtggtt gatgcttcag atgaataaat aagtccatat gacctcatgc 202800 ctgccccaa atagccacct gttgatgaat tataatctnn nnnnnnnnn nnnnnnnnn 202860 nnnnnnnnn nnnnnnngt tagtgettee tteaggatet ettgtaegge aggeetgttg 202980 gtctcttatc atttgcttgt ctgtaaagga ttttatttct cctttgctta tgaagtttag 203040 tttagctgga tgtgaaattc tgagtagaaa attattttct ttaagaatct taaatattgc 203100 ccccactgt tttctgactc atagggtttc tgcagagaga tccgctgtta gtctgatgag 203160 cttcccttgt gggtaacctg acctttctct ctggctgctc ttaacctttt ttcctttatt 203220 tcaactttgg tgaatctgat gattatgtgt cttgggttac ccttctctag gagtgtcttt 203280 gtggtgttct ctgtatttcc cgaatttgaa ttttggcctg tcttgctagg ttggggaagt 203340 tctcctggat aatatcctga agagtgtttt ccaacttgct tccattctcc ccatcacttt 203400 tcaggtacac caagcaaatg tagatttggt cttttcacat agtcccatat ttcttggagg 203460 ctttgttctt tccttttcat tcttttttct ctaatcttgt tttcacattt tatttcatta 203520 atttgatctt cagtcgctga tatcctttct tccacttgat tgatttggct attgacactt 203580 gtgtatactt cacgaagttc tcatgctgtg tttttcagct ctatcaagtc atttattctc 203640 tactccaaac tggttattct agttagcaat ttatttaatc ttttttcaag gttcttagct 203700 teettgeatt gggttagaac atgeteettt ageteagagg agtttgttat tacceacett 203760 ctgaagccta cttctgtcaa ttcatcaaac tcattctcca tccagttttg ttcccttgct 203820 ggcgaggagt tgtgatccta tgaaggagaa gagacattct ggttttggga attttcagtc 203880 tttttgcact ggtttctccc catcttcatg gatttatcta cctttggtct ttgatgttgg 203940 tgacctttgg atggggtctc tgagtggaca tccttctgtt gatgttgatg ttattccttt 204000 ctgtttgtta gttttccttc taacagtctg gcccctctgc tgcaggtttg ctgcagtttg 204060 ctggaggtcc actccagact ctgtttgcct gggtatcact agcggaggct gcagaacaac 204120 aaagattgct gcctgttcct tcctctgcaa gcttcttccc agagggacac ccaccagctg 204180 ccagccggag ctcttttgta tgaggtgtct gttggccccc actgggaggt gtctcccagt 204240 caggcaatgt ggggtcagga cccgcttgga ggaggcagtc tgtgatgaac tattctcann 204300 

PTS-0012 -191-

agctggacta cagtgtgcac cacaatgacc agccaatttc cttgatattt ttttaagaga 204480 tgggatctta ctacgtggta caggcctcag cctcccaagt agctgggatt ataggtaaga 204540 gccaccacac ccagcccaaa ttagattgtt tctaaagaga tattctgacc acgcctttaa 204600 atatctaatc ataagtcacc tactgaaaaa ccgtccttga cttctgtatt agtttcctat 204660 tgctgctgta acacaaactt agtggcttaa aatggcacaa atgtattgtc tgacaattct 204720 ggaggtgaga atctagaatg tgtctcactg ggctaaaacc aagatgccag gctgcgttct 204780 cttctgaatg cctagcggga aattcattgt cttgcctttt accacttcct tggagaagga 204840 gtctacatgc tttttttggc gcatggccct cttctgtatt caaagctagc aatggctggt 204900 tggatctttc tcaaactcta tcactctgac ctgcctctgt cttctacttt taagtacctt 204960 gtgattccat tgggattgtc tggataactc aggatagtct ccttatttta acatcaactg 205020 tttaacaaca ttaactcgct ctttaactct ggtttctctt tgctatgtga cataagacac 205080 ttacagtttt tgagggttag gatgtggaca tcgtggaagg gagacattat tcctcctacc 205140 atggcttccc agtatctagc aaacccatcc tggctgcctg ggtcttctac actgtgggct 205200 cgaatttact ctccagcctt acccccaaga cctcatgtcg tatgtgccct cgagttccac 205260 acacaccagt ccatccagat cccccaacac accccacact cacacagete atagcattgt 205320 ttcttgcatt ttatcttctt tgatgttctc ttcattccac gctgcctccc tttactcacc 205380 accaagatga aactctgttc atcctcggac ttatagcaaa tgcatctttc tccatgaagc 205440 tttcccccta actttttccc tctggatgtt catatcataa tgtttgtacc tctctgtann 205500 gcgttaagta ggtaggtaag tgggaggaag aaagaatggc ccagattagc caatgtgaag 205680 gaaaggatgg gggggtggnt aagttaggaa ggtagggggg tggggggagag tatagacgct 205740 ggcttagntg ggggggtgga tgggtgggtg gtagggttag ggaggtagnt gggtgggtga 205800 gagtatagat ggctgggtta gctgggtggg tgggtggatg ggtgggtggt agggttaggt 205860 ggatgatgga atggatggtt ggatgagtaa ttgtggggat gagtggatgg aggccccagt 205920 ggatggacga tgagttgggc ggtgggatga gtagatgggg aggttgtttg gtttgagaat 205980 agaatctgtg gagagggaga gactgaatgg ggactgtgag gaaagacttt cccggtcccc 206040 cacatttagc aaggccagca aggaaaagag gtgtccctct tgcctggaca aagtcccaag 206100 tttctctgag atgggagagg cccctgagtg ccctctggtg acacacactc cagagactgt 206160 gggcagaget getteaceag gggggtgggg teacacetea acaceettee etgeeeggaa 206220 ccttttttt tttttttt tgatggagtt gtactctgtc gcccaggctg gagtgcagtg 206280 gtacgatete tgettactge aacetecace teetgggtte aagtgattet cetgeeteag 206340 cctcccaagt agctgcagtt acaggcacgt gcaaccacac ccggctaatt tttatatttt 206400 tagtagaaat geggttteae caegttggee aggetggtet caaaettetg aceteaagtg 206460 atctgcctgc ctcagcctcc caaagtgccg ggattacagg cgtgcgccac cgcactcagc 206520 ctccaggacc tatttagagg caacttactc ctccaaaatg aattttcatt caaaaaagta 206580 cttgtgcccc aacttgccgc ttggatgcct gaagtcatac ctcccctaat cattatttca 206640 attatgaaaa atggcatcgt ttcccaaaag cagtggcgac tttgtcaccc ctgactcaga 206700 cccagcaggt gcatgaagca ctaatccctg gctgtgggga gcagggttcc gcacacaggc 206760 PTS-0012 -1

-192- PATENT

tctgtgggat atgcccgtga cagccgattc aaaaatataa tggagaaaac gagtgcctgc 206820 ccactgcccg ctcatgaatg aggctctggg aggtagagtt agcgagagat gggggtgccc 206880 ccatggaaac gcagggctcc gggaaggcca cgtgggtgga gcagccggct cctgttccag 206940 ccccagccct gtgcaggggc agctgtgccc cagcttctca ctcacagagc tgggaacagc 207000 agetttetet gtteteaacg cecaecetgg eegeceetg geateettee cettgetete 207060 teactectea egtggetttt ttagetette gggtateetg ageaggeeca geteecteat 207120 gtgcccctc cctgaagacc tcctagccct gcctcagctt ccttgccgtt ctctcctggt 207180 acctcattga ctacctccac acagttacca ggctctgtag agcttgggat atctgttaat 207240 gtgatcgtag tctgttttct gaattagatg gtaagatgct tgcatccgtt ttatgaccgc 207300 tgtattcaca gtgtctagaa cagtgcctgg cacctagtag ctgcttaatc agaagttttg 207360 gaatgatgca aggaatgaat gaacgaatga gtgggatggg tcaaaccatg acgcacagag 207420 tctggcaggt tacagtcagg agggcagttt cactctggga gcagcagggg atgtggattt 207480 ateccaggge aatggggaet categagggt ggtggaggaa gagggeaget eecatgaetg 207540 cetgacegee tteteteete eeccaggtee acetecacet ceteaceegt tegecegget 207600 gecacattee cacetgecae ecactgecea etgggeggea ecetegatgg ggtetaceet 207660 accetcatgg agecegtett getgeecaag gaggeeceee gggtegeeeg geeagagegg 207720 ccccgagcag acaccggcca tgccttcctc gccaagcccc cagcccgctc cgggctggag 207780 eccgcctcct ccccagcaa gggctcggag ccccggcccc tagtgcctcc tgtctctggc 207840 cacgccacca tegecegeae ecetgegaag aacetegeae eteaceaege cageeeggae 207900 cegeeggege cacetgeete ggeeteggae eegcaceggg aaaagaetea aagtaaacee 207960 ttttccatcc aggaactgga actccgttct ctgggtaaga ccaccctgac agcggccacc 208020 ttcatagacg cgattatcat gcgtcaaatt gctcacgata aaggggcgcg agaaggaggt 208080 gcgctggcca acggctcccc tcgcgatggt aagacttccg gcccgcaccc accccgtctc 208140 gtggtccaaa gatatttca gatctctgct ttttactttg gcccccgttt tttttgttgt 208200 tggttttggt attttgtttt gaagcccatc cgtcctcgcc ggtttgcacg cgctgacgac 208260 tactccggcc gcgcctgccc ctctggtttg ggggcgctca tcatttgcac atcattttac 208320 catggttttt tttttttgga tttttgcttt tttttcttta atgaatggat ctgtgattct 208380 gacttcgact gcgccccat ctccctcttt gcgcctgtgt ccagggagca gggatggggc 208440 tgcgggaggg ctcgggccta cgccccacc tgccggctgc ctggatgctg tcggactggg 208500 ggaagtggag gcaggcggtg caaggagaag ctgaggcggg gcagggacct gcgctgtcga 208560 ggaggagetg ggtetggete ttgcatettg ceetgteece ageceetgta eeceagaaaa 208620 aggggagece tetgeetetg gacceetgee ttggeectag tteatggete etetetgttg 208680 gactgggatg gccgaggcta tagcccaggc ggggccccgg ggacccaggg tcactcccag 208740 ceacacece actteteact ecgececaca cacteettee ecagagacee atgetgeece 208800 catctcacgc tggcctcgcc cggcctccac cacctgaacc catctctgtc ccttcttgcc 208860 taatctctct ctgtgtctcc ctctctgtct gtctctgtcc cgggctctgc atctctctcc 208920 acctetecet tggcetecet gtetetecee aacacceete tetgcettae tgtetttggg 208980 agcccaaacc ctacccctag cttgggttcc ccttgacccc cccggggtcc cagccagctg 209040 ggagggcagc cetgeeeete gggeteegaa accetgggee eggtgeetga etetgeacce 209100

PATENT

		acggcagcag				
		tgacccacga				
cgacaagagc	cacctggagg	gggagctgcg	gcccaagcag	ccaggtacgc	cccacccagt	209280
acccaggccc	ccgaagccct	gcacagtgag	gaccctcaag	gccccatcat	gcagatagga	209340
aaacagaggt	gcctaaaggc	caaggaattg	gctggatcat	gaggctcaaa	ggcatggggc	209400
tgggatttgg	gcccagcagc	cctggggcca	gcagacaccc	cctgaccagc	tctgctctgc	209460
ctgcaggccc	cgtgaagctt	ggcggggagg	ccgcccacct	cccacacctg	cggccgctgc	209520
ctgagagcca	gccctcgtcc	agcccgctgc	tccagaccgc	cccaggggtc	aaaggtcacc	209580
		cagcacatca				
		accaggcctg				
tgtcctggcg	gggtggctgg	gggatccagg	gcatggcgct	ggggggatcc	agggcgtggg	209760
		cccgagcacc				
		atggcatctt				
		tggtctcatc				
		atgcacactg				
		ctggccccac				
		tctgtcagga				
		acaggactac				
		ctccttccct				
		cctcccgccc				
		gaggtgagcg				
		tgcctgcctc				
		: acaggcaaga				
		aatagctgat				
		acacacagco				
		a aggcctggag				
		g atttgttcca				
		a tgcgcacaca				
		a cccacacaca				
		a tgcacaccco				
		a cccctgtaga				
		c cácccccaco				
		g ccctgagcto				
		g aggacagaca				
		g ggtacaacca				
		c cgggccctc				
		t gtttaaaaa				
		t gcctaaaac				
tgtggggcc	c tggtttaga	g tggagggag	g gtgcgcccc	c tcagtaggg	a gacctctgac	211440

PATENT

cacatetggg gecettete catecaggte tecagageca aacaagaegt eggtettggg 211500 tggtggtgag gacggtattg aacctgtgtc cccaccggag ggcatgacgg agccagggca 211560 ctcccggagt gctgtgtacc cgctgctgta ccgggatggg gaacagacgg agcccaggta 211620 cttctgtggg cacatgcgct gccccggga tgctctggta tcccttgccc atccttggcc 211680 ccagtccacc gtggtgccat gtggagagtg acaagggcac agggctcagc tgggtgacct 211740 caageetgee aageaggttt caccaacttg ggggtgtgat acatgeecac ceteeetggg 211800 gagacctcag tggtagcttt ccatgctttg ggctgggatc tcagctggac caggcccccg 211860 ttgacagccc ctgttgaacc tctaagaaat aatgagctag gtgtgctggg ccagaccggg 211920 ggcgatgggt gaggtgggac ctgagaagga agctgggccc gctgcccctg gggaagggca 211980 tgatcggaac ccaatttcag tccttggggc tctcttgaga gggtcaggct ggagcaagtg 212040 gtcagaggca gcccaccacg cagccaggcg tctcccaaga cacccctagc cccaggacgg 212100 gtgaaccgca gaggagattt caggagccgt gatcttctac caggcagggg atgcaggcgt 212160 ggggggggt gaagettget tecaaatgte taaggeatet eaggtggtga gtteeceate 212220 atcaaaggca tgcaagctcg gcaccaagtg agctgatgtg aggtgtttga tcctcacagc 212280 aggatgggct ccaagtctcc aggcaacacc agccagccgc cagccttctt cagcaagctg 212340 accgagagca actccgccat ggtcaagtcc aagaagcaag agatcaacaa gaagctgaac 212400 acccacaacc ggaatgagcc tgaatacagt aaggggcctg caggctcccg gggaagcatg 212460 gggccacagg tgggcgggtg gcctgcctgg gcagctggag ccgcccagtg gcagaaaccc 212520 acggtgcacc ttcgaaagct aagtggccct gctgaccacc tccccccagg ccctttgcct 212580 cacatttggg gagccccagg gcagtttctt gatttgctgg gctttccata ggagcttact 212640 ggcacagaag aatagcaccc agcacatagt aggtgcccag tgaatacctg catgaatact 212700 gggaccaggg gttggatccc tcccacaca gggccgggcg cctcccacac tcagcacctg 212760 tgtggctttg cacccattga cgtggttgct gggtatgaac gccccactct gcttcccagt 212820 ccctagcaca gcgcctggca gttagcagat ccaccaggga atacgtgagt gggtgggcaa 212880 ataaagaatc tgtcacagtc cccgacccca agaagcctca tctgccaggg aagtttggac 212940 aaatcacaga tgcttttccc ttcctggggc tggagtagaa accttgcaga tagtcactgg 213000 cttgccgggc acggtggctc atgcctatag gcccagcact ttgggaggat gaggcaggag 213060 gattgcttga agccaggagt tcgagaccag tctgtgcaac atagcaagac cccatctcta 213120 caaaaaactt taaaaacagg cacacaccta tagtccaagc tactggggag gctgagatag 213180 gaggatttct tgagcctcgg aggtcaaggc tgcagtgagc tatgatcaca ccactgcact 213240 ccagcctgga caacagagca agacactgtc ttaaaaaaaa aaaaaatctc tgacccaggc 213300 tggtaactcc agggccctgt aagtgcagtc cagggaaccg tagcatcagc atccccaggg 213360 tactggttag aaatgcaggc ccttggccag gcgcggtggc ttacgcctgt aatcccagca 213420 ctttgggagg tcaaggcggg tggatcatat gaggtcagga gtttgagacc agcctgacca 213480 acatggtgaa accccgtctc tactaaaaat acaaaaatta gccaggcgtg gtggcggatg 213540 tctgtaaccc cagctactcg ggaggctgag gcaggagaat cacttgaacc tgggaggcgg 213600 aggttgcagg gagccgagat tgcacaactg cactccagcc tgggcaacag agcgagactc 213660 tatctcaaaa aaaaaaaaa aaagaaatgc agacgcttgg ccctgtccca ggcctgctgc 213720 atgagaacct gcaatgcaca agtttcccca ggtgatgcca gcacacctgg cctggaccac 213780

PATENT

				cctcacccac		
				atgcccgcca		
aggtaaccca	tccagccctt	gctatatggc	tgccctggtc	ccctccgctc	cctcccacc	213960
cctgctccag	ctgtcatgaa	gggacgagga	gccttcgcta	gtctgggtgt	accccctcat	214020
tctgggatga	actaaccgca	cagtaggatt	cagagtcaca	caacaggcag	gcgaggcttg	214080
ttccctgtgt	agacaggatc	ctcgctgtgc	agggaatctc	tggagttaag	atcccctcgg	214140
gtggttagta	agtatcagat	gcaccctcac	cagctggaaa	ctcaccttgc	ttcttcgcca	214200
gcctcagctg	gagatgcaca	tgtctggacg	aggggtgggc	ctgagctcag	agcacaagcc	214260
tccgagttca	ctcgggcgtt	tgttatagct	agagcttcat	tccttaaatc	cagccaggga	214320
actgggaagc	cttacttttt	ctttcaagat	caaatacagg	tgtgtggcag	agataggtgt '	214380
aaaattgaca	cgcactttta	agctgaaact	taagacttct	atgatctttt	ggacttaggg	214440
gtcccttgag	gttggagccc	catcctctag	gagggcccca	ttgtgtattt	ccttggtgag	214500
				cctggcccag		
				atcctctggt		
				ttccctgggg		
				cagatattat		
				cctgcccagt		
				tttggtcgaa		
				gtaggtgcta		
				atttatgcta		
				tgtcacctag		
				gcttagatga		
				ctgcacccga		
				ctagtcttga		
				ttgtgtttgt		
				tgcagtggtg		
				acctcagcct		
				tatttttagt		
tttcatcata	a ttggccaggo	tgatctcgaa	a ctcctgacgt	cagatgatco	acccacattg	215520
				gcccagcctg		
				ccagtctttg		
				: tggagccagc		
				ctgtgatttc		
				tttttcaaaa		
				g ctacaaacgt		
				a gaaacgtgat		
				tacaaaggag		
				ggagcagaag		
catgaaaca	c ttgccccgt	g gtgggcacg	g tggaatgggg	g cttcactggg	g ggcttttgaa	216120

-196-

PTS-0012 -1

PATENT

agcaaaggct	ggtttaacaa	aagttctgaa	aagacagcac	ctctgggggg	tgtgcaaagg 2	216180
ccccacctc	cacgtggttc	acaagaaaga	aaaaagggaa	aggaaatgtg	gttaacagaa 2	216240
aaggaggttt	ccccgattgt	caggaggtgt	tctggaagca	tcctcttggg	accggtttgt 2	216300
tgattcgacc	actttgtcct	tgggactggg	,cagctgggcc	agctggggcc	ggaccagggc :	216360
tggtcccgtg	attgtgtcta	cttctgccct	gtcccctgca	cgcaccgtaa	ctgcatggct :	216420
atgaccccgc	cctcagcgtc	cgtctctgca	cctctttctc	ctcatggctc	ctgggtgggg	216480
agaggcagag	ggaggagagc	aggcccagct	tggtggggag	gtacggggct	gcacgtccca	216540
tcacacaggt	ggaggtgggg	cagcgggagg	accatctggt	caccttctct	ctctcagtcc	216600
çttccccagc	ccccagccag	ccccagctc	tggcttgagc	caattttcta	gcagcctgtt	216660
ccccaaacag	ggtagccctc	ccatctccca	ccctctccat	taaggccact	tgagatttaa	216720
aaaaaaaca	aacaaaacag	ccccagctag	gattggaggt	gcagacgggg	cttgtgattt	216780
cccagaggac	agaataggaa	tgagaatagg	ggctggtggg	ggcatctgac	ctcccctacc	216840
ccacctccct	ggcagtgccc	aagagcttcc	ggggccccag	gtagaaggaa	ccagcctctc	216900
cccttttatc	accacccagc	aggaaaaaaa	gggtggggag	ggatagggaa	ataaatatgt	216960
tgctttgccg	aaatgtgctc	actgtgtatt	tctctctcct	cctcctcctc	ctcctccttc	217020
cctctctctc	tecettetet	ctctctgtcg	cccctctggc	tcccctccc	cggcccccat	217080
					agccaggcgg	
					gcactcatgg	
gtaaatatga	ccagtgggaa	gagteceege	cgctcagcgc	caatgctttt	aaccctctga	217260
atgccagtgc	cagcctgccc	gctgctatgc	: ccataaccgc	tgctgacgga	cggagtgacc	217320
acacactcac	ctcgccaggt	ctgcaggcca	ccccgccc	gcccccgtct	gtccccaccc	217380
ccggtgtgat	taatcctcgo	: tecteegege	tcctctgaca	acccctcct	cgagctttgg	217440
agcttgtgac	tttatttttg	g tgcgtgtttg	g acctcgttct	ggagtttgct	aatctgaagc	217500
tgggctgaca	cccccaagt	gtctgtacco	tctgccccc	agccccggcc	ctcctgccca	217560
					ccccagtcc	
tecegeette	ctccctgcgg	g ggacccggct	tcttggccca	tetgteteet	tgggggagag	217680
caggctggag	tgaagcccc	a cccacactgt	gtggacaggg	gaatggcago	: caggcctgtg	217740
ctcagcatct	gccaggccca	a ctatgtgtco	c tcagctgccc	cttagcctgg	tggggaggag	217800
					ggttccccat	
caataccct	c tgtatcggg	g cagggagct	g aggagagagt	tgcagttgto	caacctggac	217920
actgaggcc	c caagaagct	t ctggagcct	c tgtgggggt	e aggeetggee	tcaggggtcc	217980
tgacttctc	t gcacggggc	c tggatcctg	c ctagccttag	g catggtcctq	g gggccacgct	218040
caaactgga	a gcccagctt	c atgcttagg	g ttccagccc	c tggggctgg	g gtcgctgcag	218100
gacagccca	g ggggctatt	g caaacagca	g acagtttag	c cacetecec	c tgcccagcag	218160
aaactatct	c caccctcca	g gctcatggc	t ggccatctg	g tcaaccctg	g cttcccagct	218220
ggggcgggc	a gcagggagg	a ggggttcac	g ttactgctc	t ccctccctc	t ttggagggco	218280
catggcagg	a cctcaccct	g cccctgtgg	c cccaccgta	g cgtcggtgc	t gtcttcactg	218340
cccaacgca	g ccccttccc	a tettgteee	c ctgcaggtg	g cggcgggaa	g gccaaggtct	218400
ctggcagac	c cagcagccg	a aaagccaag	t cccggccc	c gggcctggc	a tctggggacc	218460

PTS-0012 -197- PATENT

ggccaccctc tgtctcctca gtgcactcgg agggagactg caaccgccgg acgccgctca 218520 ccaaccgcgt gtgggaggac aggccctcgt ccgcaggtgg gcaccaggtg gggacagggc 218580 tgggctcgct gagcccccaa cactgggctg tgaatgctgc cggggcactg aatgctgagc 218640 geetgetgea tgeagagete agaeteggge etgttetgtg gaaaegetgt eeaggggeet 218700 gggcagctga gcctggctca cgaaccatca ggatgcttct gccaggggca caggcagagg 218760 aaaagggtgt ggttggggcc ggccagatca catgggcctg gtggaccatc caggggagcc 218820 tggacttcct ttgatgggta gtgaggaggc gtggagggct ttcggaaggg aaatgctcat 218880 ctaacatagg gtcagaaggc ccctgggaga atagaccaga gggacggtga ataggctact 218940 gctatagtcc aggcaaaaga cagcggcagg gtgtgaacag ggacggaagt agaacaggtg 219000 aagagaggca gacggttctg agacctgttc gcaattagaa aggtctggga ggactgttgg 219060 acagaaacgc tgaggcctct gttcccggtg tggtgggcag gcggccagca ggggctgccg 219120 ggctcacaga ggcctcctgg gcatctttcg cttcttcccg caggttccac gccattcccc 219180 tacaaccccc tgatcatgcg gctgcaggcg ggtgtcatgg cttccccacc cccaccgggc 219240 ctcccgcgg gcagcgggcc cctcgctggc ccccaccacg cctgggacga ggagcccaag 219300 ccactgetet getegeagta egagacaete teegacageg agtgaeteag aacagggegg 219360 ggggggggc ggtgtcaggt cccagcgagc cacaggaacg gccctgcagg agcagggcgg 219420 ctgccgactc ccccaaccaa ggaaggagcc cctgagtccg cctgcgcctc catccatctg 219480 tecgtecaga geeggeatee ttgeetgtet aaageettaa etaagaetee egeeeeggge 219540 tggccctgtg cagaccttac tcaggggatg tttacctggt gctcgggaag ggaggggaag 219600 gggccgggga gggggcacgg caggcgtgtg gcagccacac gcaggcggcc agggcggcca 219660 gggacccaaa gcaggatgac cacgcacctc cacgccactg cctcccccga atgcatttgg 219720 aaccaaagtc taaactgagc tegeageece egegeeetee eteegeetee cateeegett 219780 agegetetgg acagatggae geaggeeetg tecageeece agtgegeteg tteeggteee 219840 cacagactgc cccagccaac gagattgctg gaaaccaagt caggccaggt gggcggacaa 219900 aagggccagg tgcggcctgg ggggaacgga tgctccgagg actggactgt tttttcaca 219960 catcgttgcc gcagcggtgg gaaggaaagg cagatgtaaa tgatgtgttg gtttacaggg 220020 tatatttttg ataccttcaa tgaattaatt cagatgtttt acgcaaggaa ggacttaccc 220080 agtattactg ctgctgtgct tttgatctct gcttaccgtt caagaggcgt gtgcaggccg 220140 acagtcggtg accccatcac tcgcaggacc aagggggcgg ggactgctgg ctcacgcccc 220200 gctgtgtcct ccctccctcc cttccttggg cagaatgaat tcgatgcgta ttctgtggcc 220260 gccatctgcg cagggtggtg gtattctgtc atttacacac gtcgttctaa ttaaaaagcg 220320 aattatactc cagttacaaa ggtttcttct ctacctcaga ctgggcagcc aatagggcag 220380 gcgtttaggg gacagtggga gtatacccct ggagggccaa ggccacatcc gcctgagtca 220440 ccagggagtg gatecttttg caagttgaat atttataccc ttggtaagga catcaccatg 220500 aggacatcaa atagtcacat ctgtggtgaa ggtctcaagt gttcacaccc atggtaagag 220560 tgtgtcagat gttcacatgg gttcacaccc atgtgtcagg tattcacatg atggtcaggg 220620 tgtcatgttc acactcatgg tgagagggtg tcaggtattc acacccatgt atcaggtatt 220680 cacaccatgc tgagggtgtc aagtagtcac acccatggta agagtgtcag atgttcatac 220740 tcatggtgtt aggtattcac accatggcga gggtgtcaga tgttcacaca tggtgtcagg 220800

PATENT

70 .

tgttcacacc atggtgaggg tgtcatgttc acactcatgg tgtcaggtat tcacaccata 22	0860
gtgaggtgt cagatgttca cacatggtga gagggtgcca ggtattcatt cccatgtgtc 22	0920
aggtgttcac accgtggtga gggtgtcaag tggtcacacc atggtgagag ggtgtcagat 22	0980
gttcacaccc atgtgtcagg 22	1000
<210> 13	
<211> 2930	
<212> DNA	
<213> H. sapiens	
<220>	
<220>	
<221> CDS	
<222> (456)(2765)	
<400> 13	60
tttgttagtt tgtctgtttg cacttaaagt tctaagcact ttggaaagtt tctaagcaac	120
ttctcacttc caagcaacaa cttaaccaac actaacaact tactattatt aattagtatt	180
ttcttggctc accccgcac agcaccgtgc ccgagcacca cccacacccc atctcgccct	240
atgageacct gettegggge gtgagtggeg tggacetgta tegeageeac atceceetgg	300
cettegacce cacetecata eccegeggea tecetetgga egeageeget geetactace	360
tgccccgaca cctggccccc aaccccacct acccgcacct gtacccaccc tacctcatcc	420
gcggctaccc cgacacggcg gcgctggaga accggcagac catcatcaat gactacatca	473
cctcgcagca gatgcaccac aacgcggcca ccgcc atg gcc cag cga gct gat Met Ala Gln Arg Ala Asp	
1 5	
•	521
atg ctg agg ggc ctc tcg ccc cgc gag tcc tcg ctg gca ctc aac tac	
Met Leu Arg Gly Leu Ser Pro Arg Glu Ser Ser Leu Ala Leu Asn Tyr	
gct gcg ggt ccc cga ggc atc atc gac ctg tcc caa gtg cca cac ctg	569
Ala Ala Gly Pro Arg Gly Ile Ile Asp Leu Ser Gln Val Pro His Leu	•
35	
cct gtg ctc gtg ccc ccg aca cca ggc acc cca gcc acc gcc atg gac	617
Pro Val Leu Val Pro Pro Thr Pro Gly Thr Pro Ala Thr Ala Met Asp	
A.C. 5.0	
cgc ctt gcc tac ctc ccc acc gcg ccc cag ccc ttc agc agc cgc cac	665
Arg Leu Ala Tyr Leu Pro Thr Ala Pro Gln Pro Phe Ser Ser Arg His	
With new wire 112 new 120 time 122 time 122	

65

60

55

-199-

PTS-0012

PATENT

	713
age age tee cea ete tee cea gga ggt cea aca cae ttg aca aaa eea	,
Ser Ser Ser Pro Leu Ser Pro Gly Gly Pro Thr His Leu Thr Lys Pro	
75	761
acc acc acg tcc tcg tcc gag cgg gag cga gac cgg gat cga gag cgg	
Thr Thr Ser Ser Ser Glu Arg Glu Arg Asp Arg Asp Arg Glu Arg	
gac cgg gat cgg gag cgg gaa aag tcc atc ctc acg tcc acc acg acg	809
Asp Arg Asp Arg Glu Arg Glu Lys Ser Ile Leu Thr Ser Thr Thr	
110 115	
gtg gag cac gca ccc atc tgg aga cct ggt aca gag cag agc agc ggc	857
Val Glu His Ala Pro Ile Trp Arg Pro Gly Thr Glu Gln Ser Ser Gly	
120 125 130	
age age gge age gge ggg ggt ggg ggc age age age ege eee gee	905
Ser Ser Gly Ser Ser Gly Gly Gly Gly Ser Ser Arg Pro Ala	
135 140 145 150	
tec cac tee cat gee cac cag cac teg cee ate tee cet egg acc cag	953
Ser His Ser His Ala His Gln His Ser Pro Ile Ser Pro Arg Thr Gln	
155 160 165	
gat gcc ctc cag cag aga ccc agt gtg ctt cac aac aca ggc atg aag	1001
Asp Ala Leu Gln Gln Arg Pro Ser Val Leu His Asn Thr Gly Met Lys	
170 175 180	
ggt atc atc acc gct gtg gag ccc agc acg ccc acg gtc ctg agg tcc	1049
Gly Ile Ile Thr Ala Val Glu Pro Ser Thr Pro Thr Val Leu Arg Ser	
185 . 190 . 195	1007
ace tee ace tee tea eee gtt ege eea get gee aca tte eea eet gee	1097
Thr Ser Thr Ser Ser Pro Val Arg Pro Ala Ala Thr Phe Pro Pro Ala	
200 205 210	1145
acc cac tgc cca ctg ggc ggc acc ctc gat ggg gtc tac cct acc ctc	1140
Thr His Cys Pro Leu Gly Gly Thr Leu Asp Gly Val Tyr Pro Thr Leu	
215 220 223	1193
atg gag ccc gtc ttg ctg ccc aag gag gcc ccc cgg gtc gcc cgg cca	
Met Glu Pro Val Leu Leu Pro Lys Glu Ala Pro Arg Val Ala Arg Pro	
235	1241
gag egg eee ega gea gae ace gge eat gee tte ete gee aag eee eea	
Glu Arg Pro Arg Ala Asp Thr Gly His Ala Phe Leu Ala Lys Pro Pro	
250 253	1289
gcc cgc tcc ggg ctg gag ccc gcc tcc tcc ccc agc aag ggc tcg gag Ala Arg Ser Gly Leu Glu Pro Ala Ser Ser Pro Ser Lys Gly Ser Glu	
275	
265 270 273	

PTS-0012 -200-

cee egg eee cta gtg eet eet gte tet gge eae gee ace ate gee ege 1337 Pro Arg Pro Leu Val Pro Pro Val Ser Gly His Ala Thr Ile Ala Arg 290 285 280 acc cct gcg aag aac ctc gca cct cac cac gcc agc ccg gac ccg ccg 1385 Thr Pro Ala Lys Asn Leu Ala Pro His His Ala Ser Pro Asp Pro Pro 310 305 300 295 gcg cca cct gcc tcg gcc tcg gac ccg cac cgg gaa aag act caa agt 1433 Ala Pro Pro Ala Ser Ala Ser Asp Pro His Arg Glu Lys Thr Gln Ser 315 aaa ccc ttt tcc atc cag gaa ctg gaa ctc cgt tct ctg,ggt tac cac 1481 Lys Pro Phe Ser Ile Gln Glu Leu Glu Leu Arg Ser Leu Gly Tyr His ggc agc agc tac agc ccc gaa ggg gtg gag ccc gtc agc cct gtg agc 1529 Gly Ser Ser Tyr Ser Pro Glu Gly Val Glu Pro Val Ser Pro Val Ser 350 345 tca ccc agt ctg acc cac gac aag ggg ctc ccc aag cac ctg gaa gag 1577 Şer Pro Ser Leu Thr His Asp Lys Gly Leu Pro Lys His Leu Glu Glu 365 360 ctc gac aag agc cac ctg gag ggg gag ctg cgg ccc aag cag cca ggc 1625 Leu Asp Lys Ser His Leu Glu Gly Glu Leu Arg Pro Lys Gln Pro Gly 385 380 375 ccc gtg aag ctt ggc ggg gag gcc gcc cac ctc cca cac ctg cgg ccg 1673 Pro Val Lys Leu Gly Gly Glu Ala Ala His Leu Pro His Leu Arg Pro 405 395 ctg cct gag age cag ccc tcg tcc age ccg ctg ctc cag acc gcc cca 1721 Leu Pro Glu Ser Gln Pro Ser Ser Pro Leu Leu Gln Thr Ala Pro 415 410 ggg gtc aaa ggt cac cag cgg gtg gtc acc ctg gcc cag cac atc agt 1769 Gly Val Lys Gly His Gln Arg Val Val Thr Leu Ala Gln His Ile Ser 430 gag gtc atc aca cag gac tac acc cgg cac cac cca cag cag ctc agc 1817 Glu Val Ile Thr Gln Asp Tyr Thr Arg His His Pro Gln Gln Leu Ser 445 440 gca ccc ctg ccc gcc ccc ctc tac tcc ttc cct ggg gcc agc tgc ccc 1865 Ala Pro Leu Pro Ala Pro Leu Tyr Ser Phe Pro Gly Ala Ser Cys Pro 465 460 455 gtc ctg gac ctc cgc cgc cca ccc agt gac ctc tac ctc ccg ccc ccg 1913 Val Leu Asp Leu Arg Arg Pro Pro Ser Asp Leu Tyr Leu Pro Pro 485 480 475

PTS-0012 -201- PATENT

and cat age age egg gge tee eee cae age gaa ggg gge and	1961
Asp His Gly Ala Pro Ala Arg Gly Ser Pro His Ser Glu Gly Lys	
490 495 500	
agg tot coa gag coa aac aag acg tog gto ttg ggt ggt ggt gag gac	2009
Arg Ser Pro Glu Pro Asn Lys Thr Ser Val Leu Gly Gly Glu Asp	
505 510 515	
ggt att gaa cct gtg tcc cca ccg gag ggc atg acg gag cca ggg cac	2057
Gly Ile Glu Pro Val Ser Pro Pro Glu Gly Met Thr Glu Pro Gly His	
520 525 530	2105
tcc cgg agt gct gtg tac ccg ctg ctg tac cgg gat ggg gaa cag acg	2105
Ser Arg Ser Ala Val Tyr Pro Leu Leu Tyr Arg Asp Gly Glu Gin Int	
535 540 545 550	2153 ,
gag ccc agc agg atg ggc tcc aag tct cca ggc aac acc agc cag ccg	2133 ,
Glu Pro Ser Arg Met Gly Ser Lys Ser Pro Gly Asn Thr Ser Gln Pro	
555	2201
cca gcc ttc ttc agc aag ctg acc gag agc aac tcc gcc atg gtc aag	
Pro Ala Phe Phe Ser Lys Leu Thr Glu Ser Asn Ser Ala Met Val Lys	
570 575	2249
tcc aag aag caa gag atc aac aag aag ctg aac acc cac aac cgg aat	
Ser Lys Lys Gln Glu Ile Asn Lys Lys Leu Asn Thr His Asn Arg Asn	
585	2297
gag cct gaa tac aat atc agc cag cct ggg acg gag atc ttc aat atg	
Glu Pro Glu Tyr Asn Ile Ser Gln Pro Gly Thr Glu Ile Phe Asn Met	•
600	2345
ccc gcc atc acc gga aca ggc ctt atg acc tat aga agc cag gcg gtg	
Pro Ala Ile Thr Gly Thr Gly Leu Met Thr Tyr Arg Ser Gln Ala Val	
615	2393
cag gaa cat gcc agc acc aac atg ggg ctg gag gcc ata att aga aag Gln Glu His Ala Ser Thr Asn Met Gly Leu Glu Ala Ile Ile Arg Lys	
640 643	,
gca ctc atg ggt ggc ggc ggg aag gcc aag gtc tct ggc aga ccc agc	2441
gca ctc atg ggt ggc ggc ggg atg gcc atg gv Ala Leu Met Gly Gly Gly Lys Ala Lys Val Ser Gly Arg Pro Ser	
cee 660	
age cga aaa gee aag tee eeg gee eeg gge etg gea tet ggg gae egg	2489
agc cga aaa gcc aag tee eeg gee eeg ggo oog y Ser Arg Lys Ala Lys Ser Pro Ala Pro Gly Leu Ala Ser Gly Asp Arg	
675	
cca ccc tct gtc tcc tca gtg cac tcg gag gga gac tgc aac cgc cgg	2537
Pro Pro Ser Val Ser Ser Val His Ser Glu Gly Asp Cys Asn Arg Arg	
690	
680	

-202-

PTS-0012 -2

PATENT

												_		~	aat	2585
acg	ccg	ctc	acc	aac	cgc	gtg	tgg	gag	gac	agg	ccc	tcg	tcc	gca	-1	2303
ጥከተ	Pro	Leu	Thr	Asn	Arg	Val	Trp	Glu	Asp	Arg	Pro	Ser	Ser	Ala	GIA	
695					700					705					710	
693	acg					220	ccc	cta	atc	atg	cgg	ctg	cag	gcg	ggt	2633
tcç	acg	cca	EEC	CCC	Lac	200	D	Tou	Tla	Met	Arg	Leu	Gln	Ala	Gly	
Ser	Thr	Pro	Phe	Pro	Tyr	Asn	PIO	neu		ricc	9			725	Gly	
				715					720					•		0.001
atc	atα	act	tcc	cca	CCC	cca	ccg	ggc	ctc	ccc	gcg	ggc	agc	ggg	CCC	2681
77-1	Wor	מות	Sar	Pro	Pro	Pro	Pro	Gly	Leu	Pro	Ala	Gly	Ser	Gly	Pro	
Var	Mec	ATG						735					740			
			730									220	cca	cta	ctc	2729
ctc	gct	ggc	gcc	cac	cac	gcc	tgg	gac	gag	gag	CCC	aay			ctc	
Leu	Ala	Gly	Ala	His	His	Ala	Trp	Asp	Glu	Glu	Pro	ь Гла	Pro	) Lec	Leu	
		745					750					755	•			
	tc:				raca	cto	: tcc	gac	ago	gaç	g tga	cto	cagaa	acag		2775
tgo	CCC	, cag	Lac	, gas	, acc		Con	- Aer	. Ser	- Gl1	1					
Суз	s Sei	Glr	туз	c Glu	נטוני נ			L AS	, 501	. 01	-					
	760	)				765										2835
aa	caaa	aaaa	gcgg	gggg	gcg g	gtgto	cagg	tc c	cagc	gagc	c ac	agga	acgg	ccc	tgcagga	
35	- 555.	caac	tace	cgac	tcc (	ccca	acca	ag g	aagg	agcc	c ct	gagt	ccgc	ctg	cgcctcc	2895
																2930
at	ccat	ctgt	ccg	TCCa	yay '	ccyy	call		5000							

<210> 14

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 14

agtcctcgtc atcagctcac

20

<210> 15

<211> 20

<212> DNA

<213> Artificial Sequence

-203-

PATENT

<223>	Antisense	Oligonucleotide

<400> 15

ctcttggcag tggtggccct

20

<210> 16

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 16

atgttcctgc accgcctggc

20

<210> 17

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 17

ctccagcgag gctgtgtcct

20

<210> 18

<211> 20

<212> DNA

<213> Artificial Sequence

-204-

PATENT

<223> Antisense Oligonucleotide

· <400> 18

tcactggcac cagaaactgc

20

<210> 19

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 19

tggagcccga catggtggtg

20

<210> 20

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 20

ccgtggcggc accagctcca

20

<210> 21

<211> 20

<212> DNA

<213> Artificial Sequence

-205-

PATENT

<223> Antisense	Oligonucleotide
-----------------	-----------------

<400> 21

gctggcccac cctctgcatg

20

<210> 22

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 22

gctgttggca gttttgcggc

20

<210> 23

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 23

ttgacagtgg cttcagcctc

20

<210> 24

<211> 20

<212> DNA

<213> Artificial Sequence

-206-

PATENT

<223> Antisense Oligonucleoti	de
-------------------------------	----

<400> 24

aggettetet geeteettgt

20

<210> 25

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 25

tgtgctggga atgcctttgg

20

<210> 26

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 26

ctccttgggc agcaagacgg

20

<210> 27

<211> 20

<212> DNA

<213> Artificial Sequence

-207-

PATENT

<223> Antisense Oligonucleotide

<400> 27

gccgccacct ggcgaggtga

20

<210> 28

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 28

tgttctgagt cactcgctgt

20

<210> 29

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 29

catcatttac atctgccttt

20

<210> 30

<211> 20

<212> DNA

<213> Artificial Sequence

-208-

PATENT

<223> Antisense	Oligonucleotide
-----------------	-----------------

· <400> 30

ggcccaccct gctctgcatg

20

<210> 31

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 31

gcatgtaagg cttcagcctc

20

<210> 32

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 32

ctcattccca gaggcatgta

20

<21,0> 33

<211> 20

<212> DNA

<213> Artificial Sequence



-209-

PATENT

<223> Antisense Oligonucleotide

<400> 33

ttgacagtgg ctgggccact

20

<210> 34

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 34

gctgcgaagg cctccttgtc

20

<210> 35

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 35

atgaacctac cagaaactgc

20

<210> 36

<211> 20

<212> DNA

<213> Artificial Sequence



<212> DNA

<220>

<213> Artificial Sequence

-210-

PATENT

<223> Ant	tisense Oligonucleotide	
<400> 36		20
accagaca	ag gctctgggct	20
<210> 37		
<211> 20	•	
<212> DN	rtificial Sequence	
<213> AI	rtilicial bequence	
<220>		
<223> A	ntisense Oligonucleotide	
<400> 3	7	20
tcactgg	gcac ctgcgggaaa	
212 3	20	-
<210> 3		
<211> 2		
<212> I	Artificial Sequence	
<2137 E	BIGITION Softens	
<220>		
		•
<223>	Antisense Oligonucleotide	
	ų	
<400>		20
accccc	ettac cgtgtgcgtc	20
<210>		
<211>	20	



-211-

PATENT

<223> Antisense Oligonucleotide

<400> 39

cccagtgtcc tgaattccta

20

<210> 40

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 40

cagccttctt ctgcagggtg

20

<210> 41

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 41

cgctggccca ccctgctggg

20

<210> 42

<211> 20

<212> DNA

<213> Artificial Sequence

-212-

PATENT

<223> Antisense Oligonucleotide

<400> 42

gaccgagttc agccccaggc

20

<210> 43

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 43

gcatgtaagg ctggaaggaa

20

<210> 44

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 44

acattcgtac ctgggccact

20

<210> 45

<211> 20

<212> DNA

<213> Artificial Sequence

-213-

PTS-0012

PATENT

<223> Antisense Oligonucleotide

<400> 45

ggcttctctg ctgagggcag

20

<210> 46

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 46

gctgcgaagg ctgggaagaa

20

<210> 47

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

**<400> 47** 

cacttgttac ttactgccct

. 20

<210> 48

<211> 20

<212> DNA

<213> Artificial Sequence

-214-

PTS-0012

PATENT

<223> Antisense Oligonucleotide

<400> 48

tcatatttac ccatgagtgc

20

<210> 49'

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 49

ggcctgcaga cctggcgagg

20

<210> 50

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 50

gccgccaccc atgagtgcct

20

<210> 51

<211> 20

<212> DNA

<213> H. sapiens

-215-

PATENT

<400>	51	
adddco	acca	ctgccaagag

20

<210> 52

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 52 gccaggcggt gcaggaacat

20

D

<210> 53

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 53

aggacacagc ctcgctggag

20

<210> 54

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 54.

tggagctggt gccgccacgg

20

<210> 55

<211> 20

-216-

PATENT

_	2	1	2	>	DI	ΝA

<213> H. sapiens

<220>

<400> 55

catgcagagg gtgggccagc

20

<210> 56

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 56

acaaggaggc agagaagcct

20

<210> 57

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 57

ccaaaggcat tcccagcaca

20

<210> 58

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 58

-217-

PTS-0012

PATENT

ccgtcttgct gcccaaggag

20

<210> 59

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 59

tcacctcgcc aggtggcggc

20

<210> 60

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 60

acagcgagtg actcagaaca

20

<210> 61

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 61

catgcagagc agggtgggcc

20

<210> 62

<211> 20

<212> DNA

_2 -218-

PTS-0012

PATENT

<213> H. sapiens

<220>

<400> 62

tacatgcctc tgggaatgag

20

<210> 63

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 63

gacaaggagg ccttcgcagc

20

<210> 64

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 64

taggaattca ggacactggg

20

<210> 65

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 65

cccagcaggg tgggccagcg

20

<210> 66

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 66

ttccttccag ccttacatgc

20

<210> 67

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 67

agtggcccag gtacgaatgt

20

<210> 68

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 68

ctgccctcag cagagaagcc

20

<210> 69

<211> 20

<212> DNA

<213> H. sapiens



-220-

PATENT

<220>

<400> 69

ttcttcccag ccttcgcagc

20

<210> 70

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 70

agggcagtaa gtaacaagtg

20

<210> 71

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 71

gcactcatgg gtaaatatga

20

<210> 72

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 72

cctcgccagg tctgcaggcc

20





-221-

PATENT

<210> 73

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 73

aggcactcat gggtggcggc

20